



AUSTRALIAN NSP SURVEY 20 YEAR NATIONAL DATA REPORT 1995-2014

Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees

Never Stand Still

Medicine

The Kirby Institute

ACT IV League, Directions ACT, Canberra, ACON Hunter, Albury Base Hospital & Community Health Centre, Auburn NSP Service, Ballina/Byron Harm Reduction Services, Blacktown NSP Service, Central Access Service, St George & Sutherland, Cofts Harbour/Grafton Harm Reduction Services, Fairfield Harm Reduction, Cabramatta & Fairfield, First Step Program, Kemplia, Gosford NSP Service, Health ConneXions, Liverpool, Indo-Chinese Outreach Network, Bankstown, Cabramatta & Liverpool, Kirketon Road Centre, Clinic 180 and K2 Kings Cross, Jetty NSP Service, Merrylands NSP Service, Mt Druitt NSP Service, Murwillumbah/Tweed Harm Reduction Services, Newcastle Harm Minimisation Program, Nimbin/Lismore Harm Reduction Services, NSW Users and AIDS Association (NUAA), Parramatta NSP Service, Harm Minimisation Program Redfern and Canterbury, Response User Services in Health (RUSH), Ryde, Manly, St Leonards, South Court Primary Care, Nepean, Wagga Wagga NSP Service, NT AIDS and Hepatitis C Council, Darwin, Palmerston and Alice Springs, Bodyline, Biala Community Alcohol and Drug Services, Brisbane, Cairns Needle and Syringe Program, Cairns Youth Link, Gold Coast Hospital, Kobi House, Toowoomba, Logan Youth Health Service, Mackay Sexual Health Services, QulHN, Brisbane, Gold Coast and Sunshine Coast, Townsville ATODS NSP, West Sexual Health Service, Ipswich, Hindmarsh Centre CNP, Lyell McEwin, Nunkuwarrin Yunti, SAVIVE, Noarlunga, SAVIVE, Norwood, SAVIVE, Parks, SAVIVE, Port Adelaide, SAVIVE, Street Link Youth Services, Warinilla Clinic, Clarence Community Health Centre, Salvation Army Launceston, Anglicare Glenorchy and Hobart, The Link- Youth Health Service, Users Health Support League, Hobart, Ballarat CHS, Barwon NSP, Geelong, Health Works, Western Regional Health Region, Innerspace/MINE, Collingwood, North Richmond NSP Services, Northcote Services, SHARPE, Frankston, South East Alcohol and Drug Service, Dandenong, St Kilda Services, Western Australia Substance Users Association (WASUA), Perth and South Coast AIDS Council Mobile Exchange, ACT IV League, Directions ACT, Canberra, ACON Hunter, Albury Base Hospital & Community Health Centre, Auburn NSP Service, Ballina/Byron Harm Reduction

The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW Australia.

June 2015



AUSTRALIAN NSP SURVEY

Prevalence of HIV, HCV and injecting and sexual behaviour
among Needle and Syringe Program attendees

20 YEAR NATIONAL DATA REPORT

1995 - 2014

Report prepared by

Jenny Iversen and Lisa Maher

The Kirby Institute
for infection and immunity in society
UNSW Australia

June 2015

The Australian Needle and Syringe Program Survey is funded by the Australian Government Department of Health. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW Australia.

ACKNOWLEDGMENTS

We are proud to present this special 20 Year National Data Report and acknowledge the many people who have assisted in the development and conduct of the Australian Needle and Syringe Program Survey (ANSPS) since its inception in 1995. We would particularly like to acknowledge the more than 45,000 occasions that Needle and Syringe Program (NSP) clients have participated in this project, as well as the ongoing support and assistance provided by both staff and management at the participating NSP services. Special thanks are also due to the laboratory staff at St Vincent's Centre for Applied Research (AMR) and NSW State Reference Laboratory for HIV at St Vincent's Hospital, in particular Mr Philip Cunningham and Ms Beth Catlett and to other staff who have been involved in serological testing over the past twenty years. Mr Sammy Chow, Ms Rachel McCleave, Ms Samantha Chivers and Ms Louise Geddes also made a contribution to the preparation of tables in this report. Mr Greg Smith and Ms Ashwin Prekesh from Educational Assessment Australia, UNSW Global have been invaluable in their work scanning and validating completed surveys since 2006.

We would also like to acknowledge the original investigators and steering committee responsible for developing the survey methodology, particularly Dr Alex Wodak, Professor John Kaldor and the late Dr Margaret MacDonald who was responsible for the development and conduct of the ANSPS until 2003.

In 2014, the project received support and input from the following members of the ANSPS National Advisory Group: Ms Tracey Dobie (Australian Capital Territory); Ms Rose Mason (New South Wales); Mr Damon Brogan (Northern Territory); Mr Robert Kemp (Queensland); Mr Stephen Lymb (South Australia); Ms Francine Smith (Tasmania); Mr Roland Jauernig (Victoria); Ms Jude Bevan (Western Australia); Ms Annie Madden (Australian Injecting and Illicit Drug Users League); Mr John Ryan (Anex); Professor John Kaldor, Professor Lisa Maher and Dr Jenny Iversen (The Kirby Institute). We are particularly grateful to the current Advisory Group chair Mr Robert Kemp.

Finally, we are grateful to the Australian Government Department of Health for funding the Australian NSP Survey and their ongoing commitment to the surveillance of blood borne viral infections among people who inject drugs.

TABLE OF CONTENTS

Key Findings.....	i
1. Australian NSP Survey	1
2. Australian Capital Territory	39
3. New South Wales	63
4. Northern Territory	95
5. Queensland	119
6. South Australia	151
7. Tasmania.....	176
8. Victoria.....	200
9. Western Australia	226
Appendix 1: References	251
Appendix 2: Methodological notes.....	253
Appendix 3: List of tables	254
Appendix 4: Participating NSP services	255

ABBREVIATIONS

ACT	Australian Capital Territory
AIVL	Australian Injecting & Illicit Drug Users League
ANSPS	Australian Needle and Syringe Program Survey
BBV	Blood-borne viral
DBS	Dried blood spot
HCV	Hepatitis C virus
HIV	Human immunodeficiency virus
NSP	Needle syringe program
NSW	New South Wales
NT	Northern Territory
OST	Opioid substitution therapy
PIEDs	Performance and image-enhancing drugs
PWID	People who inject drugs
RSS	Receptive syringe sharing
SA	South Australia
WA	Western Australia

KEY FINDINGS

- The Australian NSP Survey (ANSPS) functions as a strategic early-warning system designed to monitor blood borne viral (BBV) infections and associated risk behaviour among people who inject drugs.
- The ANSPS has been conducted annually since 1995 and NSP attendees have participated on more than 45,000 occasions. Around two thirds of Australia's ~75 primary NSP services participate in the ANSPS.
- The ANSPS has resulted in numerous publications, including annual National Data Reports as well as 17 peer-reviewed publications in scientific journals.

Demographic characteristics

- The median age of respondents was relatively stable at 27 to 29 years over the period 1995 to 2001, with an incremental increase in all subsequent years, from 30 years in 2002 to 39 years in 2014. There was a concomitant decline in the proportion of respondents aged less than 25 years over the same period, from 25% in 2002 to 6% in 2014.
- The proportion of new initiates (0-3 years since fist injection) declined from around one in four in the late 1990s to one in ten over the period 2010 to 2014. The median time since first injection more than doubled from a low of seven years in 1998 to 19 years in 2014. The median age at first injection remained unchanged at 18-19 years in all survey years.
- The proportion of respondents from an Indigenous background increased over the survey period, from 5% in 1995 to 14% in 2014.

Drugs last injected

- While there were temporal shifts in the patterns of drugs injected as reported by ANSPS respondents over the past 20 years, heroin and methamphetamine remained the two most commonly reported drugs last injected in all years 1995 to 2014.
- Heroin was the most commonly reported drug last injected in the late 1990s, reported by more than half of ANSPS respondents during this period. However, since 2001, prevalence of heroin as the last drug injected remained relatively stable and was reported by around one third of ANSPS respondents in most years.
- Methamphetamine was reported as the drug last injected by less than half of survey respondents in all survey years. Prevalence of methamphetamine injection increased suddenly in 2001 and remained stable over the period 2001 to 2006 when it was reported by around one third of ANSPS respondents. Prevalence declined to one quarter of respondents over the period 2006 to 2009, however, prevalence increased again over the period 2010 to 2014 and methamphetamine was reported as the last drug injected by one third of respondents in 2014.
- The proportion of respondents who reported last injecting pharmaceutical opioids increased from 6% in 2001 to 16% in 2010. Since 2010, prevalence has declined, with 11% of respondents last injecting this class of drugs in 2014.
- The proportion of ANSPS respondents who reported last injecting performance and image-enhancing drugs (PIEDs) was stable at 2% to 3% over the period 1995 to 2010, however, prevalence increased from 2% in 2010 to 7% in 2014.
- Among new initiates, 20% reported last injecting opioids (heroin and pharmaceutical opioids), 32% reported last injecting methamphetamine and 38% reported last injecting PIEDs in 2014.

Injection risk behaviour

- Reports of public injection in the month preceding survey participation declined from more than half of all ANSPS respondents in the late 1990s to one third of respondents in 2014.
- Prevalence of reuse and receptive sharing of syringes and drug preparation equipment has declined since collection of these data began in 1997, 1995 and 1999 respectively.
- Reports of re-use of syringes declined from 33% in 1997 to 21% in 2014, prevalence of receptive syringe sharing declined from 31% in 1995 to 16% in 2014 and reports of receptive sharing of drug preparation equipment declined from 54% in 1999 to 30% in 2014.

HIV antibody prevalence

- HIV antibody prevalence remained low at 2.1% or less in all survey years, with prevalence of 1.7% observed in 2014.
- HIV antibody prevalence was stable over the period 2010 to 2014, except among men, where prevalence increased from 1.3% in 2010 to 2.1% in 2014.
- HIV prevalence was highest among respondents who reported male homosexual identity, with this group comprising between 2% to 5% of annual survey samples. HIV prevalence ranged from 14% in 2000 to 38% in 2009 among this sub-population and was 30% in 2014.
- In 2014, the median age of HIV antibody positive respondents was 44 years and more than half reported last injecting methamphetamine.

HCV antibody prevalence

- HCV antibody prevalence was high, with more than half of ANSPS respondents testing HCV antibody positive in most survey years. HCV antibody prevalence was highest at 60% or greater in 1995 and between 2004 and 2008. HCV antibody prevalence was stable at 53% to 54% in all years over the period 2010 to 2014.
- HCV antibody prevalence was highest among respondents aged 35 years or older and among respondents who initiated injection more than 10 years prior to survey participation.
- Among new initiates, HCV antibody prevalence was highest in the period following changes to heroin markets, with prevalence of 38% in 2002. HCV prevalence subsequently declined to >20%, a finding that supports a decline in HCV incidence in recent years.
- In 2014, the median age of HCV antibody positive respondents was 41 years and prevalence was highest among respondents who reported last injecting opioids (including heroin), with two thirds of this sub-population exposed to HCV.

Testing and treatment uptake

- More than three quarters on ANSPS respondents reported a history of HIV and HCV testing in all survey years. However, the proportion of respondents reporting BBV testing in the previous 12 months declined to around one in two for both HIV and HCV in 2014.
- Among respondents with self-reported and serologically confirmed exposure to HCV infection, the proportion who reported currently receiving hepatitis C antiviral treatment was low at 2% or less in all survey years. Notwithstanding, the proportion of respondents who reported a history of HCV treatment increased over the decade 2005 to 2014, with around one in ten respondents reporting a history of HCV treatment in 2014.
- The proportion of respondents who reported a history of Opioid Substitution Therapy (OST) increased from 55% in 2000 to 63% in 2014. There was a concurrent increase in the proportion of respondents reporting current OST, from 28% in 2000 to 38% in 2014.

1. NATIONAL INTRODUCTION

The Australian Needle and Syringe Program Survey (ANSPS) provides serial point prevalence estimates of exposure to human immunodeficiency virus (HIV) and hepatitis C (HCV) and monitors sexual and injecting behaviour among people who inject drugs (PWID) in Australia. Conducted annually since 1995, Needle and Syringe Programs from all states and territories participate and in 2014, around two thirds of Australia's ~75 primary NSP services participated in the ANSPS. This report presents national and jurisdictional results over the twenty year period, from 1995 to 2014.

The ANSPS is funded by the Australian Government Department of Health and is supported by a National Advisory Group comprising representatives from state and territory Health Departments, Needle and Syringe Programs (NSPs) and Australia's national peak organisation (AIVL) representing jurisdictional drug user organisations. Ethical approvals for the survey were obtained from Institutional Ethics Committees associated with the investigators and participating NSP services.

Over the 20 years since its inception, the ANSPS has resulted in numerous publications, including annual National Data Reports and 17 peer-reviewed publications in scientific journals on a range of topics including HIV and HCV incidence, injection related injury and disease, HCV antiviral treatment, housing stability, access to healthcare and drug trends (see Appendix 1). This contribution to the scientific literature recognises the value of the ANSPS and demonstrates the potential for well-established bio-behavioural surveillance systems to investigate important epidemiological aspects of HIV and HCV infection among PWID. In addition, data from the ANSPS has informed policy and practice, including successive national and jurisdictional HIV and hepatitis C strategies and provides key indicators for the monitoring of the impact of these strategies on public health.

1.1 Design and methodology

The ANSPS consists of a brief self-administered questionnaire and the provision of a capillary dried blood spot (DBS) for HIV and HCV antibody testing. The survey was conducted over a one to two week period in October in all years, with the exception of 1995 and 1996 when the survey was conducted in March and June respectively.


Sample selection

Needle and Syringe Program (NSP) services were initially selected to participate in the ANSPS on the basis of the number of client occasions of service per week, willingness to participate and representation from all jurisdictions. Sample sizes have ranged from 1072 (in 1995) to 2697 (in 2009). Thirty NSP services have participated in 15 or more survey years; including 15 services that have participated each year since 1995 (see Appendix 4). These combined services recruited ~35,000 respondents, comprising more than 75% of the total ~45,000 respondents between 1995 and 2014 (Figure 1.1.1).

Staff at NSP services record the age and gender of both ANSP respondents and non-respondents, as well as whether each individual is a new or repeat client. These records are then used to calculate annual ANSPS response rates, with only one attendance per person included in the response rate denominator. Annual response rates have ranged

from 38% in 2006 to 60% in 1997 (Table 1.1.1). In 2014, around one in four respondents reported participation in the ANSPS in a previous year.

Figure 1.1.1 Survey respondents by site participation and survey year



In 2006, response rate data were used to compare the demographic and drug use characteristics of respondents and non-respondents with a view to assessing the representativeness of the ANSPS survey sample (Topp et al, 2008a). As previously identified (MacDonald et al, 1997), Topp et al reported that females were more likely to agree to participate in the survey than males. Nonetheless, Topp et al concluded that inferences derived from ANSPS samples can be reasonably applied to the broader NSP client population, that repeat respondents are unlikely to exert an undue influence on ANSPS results and that the ANSPS sample is as representative of Australia’s PWID population as practical to obtain.

Data collection and analysis

During the survey period, all NSP attendees are invited to participate in the ANSPS by NSP staff. Verbal, rather than written consent is obtained and participation is anonymous and voluntary. Consenting NSP attendees complete a brief self-administered questionnaire and provide a capillary DBS. In each of the past sixteen years the questionnaire has collected data on demographic characteristics, injecting and sexual behaviours, and history of BBV testing, imprisonment and drug treatment. The survey instrument has undergone minor modification over time (see methodological notes at Appendix 2 for details); however, the core elements and key survey questions have remained the same over the 20 year period. The survey is designed to be self-completed, although assistance for clients is available where necessary (White, Day & Maher, 2007).

Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Completed DBS were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using Genetic Systems HIV-1 ELISA tests. Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France).

A modified third generation enzyme immunoassay (Monalisa anti-HCV Plus Version 2 EIA, Biorad, France) was used to test for HCV antibody. A modified cut-off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut-off ratio was greater than or equal to one on initial and subsequent testing.


Data were analysed using Stata 12 (Stata Corporation, College Station TX). Chi square tests were used to analyse 2014 HIV and hepatitis C virus (HCV) seroprevalence data and to assess temporal seroprevalence trends over 20 and 5 years. Statistical significance was set at $P < 0.05$.

1.2 Demographic characteristics

Two thirds of survey respondents were male in all survey years, with one third female and less than one percent identifying as transgender (Table 1.1.1). The majority of respondents identified as heterosexual (range 76% to 83%), with smaller proportions identifying as bisexual (9% to 12%) or homosexual (3% to 7%). Females comprised a greater proportion of bisexual respondents (66%), while males comprised a greater proportion of respondents identifying as homosexual (58%).

The proportion of Indigenous respondents increased from 5% in 1995 to 14% in 2014 (χ^2 trend $p < 0.001$). The proportion of Indigenous respondents from services participating in all 20 survey years also increased from 5% to 12% (χ^2 trend $p < 0.001$), suggesting that this increase is not attributable to site variation or greater participation of PWID from rural/regional locations. The majority of respondents in all survey years reported being born in Australia (70% to 87%) and that their parents spoke English at home (67% to 95%, data available from 1999). The proportion of respondents that reported their parents spoke a language other than English at home and those born in Asia declined from 2004; however, this is largely attributable to the withdrawal of an NSP site that specifically targeted this group.


Figure 1.2.1 Proportion of younger and older PWID by survey year



Consistent with a nationwide increase in heroin injection, the proportion of young people (those aged less than 25 years) increased between 1995 and 1998, but declined significantly in subsequent years (Figure 1.2.1). There was a concomitant increase in the median age of respondents, from 27 years in 1997 to 39 years in 2014. In 1995 one in ten ANSPS respondents were aged 40 years or older, compared to almost one in two in 2014 (Figure 1.2.1). The median age at first injection remained stable at 18-19 years across all survey years.

In this report, new initiates to injection drug use are defined as PWID who first injected within the 3 years prior to ANSPS participation (0-3 years since first injection). Separate analysis of this group can be used as a proxy to provide information on uptake of injection drug use and incidence of blood borne viral infections. In the 1990s around one in four ANSPS respondents were new initiates to injection drug use, however, by 2004 the number of new initiates declined to less than one in ten (χ^2 trend $p < 0.001$, Figure 1.2.2) and has remained stable at 9%-10% over the period 2010 to 2014 (χ^2 trend $p = 0.705$).

Figure 1.2.2 Proportion of new initiates to injection by survey year




1.3 Injecting behaviour

Drug last injected

During the 1990s, heroin was the most commonly reported drug last injected; reported by more than half of respondents in all years between 1996 and 2000 (Figure 1.3.1, Table 1.1.2). In 2001, coinciding with the well-documented changes to the heroin market in Australia (Maher et al., 2007; Degenhardt, Day, Gilmour, & Hall, 2006; Topp, Day, & Degenhardt, 2003), there was a sudden and dramatic decline in the proportion of respondents who reported heroin as the drug last injected. From 2001, heroin was reported as the drug last injected by approximately one third of respondents. Over the past 10 years (2005-2014) reports of heroin as the last drug injected have remained stable (χ^2 trend $p = 0.832$), although a decline in heroin injection was observed between 2010 and 2014 (from 34% in 2010 to 31% in 2014, χ^2 trend $p = 0.015$).

The proportion of ANSPS respondents who reported last injecting other opioids, including pharmaceutical opioids and opioid substitution therapies (OST), increased over the twenty year period 1995 to 2014 (χ^2 trend $p < 0.001$). The increase was most notable following changes to heroin markets in 2001, however, reports of injection of other opioids significantly declined over the past five years (from 29% in 2010 to 20% in 2014, χ^2 trend $p < 0.001$). In 2014, just over half (51%) of ANSPS respondents reported last injecting heroin or other opioids.

Figure 1.3.1 Heroin, pharmaceutical opioids and OST as the last drug injected by survey year




The proportion of respondents who reported methamphetamine as the last drug injected increased over the twenty year period (χ^2 trend $p < 0.001$), with a notable increase in methamphetamine injection observed in 2001 (Figure 1.3.2). Over the ten year period, 2005 to 2014, methamphetamine injection declined (χ^2 trend $p = 0.012$), although an increase in methamphetamine injection was observed in more recent years, from 26% in 2010 to 33% in 2014 (χ^2 trend $p < 0.001$).

Cocaine was reported as the drug last injected by a minority of ANSPS respondents in all survey years except 2001, when 12% of respondents reported last injecting this drug. Reports of cocaine as the last drug injected declined over the period 2005 to 2014 (χ^2 trend $p < 0.001$) and were stable at 1% of ANSPS respondents over the period 2010 to 2014 (χ^2 trend $p = 0.796$). More than half the reports of cocaine injection occurred in New South Wales (NSW) in all survey years.


Reports of anabolic steroids and other performance and image-enhancing drugs (PIEDs) were low and stable at 1% to 2% of ANSPS respondents in the survey years 1995 to 2009. However, reports of PIEDs as the last drug injected increased over the past five years, from 2% in 2010 to 7% in 2014 (χ^2 trend $p < 0.001$). The majority (>90%) of reports of PIEDs as last drug injected occurred in NSW and Queensland.

Figure 1.3.2 Methamphetamine, cocaine and PIEDs as the last drug injected by survey year



Heroin was the most common drug last injected among new initiates to injection over the period 1996 to 2000, with almost half of new initiates reporting last injecting this drug. In the period following changes to Australia’s heroin markets in 2001, methamphetamine was the drug most commonly injected by new initiates, with almost half of new initiates reporting last injecting methamphetamine over the period 2001 to 2007 (Figure 1.3.3). Reports of injection of other opioids among new initiates also increased over the same period, from 5% in 2001 to 20% in 2009 (χ^2 trend $p < 0.001$). However, in more recent years, reports of injection of opioids (heroin and/or other opioids) have significantly declined among new initiates, from around one in two in 2009 to one in five in 2014 (χ^2 trend $p < 0.001$).

Figure 1.3.3 Drug last injected among new initiates to injection by survey year




Reports of methamphetamine as the last drug injected were stable among new initiates over the five year period 2010 to 2014 (χ^2 trend $p=0.233$), although a notable increase was observed over a shorter time period, from around one in five new initiates reporting last injecting methamphetamine in 2011, to one in three in 2014 (χ^2 trend $p<0.001$). Relatively few new initiates reported last injecting PIEDs between 1995 and 2009, however a significant increase in PIEDs injection was observed among this group between 2009 and 2012 (χ^2 trend $p<0.001$), with this group accounting for 38% of new initiates in 2014 (Figure 1.3.3).

Injection risk behaviour

Reported prevalence of reuse and receptive sharing of syringes and drug preparation equipment declined significantly since collection of these data began in 1997, 1995 and 1999 respectively (Figure 1.3.4). Prevalence of re-use of syringes (including reuse of one's own syringe) declined from 31% in 1997 to 21% in 2014 (χ^2 trend $p<0.001$), although reuse of syringes was stable over the period 2010 to 2014 (χ^2 trend $p=0.647$). Prevalence of the key indicators of BBV risk behaviour, receptive syringe sharing (RSS) halved around from 30% in 1995 to approximately 15% in most years since 2000 (χ^2 trend $p<0.001$), although RSS increased from 12% in 2010 to 16% in 2014 (χ^2 trend $p=0.032$). Receptive sharing of drug preparation equipment declined from 45% in 1999 to 30% in 2014 (χ^2 trend $p<0.001$), although an increase was observed between 2010 (25%) and 2014 (30%, χ^2 trend $p=0.042$). Spoons and water identified as the two most commonly shared drug preparation items in all survey years (Table 1.1.3).

Figure 1.3.4 Re-use of syringes and receptive sharing of syringes and drug preparation equipment by survey year



Data collection on public injection commenced in 1997, and with the exception of the period between 1997 and 2000, the proportion of respondents who reported injection in at least one public location (street, car, public toilet, beach, park or squat) in the month preceding the survey declined significantly over the survey period (χ^2 trend $p<0.001$). In 2000, 57% of ANSPS respondents reported recent public injection, however this proportion declined to 45% of respondents in 2009 and further declined to 36% of respondents in 2014 (χ^2 trend $p=0.007$).

In 1999, 57% of respondents reported procurement of syringes from a pharmacy in the month prior to survey participation. However, procurement of syringes from pharmacies declined significantly in subsequent years, to around 40% of respondents in 2005 and to 20% of respondents in 2014 (χ^2 trend $p < 0.001$), possibly reflecting the increased capacity of the public sector NSP to meet demand for injecting equipment. The proportion of respondents who reported syringe procurement from an NSP in the month prior to ANSPS participation remained stable at 85% to 90% of respondents in all survey years.


1.4 Sexual behaviour

Around half of ANSPS respondents reported having a regular sex partner (Table 1.1.4). Of these, the majority (69% to 74%) did not use condoms with their regular sex partner. Around 15% of respondents reported sex with other partners in the month preceding survey participation. Rates of condom use were higher among those reporting sex with non-regular partners, with between two thirds and three quarters of respondents reporting condom use on some or every occasion. Less than 10% of survey respondents reported sex work in the month prior to survey participation in all years 1995 to 2014. Condom use among with commercial partners was high at between 83% and 96%. Among respondents who reported sex work in the previous month, the proportion of men significantly increased from around one in four ($n=14$, 26%) in 1995 to almost one in two ($n=61$, 46%) in 2014 (χ^2 trend $p=0.036$). Nonetheless, prevalence of sex work was higher among female ANSPS respondents, ranging from 8% in 2013 to 19% in 2000, compared to 2% to 4% among male respondents.

1.5 Imprisonment

The proportion of ANSPS respondents with a history of imprisonment was relatively stable over the period 2002 (when data collection commenced) to 2014, with just under half (range 45% to 50%) of respondents reporting ever being in prison (Figure 1.5.1).

Figure 1.5.1 Prison history and proportion of respondents who reported injecting in prison in the last 12 months by survey year




The proportion of respondents reporting incarceration in the 12 months preceding survey participation halved from around one in five respondents in the period 2000 to 2004, to around one in ten respondents in the period 2010 to 2014 (χ^2 trend $p < 0.001$). Of the respondents who were recently incarcerated, between one third and one half reported injecting in prison, although this proportion declined from a high of 50% in 2004 to 36% in 2014 (χ^2 trend $p < 0.004$, Table 1.1.1).

1.6 Opioid substitution treatment

More than half of ANSPS respondents reported a history of opioid substitution therapy (OST, including methadone, buprenorphine or buprenorphine-naloxone) in all survey years 1995 to 2014, with the proportion increasing significantly from 54% in 2000 to 70% in 2007 (χ^2 trend $p < 0.001$, Figure 1.6.1, Table 1.1.7). Similarly, the proportion of respondents who reported current OST increased from 29% in 2000 to 43% in 2007 (χ^2 trend $p < 0.001$). In 2014, around two in three respondents reported a history of OST and one in three reported current OST. Among ANSPS respondents who reported last injecting opioids in 2014, one in two reported currently receiving OST, likely a reflection on improved access to and coverage of these programs over the past decade.


Figure 1.6.1 Current and history of opioid substitution therapy by survey year



1.7 Testing for blood borne viral infections

A high proportion of ANSPS respondents reported a lifetime history of testing for HCV and HIV in all years from 1995 to 2014, ranging from 77% to 91% and 82% to 90% respectively (Table 1.7.1). The proportion of respondents who reported never having had an HIV test remained relatively stable at between 9% and 14%, while the proportion never undertaking HCV testing declined from 20% in 1995 to 9% in 2014 (χ^2 trend $p < 0.001$). As might be expected with a potentially chronic disease, the proportion of respondents who reported a recent HCV test (last 12 months) significantly declined over the survey period, from 68% in 1997 (when data collection commenced) to 54% in 2014 (χ^2 trend $p < 0.001$). The proportion of respondents reporting a recent HIV test also significantly declined, from 69% in 1995 to 49% in 2014 (χ^2 trend $p < 0.001$, Figure 1.9).


Figure 1.7.1 HCV and HIV testing in the last 12 months by survey year



1.8 Hepatitis C treatment

Among respondents who self-reported HCV infection and where exposure was serologically confirmed, the proportion who reported currently receiving hepatitis C antiviral treatment was low in all survey years (Figure 1.8.1). The proportion of respondents currently receiving HCV treatment increased from <0.5% in 2003 when pegylated interferon and ribavirin became available in Australia, to almost 2% in 2010 (χ^2 trend $p < 0.001$). However, current HCV treatment uptake declined over the period 2010 to 2014 (χ^2 trend $p = 0.046$), most likely due to deferral of treatment in anticipation of the availability of new direct acting antiviral therapies (Iversen et al 2013).

Figure 1.8.1 Current and history of HCV antiviral therapy by survey year



The proportion of ANSPS respondents with self-reported and serologically confirmed exposure to HCV who reported ever receiving HCV antiviral therapy significantly increased over the decade from 2005 to 2014 (χ^2 trend $p < 0.000$), with around one in ten respondents reporting a history of HCV treatment in 2014.

1.9 Blood borne viral infections

HIV antibody prevalence

HIV antibody prevalence was low at 2.1% or less in all survey years (Figure 1.9.1, Table 1.2.1). HIV prevalence was highest among respondents reporting male homosexual identity (Table 1.2.2). This sub-population comprised between 2% and 5% of annual survey samples and HIV prevalence in this group increased from 23% in 1995 to 30% in 2014 (χ^2 trend $p < 0.001$, Figure 1.9.2). Male homosexual identity is the strongest independent correlate of HIV antibody-positive serostatus among ANSPS respondents (Topp et al., 2011). In 2014, the median age of HIV positive respondents was 44 years and more than half (54%) reported last injecting methamphetamine (Table 1.2.4).

Figure 1.9.1 HIV antibody prevalence by survey year






Figure 1.9.2 HIV antibody prevalence by sexual identity, gender and survey year



HCV antibody prevalence


Notwithstanding some minor variation, HCV antibody prevalence among ANSPS respondents was high in all survey years (Figure 1.9.3, Table 1.3.1). HCV prevalence was highest at 60% or more in 1995 and between 2004 and 2008, while prevalence around 50% was observed between 1996 and 1999 and from 2009 to 2014. A similar pattern of HCV antibody prevalence was observed among respondents recruited from the 15 NSP services that participated in all 20 survey years, indicating that site variation was not responsible for fluctuations in prevalence.

Figure 1.9.3 HCV antibody prevalence by survey year




HCV antibody prevalence was higher among respondents with longer injection histories (Figure 1.9.4) and among older respondents (Table 1.3.2). Among new initiates, HCV antibody prevalence was highest in the period following changes to heroin markets, with prevalence of 38% in 2002. HCV prevalence subsequently declined to less than 20%, a finding that supports a decline in HCV incidence in recent years (Iversen et al 2012).

Figure 1.9.4 HCV antibody prevalence by time since first injection and survey year



HCV antibody prevalence varied according to the drug most recently injected (Figure 1.9.5, Table 1.3.3). Prevalence was highest among respondents who reported last injecting opioids, with HCV prevalence ranging between 53% and 83% among people who reported last injecting heroin and between 53% and 83% among people who reported last injecting other opioids (pharmaceutical opioids or OST). HCV antibody prevalence was lower among respondents who reported last injecting methamphetamine in all survey years, although HCV prevalence increased among this sub population, from around 20% in the late 1990s to 48% in 2014 (χ^2 trend $p < 0.001$, Table 1.3.3).

Figure 1.9.5 HCV antibody prevalence by drug last injected and survey year



HCV antibody prevalence was higher among women when compared to men in most survey years, with significant differences observed among respondents with shorter injection histories (Iversen et al., 2010, Figure 1.9.6, Table 1.3.2).

Figure 1.9.6 HCV antibody prevalence among new initiates by gender and survey year




Table 1.1.1 Number (percentage) of respondents by demographic characteristic and year

National	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Number of sites	20	19	23	33	33	36	37	44	47	46
N° surveyed	N=1072	N=1497	N=1978	N=2665	N=2503	N=2694	N=2454	N=2445	N=2495	N=2035
Response rate	41%	54%	60%	42%	45%	50%	46%	42%	45%	50%
Gender (%)										
Male	703 (66)	1003 (67)	1297 (66)	1719 (65)	1616 (65)	1760 (65)	1616 (66)	1618 (66)	1650 (66)	1360 (67)
Female	353 (33)	477 (32)	674 (34)	935 (35)	875 (35)	918 (34)	814 (33)	806 (33)	819 (33)	659 (32)
Transgender	3 (<1)	1 (<1)	6 (<1)	6 (<1)	9 (<1)	10 (<1)	17 (<1)	14 (<1)	16 (<1)	7 (<1)
Not reported	13 (1)	16 (1)	1 (<1)	5 (<1)	3 (<1)	6 (<1)	7 (<1)	7 (<1)	10 (<1)	9 (<1)
Sexual identity (%)										
Heterosexual	848 (79)	1168 (78)	1564 (79)	2158 (81)	1890 (76)	2069 (77)	1893(77)	1858 (76)	1908 (77)	1669 (82)
Bisexual	126 (12)	164 (11)	223 (11)	244 (9)	312 (12)	291 (11)	234 (10)	260 (11)	243 (10)	173 (9)
Homosexual	69 (6)	111 (7)	118 (6)	159 (6)	132 (5)	169 (6)	136 (5)	101 (4)	134 (5)	84 (4)
Not reported	29 (3)	54 (4)	73 (4)	104 (4)	169 (7)	165 (6)	191 (8)	226 (9)	210 (8)	109 (5)
Age and time since first injection (years)										
<i>Median age</i>	29	28	27	28	28	28	29	30	31	32
<i>Age range</i>	14-54	13-59	15-58	14-63	14-69	14-61	14-62	14-63	15-64	16-65
<i>Age group (%)</i>										
≤24 years	323 (30)	515 (24)	719 (36)	950 (36)	815 (33)	847 (31)	688 (28)	615 (25)	512 (21)	389 (19)
25+ years	741 (69)	977 (65)	1258 (64)	1713 (64)	1682 (67)	1842 (68)	1761 (72)	1825 (75)	1978 (79)	1637 (80)
Not reported	8 (<1)	5 (<1)	1 (<1)	2 (<1)	6 (<1)	5 (<1)	5 (<1)	5 (<1)	5 (<1)	9 (<1)
<i>Median age 1st injection</i>	18	18	18	18	18	18	18	18	18	18
<i>Age range</i>	10-48	10-48	10-50	10-47	10-55	10-54	10-53	10-56	10-50	10-56
<i>N° not reported</i>	20	49	42	52	64	72	76	72	82	53
<i>Median years injection</i>	10	8	8	7	8	8	9	10	11	11
<i>Range</i>	<1-33	<1-37	<1-37	<1-40	<1-36	<1-41	<1-44	<1-43	<1-45	<1-46
<i>Time since first injection</i>										
≤3 years	221 (21)	353 (24)	494 (25)	679 (25)	577 (23)	536 (20)	454 (19)	363 (15)	307 (12)	234 (12)
4+ years	827 (77)	1091 (73)	1437 (73)	1931 (72)	1855 (74)	2076 (77)	1912 (78)	2003 (82)	2094 (84)	1739 (85)
Not reported	24 (2)	53 (4)	47 (2)	55 (2)	71 (3)	82 (3)	88 (4)	80 (3)	94 (4)	62 (3)

Table 1.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
National										
Number of sites	48	42	51	53	51	53	52	52	50	51
N° surveyed	N=1800	N=1961	N=1912	N=2270	N=2697	N=2396	N=2395	N=2391	N=2407	N=2378
Response rate	44%	38%	39%	39%	45%	39%	41%	46%	44%	48%
Gender (%)										
Male	1149 (64)	1265 (65)	1241 (65)	1456 (64)	1756 (65)	1611 (67)	1602 (67)	1623 (68)	1636 (68)	1635 (69)
Female	642 (36)	683 (35)	660 (35)	803 (35)	924 (34)	771 (32)	780 (33)	753 (31)	754 (31)	725 (30)
Transgender	8 (<1)	10 (<1)	9 (<1)	6 (<1)	9 (<1)	8 (<1)	10 (<1)	11 (<1)	13 (<1)	16 (<1)
Not reported	1 (<1)	3 (<1)	2 (<1)	5 (<1)	8 (<1)	6 (<1)	3 (<1)	4 (<1)	4 (<1)	2 (<1)
Sexual identity (%)										
Heterosexual	1464 (81)	1611 (82)	1570 (82)	1843 (81)	2236 (83)	1987 (83)	1982 (83)	1949 (82)	1934 (80)	1914 (80)
Bisexual	150 (8)	176 (9)	177 (9)	219 (10)	236 (9)	195 (8)	208 (9)	210 (9)	180 (7)	209 (9)
Homosexual	99 (6)	109 (6)	116 (6)	115 (5)	89 (3)	88 (4)	96 (4)	82 (3)	108 (4)	92 (4)
Not reported	87 (5)	65 (3)	49 (3)	93 (4)	136 (5)	126 (5)	109 (5)	150 (6)	185 (8)	163 (7)
Age and time since first injection (years)										
<i>Median age</i>	34	34	35	36	36	37	37	38	39	39
<i>Age range</i>	15-66	13-68	14-69	16-70	15-66	15-73	16-65	16-71	15-67	14-68
Age group (%)										
≤24 years	259 (14)	237 (12)	183 (10)	208 (9)	285 (11)	203 (8)	182 (8)	176 (7)	181 (8)	143 (6)
25+ years	1536 (85)	1717 (88)	1726 (90)	2056 (91)	2411 (89)	2191 (91)	2205 (92)	2212 (93)	2217 (92)	2226 (94)
Not reported	5 (<1)	7 (<1)	3 (<1)	6 (<1)	1 (<1)	2 (<1)	8 (<1)	3 (<1)	9 (<1)	9 (<1)
<i>Median age 1st injection</i>	18	18	18	18	18	18	18	18	19	18
<i>Age range</i>	10-55	10-52	10-56	10-60	10-58	10-63	10-56	10-70	10-61	10-57
<i>N° not reported</i>	67	71	51	46	67	51	62	67	91	67
<i>Median years injection</i>	13	14	15	15	15	16	17	17	18	19
<i>Range</i>	<1-46	<1-45	<1-49	<1-48	<1-46	<1-60	<1-41	<1-53	<1-51	<1-49
Time since first injection										
≤3 years	148 (8)	150 (8)	135 (7)	178 (8)	210 (8)	165 (7)	220 (9)	225 (9)	227 (9)	208 (9)
4+ years	1584 (88)	1737 (89)	1726 (90)	2043 (90)	2420 (90)	2172 (91)	2110 (88)	2098 (88)	2089 (87)	2097 (88)
Not reported	68 (4)	74 (4)	51 (3)	49 (2)	67 (2)	59 (3)	65 (3)	68 (3)	91 (4)	73 (3)

Table 1.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

National N° surveyed	1995 N=1072	1996 N=1497	1997 N=1978	1998 N=2665	1999 N=2503	2000 N=2694	2001 N=2454	2002 N=2445	2003 N=2495	2004 N=2035
Aboriginal and Torres Strait Islander origin (%)										
No	987 (92)	1333 (89)	1844 (93)	2442 (92)	2237 (90)	2391 (88)	2196 (89)	2183 (89)	2221 (89)	1813 (89)
Yes	52 (5)	66 (4)	101 (5)	167 (6)	182 (7)	233 (9)	188 (8)	183 (8)	203 (8)	165 (8)
Not reported	33 (3)	98 (7)	33 (2)	56 (2)	84 (3)	70 (3)	70 (3)	79 (3)	71 (3)	57 (3)
Region/country of birth (%)										
Australia	--	--	--	--	2201 (88)	1891 (70)	1824 (74)	1955 (80)	2026 (81)	1613 (79)
Other Oceania	--	--	--	--	--	105 (4)	95 (4)	73 (3)	93 (4)	63 (3)
Asia	--	--	--	--	29 (1)	86 (3)	89 (4)	112 (5)	145 (6)	145 (7)
UK & Ireland	--	--	--	--	--	116 (4)	102 (4)	118 (5)	114 (4)	91 (5)
Other	--	--	--	--	161 (6)	91 (4)	93 (4)	101 (4)	91 (4)	83 (4)
Not reported	--	--	--	--	112 (5)	405 (15)	251 (10)	86 (3)	26 (1)	40 (2)
Main language spoken at home by parents (%)										
English	--	--	--	--	2196 (88)	2306 (85)	2059 (84)	2044 (84)	2111 (84)	1354 (67)
Non-English	--	--	--	--	161 (6)	259 (10)	271 (11)	290 (12)	267 (11)	228 (11)
Not reported	--	--	--	--	146 (6)	129 (5)	124 (5)	111 (4)	117 (5)	453 (22)
Imprisonment last year (%)										
No	897 (84)	1261 (84)	1684 (85)	2193 (83)	2070 (83)	2142 (80)	1947 (80)	1992 (81)	2047 (82)	1631 (80)
Yes	159 (15)	181 (12)	285 (14)	439 (16)	397 (16)	486 (18)	424 (17)	407 (17)	406 (16)	373 (18)
Not reported	16 (1)	55 (4)	9 (1)	33 (1)	36 (1)	66 (2)	83 (3)	46 (2)	42 (2)	31 (2)
Injected in prison last year (%)										
N° in prison	N=159	N=181	N=285	N=439	N=397	N=486	N=424	N=407	N=406	N=373
Injected in prison	55 (35)	74 (41)	109 (38)	182 (41)	166 (42)	202 (42)	156 (37)	149 (37)	134 (33)	198 (53)
Frequency of injection last month (%)										
Not last month	80 (7)	103 (7)	139 (7)	150 (6)	174 (7)	171 (6)	223 (9)	225 (9)	226 (9)	145 (7)
Less than weekly	195 (18)	292 (19)	494 (25)	349 (13)	369 (15)	340 (13)	447 (18)	393 (16)	470 (19)	348 (17)
Weekly not daily	352 (33)	490 (33)	311 (16)	632 (24)	550 (22)	599 (22)	607 (25)	581 (24)	610 (24)	530 (26)
Daily or more	438 (41)	601 (40)	1023 (51)	1529 (57)	1388 (55)	1547 (58)	1135 (46)	1221 (50)	1149 (46)	982 (48)
Not reported	7 (1)	11 (1)	11 (1)	5 (<1)	22 (1)	37 (1)	42 (2)	25 (1)	40 (2)	30 (2)

Table 1.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
National										
N° surveyed	N=1800	N=1961	N=1912	N=2270	N=2697	N=2396	N=2395	N=2391	N=2407	N=2378
Aboriginal and Torres Strait Islander origin (%)										
No	1563 (87)	1695 (86)	1663 (87)	1934 (85)	2296 (85)	2071 (86)	2065 (86)	2056 (86)	2003 (83)	2010 (85)
Yes	185 (10)	203 (10)	203 (11)	250 (11)	323 (12)	275 (11)	276 (12)	294 (12)	324 (13)	321 (14)
Not reported	52 (3)	63 (3)	46 (2)	86 (4)	78 (3)	50 (2)	54 (2)	41 (2)	80 (3)	47 (2)
Region/country of birth (%)										
Australia	1551 (86)	1668 (85)	1649 (86)	1918 (84)	2333 (87)	2088 (87)	2046 (85)	2070 (87)	2070 (86)	2021 (85)
Other Oceania	54 (3)	62 (3)	46 (2)	83 (4)	85 (3)	76 (3)	80 (3)	86 (4)	74 (3)	89 (4)
Asia	14 (1)	17 (<1)	22 (1)	32 (1)	25 (1)	29 (1)	31 (1)	26 (1)	35 (1)	40 (2)
UK & Ireland	95 (5)	105 (5)	85 (4)	125 (6)	120 (4)	94 (4)	111 (5)	105 (4)	108 (4)	100 (4)
Other	72 (4)	73 (4)	72 (4)	68 (3)	89 (3)	69 (3)	101 (4)	85 (4)	109 (5)	107 (5)
Not reported	14 (1)	36 (2)	38 (2)	44 (2)	45 (2)	40 (2)	26 (1)	19 (<1)	11 (<1)	21 (<1)
Main language spoken at home by parents (%)										
English	1543 (85)	1735 (88)	1778 (93)	2128 (94)	2548 (94)	2275 (95)	2237 (93)	2252 (94)	2239 (93)	2195 (92)
Non-English	105 (6)	121 (6)	102 (5)	109 (5)	113 (4)	90 (4)	134 (6)	129 (5)	159 (7)	165 (7)
Not reported	161 (9)	105 (5)	32 (2)	33 (1)	36 (1)	31 (1)	24 (1)	10 (<1)	9 (<1)	18 (<1)
Imprisonment last year (%)										
No	1477 (82)	1622 (83)	1569 (82)	1812 (80)	2238 (83)	1762 (74)	2049 (86)	2037 (85)	1990 (83)	1947 (82)
Yes	252 (14)	247 (13)	254 (13)	287 (13)	339 (13)	226 (9)	238 (10)	261 (11)	252 (10)	254 (11)
Not reported	71 (4)	92 (5)	89 (5)	171 (8)	120 (4)	408 (17)	108 (5)	93 (4)	165 (7)	177 (7)
Injected in prison last year (%)										
N° in prison	N=252	N=247	N=254	N=287	N=339	N=226	N=238	N=261	N=252	N=254
Injected in prison	87 (35)	90 (36)	95 (37)	96 (33)	113 (33)	69 (31)	75 (32)	90 (34)	74 (29)	91 (36)
Frequency of injection last month (%)										
Not last month	160 (9)	182 (9)	155 (8)	230 (10)	270 (10)	259 (11)	250 (10)	235 (10)	223 (9)	206 (9)
Less than weekly	297 (17)	368 (19)	337 (18)	343 (15)	418 (15)	423 (18)	387 (16)	444 (19)	451 (19)	364 (15)
Weekly not daily	458 (25)	476 (24)	484 (25)	576 (25)	618 (23)	563 (24)	563 (24)	554 (23)	590 (25)	617 (26)
Daily or more	879 (49)	919 (47)	900 (47)	1099 (48)	1361 (50)	1119 (47)	1159 (48)	1130 (47)	1070 (44)	1160 (49)
Not reported	6 (<1)	16 (<1)	36 (2)	22 (1)	30 (1)	32 (1)	36 (2)	28 (1)	73 (3)	31 (1)
Experienced overdose in the previous 12 months										
Yes	--	--	--	--	--	--	--	--	279 (12)	367 (15)

Table 1.1.2 Number (percentage) of respondents by drug last injected and year

National N° surveyed	1995 N=1072	1996 N=1497	1997 N=1978	1998 N=2665	1999 N=2503	2000 N=2694	2001 N=2454	2002 N=2445	2003 N=2495	2004 N=2035
Drug last injected (%)										
Cocaine	18 (2)	33 (2)	37 (2)	65 (2)	60 (2)	107 (4)	164 (7)	29 (1)	26 (1)	52 (2)
Methamphetamine	233 (22)	278 (18)	367 (18)	570 (21)	647 (26)	583 (22)	914(37)	809 (33)	831 (33)	665 (33)
Heroin	470 (44)	796 (53)	1090 (55)	1369 (51)	1333 (53)	1517 (56)	745 (30)	881 (36)	902 (36)	738 (36)
Pharm. opioids	29 (3)	41 (3)	77 (4)	116 (4)	95 (4)	97 (4)	151 (6)	180 (7)	213 (9)	164 (8)
Methadone	204 (19)	169 (11)	211 (11)	220 (8)	84 (3)	94 (3)	127 (5)	165 (7)	154 (6)	135 (7)
Buprenorphine	--	--	--	--	--	--	--	25 (1)	14 (<1)	42 (2)
Buprenorphine/naloxone	--	--	--	--	--	--	--	--	--	--
PIEDs	11 (1)	30 (2)	34 (2)	30 (1)	40 (2)	43 (2)	31 (1)	47 (2)	52 (2)	25 (1)
More than one	92 (9)	129 (9)	135 (7)	266 (10)	199 (8)	199 (7)	258(11)	246 (10)	178 (7)	136 (7)
Other	9 (1)	16 (1)	16 (1)	14 (1)	12 (<1)	14 (1)	26 (1)	30 (1)	78 (3)	27 (2)
Not reported	6 (1)	5 (<1)	11 (1)	15 (1)	33 (1)	40 (1)	38 (2)	33 (1)	47 (2)	51 (2)

National N° surveyed	2005 N=1800	2006 N=1961	2007 N=1912	2008 N=2270	2009 N= 2697	2010 N=2396	2011 N=2395	2012 N=2391	2013 N=2407	2014 N=2378
Drug last injected (%)										
Cocaine	53 (3)	44 (2)	33 (2)	53 (2)	66 (2)	31 (1)	23 (1)	21 (1)	31 (1)	29 (1)
Methamphetamine	573 (32)	737 (38)	574 (30)	645 (28)	657 (24)	628 (26)	649 (27)	621 (26)	703 (29)	779 (33)
Heroin	618 (34)	510 (26)	593 (31)	781 (34)	917 (34)	808 (34)	802 (33)	799 (33)	709 (29)	727 (31)
Pharm. opioids	158 (9)	236 (12)	268 (14)	345 (15)	426 (16)	382 (16)	358 (15)	341 (14)	332 (14)	252 (11)
Methadone	166 (9)	180 (9)	187 (10)	192 (8)	232 (9)	177 (7)	173 (7)	159 (7)	163 (7)	139 (6)
Buprenorphine	56 (3)	101 (5)	99 (5)	104 (5)	134 (5)	100 (4)	94 (4)	84 (4)	78 (3)	53 (2)
Buprenorphine/naloxone	--	--	--	--	35 (1)	46 (2)	43 (2)	46 (2)	46 (2)	42 (2)
PIEDs	29 (1)	36 (2)	20 (1)	35 (2)	43 (2)	57 (2)	109 (5)	162 (7)	157 (7)	156 (7)
More than one	40 (2)	36 (2)	53 (3)	53 (2)	86 (3)	118 (5)	106 (4)	121 (5)	156 (6)	128 (5)
Other	39 (2)	32 (2)	51 (3)	21 (1)	34 (1)	37 (2)	33 (1)	22 (1)	19 (1)	62 (3)
Not reported	68 (4)	49 (3)	34 (2)	41 (2)	67 (2)	12 (<1)	5 (<1)	15 (1)	13 (1)	11 (<1)

Table 1.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
National										
N° injected last month	N=985	N=1383	N=1828	N=2510	N=2307	N=2486	N=2189	N=2194	N=2229	N=1860
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	--	--	--	--	926 (40)	821 (33)	626 (29)	594 (27)	628 (28)	507 (27)
Water	--	--	--	--	651 (28)	550 (22)	457 (21)	479 (21)	460 (21)	400 (22)
Filter	--	--	--	--	525 (23)	455 (18)	348 (16)	393 (18)	368 (17)	299 (16)
Drug mix	--	--	--	--	425 (18)	341 (14)	303 (14)	344 (16)	292 (13)	224 (12)
None	--	--	--	--	--	--	--	--	--	--
Public injecting in last month (%)										
Any public	--	--	814 (45)	1228 (49)	1258 (55)	1426 (57)	1068 (49)	1116 (51)	1027 (46)	826 (44)
All private	--	--	942 (52)	1173 (47)	909 (39)	922 (37)	1120 (51)	996 (45)	1122 (50)	918 (49)
Not reported	--	--	72 (4)	109 (4)	140 (6)	138 (6)	1 (<1)	83 (4)	80 (4)	116 (6)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	--	--	--	--	2173 (87)	2341 (87)	2064 (84)	2055 (84)	2080 (83)	1730 (85)
Pharmacy	--	--	--	--	1418 (57)	1467 (54)	1224 (50)	1181 (48)	1104 (44)	935 (46)
National										
N° injected last month	N=1622	N=1763	N=1721	N=2018	N=2397	N=2109	N=2109	N=2128	N=2111	N=2141
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	365 (23)	351 (20)	379 (24)	436 (24)	541 (25)	446 (21)	481 (22)	450 (21)	511 (24)	460 (21)
Water	293 (18)	255 (15)	274 (17)	314 (17)	358 (16)	316 (15)	310 (15)	311 (15)	373 (18)	362 (17)
Filter	201 (12)	173 (10)	208 (13)	219 (12)	273 (12)	212 (10)	222 (11)	226 (11)	241 (11)	223 (10)
Drug mix	192 (12)	140 (8)	136 (9)	155 (8)	202 (9)	177 (8)	174 (8)	190 (9)	189 (9)	177 (8)
None	--	1064 (62)	1024 (65)	1181 (64)	1409 (64)	1319 (63)	1387 (66)	1421 (67)	1436 (68)	1477 (69)
Public injecting in last month (%)										
Any public	698 (43)	761 (43)	799 (46)	886 (44)	1079 (45)	887 (42)	882 (42)	836 (39)	828 (39)	781 (36)
All private	796 (49)	922 (52)	881 (51)	1104 (55)	1298 (54)	1069 (51)	1154 (55)	1222 (57)	1262 (60)	1346 (63)
Not reported	120 (8)	80 (5)	41 (2)	28 (1)	20 (<1)	153 (7)	73 (3)	70 (3)	21 (1)	14 (<1)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	1559 (87)	1657 (85)	1285 (67)	1879 (83)	1569 (65)	2063 (86)	1917 (91)	1888 (89)	1952 (92)	1916 (89)
Pharmacy	691 (38)	850 (43)	387 (20)	876 (39)	601 (25)	450 (19)	415 (20)	503 (24)	436 (21)	456 (21)

Table 1.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

National N° injected last month	1995 N=985	1996 N=1383	1997 N=1828	1998 N=2510	1999 N=2307	2000 N=2486	2001 N=2189	2002 N=2194	2003 N=2229	2004 N=1860
Use of sterile needles and syringes last month (%)										
All injections	--	--	1215 (66)	1628 (65)	1530 (66)	1688 (67)	1568 (72)	1591 (72)	1671 (75)	1328 (71)
Most of the time	--	--	494 (27)	640 (26)	600 (26)	610 (24)	492 (22)	466 (21)	447 (20)	411 (22)
Half of the time	--	--	38 (2)	86 (3)	75 (3)	71 (3)	41 (2)	57 (3)	43 (2)	39 (2)
Some of the time	--	--	21 (1)	84 (3)	27 (1)	38 (2)	30 (1)	28 (1)	32 (1)	36 (2)
Not last month	--	--	11 (1)	7 (<1)	8 (<1)	13 (1)	9 (<1)	17 (1)	7 (<1)	11 (1)
Not reported	--	--	49 (3)	65 (3)	67 (3)	66 (3)	49 (2)	35 (2)	29 (1)	35 (2)
Re-used someone else's used needle & syringe last month (%)										
None	677 (69)	1001 (72)	1485 (81)	2010 (80)	1734 (75)	1986 (80)	1776 (81)	1767 (80)	1848 (83)	1473 (79)
Once	101 (10)	155 (11)	76 (4)	151 (6)	165 (7)	155 (6)	122 (6)	112 (5)	121 (5)	113 (6)
Twice	101 (10)	116 (8)	72 (4)	126 (5)	107 (5)	113 (5)	77 (3)	102 (5)	73 (3)	92 (5)
3-5 times	71 (7)	64 (5)	70 (4)	98 (4)	94 (4)	88 (4)	69 (3)	74 (3)	77 (3)	83 (5)
>5 times	34 (3)	44 (3)	42 (2)	62 (2)	75 (3)	55 (2)	60 (3)	56 (3)	49 (2)	45 (2)
Not reported	1 (<1)	3 (<1)	83 (5)	63 (3)	132 (6)	89 (3)	85 (4)	83 (4)	61 (3)	54 (3)
Number of people needle & syringe was re-used after last month (%)										
None	677 (69)	1001 (72)	1485 (81)	2010 (80)	1734 (75)	1986 (80)	1777 (81)	1767 (80)	1793 (80)	1473 (79)
One	187 (19)	242 (18)	255 (14)	354 (14)	360 (16)	315 (13)	190 (9)	209 (10)	216 (10)	168 (9)
Two	87 (9)	121 (9)	32 (2)	54 (2)	46 (2)	34 (1)	28 (1)	32 (2)	28 (1)	31 (2)
Three to five	12 (1)	6 (<1)	8 (<1)	14 (1)	31 (1)	30 (1)	20 (1)	18 (<1)	17 (<1)	14 (1)
More than five	12 (1)	10 (1)	7 (<1)	10 (<1)	32 (1)	24 (1)	20 (1)	18 (<1)	12 (<1)	9 (1)
Don't know	9 (1)	2 (<1)	0 (0)	5 (<1)	21 (1)	14 (1)	31 (1)	38 (2)	47 (2)	44 (2)
Not reported	1 (<1)	1 (<1)	41 (2)	63 (3)	83 (4)	83 (3)	123 (6)	112 (5)	116 (5)	121 (6)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	--	--	175 (10)	255 (10)	271 (12)	226 (9)	177 (8)	157 (7)	165 (7)	122 (7)
Casual sex partner	--	--	12 (1)	24 (1)	24 (1)	26 (1)	25 (1)	20 (1)	26 (1)	17 (1)
Close friend	--	--	72 (4)	135 (5)	155 (7)	124 (5)	93 (4)	99 (5)	93 (4)	81 (4)
Acquaintance	--	--	24 (1)	42 (2)	52 (2)	54 (2)	49 (2)	34 (2)	44 (2)	36 (2)
Other	--	--	1 (<1)	4 (<1)	33 (1)	24 (1)	14 (1)	20 (1)	9 (<1)	16 (1)

Table 1.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

National	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
N° injected last month	N=1622	N=1763	N=1721	N=2018	N=2397	N=2109	N=2109	N=2128	N=2111	N=2141
Use of sterile needles and syringes last month (%)										
All injections	1183 (73)	1262 (72)	1234 (72)	1429 (71)	1783 (74)	1477 (70)	1569 (74)	1593 (75)	1586 (75)	1657 (77)
Most of the time	360 (22)	371 (21)	374 (22)	475 (24)	503 (21)	398 (19)	383 (18)	366 (17)	420 (20)	381 (18)
Half of the time	36 (2)	47 (3)	41 (2)	48 (2)	39 (2)	38 (2)	41 (2)	36 (2)	34 (2)	33 (2)
Some of the time	18 (1)	24 (1)	25 (1)	28 (1)	35 (1)	28 (1)	26 (1)	21 (1)	31 (1)	20 (1)
Not last month	4 (0)	17 (<1)	3 (<1)	13 (<1)	8 (<1)	8 (<1)	4 (<1)	15 (<1)	9 (<1)	8 (<1)
Not reported	21 (1)	42 (2)	44 (3)	25 (1)	29 (1)	160 (8)	86 (4)	97 (5)	31 (1)	42 (2)
Re-used someone else's used needle & syringe last month (%)										
None	1344 (83)	1432 (81)	1381 (80)	1640 (81)	1963 (82)	1595 (76)	1663 (79)	1713 (81)	1770 (84)	1772 (83)
Once	60 (4)	88 (5)	104 (6)	108 (5)	124 (5)	87 (4)	104 (5)	148 (7)	105 (5)	129 (6)
Twice	57 (4)	64 (4)	53 (3)	101 (5)	93 (4)	70 (3)	80 (4)	60 (3)	79 (4)	84 (4)
3-5 times	55 (3)	62 (4)	70 (4)	70 (3)	86 (4)	58 (3)	74 (4)	61 (3)	63 (3)	71 (3)
>5 times	37 (2)	47 (3)	36 (2)	55 (3)	73 (3)	47 (2)	58 (3)	67 (3)	67 (3)	48 (2)
Not reported	73 (4)	70 (4)	77 (4)	44 (2)	58 (2)	252 (12)	130 (6)	79 (4)	27 (1)	37 (2)
Number of people needle & syringe was re-used after last month (%)										
None	1344 (78)	1432 (81)	1381 (80)	1640 (81)	1963 (82)	1595 (76)	1663 (79)	1713 (81)	1770 (84)	1772 (83)
One	116 (7)	129 (7)	125 (7)	169 (8)	185 (8)	127 (6)	166 (8)	158 (7)	139 (7)	136 (6)
Two	10 (1)	19 (1)	22 (1)	19 (<1)	26 (1)	21 (1)	23 (1)	23 (1)	31 (1)	27 (1)
Three to five	9 (1)	8 (<1)	14 (<1)	17 (<1)	15 (<1)	25 (1)	14 (<1)	11 (<1)	13 (1)	12 (<1)
More than five	10 (1)	11 (<1)	8 (<1)	7 (<1)	10 (<1)	19 (1)	14 (<1)	22 (1)	19 (1)	18 (1)
Don't know	36 (2)	46 (3)	43 (3)	71 (4)	58 (2)	41 (2)	64 (3)	48 (2)	69 (3)	60 (3)
Not reported	97 (6)	118 (7)	128 (7)	95 (5)	140 (6)	281 (13)	165 (8)	153 (7)	70 (3)	116 (5)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	137 (8)	104 (6)	119 (7)	136 (7)	151 (6)	177 (8)	196 (9)	113 (5)	131 (6)	132 (6)
Casual sex partner	6 (<1)	14 (<1)	12 (<1)	12 (<1)	4 (<1)	16 (<1)	9 (<1)	8 (<1)	19 (1)	10 (<1)
Close friend	66 (4)	57 (3)	64 (4)	84 (4)	86 (4)	105 (5)	125 (6)	96 (5)	88 (4)	62 (3)
Acquaintance	31 (2)	26 (1)	23 (1)	29 (1)	32 (1)	38 (2)	59 (3)	44 (2)	54 (3)	36 (2)
Other	13 (1)	10 (<1)	16 (1)	21 (1)	29 (1)	38 (2)	48 (2)	21 (1)	32 (2)	26 (1)

Table 1.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

National N° surveyed	1995 N=1072	1996 N=1497	1997 N=1978	1998 N=2665	1999 N=2503	2000 N=2694	2001 N=2454	2002 N=2445	2003 N=2495	2004 N=2035
Sex last month (%)										
No	260 (24)	397 (27)	680 (34)	831 (31)	783 (31)	898 (33)	714 (29)	682 (28)	531 (21)	618 (30)
Yes	762 (71)	1070 (71)	1289 (65)	1807 (68)	1687 (68)	1763 (66)	1696 (69)	1706 (70)	1916 (77)	1368 (67)
Not reported	50 (5)	30 (2)	9 (1)	27 (1)	33 (1)	33 (1)	44 (2)	57 (2)	48 (2)	49 (3)
Condom use at last sex (%)										
No	602 (56)	689 (46)	1251 (64)	1691 (63)	1548 (62)	1638 (61)	1561 (64)	1577 (65)	1677 (67)	1382 (68)
Yes	281 (26)	351 (23)	699 (35)	904 (34)	879 (35)	964 (36)	797 (32)	813 (33)	756 (30)	601 (29)
Not reported	189 (18)	457 (31)	28 (1)	70 (3)	76 (3)	92 (3)	96 (4)	55 (2)	62 (3)	52 (3)
Condom use with regular sex partner(s) last month (%)										
No	--	629 (66)	782 (66)	965 (65)	971 (68)	970 (66)	747 (65)	721 (64)	758 (66)	626 (68)
Sometimes	--	115 (12)	160 (14)	193 (13)	164 (11)	164 (11)	174 (15)	144 (13)	136 (12)	114 (12)
Always	--	209 (22)	243 (20)	320 (22)	301 (21)	338 (23)	235 (20)	266 (24)	259 (22)	183 (20)
Condom use with new sex partner(s) last month (%)										
No	--	130 (33)	175 (32)	141 (33)	238 (39)	192 (32)	380 (42)	356 (42)	338 (45)	300 (46)
Sometimes	--	42 (11)	68 (13)	65 (15)	74 (12)	80 (14)	153 (17)	128 (15)	117 (15)	107 (17)
Always	--	219 (56)	294 (55)	220 (52)	295 (49)	317 (54)	369 (41)	361 (43)	304 (40)	239 (37)
Condom use with casual sex partner(s) last month (%)										
No	--	--	--	188 (31)	260 (36)	257 (34)	323 (42)	321 (41)	317 (45)	260 (45)
Sometimes	--	--	--	104 (17)	110 (15)	113 (15)	141 (18)	142 (18)	107 (15)	106 (19)
Always	--	--	--	314 (52)	353 (49)	392 (51)	305 (40)	314 (40)	274 (39)	208 (36)
Sex work last month (%)										
No	979 (91)	1321 (88)	1781 (90)	2435 (92)	2216 (89)	2356 (87)	2130 (87)	2171 (89)	2230 (89)	1808 (89)
Yes	54 (5)	104 (7)	155 (8)	167 (6)	221 (9)	258 (10)	224 (9)	201 (8)	183 (7)	172 (8)
Not reported	39 (4)	72 (5)	42 (2)	63 (2)	66 (3)	80 (3)	100 (4)	73 (3)	82 (3)	55 (3)
Condom used at last sex work (%)										
Yes	46 (96)	90 (89)	119 (89)	138 (91)	185 (92)	204 (95)	161 (90)	153 (89)	148 (89)	149 (90)

Table 1.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

National	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
N° surveyed	N=1800	N=1961	N=1912	N=2270	N= 2697	N=2396	N=2395	N=2391	N=2407	N=2378
Sex with a regular partner last month (%)										
No	800 (44)	831 (42)	813 (43)	1015 (45)	1215 (45)	1082 (45)	1105 (46)	1173 (49)	1176 (49)	1166 (49)
Yes	966 (54)	1074 (55)	1026 (54)	1190 (52)	1382 (51)	1210 (51)	1133 (47)	1152 (48)	1151 (48)	1114 (47)
Not reported	34 (2)	56 (3)	73 (4)	65 (3)	100 (4)	104 (4)	157 (7)	66 (3)	80 (3)	98 (4)
Condom used with regular partner last month (%)										
Never	N=966	N=1074	N=1026	N=1190	N=1382	N=1210	N=1133	N=1152	N=1151	N=1114
Sometimes	686 (71)	750 (70)	756 (74)	828 (70)	999 (72)	840 (69)	800 (71)	815 (71)	801 (70)	800 (72)
Every time	133 (14)	150 (14)	131 (13)	144 (12)	179 (13)	154 (13)	133 (12)	147 (13)	166 (14)	145 (13)
Not reported	103 (11)	96 (9)	103 (10)	154 (13)	135 (10)	145 (12)	141 (12)	127 (11)	113 (10)	110 (10)
	44 (5)	78 (7)	36 (4)	64 (5)	69 (5)	71 (6)	59 (5)	63 (5)	71 (6)	59 (5)
Sex with other partner(s) last month (%)										
No	1461 (81)	1569 (80)	1562 (82)	1838 (81)	2186 (81)	1923 (80)	1966 (82)	1953 (82)	1929 (80)	1895 (80)
Yes	296 (16)	296 (15)	279 (15)	345 (15)	378 (14)	327 (14)	330 (14)	336 (14)	364 (15)	357 (15)
Not reported	43 (2)	96 (5)	71 (4)	87 (4)	133 (5)	146 (6)	99 (4)	102 (4)	114 (5)	126 (5)
Condom used with other partner(s) last month (%)										
Never	N=296	N=296	N=279	N=345	N=378	N=327	N=330	N=336	N=364	N=357
Sometimes	74 (25)	77 (26)	91 (33)	85 (25)	129 (34)	116 (35)	108 (33)	115 (34)	117 (32)	118 (33)
Every time	76 (26)	74 (25)	69 (25)	101 (29)	96 (25)	72 (22)	80 (24)	92 (27)	103 (28)	98 (27)
Not reported	135 (46)	127 (43)	105 (38)	143 (41)	148 (39)	124 (38)	127 (38)	109 (32)	128 (35)	101 (28)
	11 (4)	18 (6)	14 (5)	16 (5)	5 (1)	15 (5)	15 (5)	20 (6)	16 (4)	40 (11)
Sex work last month (%)										
No	1653 (92)	1736 (89)	1721 (90)	1991 (88)	2458 (91)	2092 (87)	2169 (91)	2195 (92)	2141 (89)	2050 (86)
Yes	108 (6)	125 (6)	115 (6)	139 (6)	130 (5)	128 (5)	114 (5)	119 (5)	98 (4)	133 (6)
Not reported	39 (2)	100 (5)	76 (4)	140 (6)	109 (4)	176 (7)	112 (5)	77 (3)	168 (7)	195 (8)
Condom used at last sex work (%)										
Yes	204 (95)	101 (86)	92 (87)	105 (83)	106 (84)	95 (78)	88 (85)	98 (84)	72 (83)	83 (69)

Table 1.1.5 Number (percentage) of respondents by testing for HIV and HCV infection by year

National N° surveyed	1995 N=1072	1996 N=1497	1997 N=1978	1998 N=2665	1999 N=2503	2000 N=2694	2001 N=2454	2002 N=2445	2003 N=2495	2004 N=2035
Previous HIV test (%)										
Yes, ever	962 (90)	1317 (88)	1747 (88)	2301 (86)	2145 (86)	2343 (87)	2113 (86)	2145 (88)	2213 (89)	1783 (88)
Yes, last year	737 (69)	1029 (69)	1358 (68)	1818 (68)	1590 (64)	1770 (66)	1509 (61)	1596 (65)	1562 (63)	1223 (60)
>1 year ago	225 (21)	288 (19)	389 (20)	575 (22)	555 (22)	573 (21)	604 (25)	549 (23)	651 (26)	560 (28)
Never tested	97 (9)	176 (12)	219 (11)	347 (13)	329 (13)	325 (12)	304 (12)	274 (11)	256 (10)	214 (10)
Not reported	13 (1)	4 (<1)	12(1)	17(1)	29(1)	26(1)	37(2)	26(1)	26(1)	38(2)
Previous HCV test (%)										
Yes, ever	825 (77)	1200 (80)	1672 (84)	2207 (83)	2124 (85)	2377 (88)	2160 (88)	2138 (87)	2188 (88)	1814 (89)
Yes, last year	--	--	1347 (68)	1730 (65)	1613 (65)	1869 (69)	1601 (65)	1612 (65)	1590 (64)	1287 (63)
>1 year ago	--	--	325 (16)	477 (18)	511 (20)	508 (19)	559 (23)	526 (22)	598 (24)	527 (26)
Never tested	220 (20)	272 (18)	291 (15)	440 (16)	350 (14)	286 (11)	260 (11)	283 (13)	285 (11)	191 (9)
Not reported	27 (3)	25 (2)	15 (1)	18 (1)	29 (1)	31 (1)	34 (1)	24 (1)	22 (1)	30 (2)
Previous HIV test (%)										
National N° surveyed										
2005 N=1800										
2006 N=1961										
2007 N=1912										
2008 N=2270										
2009 N=2697										
2010 N=2396										
2011 N=2395										
2012 N=2391										
2013 N=2407										
2014 N=2378										
Previous HIV test (%)										
Yes, ever	1599 (89)	1735 (89)	1694 (88)	1942 (86)	2282 (84)	1960 (82)	2021 (84)	1997 (83)	2017 (84)	1951 (82)
Yes, last year	1035 (58)	1117 (57)	1077 (56)	1124 (50)	1360 (50)	1141 (48)	1172 (49)	1157 (48)	1205 (50)	1170 (49)
>1 year ago	564 (31)	618 (32)	617 (32)	818 (36)	922 (34)	819 (34)	849 (35)	840 (35)	812 (34)	781 (33)
Never tested	191 (11)	187 (10)	187 (10)	215 (9)	310 (11)	282 (12)	287 (12)	299 (13)	320 (13)	332 (14)
Not reported	10(1)	39(2)	31(2)	113 (5)	105 (4)	154 (6)	87 (4)	95 (4)	70 (3)	95 (4)
Previous HCV test (%)										
Yes, ever	1610 (90)	1755 (90)	1743 (91)	2026 (89)	2404 (89)	2030 (87)	2083 (87)	2086 (88)	2013 (83)	2047 (86)
Yes, last year	1089 (61)	1176 (60)	1147 (60)	1257 (55)	1549 (57)	1280 (53)	1289 (54)	1305 (55)	1235 (51)	1276 (54)
>1 year ago	521 (29)	579 (30)	596 (31)	769 (34)	855 (32)	750 (31)	794 (33)	781 (33)	778 (32)	771 (32)
Never tested	179 (10)	166 (8)	141 (7)	154 (7)	196 (7)	190 (8)	169 (7)	181 (8)	196 (8)	214 (9)
Not reported	11 (1)	40(2)	28 (1)	90 (4)	97 (4)	176 (7)	143 (6)	124 (5)	198 (8)	117 (5)

Table 1.1.6 Number (percentage) of respondents by HCV treatment by year

	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
National										
Self-report HCV diagnosis	--	--	--	--	N=930	N=1105	N=1000	N=1072	N=1110	N=931
Any treatment for HCV (%)										
Interferon+/Ribavirin	--	--	--	--	25 (3)	46 (4)	38 (4)	44 (4)	46 (4)	51 (5)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	35 (4)	33 (3)	30 (3)	36 (3)	32 (3)	27 (3)
No treatment	--	--	--	--	854 (91)	1003 (91)	910 (91)	965 (90)	1006 (91)	824 (89)
Not reported	--	--	--	--	16 (2)	23 (2)	22 (2)	27 (3)	26 (2)	29 (3)
Current treatment for HCV (%)					N=20	N=27	N=21	N=10	N=19	N=21
Interferon +/- Ribavirin	--	--	--	--	5	7	8	3	7	12
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	15	20	13	7	12	9

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
National										
Self-report HCV diagnosis	N=826	N=894	N=848	N=1203	N=1383	N=1274	N=1267	N=1269	N=1230	N=1194
Any treatment for HCV (%)										
Interferon+/or Ribavirin	39 (5)	50 (6)	43 (5)	107 (9)	126 (9)	136 (11)	121 (10)	122 (10)	129 (10)	146 (12)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	11 (1)	14 (1)
Other	20 (2)	18 (2)	17 (2)	21 (2)	17 (1)	17 (1)	18 (1)	14 (1)	16 (1)	18 (2)
No treatment	759 (92)	791 (88)	747 (88)	1039 (86)	1174 (85)	1072 (84)	1054 (83)	1078 (85)	1017 (83)	956 (80)
Not reported	8 (1)	35 (4)	41 (5)	36 (3)	66 (5)	49 (4)	74 (6)	55 (4)	57 (5)	39 (3)
Current treatment for HCV (%)	N=20	N=21	N=15	N=27	N=25	N=32	N=36	N=27	N=39	N=31
Interferon +/- Ribavirin	11	11	6	18	21	26	28	18	24	13
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	9	8
Other	9	10	9	9	4	6	8	9	6	10

Table 1.1.7 Number (percentage) of respondents by drug treatment by year

National N° surveyed	1995 N=1072	1996 N=1497	1997 N=1978	1998 N=2665	1999 N=2503	2000 N=2694	2001 N=2454	2002 N=2445	2003 N=2495	2004 N=2035
Ever any treatment/therapy for drug use (%)										
No	333 (31)	498 (33)	619 (31)	912 (34)	880 (35)	812 (30)	783 (32)	721 (29)	838 (34)	421 (21)
Yes	734 (68)	990 (66)	1354 (68)	1745 (65)	1606 (64)	1831 (68)	1651 (67)	1700 (70)	1647 (66)	1552 (76)
Not reported	5 (1)	9 (1)	5 (1)	8 (1)	17 (1)	51 (2)	20 (1)	20 (1)	10 (<1)	62 (3)
History of methadone maintenance treatment (%)										
Current	426 (40)	528 (35)	666 (34)	828 (31)	699 (28)	710 (26)	649 (26)	648 (27)	725 (29)	621 (31)
Previous	170 (16)	273 (18)	369 (19)	485 (18)	518 (21)	675 (25)	586 (24)	636 (26)	617 (25)	467 (23)
Never	471 (44)	687 (46)	938 (47)	1344 (50)	1272 (51)	1292 (48)	1192 (49)	1130 (46)	1139 (46)	842 (41)
Not reported	5 (<1)	9 (1)	5 (<1)	8 (1)	12 (<1)	17 (1)	27 (1)	30 (1)	14 (<1)	105 (5)
History of other pharmacotherapy treatment (%)										
Current	--	--	--	--	--	62 (2)	116 (5)	206 (8)	288 (12)	297 (15)
Previous	--	--	--	--	--	289 (11)	246 (10)	312 (13)	432 (17)	377 (18)
Never	--	--	--	--	--	2084 (77)	2035 (83)	1875 (77)	1731 (69)	1294 (64)
Not reported	--	--	--	--	--	258 (10)	57 (2)	51 (2)	44 (2)	67 (3)
National N° surveyed										
2005 N=1800										
2006 N=1961										
2007 N=1912										
2008 N=2270										
2009 N=2697										
2010 N=2396										
2011 N=2395										
2012 N=2391										
2013 N=2407										
2014 N=2378										
Ever any treatment/therapy for drug use (%)										
No	406 (23)	414 (21)	370 (19)	444 (20)	509 (19)	425 (18)	489 (20)	539 (23)	575 (24)	582 (24)
Yes	1374 (76)	1495 (76)	1504 (79)	1785 (79)	2144 (80)	1910 (80)	1842 (77)	1826 (76)	1800 (75)	1750 (74)
Not reported	20 (1)	51 (3)	38 (2)	41 (2)	44 (2)	61 (3)	64 (3)	26 (1)	32 (1)	46 (2)
History of methadone maintenance treatment (%)										
Current	600 (33)	575 (29)	605 (32)	696 (31)	823 (31)	725 (30)	693 (29)	712 (30)	718 (29)	641 (27)
Previous	426 (24)	519 (26)	539 (28)	587 (26)	645 (24)	600 (25)	586 (24)	622 (26)	559 (23)	565 (24)
Never	753 (42)	821 (42)	740 (39)	938 (41)	1167 (43)	946 (39)	1006 (42)	1041 (44)	1112 (46)	1123 (47)
Not reported	21 (1)	46 (2)	28 (1)	49 (2)	62 (2)	125 (5)	110 (5)	16 (1)	18 (1)	49 (2)
History of other pharmacotherapy treatment (%)										
Current	278 (15)	252 (13)	261 (14)	360 (16)	432 (16)	371 (15)	231 (10)	241 (10)	193 (8)	197 (8)
Previous	360 (20)	429 (22)	437 (23)	554 (24)	671 (25)	634 (26)	641 (27)	665 (28)	694 (29)	653 (27)
Never	1135 (63)	1230 (63)	1168 (61)	1312 (58)	1551 (58)	1374 (57)	1426 (60)	1456 (61)	1475 (61)	1472 (62)
Not reported	27 (2)	50 (3)	46 (2)	44 (2)	43 (2)	17 (1)	97 (4)	29 (1)	45 (2)	56 (2)

HIV antibody prevalence

Table 1.2.1 HIV antibody prevalence by gender and year

National	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995	655	15 (2.3)	335	5 (1.5)	1004	21 (2.1)
1996	996	20 (2.0)	469	7 (1.5)	1482	27 (1.8)
1997	1187	24 (2.0)	621	4 (0.6)	1814	28 (1.5)
1998	1566	16 (1.0)	853	4 (0.5)	2430	20 (0.8)
1999	1531	26 (1.7)	840	8 (1.0)	2383	34 (1.4)
2000	1639	21 (1.3)	871	0 (0.0)	2525	22 (0.9)
2001	1540	20 (1.3)	778	1 (0.1)	2342	21 (0.9)
2002	1552	25 (1.6)	785	4 (0.5)	2358	31 (1.3)
2003	1600	22 (1.4)	794	2 (0.3)	2418	25 (1.0)
2004	1216	17 (1.4)	595	3 (0.5)	1825	20 (1.1)
2005	1072	15 (1.4)	614	0 (0.0)	1703	15 (0.9)
2006	1223	26 (2.1)	661	2 (0.3)	1897	29 (1.5)
2007	1195	25 (2.1)	639	2 (0.3)	1845	28 (1.5)
2008	1396	29 (2.1)	764	3 (0.4)	2170	33 (1.5)
2009	1725	28 (1.6)	915	2 (0.2)	2657	31 (1.2)
2010	1579	21 (1.3)	759	2 (0.3)	2352	23 (1.0)
2011	1560	21 (1.4)	764	7 (0.9)	2337	29 (1.2)
2012	1546	18 (1.2)	718	9 (1.3)	2279	28 (1.2)
2013	1563	41 (2.6)	727	6 (0.8)	2307	48 (2.1)
2014	1558	33 (2.1)	702	3 (0.4)	2273	39 (1.7)
X^2 p trend: 1995-2014		0.273		0.678		0.199
X^2 p trend: 2010-2014		0.007		0.774		0.004

Table 1.2.2 HIV antibody prevalence by sexual identity, gender and year

National	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
Heterosexual	555	5 (0.9)	239	3 (1.3)	799	9 (1.1)
Bisexual	43	1 (2.3)	69	1 (1.5)	116	2 (1.7)
Homosexual	40	9 (22.5)	22	1 (4.6)	65	10 (15.4)
1996						
Heterosexual	824	4 (0.5)	326	5 (1.5)	1159	9 (0.8)
Bisexual	68	3 (4.4)	91	0 (0.0)	160	3 (1.9)
Homosexual	70	13 (18.6)	39	1 (2.6)	109	14 (12.8)
1997						
Heterosexual	1004	5 (0.5)	418	3 (0.7)	1426	8 (0.6)
Bisexual	77	2 (2.6)	130	1 (0.8)	208	3 (1.4)
Homosexual	54	17 (31.5)	58	0 (0.0)	112	17 (15.2)
1998						
Heterosexual	1339	4 (0.3)	620	2 (0.3)	1963	6 (0.3)
Bisexual	88	2 (2.3)	139	2 (1.4)	228	4 (1.8)
Homosexual	69	10 (14.5)	74	0 (0.0)	144	10 (6.9)
1999						
Heterosexual	1246	10 (0.8)	553	7 (1.3)	1799	17 (0.9)
Bisexual	104	2 (1.9)	187	1 (0.5)	297	3 (1.0)
Homosexual	71	12 (16.9)	52	0 (0.0)	125	12 (9.6)
2000						
Heterosexual	1374	7 (0.5)	558	0 (0.0)	1935	7 (0.4)
Bisexual	77	2 (2.6)	196	0 (0.0)	275	2 (0.7)
Homosexual	84	12 (14.3)	71	0 (0.0)	160	13 (8.1)
2001						
Heterosexual	1268	5 (0.4)	529	1 (0.2)	1808	6 (0.3)
Bisexual	69	2 (2.9)	154	0 (0.0)	227	2 (0.9)
Homosexual	80	13 (16.3)	47	0 (0.0)	129	13 (10.1)
2002						
Heterosexual	1270	7 (0.6)	525	3 (0.6)	1801	10 (0.6)
Bisexual	71	2 (2.8)	171	1 (0.6)	248	4 (1.6)
Homosexual	58	14 (24.1)	32	0 (0.0)	92	15 (16.3)
2003						
Heterosexual	1336	7 (0.5)	513	1 (0.2)	1856	8 (0.4)
Bisexual	60	2 (3.3)	168	1 (0.6)	232	4 (1.7)
Homosexual	73	12 (16.4)	48	0 (0.0)	124	12 (9.7)
2004						
Heterosexual	1058	1 (0.1)	435	2 (0.5)	1496	3 (0.2)
Bisexual	45	1 (2.2)	108	1 (0.9)	155	2 (1.3)
Homosexual	45	13 (28.9)	30	0 (0.0)	75	13 (17.3)

Table 1.2.2 HIV antibody prevalence by sexual identity, gender and year (continued)

National	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Heterosexual	945	4 (0.4)	441	0 (0.0)	1387	4 (0.3)
Bisexual	38	0 (0.0)	107	0 (0.0)	146	0 (0.0)
Homosexual	53	11 (20.8)	32	0 (0.0)	90	11 (12.2)
2006						
Heterosexual	1070	3 (0.3)	484	1 (0.2)	1557	4 (0.3)
Bisexual	55	4 (7.3)	110	1 (0.9)	171	6 (3.5)
Homosexual	59	19 (32.2)	46	0 (0.0)	107	19 (17.8)
2007						
Heterosexual	1055	5 (0.5)	458	2 (0.4)	1514	7 (0.5)
Bisexual	47	2 (4.3)	119	0 (0.0)	170	3 (1.8)
Homosexual	69	18 (26.1)	42	0 (0.0)	114	18 (15.8)
2008						
Heterosexual	1228	3 (0.2)	537	1 (0.2)	1767	4 (0.2)
Bisexual	56	3 (5.4)	152	2 (1.3)	209	6 (2.9)
Homosexual	62	23 (37.1)	48	0 (0.0)	112	23 (20.6)
2009						
Heterosexual	1517	7 (0.5)	684	2 (0.3)	2207	9 (0.4)
Bisexual	80	2 (2.5)	146	0 (0.0)	229	3 (1.3)
Homosexual	48	18 (37.5)	37	0 (0.0)	87	18 (20.7)
2010						
Heterosexual	1390	4 (0.3)	558	2 (0.4)	1954	6 (0.3)
Bisexual	61	3 (4.9)	124	0 (0.0)	188	3 (1.6)
Homosexual	48	14 (29.2)	36	0 (0.0)	85	14 (16.5)
2011						
Heterosexual	1393	6 (0.4)	547	5 (0.9)	1943	11 (0.6)
Bisexual	57	3 (5.3)	141	2 (1.4)	203	6 (3.0)
Homosexual	51	12 (23.5)	38	0 (0.0)	91	12 (13.2)
2012						
Heterosexual	1350	4 (0.3)	506	8 (1.6)	1859	12 (0.7)
Bisexual	69	2 (2.9)	127	0 (0.0)	200	3 (1.5)
Homosexual	42	9 (21.4)	31	0 (0.0)	77	9 (11.7)
2013						
Heterosexual	1322	9 (0.7)	519	6 (1.2)	1848	15 (0.8)
Bisexual	59	6 (10.2)	114	0 (0.0)	175	7 (4.0)
Homosexual	73	24 (32.9)	26	0 (0.0)	105	24 (22.9)
2014						
Heterosexual	1332	8 (0.6)	497	3 (0.6)	1832	11 (0.6)
Bisexual	58	5 (8.6)	134	0 (0.0)	199	8 (4.0)
Homosexual	64	19 (29.7)	23	0 (0.0)	88	19 (21.6)
2014 p value		<0.001		1.000		<0.001

Table 1.2.3 HIV antibody prevalence by age group, gender and year

National	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
<25 years	167	4 (2.4)	126	1 (0.8)	300	5 (1.7)
25-34 years	303	6 (2.0)	137	3 (2.2)	443	9 (2.0)
35-44 years	158	4 (2.5)	68	1 (1.5)	229	6 (2.6)
45+ years	21	1 (4.8)	3	0 (0.0)	25	1 (4.0)
1996						
<25 years	331	2 (0.6)	176	2 (1.1)	511	4 (0.8)
25-34 years	393	9 (2.3)	203	3 (1.5)	605	12 (2.0)
35-44 years	245	9 (3.7)	82	2 (2.4)	329	11 (3.3)
45+ years	24	0 (0.0)	8	0 (0.0)	32	0 (0.0)
1997						
<25 years	402	1 (0.3)	249	0 (0.0)	652	1 (0.2)
25-34 years	460	12 (2.6)	252	4 (1.6)	715	16 (2.2)
35-44 years	288	10 (3.5)	108	0 (0.0)	398	10 (2.5)
45+ years	36	1 (2.8)	12	0 (0.0)	48	1 (2.1)
1998						
<25 years	524	0 (0.0)	352	1 (0.3)	877	1 (0.1)
25-34 years	626	9 (1.4)	300	2 (0.7)	933	11 (1.2)
35-44 years	342	7 (2.1)	179	1 (0.6)	524	8 (1.5)
45+ years	72	0 (0.0)	22	0 (0.0)	94	0 (0.0)
1999						
<25 years	455	2 (0.4)	315	2 (0.6)	772	4 (0.5)
25-34 years	667	12 (1.8)	331	4 (1.2)	1002	16 (1.6)
35-44 years	313	8 (2.6)	168	2 (1.2)	484	10 (2.1)
45+ years	94	4 (4.3)	25	0 (0.0)	119	4 (3.4)
2000						
<25 years	441	1 (0.2)	346	0 (0.0)	791	1 (0.1)
25-34 years	688	12 (1.7)	333	0 (0.0)	1026	12 (1.2)
35-44 years	403	5 (1.2)	154	0 (0.0)	562	6 (1.1)
45+ years	106	3 (2.8)	38	0 (0.0)	144	3 (2.1)
2001						
<25 years	381	0 (0.0)	265	0 (0.0)	652	0 (0.0)
25-34 years	628	9 (1.4)	307	0 (0.0)	940	9 (1.0)
35-44 years	411	10 (2.4)	175	1 (0.6)	595	11 (1.9)
45+ years	118	1 (0.9)	30	0 (0.0)	151	1 (0.7)
2002						
<25 years	343	0 (0.0)	246	1 (0.4)	592	1 (0.2)
25-34 years	670	15 (2.2)	322	1 (0.3)	998	17 (1.7)
35-44 years	379	5 (1.3)	170	2 (1.2)	558	8 (1.4)
45+ years	155	5 (3.2)	46	0 (0.0)	204	5 (2.5)
2003						
<25 years	310	6 (1.9)	192	0 (0.0)	505	6 (1.2)
25-34 years	640	5 (0.8)	338	1 (0.3)	986	7 (0.7)
35-44 years	477	8 (1.7)	213	1 (0.5)	700	9 (1.3)
45+ years	170	3 (1.8)	49	0 (0.0)	222	3 (1.4)
2004						
<25 years	0	2 (1.0)	136	1 (0.7)	343	3 (0.9)
25-34 years	505	5 (1.0)	219	0 (0.0)	726	5 (0.7)
35-44 years	341	8 (2.4)	173	2 (1.2)	516	10 (1.9)
45+ years	160	1 (0.6)	67	0 (0.0)	231	1 (0.4)

Table 1.2.3 HIV antibody prevalence by age group, gender and year (continued)

National	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
<25 years	129	1 (0.8)	112	0 (0.0)	241	1 (0.4)
25-34 years	410	3 (0.7)	260	0 (0.0)	671	3 (0.5)
35-44 years	362	9 (2.5)	169	0 (0.0)	536	9 (1.7)
45+ years	176	2 (1.1)	72	0 (0.0)	251	2 (0.8)
2006						
<25 years	120	2 (1.7)	105	0 (0.0)	225	2 (0.9)
25-34 years	492	5 (1.0)	265	1 (0.4)	764	7 (0.9)
35-44 years	402	12 (3.0)	195	1 (0.5)	600	13 (2.2)
45+ years	204	7 (3.4)	94	0 (0.0)	301	7 (2.3)
2007						
<25 years	90	0 (0.0)	84	0 (0.0)	175	0 (0.0)
25-34 years	453	6 (1.3)	236	0 (0.0)	693	6 (0.9)
35-44 years	434	11 (2.5)	219	1 (0.5)	654	13 (2.0)
45+ years	216	8 (3.7)	99	1 (1.0)	320	9 (2.8)
2008						
<25 years	107	0 (0.0)	89	0 (0.0)	196	0 (0.0)
25-34 years	468	7 (1.5)	297	3 (1.0)	767	11 (1.4)
35-44 years	529	14 (2.7)	241	0 (0.0)	773	14 (1.8)
45+ years	287	8 (2.8)	136	0 (0.0)	428	8 (1.9)
2009						
<25 years	157	1 (0.6)	118	0 (0.0)	277	1 (0.4)
25-34 years	577	7 (1.2)	349	0 (0.0)	930	7 (0.8)
35-44 years	624	13 (2.1)	310	0 (0.0)	939	14 (1.5)
45+ years	367	7 (1.9)	137	1 (0.7)	510	8 (1.6)
2010						
<25 years	105	1 (1.0)	90	0 (0.0)	197	1 (0.5)
25-34 years	500	3 (0.6)	263	0 (0.0)	764	3 (0.4)
35-44 years	568	8 (1.4)	245	1 (0.4)	819	9 (1.1)
45+ years	395	8 (2.0)	155	1 (0.7)	554	9 (1.6)
2011						
<25 years	118	1 (0.9)	56	2 (3.6)	176	3 (1.7)
25-34 years	457	1 (0.2)	287	1 (0.4)	748	2 (0.3)
35-44 years	569	9 (1.6)	250	1 (0.4)	824	11 (1.3)
45+ years	410	10 (2.4)	169	3 (1.8)	580	13 (2.2)
2012						
<25 years	130	0 (0.0)	38	0 (0.0)	169	0 (0.0)
25-34 years	412	2 (0.5)	241	3 (1.2)	657	5 (0.8)
35-44 years	580	5 (0.9)	266	1 (0.4)	856	7 (0.8)
45+ years	418	11 (2.6)	172	5 (2.9)	595	16 (2.7)
2013						
<25 years	110	2 (1.8)	60	0 (0.0)	170	2 (1.2)
25-34 years	394	6 (1.5)	215	2 (0.9)	616	9 (1.5)
35-44 years	569	15 (2.6)	256	0 (0.0)	828	15 (1.8)
45+ years	483	18 (3.7)	195	4 (2.1)	684	22 (3.2)
2014						
<25 years	98	1 (1.0)	33	0 (0.0)	133	1 (0.8)
25-34 years	363	7 (1.9)	204	0 (0.0)	570	8 (1.4)
35-44 years	596	8 (1.3)	273	2 (0.7)	874	12 (1.4)
45+ years	495	17 (3.4)	190	1 (0.5)	688	18 (2.6)
2014 p value		0.114		0.681		0.224

Table 1.2.4 HIV antibody prevalence by drug last injected, gender and year

National	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
Heroin	295	9 (3.1)	146	2 (1.4)	443	11 (2.5)
Methamphetamine	133	3 (2.3)	72	0 (0.0)	210	3 (1.4)
Other opioids	139	1 (0.7)	81	1 (1.2)	224	2 (0.9)
Other drugs	84	2 (2.4)	36	2 (5.6)	123	5 (4.1)
1996						
Heroin	517	10 (1.9)	263	4 (1.5)	787	14 (1.8)
Methamphetamine	199	6 (3.0)	75	1 (1.3)	277	7 (2.5)
Other opioids	124	2 (1.6)	79	1 (1.3)	206	3 (1.5)
Other drugs	153	2 (1.3)	50	1 (2.0)	207	3 (1.5)
1997						
Heroin	647	15 (2.3)	359	1 (0.3)	1008	16 (1.6)
Methamphetamine	219	4 (1.8)	104	0 (0.0)	325	4 (1.2)
Other opioids	172	4 (2.3)	98	3 (3.1)	271	7 (2.6)
Other drugs	140	1 (0.7)	59	0 (0.0)	200	1 (0.5)
1998						
Heroin	792	6 (0.8)	462	1 (0.2)	1257	7 (0.6)
Methamphetamine	354	3 (0.9)	155	2 (1.3)	510	5 (1.0)
Other opioids	186	5 (2.7)	119	1 (0.8)	305	6 (1.8)
Other drugs	226	2 (0.9)	113	0 (0.0)	344	2 (0.6)
1999						
Heroin	784	6 (0.8)	477	4 (0.8)	1268	10 (0.8)
Methamphetamine	401	13 (3.2)	212	2 (0.9)	614	15 (2.4)
Other opioids	120	3 (2.5)	47	0 (0.0)	167	3 (1.8)
Other drugs	207	4 (1.9)	93	1 (1.1)	301	5 (1.7)
2000						
Heroin	893	9 (1.0)	543	0 (0.0)	1437	9 (0.6)
Methamphetamine	373	7 (1.9)	162	0 (0.0)	538	7 (1.3)
Other opioids	112	0 (0.0)	66	0 (0.0)	180	0 (0.0)
Other drugs	248	4 (1.6)	90	0 (0.0)	341	5 (1.5)
2001						
Heroin	453	4 (0.9)	269	1 (0.4)	725	5 (0.7)
Methamphetamine	591	13 (2.2)	263	0 (0.0)	865	13 (1.5)
Other opioids	183	0 (0.0)	81	0 (0.0)	266	0 (0.0)
Other drugs	295	3 (1.0)	151	0 (0.0)	450	3 (0.7)
2002						
Heroin	552	4 (0.7)	300	2 (0.7)	856	8 (0.9)
Methamphetamine	507	15 (3.0)	260	0 (0.0)	772	15 (1.9)
Other opioids	263	1 (0.4)	123	1 (0.8)	361	2 (0.6)
Other drugs	240	5 (2.1)	90	1 (1.1)	338	6 (1.8)
2003						
Heroin	564	7 (1.2)	311	2 (0.6)	884	10 (1.1)
Methamphetamine	538	11 (2.0)	253	0 (0.0)	797	11 (1.4)
Other opioids	248	1 (0.4)	115	0 (0.0)	367	1 (0.3)
Other drugs	228	3 (1.3)	93	0 (0.0)	324	3 (0.9)
2004						
Heroin	464	4 (0.9)	207	1 (0.5)	676	5 (0.7)
Methamphetamine	360	9 (2.5)	221	1 (0.5)	581	10 (1.7)
Other opioids	215	1 (0.5)	96	0 (0.0)	313	1 (0.3)
Other drugs	149	3 (2.0)	64	1 (1.6)	214	4 (1.9)

Table 1.2.4 HIV antibody prevalence by drug last injected, gender and year (continued)

National	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Heroin	356	3 (0.8)	235	0 (0.0)	593	3 (0.5)
Methamphetamine	338	5 (1.5)	196	0 (0.0)	539	5 (0.9)
Other opioids	234	5 (2.1)	121	0 (0.0)	356	5 (1.4)
Other drugs	104	2 (1.9)	47	0 (0.0)	152	2 (1.3)
2006						
Heroin	303	4 (1.3)	187	0 (0.0)	495	4 (0.8)
Methamphetamine	448	17 (3.8)	261	1 (0.4)	713	19 (2.7)
Other opioids	322	4 (1.2)	162	0 (0.0)	487	4 (0.8)
Other drugs	112	1 (0.9)	40	0 (0.0)	153	1 (0.7)
2007						
Heroin	348	4 (1.2)	222	0 (0.0)	574	4 (0.7)
Methamphetamine	348	10 (2.9)	204	1 (0.5)	552	11 (2.0)
Other opioids	372	10 (2.7)	160	0 (0.0)	537	10 (1.9)
Other drugs	103	1 (1.0)	45	1 (2.2)	150	3 (2.0)
2008						
Heroin	494	3 (0.6)	253	1 (0.4)	749	4 (0.5)
Methamphetamine	362	17 (4.7)	238	1 (0.4)	604	19 (3.2)
Other opioids	401	7 (1.8)	218	0 (0.0)	621	7 (1.1)
Other drugs	113	1 (0.9)	43	1 (2.3)	158	2 (1.3)
2009						
Heroin	591	5 (0.9)	311	1 (0.3)	907	6 (0.7)
Methamphetamine	402	15 (3.7)	243	1 (0.4)	649	16 (2.5)
Other opioids	546	8 (1.5)	263	0 (0.0)	814	8 (1.0)
Other drugs	146	0 (0.0)	76	0 (0.0)	225	1 (0.4)
2010						
Heroin	522	6 (1.2)	272	2 (0.7)	797	8 (1.0)
Methamphetamine	396	10 (2.5)	210	0 (0.0)	612	10 (1.6)
Other opioids	489	5 (1.0)	203	0 (0.0)	695	5 (0.7)
Other drugs	164	0 (0.0)	70	0 (0.0)	236	0 (0.0)
2011						
Heroin	513	2 (0.4)	267	4 (1.5)	783	7 (0.9)
Methamphetamine	382	12 (3.1)	247	1 (0.4)	632	13 (2.1)
Other opioids	448	6 (1.3)	202	2 (1.0)	655	8 (1.2)
Other drugs	214	1 (0.5)	46	0 (0.0)	262	1 (0.4)
2012						
Heroin	507	2 (0.4)	262	6 (2.3)	773	9 (1.2)
Methamphetamine	355	8 (2.3)	216	2 (0.9)	577	10 (1.7)
Other opioids	416	8 (1.7)	187	1 (0.5)	605	8 (1.3)
Other drugs	257	1 (0.4)	49	0 (0.0)	309	1 (0.3)
2013						
Heroin	449	5 (1.1)	230	4 (1.7)	683	9 (1.3)
Methamphetamine	413	24 (5.8)	249	2 (0.8)	668	26 (3.9)
Other opioids	423	8 (1.9)	177	0 (0.0)	601	8 (1.3)
Other drugs	269	4 (1.5)	68	0 (0.0)	342	5 (1.5)
2014						
Heroin	460	6 (1.3)	233	1 (0.4)	696	8 (1.2)
Methamphetamine	472	20 (4.2)	265	1 (0.4)	741	21 (2.8)
Other opioids	326	3 (0.9)	145	0 (0.0)	474	3 (0.6)
Other drugs	293	4 (1.4)	57	1 (1.8)	353	7 (2.0)
2014 p value		0.005		0.416		0.017

HCV antibody prevalence

Table 1.3.1 HCV antibody prevalence by gender and year

National	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995	639	400 (63)	327	208 (64)	979	618 (63)
1996	977	482 (49)	467	262 (56)	1460	752 (52)
1997	1189	570 (48)	622	344 (55)	1817	917 (50)
1998	1567	735 (47)	855	458 (54)	2433	1199 (49)
1999	1528	756 (49)	840	436 (52)	2379	1198 (50)
2000	1647	865 (53)	874	484 (55)	2536	1357 (54)
2001	1564	882 (56)	788	481 (61)	2376	1378 (58)
2002	1554	875 (56)	784	434 (55)	2359	1324 (56)
2003	1604	914 (57)	794	483 (61)	2422	1412 (58)
2004	1223	715 (58)	599	371 (62)	1836	1093 (60)
2005	1076	657 (61)	609	377 (62)	1694	1040 (61)
2006	1217	736 (60)	656	419 (64)	1886	1162 (62)
2007	1140	695 (61)	605	388 (64)	1756	1091 (62)
2008	1352	852 (63)	737	453 (61)	2099	1311 (62)
2009	1712	840 (49)	912	471 (52)	2641	1318 (50)
2010	1567	838 (53)	756	398 (53)	2337	1244 (53)
2011	1530	826 (54)	748	386 (52)	2290	1216 (53)
2012	1524	794 (52)	713	384 (54)	2252	1184 (53)
2013	1554	831 (53)	726	396 (55)	2296	1235 (54)
2014	1506	802 (53)	684	380 (56)	2203	1188 (54)
X ² p trend: 1995-2014		0.159		0.415		0.590
X ² p trend: 2010-2014		0.895		0.415		0.732

Table 1.3.2 HCV antibody prevalence by age group, gender and year

National	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	163	48 (29)	122	54 (44)	291	106 (36)
25-34 years	296	203 (69)	136	96 (71)	435	302 (69)
35-44 years	153	129 (84)	65	56 (86)	221	187 (85)
45+ years	21	16 (76)	3	2 (67)	25	19 (76)
1996						
<25 years	322	55 (17)	172	53 (31)	498	110 (22)
25-34 years	383	216 (56)	203	145 (71)	594	367 (62)
35-44 years	245	210 (86)	84	67 (80)	331	279 (84)
45+ years	24	21 (88)	8	6 (75)	32	27 (84)
1997						
<25 years	402	68 (17)	249	75 (30)	652	143 (22)
25-34 years	461	229 (50)	252	164 (65)	716	395 (55)
35-44 years	289	240 (83)	109	96 (88)	400	337 (84)
45+ years	36	32 (89)	12	9 (75)	48	41 (85)
1998						
<25 years	524	110 (21)	352	103 (29)	877	213 (24)
25-34 years	627	292 (47)	300	190 (63)	934	486 (52)
35-44 years	342	270 (79)	181	150 (83)	526	422 (80)
45+ years	72	63 (88)	22	15 (68)	94	78 (83)
1999						
<25 years	455	122 (27)	315	102 (32)	772	224 (29)
25-34 years	665	308 (46)	331	184 (56)	1000	495 (50)
35-44 years	312	253 (81)	168	126 (75)	482	381 (79)
45+ years	94	72 (77)	25	23 (92)	119	95 (80)
2000						
<25 years	441	138 (31)	347	157 (45)	792	297 (38)
25-34 years	693	340 (49)	334	196 (59)	1032	538 (52)
35-44 years	405	296 (73)	156	105 (67)	566	404 (71)
45+ years	107	91 (85)	37	26 (70)	144	117 (81)
2001						
<25 years	384	142 (37)	269	129 (48)	659	271 (41)
25-34 years	638	322 (50)	310	188 (61)	953	514 (54)
35-44 years	420	316 (75)	178	136 (76)	607	460 (76)
45+ years	120	101 (84)	30	27 (90)	153	130 (85)
2002						
<25 years	343	145 (42)	246	115 (47)	592	262 (44)
25-34 years	669	350 (52)	321	168 (52)	996	523 (53)
35-44 years	382	253 (66)	170	115 (68)	561	375 (67)
45+ years	155	125 (81)	46	36 (78)	204	162 (79)
2003						
<25 years	310	109 (35)	192	88 (46)	505	199 (39)
25-34 years	641	319 (50)	338	198 (59)	987	520 (53)
35-44 years	480	349 (73)	213	156 (73)	703	513 (73)
45+ years	170	136 (80)	49	40 (82)	222	178 (80)
2004						
<25 years	208	71 (34)	137	68 (50)	346	139 (40)
25-34 years	509	268 (53)	220	117 (53)	731	387 (53)
35-44 years	341	245 (72)	174	131 (75)	517	376 (73)
45+ years	161	129 (80)	68	55 (81)	233	188 (81)

Table 1.3.2 HCV antibody prevalence by age group, gender and year (continued)

National	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<25 years	130	37 (28)	112	56 (50)	242	93 (38)
25-34 years	413	219 (53)	259	141 (54)	673	361 (54)
35-44 years	362	261 (72)	168	125 (74)	535	388 (73)
45+ years	176	142 (81)	72	57 (79)	251	202 (80)
2006						
<25 years	118	43 (36)	104	50 (48)	222	93 (42)
25-34 years	492	250 (51)	263	156 (59)	762	409 (54)
35-44 years	400	270 (68)	193	140 (73)	596	412 (69)
45+ years	202	169 (84)	94	71 (76)	299	242 (81)
2007						
<25 years	85	27 (32)	77	37 (48)	163	65 (40)
25-34 years	434	237 (55)	223	132 (59)	661	373 (56)
35-44 years	413	270 (65)	208	144 (69)	622	414 (67)
45+ years	206	159 (77)	96	75 (78)	307	237 (77)
2008						
<25 years	105	31 (30)	89	41 (46)	194	72 (37)
25-34 years	450	249 (55)	291	173 (59)	743	423 (57)
35-44 years	514	345 (67)	226	145 (64)	743	492 (66)
45+ years	278	224 (81)	130	94 (72)	413	321 (78)
2009						
<25 years	157	31 (20)	117	42 (36)	276	73 (26)
25-34 years	572	245 (43)	348	185 (53)	924	431 (47)
35-44 years	618	339 (55)	309	171 (55)	932	513 (55)
45+ years	365	225 (62)	137	73 (53)	508	301 (59)
2010						
<25 years	103	17 (17)	90	33 (37)	195	50 (26)
25-34 years	496	227 (46)	262	130 (50)	759	358 (47)
35-44 years	565	328 (58)	244	133 (55)	815	464 (57)
45+ years	392	258 (66)	154	99 (64)	550	360 (65)
2011						
<25 years	118	18 (15)	56	16 (29)	176	34 (19)
25-34 years	447	206 (46)	279	136 (49)	730	343 (47)
35-44 years	561	329 (59)	244	139 (57)	809	470 (58)
45+ years	398	270 (68)	167	95 (57)	566	365 (64)
2012						
<25 years	129	12 (9)	38	12 (32)	168	24 (14)
25-34 years	408	179 (44)	242	132 (55)	654	314 (48)
35-44 years	575	336 (58)	262	140 (53)	842	478 (57)
45+ years	411	266 (65)	170	99 (58)	586	366 (62)
2013						
<25 years	109	11 (10)	60	15 (25)	169	26 (15)
25-34 years	392	155 (40)	215	105 (49)	613	263 (43)
35-44 years	565	346 (61)	255	148 (58)	823	494 (60)
45+ years	481	316 (66)	195	127 (65)	682	448 (66)
2014						
<25 years	98	12 (12)	33	8 (24)	133	20 (15)
25-34 years	355	136 (38)	198	109 (55)	556	247 (44)
35-44 years	572	336 (59)	266	144 (54)	843	482 (57)
45+ years	475	315 (66)	185	117 (63)	663	434 (65)
2014 p value		<0.001		<0.001		<0.001

Table 1.3.3 HCV antibody prevalence by drug last injected, years of injection and year

National	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heroin	74	28 (38)	357	260 (73)	431	288 (67)
Methamphetamine	92	14 (15)	114	59 (52)	206	73 (35)
Other opioids	13	5 (38)	204	175 (85)	218	180 (83)
Other	23	7 (30)	98	69 (70)	121	76 (63)
1996						
Heroin	146	25 (17)	629	413 (66)	775	438 (57)
Methamphetamine	134	14 (10)	139	51 (37)	273	65 (24)
Other opioids	15	5 (33)	194	163 (84)	209	168 (80)
Other drugs	39	6 (15)	159	104 (65)	198	110 (56)
1997						
Heroin	221	44 (20)	787	505 (64)	1008	549 (54)
Methamphetamine	150	12 (8)	176	50 (28)	326	62 (19)
Other opioids	23	4 (17)	249	195 (78)	272	199 (73)
Other drugs	56	7 (13)	145	95 (66)	201	102 (51)
1998						
Heroin	301	79 (26)	958	586 (61)	1259	665 (53)
Methamphetamine	213	10 (5)	297	91 (31)	510	101 (20)
Other opioids	28	8 (29)	278	218 (78)	306	226 (74)
Other drugs	80	21 (26)	264	178 (67)	344	199 (58)
1999						
Heroin	255	96 (38)	1009	665 (66)	1264	761 (60)
Methamphetamine	220	14 (6)	394	132 (34)	614	146 (24)
Other opioids	11	2 (18)	156	114 (73)	167	116 (69)
Other drugs	67	14 (21)	234	150 (64)	301	164 (54)
2000						
Heroin	260	104 (40)	1180	776 (66)	1440	880 (61)
Methamphetamine	162	19 (12)	378	137 (36)	540	156 (29)
Other opioids	14	2 (14)	167	122 (73)	181	124 (185)
Other drugs	70	23 (33)	275	162 (59)	345	185 (54)
2001						
Heroin	106	52 (49)	624	460 (74)	730	512 (70)
Methamphetamine	217	41 (19)	662	232 (49)	879	364 (41)
Other opioids	21	8 (38)	249	187 (75)	270	195 (72)
Other drugs	87	32 (37)	374	262 (70)	461	294 (64)
2002						
Heroin	100	52 (52)	755	523 (69)	855	575 (67)
Methamphetamine	150	46 (31)	622	273 (44)	772	319 (41)
Other opioids	33	11 (33)	329	208 (63)	362	219 (61)
Other drugs	62	24 (39)	276	179 (65)	338	203 (60)
2003						
Heroin	99	38 (38)	786	574 (73)	885	612 (69)
Methamphetamine	134	27 (20)	665	327 (49)	799	354 (44)
Other opioids	16	6 (38)	351	252 (72)	367	258 (70)
Other drugs	48	9 (19)	277	165 (60)	325	174 (54)
2004						
Heroin	60	23 (38)	621	445 (72)	681	468 (69)
Methamphetamine	97	21 (22)	487	227 (47)	584	248 (42)
Other opioids	16	6 (38)	298	225 (76)	314	231 (74)
Other drugs	27	6 (22)	189	125 (66)	216	131 (61)

Table 1.3.3 HCV antibody prevalence by drug last injected, years of injection and year

National	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	27	11 (41)	566	392 (69)	593	403 (68)
Methamphetamine	69	3 (4)	471	247 (52)	540	250 (46)
Other opioids	17	7 (41)	340	260 (76)	357	267 (75)
Other drugs	21	1 (5)	131	93 (71)	152	94 (62)
2006						
Heroin	20	5 (25)	473	359 (76)	493	364 (74)
Methamphetamine	71	5 (7)	639	314 (49)	710	319 (45)
Other opioids	21	11 (52)	461	349 (76)	482	360 (75)
Other drugs	27	5 (19)	125	78 (62)	152	83 (55)
2007						
Heroin	32	8 (25)	513	363 (71)	545	371 (68)
Methamphetamine	62	13 (21)	462	252 (55)	524	265 (51)
Other opioids	16	5 (31)	494	351 (71)	510	356 (70)
Other drugs	14	1 (7)	132	78 (59)	146	79 (54)
2008						
Heroin	35	13 (37)	686	511 (74)	721	524 (73)
Methamphetamine	62	10 (16)	525	255 (49)	587	265 (45)
Other opioids	39	16 (41)	570	397 (70)	609	413 (68)
Other drugs	30	8 (27)	117	75 (64)	147	83 (56)
2009						
Heroin	53	14 (26)	849	510 (60)	902	524 (58)
Methamphetamine	66	5 (8)	582	225 (39)	648	230 (35)
Other opioids	50	8 (16)	757	416 (55)	807	424 (53)
Other drugs	30	2 (7)	193	107 (55)	223	109 (49)
2010						
Heroin	39	11 (28)	753	487 (65)	792	498 (63)
Methamphetamine	43	4 (9)	567	233 (41)	610	237 (39)
Other opioids	30	9 (30)	658	387 (59)	688	396 (58)
Other drugs	47	2 (4)	188	106 (56)	235	108 (46)
2011						
Heroin	41	13 (32)	732	457 (62)	773	470 (61)
Methamphetamine	42	10 (24)	578	264 (46)	620	274 (44)
Other opioids	35	11 (31)	599	367 (61)	634	378 (60)
Other drugs	91	6 (7)	167	86 (52)	258	92 (36)
2012						
Heroin	35	8 (23)	733	470 (64)	768	478 (62)
Methamphetamine	41	13 (32)	527	236 (45)	568	249 (44)
Other opioids	23	10 (43)	574	348 (61)	597	358 (60)
Other drugs	109	5 (5)	195	89 (46)	304	94 (31)
2013						
Heroin	25	8 (32)	656	445 (68)	681	453 (67)
Methamphetamine	53	10 (19)	609	295 (48)	662	305 (46)
Other opioids	24	3 (13)	575	351 (61)	599	354 (59)
Other drugs	104	3 (3)	237	115 (49)	341	118 (35)
2014						
Heroin	17	4 (24)	639	429 (67)	674	444 (66)
Methamphetamine	46	4 (9)	658	336 (51)	717	347 (48)
Other opioids	11	3 (27)	437	272 (62)	456	279 (61)
Other drugs	83	1 (1)	240	103 (43)	347	115 (33)
2014 p value		<0.001		<0.001		<0.001

2. AUSTRALIAN CAPITAL TERRITORY

2.1 Australian Capital Territory sample


In the Australian Capital Territory (ACT), recruitment of ANSPS respondents was undertaken by one NSP in all survey years, with Directions ACT participating annually since 1997. ACT response rates and sample sizes varied over the 20 year period 1995 to 2014, ranging from 22 in 2007 to 163 in 2000. The ACT sample was relatively stable with around 80 to 100 respondents in all years since 2010 and response rates were consistently above 50% over the same period. However, the relatively small sample size in some earlier survey years is likely to have contributed to the variation in demographic and injecting characteristics observed over time in the ACT.

2.2 Demographic Characteristics

Although the gender distribution of ACT ANSPS samples varied over the period 1995 to 2010, men outnumbered women in all survey years (range 54% in 1999 to 82% in 2004). The majority of respondents (71% to 91%) identified as heterosexual, with between 6% and 20% identifying as bisexual or homosexual. Although the proportion of Indigenous respondents increased nationally over time, this was not the case in the ACT (χ^2 trend $p=0.054$, range 0% to 18%). In 2014, 11% of ACT ANSPS respondents reported an Indigenous background. The majority of ACT survey respondents were born in Australia (79% to 92%) and reported that their parents spoke English at home (77% to 98%) across all survey years in which these data were available (Table 2.1.1).

The proportion of young people (those aged less than 25 years) increased between 1995 and 1998, but declined significantly in subsequent years (Figure 2.2.1). There was a concomitant increase in the median age of respondents, from a low of 23 years in 1997 to 41 years in 2014. In 1995 less than 10% of ACT ANSPS respondents were aged 40 years or older, increasing to more than half in 2014 (Figure 2.2.1). The median age at first injection remained relatively stable at 16-18 years across all survey years.

Figure 2.2.1 ACT proportion of younger and older PWID by year




2.3 Injecting behaviour

Drug last injected

Heroin and methamphetamine were the most commonly reported drugs last injected in the ACT in all survey years. Heroin was reported as the drug most recently injected by the majority of ANSPS respondents in all survey years except 2001, coinciding with substantial changes in heroin availability that occurred in Australia at that time (Maher et al., 2007; Degenhardt et al., 2006; Topp et al., 2003).

A small proportion of ACT respondents (<20%) reported last injecting methamphetamine during the 1990s, increasing to 40% in 2001 and fluctuating between 24% and 31% over the period 2010 to 2014 (Figure 2.3.1). Prevalence of recent injection of OST (methadone, buprenorphine or buprenorphine-naloxone) and pharmaceutical opioids varied over the survey period, likely due to the small sample sizes observed in some survey years (Table 2.1.2).

Figure 2.3.1 ACT prevalence of heroin and methamphetamine as the drug last injected by year




Injection risk behaviour

Prevalence of re-use of syringes (including re-use of one's own used syringe) in the month preceding survey participation has been relatively stable in the ACT since 1997 (when data collection commenced), reported by around one third of survey respondents in most years. Reports of receptive sharing of syringes varied substantially, from 4% of respondents in 2005 to 44% in 2007. Receptive sharing of drug preparation equipment also varied ranging from 24% in 2011 to 66% in 2007. These fluctuations are likely due to the small sample size in some survey years. As observed in other jurisdictions, spoons and water were the most common drug preparation items receptively shared by respondents in the ACT.

As occurred nationally and in other jurisdictions, prevalence of public injecting in the month preceding survey participation declined significantly from a high of 79% in 1999 to 28% in 2014 in the ACT (χ^2 trend $p=0.001$, Table 2.1.3).


Figure 2.3.2 ACT re-use of syringes and receptive sharing (RS) of syringes and drug preparation equipment by year



2.4 Imprisonment, OST and BBV testing


The proportion of ACT ANSPS respondents who reported a history of imprisonment was relatively stable, with around one in two ANSPS respondents reporting ever being in prison in most survey years (Figure 2.4.1). The proportion of respondents reporting incarceration in the 12 months preceding survey participation was stable, with between 5% and 20% of ANSPS respondents reporting recent imprisonment over the period 1995 to 2014 (χ^2 trend $p=0.058$). Among ACT respondents who were recently imprisoned, between one third and one half reported injecting in prison in most survey years (Table 2.1.1).

Figure 2.4.1 ACT prison history and proportion of respondents who reported injecting in prison in the last 12 months by year




More than half of ACT ANSPS respondents reported a history of OST in all survey years except 1997, with the proportion increasing significantly from around 50% in the late 1990s to around 80% in 2014 (χ^2 trend $p < 0.001$, Figure 2.4.2, Table 2.1.7). Similarly, the proportion of respondents who reported current OST increased from a low of 18% in 1997 to 52% in 2014 (χ^2 trend $p < 0.001$).

Figure 2.4.2 ACT current and history of OST by year



More than three quarters of ACT ANSPS respondents reported a lifetime history of testing for HCV and/or HIV in all survey years (Table 2.1.5). The proportion of respondents who reported a recent HCV antibody test (last 12 months) significantly declined over the survey period, from 75% in 1998 to 41% in 2014 (χ^2 trend $p < 0.001$). The proportion of ACT respondents reporting a recent HIV test also declined significantly, from around 70% in the late 1990s to 51% in 2014 (χ^2 trend $p < 0.001$, Figure 2.4.3).

Figure 2.4.3 ACT HCV and HIV testing in the last 12 months by year



2.5 Blood borne viral infections


HIV antibody prevalence

HIV antibodies were rarely detected among ACT ANSPS respondents, with no cases identified since 1999 (Table 2.2.1). Over the 20 year period, 1995 to 2014, HIV antibody prevalence declined from 2.8% in 1995 to 0% in 2014 (χ^2 trend $p=0.015$).

HCV antibody prevalence

Although HCV antibody prevalence fluctuated in the ACT (most likely due to small sample sizes in some years), prevalence was consistently higher than that observed nationally in all years from 2000 to 2014 (Figure 2.5.1, Table 2.3.1). Consistent with the national trend, HCV antibody prevalence declined in the ACT in recent years, and was stable at between 60% and 67% over the period 2010 to 2014 (χ^2 trend $p=0.906$, Figure 2.5.1).

Figure 2.5.1 ACT and National HCV antibody prevalence by year



HCV antibody prevalence was high among both males and females in all survey years, with all male ACT ANSPS respondents testing HCV antibody positive in 2007 and all female respondents testing HCV antibody positive in 2005 (Figure 2.5.2, Table 2.3.1).

Figure 2.5.2 ACT HCV antibody prevalence by gender and year




Table 2.1.1 Number (percentage) of respondents by demographic characteristic and year

Australian Capital Territory	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Number of sites	1	1	1	1	1	1	1	1	1	1
N° surveyed	N=72	N=125	N=87	N=138	N=94	N=163	N=44	N=62	N=60	N=28
Response rate	97%	89%	49%	91%	55%	56%	40%	29%	58%	--
Gender (%)										
Male	47 (65)	69 (55)	59 (68)	87 (63)	51 (54)	120 (74)	34 (77)	41 (66)	41 (68)	23 (82)
Female	24 (34)	55 (44)	28 (32)	51 (37)	43 (46)	43 (26)	10 (23)	21 (34)	19 (32)	5 (18)
Transgender	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)										
Heterosexual	59 (82)	97 (78)	64 (74)	118 (86)	69 (73)	139 (85)	39 (88)	45 (72)	43 (72)	23 (82)
Bisexual	9 (13)	15 (12)	13 (15)	13 (9)	7 (7)	12 (8)	2 (5)	6 (10)	7 (12)	1 (4)
Homosexual	3 (4)	9 (7)	3 (3)	2 (1)	10 (11)	2 (1)	1 (2)	1 (2)	5 (8)	2 (7)
Not reported	1 (1)	4 (3)	7 (8)	5 (4)	8 (9)	10 (6)	2 (5)	10 (16)	5 (8)	2 (7)
Age and time since first injection (years)										
<i>Median age</i>	32	30	23	25	25	27	28	31	33.5	34
<i>Age range</i>	17-41	13-49	15-45	16-45	16-46	16-47	19-45	18-54	18-58	17-50
<i>Age group (%)</i>										
≤24 years	13 (18)	33 (26)	51 (59)	64 (46)	43 (46)	65 (40)	14 (32)	14 (23)	10 (17)	5 (18)
25+ years	59 (82)	91 (73)	36 (41)	74 (54)	51 (54)	98 (60)	30 (68)	48 (77)	50 (83)	23 (82)
Not reported	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1st injection</i>	18	18	17	17	17	17	17	17	18	18
<i>Age range</i>	13-33	11-33	12-33	12-32	12-34	10-42	11-40	13-39	13-40	14-45
<i>N° not reported</i>	1	5	3	1	2	4	1	2	1	1
<i>Median years injection</i>	12	10	5	7	6.5	8	11	12	12	14
<i>Range</i>	1-23	<1-34	<1-25	<1-31	<1-28	<1-32	1-30	1-40	<1-44	<1-35
<i>Time since first injection</i>										
≤3 years	9 (13)	17 (14)	32 (37)	39 (28)	29 (31)	47 (29)	3 (7)	7 (11)	5 (8)	3 (11)
4+ years	61 (85)	103 (83)	52 (60)	98 (71)	63 (67)	111 (68)	40 (91)	53 (85)	53 (88)	24 (86)
Not reported	2 (3)	5 (4)	3 (3)	1 (1)	2 (2)	5 (3)	1 (2)	2 (3)	2 (3)	1 (4)

Table 2.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

Australian Capital Territory	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Number of sites	1	1	1	1	1	1	1	1	1	1
N° surveyed	N=39	N=52	N=22	N=31	N=63	N=97	N=100	N=78	N=100	N=99
Response rate	70%	--	--	--	67%	83%	56%	65%	80%	69%
Gender (%)										
Male	30 (77)	31 (60)	12 (55)	22 (71)	39 (62)	72 (74)	68 (68)	53 (68)	67 (67)	76 (77)
Female	9 (23)	20 (39)	10 (45)	9 (29)	24 (38)	25 (26)	32 (32)	25 (32)	32 (32)	23 (23)
Transgender	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)										
Heterosexual	33 (85)	44 (85)	19 (86)	22 (71)	52 (83)	81 (83)	83 (83)	71 (91)	85 (85)	81 (82)
Bisexual	2 (5)	7 (13)	1 (5)	3 (10)	7 (11)	5 (5)	5 (5)	5 (6)	4 (4)	9 (9)
Homosexual	1 (3)	1 (2)	2 (9)	3 (10)	1 (2)	1 (1)	5 (5)	0 (0)	1 (1)	2 (2)
Not reported	3 (8)	0 (0)	0 (0)	3 (10)	3 (5)	10 (10)	7 (7)	2 (3)	10 (10)	7 (7)
Age and time since first injection (years)										
<i>Median age</i>	36	33	29.5	36	32	35	35	40	40	41
<i>Age range</i>	15-57	15-60	17-61	22-56	16-60	19-64	22-65	20-66	20-67	19-60
Age group (%)										
≤24 years	6 (15)	7 (13)	5 (23)	3 (10)	15 (23)	3 (3)	4 (4)	4 (5)	4 (4)	6 (6)
25+ years	33 (85)	44 (85)	17 (77)	28 (90)	48 (76)	94 (97)	96 (96)	74 (95)	96 (96)	92 (93)
Not reported	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
<i>Median age 1st injection</i>	17	17	16	18	17	18	18	18	17	17
<i>Age range</i>	11-28	12-39	12-33	11-40	12-42	10-40	10-55	12-41	10-51	12-55
<i>N° not reported</i>	9	2	1	0	1	2	2	0	6	1
Median years injection										
<i>Range</i>	<1-32	<1-45	2-47	2-38	1-36	2-49	1-49	<1-51	<1-51	1-38
Time since first injection										
≤3 years	1 (3)	2 (4)	1 (5)	1 (3)	7 (11)	1 (1)	6 (6)	3 (4)	4 (4)	5 (5)
4+ years	29 (74)	48 (92)	20 (91)	30 (97)	55 (87)	94 (97)	92 (92)	75 (96)	90 (90)	92 (93)
Not reported	9 (23)	2 (4)	1 (5)	0 (0)	1 (2)	2 (2)	2 (2)	0 (0)	6 (6)	2 (2)

Table 2.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

Australian Capital Territory	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
N° surveyed	N=72	N=125	N=87	N=138	N=94	N=163	N=44	N=62	N=60	N=28
Aboriginal and Torres Strait Islander origin (%)										
No	65 (90)	110 (88)	83 (95)	123 (89)	76 (81)	140 (87)	39 (89)	53 (85)	56 (93)	23 (82)
Yes	5 (7)	7 (6)	4 (5)	12 (9)	16 (17)	18 (11)	5 (11)	8 (13)	4 (7)	3 (11)
Not reported	2 (3)	8 (6)	0 (0)	3 (2)	2 (2)	5 (3)	0 (0)	1 (2)	0 (0)	2 (7)
Region/country of birth (%)										
Australia	--	--	--	--	84 (89)	139 (85)	37 (84)	52 (84)	52 (87)	26 (92)
Other Oceania	--	--	--	--	--	2 (1)	2 (5)	0 (0)	0 (0)	0 (0)
Asia	--	--	--	--	1 (1)	3 (2)	0 (0)	0 (0)	3 (5)	1 (4)
UK & Ireland	--	--	--	--	--	8 (5)	2 (5)	4 (6)	4 (7)	1 (4)
Other	--	--	--	--	7 (8)	9 (6)	3 (7)	5 (8)	1 (1)	0 (0)
Not reported	--	--	--	--	2 (2)	2 (1)	0 (0)	1 (2)	0 (0)	0 (0)
Main language spoken at home by parents (%)										
English	--	--	--	--	84 (89)	142 (87)	39 (89)	54 (87)	59 (98)	23 (82)
Non-English	--	--	--	--	8 (9)	17 (10)	3 (7)	5 (8)	1 (2)	0 (0)
Not reported	--	--	--	--	2 (2)	4 (3)	2 (4)	3 (5)	0 (0)	5 (18)
Imprisonment last year (%)										
No	64 (89)	107 (85)	71 (82)	110 (80)	76 (81)	139 (85)	29 (66)	56 (90)	49 (82)	22 (79)
Yes	7 (10)	12 (10)	15 (17)	26 (19)	17 (18)	23 (14)	15 (34)	6 (10)	11 (18)	6 (21)
Not reported	1 (1)	6 (5)	1 (1)	2 (1)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Injected in prison last year (%)										
N° in prison	N=7	N=12	N=15	N=26	N=17	N=23	N=15	N=6	N=11	N=6
Injected in prison	3 (43)	4 (33)	6 (40)	5 (19)	6 (35)	8 (35)	3 (20)	2 (33)	1 (9)	2 (33)
Frequency of injection last month (%)										
Not last month	15 (21)	13 (10)	5 (6)	6 (4)	13 (14)	9 (6)	3 (7)	7 (11)	1 (2)	1 (3)
Less than weekly	19 (26)	25 (20)	21 (24)	14 (10)	19 (20)	25 (15)	10 (23)	9 (15)	11 (18)	8 (29)
Weekly not daily	23 (32)	40 (32)	13 (15)	34 (25)	11 (12)	27 (16)	19 (43)	16 (26)	14 (23)	5 (18)
Daily or more	15 (21)	45 (36)	47 (54)	84 (61)	51 (54)	101 (62)	11 (25)	30 (48)	34 (57)	12 (43)
Not reported	0 (0)	2 (2)	1 (1)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)	2 (7)

Table 2.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Australian Capital Territory										
N° surveyed	N=39	N=52	N=22	N=31	N=63	N=97	N=100	N=78	N=100	N=99
Aboriginal and Torres Strait Islander origin (%)										
No	31 (79)	49 (94)	21 (95)	25 (81)	56 (89)	79 (81)	85 (85)	71 (91)	80 (80)	87 (88)
Yes	7 (18)	3 (6)	0 (0)	4 (13)	5 (8)	17 (18)	12 (12)	4 (5)	18 (18)	11 (11)
Not reported	1 (3)	0 (0)	1 (5)	2 (6)	2 (3)	1 (1)	3 (3)	3 (4)	2 (2)	1 (1)
Region/country of birth (%)										
Australia	32 (82)	43 (83)	18 (82)	25 (81)	50 (79)	89 (92)	90 (90)	71 (91)	88 (88)	88 (89)
Other Oceania	1 (3)	2 (4)	0 (0)	0 (0)	2 (3)	2 (2)	4 (4)	1 (1)	0 (0)	3 (3)
Asia	1 (3)	1 (2)	1 (5)	2 (6)	1 (2)	0 (0)	0 (0)	1 (1)	2 (2)	2 (2)
UK & Ireland	2 (5)	1 (2)	2 (9)	1 (3)	8 (13)	4 (4)	0 (0)	5 (6)	5 (5)	4 (4)
Other	3 (8)	4 (8)	1 (5)	2 (6)	2 (3)	0 (0)	6 (6)	0 (0)	4 (4)	1 (1)
Not reported	0 (0)	1 (2)	0 (0)	1 (3)	0 (0)	2 (2)	0 (0)	0 (0)	1 (1)	1 (1)
Main language spoken at home by parents (%)										
English	30 (77)	42 (81)	20 (91)	30 (97)	61 (97)	95 (98)	95 (95)	75 (96)	93 (93)	92 (93)
Non-English	9 (23)	7 (13)	2 (9)	1 (3)	2 (3)	2 (2)	5 (5)	3 (4)	7 (7)	6 (6)
Not reported	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Imprisonment last year (%)										
No	33 (85)	44 (85)	19 (86)	26 (84)	51 (81)	67 (69)	89 (89)	67 (86)	76 (76)	83 (84)
Yes	4 (10)	7 (13)	2 (9)	2 (6)	9 (14)	14 (14)	6 (6)	4 (5)	16 (16)	9 (9)
Not reported	2 (5)	1 (2)	1 (5)	3 (10)	3 (5)	16 (16)	5 (5)	7 (9)	8 (8)	7 (7)
Injected in prison last year (%)										
N° in prison	N=4	N=7	N=2	N=2	N=9	N=14	N=6	N=4	N=16	N=9
Injected in prison	2 (50)	4 (57)	1 (50)	0 (0)	1 (11)	4 (29)	2 (33)	3 (75)	4 (25)	3 (33)
Frequency of injection last month (%)										
Not last month	8 (21)	7 (13)	3 (14)	0 (0)	4 (6)	8 (8)	10 (10)	2 (3)	5 (5)	3 (3)
Less than weekly	4 (10)	13 (25)	1 (5)	3 (10)	10 (16)	15 (15)	16 (16)	10 (13)	17 (17)	13 (13)
Weekly not daily	15 (38)	19 (37)	9 (41)	15 (48)	12 (19)	30 (31)	22 (22)	22 (28)	28 (28)	40 (40)
Daily or more	12 (31)	13 (25)	8 (36)	13 (42)	37 (59)	42 (43)	50 (50)	44 (56)	47 (47)	43 (43)
Not reported	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	2 (2)	2 (2)	0 (0)	3 (3)	0 (0)
Experienced overdose in the previous 12 months										
Yes	--	--	--	--	--	--	--	--	10 (10)	18 (18)

Table 2.1.2 Number (percentage) of respondents by drug last injected and year

Australian Capital Territory N° surveyed	1995 N=72	1996 N=125	1997 N=87	1998 N=138	1999 N=94	2000 N=163	2001 N=44	2002 N=62	2003 N=60	2004 N=28
Drug last injected (%)										
Cocaine	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)	3 (5)	0 (0)
Methamphetamine	10 (14)	9 (7)	8 (9)	8 (6)	15 (16)	10 (6)	18 (41)	10 (16)	17 (28)	9 (32)
Heroin	43 (61)	89 (71)	69 (79)	117 (85)	72 (77)	130 (80)	13 (30)	41 (67)	30 (50)	14 (50)
Pharm. opioids	3 (4)	0 (0)	0 (0)	2 (1)	0 (0)	3 (2)	1 (2)	0 (0)	0 (0)	0 (0)
Methadone	7 (10)	11 (9)	5 (6)	4 (3)	1 (1)	3 (2)	9 (20)	5 (8)	5 (8)	4 (14)
Buprenorphine	--	--	--	--	--	--	--	--	1 (2)	0 (0)
Buprenorphine/naloxone	--	--	--	--	--	--	--	--	--	--
PIEDs	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)	0 (0)	0 (0)
More than one	5 (7)	15 (12)	4 (5)	7 (5)	5 (5)	13 (8)	2 (5)	6 (9)	2 (3)	0 (0)
Other	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (3)	1 (4)
Not reported	1 (1)	1 (1)	1 (1)	0 (0)	0 (0)	1 (1)	1 (2)	0 (0)	0 (0)	0 (0)

Australian Capital Territory N° surveyed	2005 N=39	2006 N=52	2007 N=22	2008 N=31	2009 N=63	2010 N=97	2011 N=100	2012 N=78	2013 N=100	2014 N=99
Drug last injected (%)										
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	2 (3)	4 (4)	0 (0)	1 (1)	0 (0)	0 (0)
Methamphetamine	10 (26)	21 (40)	9 (41)	9 (29)	15 (24)	26 (27)	24 (24)	23 (29)	30 (30)	31 (31)
Heroin	14 (36)	20 (38)	9 (41)	14 (45)	24 (38)	28 (29)	44 (44)	30 (38)	56 (56)	44 (44)
Pharm. opioids	2 (5)	1 (2)	1 (5)	2 (6)	6 (10)	3 (3)	3 (3)	3 (4)	4 (4)	6 (6)
Methadone	3 (8)	6 (12)	0 (0)	2 (6)	2 (3)	16 (16)	12 (12)	9 (12)	6 (6)	6 (6)
Buprenorphine	0 (0)	3 (6)	2 (9)	3 (10)	6 (10)	10 (10)	7 (7)	3 (4)	0 (0)	2 (2)
Buprenorphine/naloxone	--	--	--	--	4 (6)	1 (1)	1 (1)	0 (0)	1 (1)	2 (2)
PIEDs	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
More than one	2 (5)	0 (0)	1 (5)	0 (0)	2 (3)	7 (7)	5 (5)	5 (6)	3 (3)	4 (4)
Other	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (2)	3 (3)	3 (4)	0 (0)	4 (4)
Not reported	8 (20)	0 (0)	0 (0)	1 (3)	2 (3)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)

Table 2.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

Australian Capital Territory N° injected last month	1995 N=57	1996 N=110	1997 N=81	1998 N=132	1999 N=81	2000 N=153	2001 N=40	2002 N=55	2003 N=59	2004 N=25
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	--	--	--	--	31 (38)	61 (40)	14 (35)	25 (45)	26 (44)	11 (44)
Water	--	--	--	--	20 (25)	31 (20)	4 (10)	15 (27)	14 (24)	7 (28)
Filter	--	--	--	--	22 (27)	35 (23)	3 (8)	15 (27)	15 (25)	7 (28)
Drug mix	--	--	--	--	14 (17)	21 (14)	4 (10)	11 (20)	21 (36)	5 (20)
None	--	--	--	--	--	--	--	--	--	--
Public injecting in last month (%)										
Any public	--	--	64 (79)	101 (77)	64 (79)	109 (71)	29 (73)	39 (71)	42 (71)	17 (65)
All private	--	--	17 (21)	25 (19)	15 (19)	35 (23)	11 (28)	15 (27)	16 (27)	8 (31)
Not reported	--	--	0 (0)	6 (5)	2 (2)	9 (6)	0 (0)	1 (2)	1 (2)	0 (0)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	--	--	--	--	76 (94)	146 (95)	37 (93)	52 (95)	57 (97)	22 (88)
Pharmacy	--	--	--	--	43 (53)	71 (46)	18 (45)	26 (47)	30 (51)	15 (60)
Australian Capital Territory										
N° injected last month	2005 N=27	2006 N=45	2007 N=18	2008 N=31	2009 N=59	2010 N=87	2011 N=88	2012 N=76	2013 N=92	2014 N=96
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	10 (32)	17 (40)	6 (35)	11 (37)	20 (38)	18 (21)	12 (14)	19 (25)	33 (36)	32 (33)
Water	9 (29)	12 (28)	9 (53)	8 (27)	14 (26)	16 (18)	14 (16)	13 (17)	16 (17)	10 (10)
Filter	5 (16)	7 (16)	4 (24)	6 (20)	4 (8)	8 (9)	11 (13)	6 (8)	14 (15)	9 (9)
Drug mix	7 (23)	7 (16)	4 (24)	7 (23)	7 (13)	9 (10)	9 (10)	5 (7)	12 (13)	11 (11)
None	--	21 (49)	5 (30)	19 (63)	28 (53)	53 (61)	64 (73)	51 (67)	53 (58)	57 (59)
Public injecting in last month (%)										
Any public	16 (59)	27 (60)	11 (61)	20 (64)	30 (51)	40 (46)	40 (45)	33 (43)	43 (47)	27 (28)
All private	9 (33)	16 (36)	6 (33)	11 (35)	28 (47)	44 (51)	47 (53)	42 (55)	49 (53)	69 (72)
Not reported	2 (7)	2 (4)	1 (6)	0 (0)	1 (2)	3 (3)	1 (1)	1 (1)	0 (0)	0 (0)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	23 (85)	42 (93)	16 (88)	29 (94)	34 (58)	82 (94)	81 (92)	70 (92)	81 (81)	83 (86)
Pharmacy	14 (52)	25 (56)	9 (50)	20 (65)	30 (51)	21 (24)	17 (19)	27 (36)	30 (30)	29 (30)

Table 2.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

Australian Capital Territory N° injected last month	1995 N=57	1996 N=110	1997 N=81	1998 N=132	1999 N=81	2000 N=153	2001 N=40	2002 N=55	2003 N=59	2004 N=25
Use of sterile needles and syringes last month (%)										
All injections	--	--	55 (68)	84 (64)	56 (69)	114 (74)	26 (65)	39 (71)	40 (68)	17 (68)
Most of the time	--	--	23 (29)	38 (29)	19 (24)	36 (23)	13 (33)	15 (27)	16 (27)	8 (32)
Half of the time	--	--	2 (2)	3 (2)	2 (2)	1 (1)	1 (3)	1 (2)	1 (2)	0 (0)
Some of the time	--	--	1 (1)	3 (2)	2 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
Not last month	--	--	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)	1 (2)	0 (0)
Not reported	--	--	0 (0)	4 (3)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Re-used someone else's used needle & syringe last month (%)										
None	34 (60)	83 (75)	67 (83)	100 (76)	56 (69)	121 (79)	28 (70)	38 (70)	41 (70)	20 (80)
Once	10 (18)	16 (14)	1 (1)	12 (9)	10 (13)	15 (10)	8 (20)	4 (7)	7 (12)	2 (8)
Twice	3 (5)	6 (5)	4 (5)	8 (6)	5 (6)	5 (3)	2 (5)	4 (7)	4 (7)	1 (4)
3-5 times	6 (10)	1 (1)	7 (9)	6 (4)	9 (11)	4 (3)	0 (0)	2 (4)	2 (3)	1 (4)
>5 times	4 (7)	4 (4)	0 (0)	2 (2)	0 (0)	7 (4)	1 (3)	3 (5)	3 (5)	0 (0)
Not reported	0 (0)	0 (0)	2 (2)	4 (3)	1 (1)	1 (1)	1 (3)	4 (7)	2 (3)	1 (4)
Number of people needle & syringe was re-used after last month (%)										
None	34 (60)	83 (76)	67 (83)	100 (76)	56 (69)	121 (79)	28 (70)	38 (68)	39 (66)	20 (80)
One	11 (19)	10 (9)	12 (15)	23 (17)	17 (21)	21 (14)	9 (21)	6 (11)	6 (10)	1 (4)
Two	3 (5)	17 (15)	1 (1)	3 (2)	3 (4)	0 (0)	1 (3)	2 (4)	1 (2)	0 (0)
Three to five	1 (2)	0 (0)	1 (1)	2 (1)	1 (1)	3 (2)	0 (0)	0 (0)	2 (3)	0 (0)
More than five	1 (2)	0 (0)	0 (0)	0 (0)	2 (3)	2 (1)	1 (3)	2 (4)	2 (3)	0 (0)
Don't know	7 (12)	0 (0)	0 (0)	0 (0)	1 (1)	5 (3)	0 (0)	2 (4)	4 (7)	1 (4)
Not reported	0 (0)	0 (0)	0 (0)	4 (3)	1 (1)	1 (1)	1 (3)	5 (9)	5 (9)	3 (12)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	--	--	8 (10)	13 (10)	10 (12)	15 (10)	5 (13)	6 (11)	3 (5)	1 (4)
Casual sex partner	--	--	2 (2)	2 (2)	0 (0)	3 (2)	0 (0)	1 (2)	1 (5)	0 (0)
Close friend	--	--	5 (6)	14 (11)	10 (12)	6 (4)	3 (8)	5 (9)	4 (20)	1 (4)
Acquaintance	--	--	3 (4)	1 (1)	3 (4)	8 (5)	2 (5)	2 (4)	3 (15)	0 (0)
Other	--	--	0 (0)	2 (2)	2 (2)	3 (2)	1 (3)	3 (5)	1 (5)	0 (0)

Table 2.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

Australian Capital Territory N° injected last month	2005 N=27	2006 N=45	2007 N=18	2008 N=31	2009 N=59	2010 N=87	2011 N=88	2012 N=76	2013 N=92	2014 N=96
Use of sterile needles and syringes last month (%)										
All injections	19 (70)	32 (71)	9 (50)	24 (77)	43 (73)	58 (67)	59 (67)	56 (74)	60 (65)	77 (80)
Most of the time	7 (26)	12 (27)	6 (33)	6 (19)	15 (25)	24 (28)	24 (27)	17 (22)	29 (32)	16 (17)
Half of the time	0 (0)	1 (2)	1 (6)	1 (3)	1 (2)	0 (0)	2 (2)	0 (0)	2 (2)	1 (1)
Some of the time	1 (4)	0 (0)	1 (6)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	1 (1)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)	4 (5)	2 (2)	1 (1)	1 (1)	1 (1)
Re-used someone else's used needle & syringe last month (%)										
None	25 (93)	35 (78)	9 (50)	25 (81)	51 (86)	62 (71)	75 (85)	60 (79)	74 (80)	82 (85)
Once	1 (4)	3 (7)	3 (17)	2 (6)	1 (2)	3 (3)	4 (5)	6 (8)	9 (10)	6 (6)
Twice	0 (0)	0 (0)	1 (6)	2 (6)	1 (2)	7 (8)	0 (0)	1 (1)	1 (1)	3 (3)
3-5 times	0 (0)	3 (7)	2 (11)	1 (3)	4 (7)	3 (3)	2 (2)	1 (1)	4 (4)	3 (3)
>5 times	0 (0)	3 (7)	2 (11)	1 (3)	1 (2)	2 (2)	3 (3)	5 (7)	3 (3)	0 (0)
Not reported	1 (4)	1 (2)	1 (6)	0 (0)	1 (2)	10 (11)	4 (5)	3 (4)	1 (1)	2 (2)
Number of people needle & syringe was re-used after last month (%)										
None	21 (68)	35 (78)	9 (50)	25 (81)	51 (86)	62 (71)	75 (85)	60 (79)	74 (80)	82 (85)
One	4 (13)	3 (7)	2 (11)	3 (10)	4 (7)	8 (9)	4 (5)	4 (5)	9 (10)	5 (5)
Two	0 (0)	2 (4)	3 (17)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	3 (3)
Three to five	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)	2 (2)	0 (0)	0 (0)	1 (1)	0 (0)
More than five	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	3 (4)	1 (1)	0 (0)
Don't know	2 (6)	1 (2)	2 (11)	1 (3)	2 (3)	3 (3)	3 (3)	4 (5)	3 (3)	2 (2)
Not reported	4 (13)	2 (4)	2 (11)	2 (6)	1 (2)	10 (11)	4 (4)	5 (7)	3 (3)	4 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	3 (11)	4 (9)	2 (11)	2 (6)	4 (7)	8 (9)	8 (9)	2 (3)	8 (9)	6 (6)
Casual sex partner	0 (0)	1 (2)	0 (0)	1 (3)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)
Close friend	2 (7)	3 (7)	3 (17)	0 (0)	2 (3)	5 (6)	3 (3)	3 (4)	8 (9)	1 (1)
Acquaintance	1 (4)	3 (7)	2 (11)	0 (0)	1 (2)	4 (5)	1 (1)	4 (5)	2 (2)	2 (2)
Other	0 (0)	0 (0)	1 (6)	1 (3)	0 (0)	2 (2)	2 (2)	0 (0)	0 (0)	1 (1)

Table 2.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

Australian Capital Territory N° surveyed	1995 N=72	1996 N=125	1997 N=87	1998 N=138	1999 N=94	2000 N=163	2001 N=44	2002 N=62	2003 N=60	2004 N=28
Sex last month (%)										
No	18 (25)	42 (34)	29 (33)	53 (38)	42 (45)	56 (34)	15 (34)	23 (37)	22 (37)	13 (46)
Yes	49 (68)	80 (64)	58 (67)	85 (62)	51 (54)	106 (65)	29 (66)	38 (61)	37 (62)	14 (50)
Not reported	5 (7)	3 (2)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	1 (2)	1 (1)	1 (4)
Condom use at last sex (%)										
No	41 (57)	57 (45)	55 (64)	91 (66)	53 (56)	95 (58)	30 (68)	39 (63)	39 (65)	23 (82)
Yes	15 (21)	22 (18)	30 (34)	41 (30)	38 (41)	66 (41)	13 (30)	22 (35)	20 (33)	5 (18)
Not reported	16 (22)	46 (37)	2 (2)	6 (4)	3 (3)	2 (1)	1 (2)	1 (2)	1 (2)	0 (0)
Condom use with regular sex partner(s) last month (%)										
No	--	50 (67)	36 (70)	42 (60)	33 (81)	58 (63)	16 (67)	10 (44)	14 (67)	5 (72)
Sometimes	--	13 (18)	8 (15)	14 (20)	3 (7)	15 (16)	6 (25)	6 (26)	2 (9)	1 (14)
Always	--	11 (15)	8 (15)	14 (20)	5 (12)	19 (21)	2 (8)	7 (30)	5 (24)	1 (14)
Condom use with new sex partner(s) last month (%)										
No	--	14 (48)	12 (34)	8 (30)	6 (35)	8 (25)	3 (25)	12 (57)	7 (39)	2 (50)
Sometimes	--	1 (3)	5 (14)	4 (15)	2 (12)	5 (16)	5 (42)	3 (14)	4 (22)	1 (25)
Always	--	14 (48)	18 (51)	25 (56)	9 (53)	19 (59)	4 (33)	6 (29)	7 (39)	1 (25)
Condom use with casual sex partner(s) last month (%)										
No	--	--	--	12 (32)	9 (39)	11 (28)	5 (46)	7 (42)	7 (44)	5 (71)
Sometimes	--	--	--	10 (27)	2 (9)	14 (35)	2 (18)	5 (29)	3 (19)	2 (29)
Always	--	--	--	15 (41)	12 (52)	15 (37)	4 (36)	5 (29)	6 (37)	0 (0)
Sex work last month (%)										
No	68 (94)	105 (84)	78 (90)	126 (91)	86 (91)	148 (91)	43 (98)	58 (94)	54 (90)	26 (93)
Yes	2 (3)	10 (8)	7 (8)	8 (6)	7 (7)	11 (7)	1 (2)	3 (5)	4 (7)	2 (7)
Not reported	2 (3)	10 (8)	2 (2)	4 (3)	1 (1)	4 (2)	0 (0)	1 (1)	2 (3)	0 (0)
Condom used at last sex work (%)										
Yes	2 (100)	8 (80)	6 (86)	7 (100)	7 (100)	9 (100)	1 (100)	3 (100)	4 (100)	2 (100)

Table 2.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

Australian Capital Territory N° surveyed	2005 N=39	2006 N=52	2007 N=22	2008 N=31	2009 N=63	2010 N=97	2011 N=100	2012 N=78	2013 N=100	2014 N=99
Sex with a regular partner last month (%)										
No	19 (49)	30 (58)	11 (50)	22 (71)	34 (54)	50 (52)	54 (54)	53 (68)	59 (59)	58 (59)
Yes	19 (49)	22 (42)	9 (41)	8 (26)	28 (44)	41 (42)	44 (44)	24 (31)	36 (36)	35 (35)
Not reported	1 (3)	0 (0)	2 (9)	1 (3)	1 (2)	6 (6)	2 (2)	1 (1)	5 (5)	6 (6)
Condom used with regular partner last month (%)										
Never	N=19	N=22	N=9	N=8	N=28	N=41	N=44	N=24	N=36	N=35
Sometimes	14 (74)	15 (68)	7 (78)	3 (38)	20 (71)	23 (56)	31 (70)	13 (54)	24 (67)	27 (77)
Every time	2 (11)	1 (5)	2 (22)	2 (25)	4 (14)	7 (17)	9 (20)	9 (38)	5 (14)	5 (14)
Not reported	1 (5)	5 (23)	0 (0)	2 (25)	3 (11)	9 (22)	3 (7)	2 (8)	2 (6)	2 (6)
Not reported	2 (11)	1 (5)	0 (0)	1 (12)	1 (4)	2 (5)	1 (2)	0 (0)	5 (14)	1 (3)
Sex with other partner(s) last month (%)										
No	32 (82)	40 (77)	14 (64)	26 (84)	59 (94)	82 (85)	91 (91)	63 (81)	86 (86)	86 (87)
Yes	5 (13)	10 (19)	7 (32)	3 (10)	2 (3)	6 (6)	6 (6)	11 (14)	11 (11)	8 (8)
Not reported	2 (5)	2 (4)	1 (5)	2 (6)	2 (3)	9 (9)	3 (3)	4 (5)	3 (3)	5 (5)
Condom used with other partner(s) last month (%)										
Never	N=5	N=10	N=7	N=3	N=2	N=6	N=6	N=11	N=11	N=8
Sometimes	3 (43)	4 (40)	3 (43)	2 (67)	1 (50)	2 (33)	2 (33)	2 (18)	5 (45)	3 (38)
Every time	3 (43)	1 (10)	2 (29)	1 (33)	0 (0)	2 (33)	2 (33)	3 (27)	2 (18)	3 (38)
Not reported	0 (0)	4 (40)	2 (29)	0 (0)	1 (50)	1 (17)	2 (33)	6 (55)	4 (36)	2 (25)
Not reported	1 (14)	1 (10)	0 (0)	0 (0)	0 (0)	1 (17)	0 (0)	0 (0)	0 (0)	0 (0)
Sex work last month (%)										
No	38 (97)	47 (90)	20 (91)	29 (94)	60 (95)	85 (88)	91 (91)	72 (92)	92 (92)	89 (90)
Yes	1 (3)	3 (6)	1 (5)	2 (6)	0 (0)	2 (2)	2 (2)	3 (4)	2 (2)	4 (4)
Not reported	0 (0)	2 (4)	1 (5)	0 (0)	3 (5)	10 (10)	7 (7)	3 (4)	6 (6)	6 (6)
Condom used at last sex work (%)										
Yes	1 (100)	2 (67)	1 (100)	0 (0)	0 (0)	2 (100)	1 (100)	2 (67)	1 (50)	3 (75)

Table 2.1.5 Number (percentage) of respondents by testing for HIV and HCV infection by year

Australian Capital Territory N° surveyed	1995 N=72	1996 N=125	1997 N=87	1998 N=138	1999 N=94	2000 N=163	2001 N=44	2002 N=62	2003 N=60	2004 N=28
Previous HIV test (%)										
Yes, ever	63 (88)	114 (91)	74 (85)	124 (90)	77 (82)	143 (88)	38 (86)	57 (92)	56 (93)	22 (79)
Yes, last year	46 (64)	73 (58)	60 (69)	92 (67)	55 (59)	101 (62)	24 (54)	41 (65)	34 (57)	19 (68)
>1 year ago	17 (24)	35 (28)	14 (16)	29 (21)	22 (23)	42 (26)	14 (32)	16 (26)	22 (37)	3 (11)
Never tested	8 (11)	6 (5)	0 (0)	3 (2)	17 (18)	20 (12)	6 (14)	4 (7)	3 (5)	5 (18)
Not reported	1 (1)	11 (9)	13 (15)	14 (10)	0 (0)	0 (0)	0 (0)	1 (2)	1 (1)	1 (3)
Previous HCV test (%)										
Yes, ever	59 (82)	106 (84)	76 (87)	124 (90)	78 (83)	147 (90)	39 (89)	59 (95)	56 (93)	23 (82)
Yes, last year	--	--	59 (68)	102 (74)	61 (65)	109 (67)	26 (59)	40 (65)	39 (65)	17 (61)
>1 year ago	--	--	16 (18)	20 (15)	17 (18)	38 (23)	13 (30)	19 (31)	17 (28)	6 (21)
Never tested	9 (13)	17 (14)	1 (1)	2 (1)	16 (17)	16 (10)	5 (11)	2 (3)	4 (7)	5 (18)
Not reported	4 (5)	2 (2)	11 (13)	14 (10)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
Australian Capital Territory										
N° surveyed	2005 N=39	2006 N=52	2007 N=22	2008 N=31	2009 N=63	2010 N=97	2011 N=100	2012 N=78	2013 N=100	2014 N=99
Previous HIV test (%)										
Yes, ever	34 (87)	51 (98)	22 (100)	29 (94)	55 (87)	71 (73)	83 (83)	72 (92)	88 (88)	82 (83)
Yes, last year	20 (51)	39 (75)	13 (59)	8 (26)	30 (48)	50 (52)	43 (43)	42 (54)	44 (44)	50 (51)
>1 year ago	14 (36)	12 (23)	9 (41)	21 (68)	25 (40)	21 (22)	40 (40)	30 (38)	44 (44)	32 (32)
Never tested	4 (10)	1 (2)	0 (0)	1 (3)	5 (8)	15 (15)	14 (14)	3 (4)	8 (8)	12 (12)
Not reported	1 (3)	0 (0)	0 (0)	1 (3)	3 (5)	11 (11)	3 (3)	3 (4)	4 (4)	5 (5)
Previous HCV test (%)										
Yes, ever	35 (90)	50 (96)	22 (100)	29 (94)	58 (92)	76 (78)	91 (91)	73 (94)	86 (86)	88 (89)
Yes, last year	24 (62)	38 (73)	12 (55)	11 (35)	34 (54)	49 (51)	53 (53)	44 (56)	41 (41)	53 (54)
>1 year ago	11 (28)	12 (23)	10 (45)	18 (58)	24 (38)	27 (28)	38 (38)	29 (37)	45 (45)	35 (35)
Never tested	2 (5)	1 (2)	0 (0)	1 (3)	4 (6)	9 (9)	5 (5)	2 (3)	5 (5)	7 (7)
Not reported	2 (5)	1 (2)	0 (0)	1 (3)	1 (2)	12 (12)	4 (4)	3 (4)	9 (9)	4 (4)

Table 2.1.6 Number (percentage) of respondents by HCV treatment by year

Australian Capital Territory	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Self-report HCV diagnosis	--	--	--	--	N=45	N=83	N=25	N=38	N=37	N=17
Any treatment for HCV (%)										
Interferon+/Ribavirin	--	--	--	--	0 (0)	4 (5)	0 (0)	1 (3)	2 (5)	0 (0)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	1 (2)	1 (1)	0 (0)	2 (5)	1 (3)	0 (0)
No treatment	--	--	--	--	44 (98)	77 (94)	24 (96)	34 (89)	34 (91)	17 (100)
Not reported	--	--	--	--	0 (0)	1 (1)	1 (4)	1 (3)	0 (0)	0 (0)
Current treatment for HCV (%)										
Interferon +/-or Ribavirin	--	--	--	--	0	3	0	0	0	0
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	0	1	0	0	0	0

Australian Capital Territory	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Self-report HCV diagnosis	N=21	N=34	N=12	N=18	N=31	N=57	N=55	N=46	N=62	N=63
Any treatment for HCV (%)										
Interferon+/or Ribavirin	1 (5)	2 (6)	1 (8)	2 (11)	2 (6)	4 (7)	6 (11)	1 (2)	4 (6)	5 (8)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	0 (0)	0 (0)
Other	17 (81)	0 (0)	0 (0)	1 (6)	0 (0)	1 (2)	1 (2)	2 (4)	0 (0)	0 (0)
No treatment	2 (10)	31 (91)	11 (92)	15 (83)	29 (94)	52 (91)	48 (87)	42 (91)	55 (89)	55 (87)
Not reported	1 (5)	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	3 (5)	3 (5)
Current treatment for HCV (%)										
Interferon +/-or Ribavirin	1	0	0	0	0	3	1	0	2	0
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	2	0
Other	0	1	0	0	0	0	0	0	2	0

Table 2.1.7 Number (percentage) of respondents by drug treatment by year

ACT N° surveyed	1995 N=72	1996 N=125	1997 N=87	1998 N=138	1999 N=94	2000 N=163	2001 N=44	2002 N=62	2003 N=60	2004 N=28
Ever any treatment/therapy for drug use (%)										
No	13 (18)	20 (16)	20 (23)	33 (24)	24 (26)	29 (18)	4 (9)	11 (18)	10 (17)	5 (18)
Yes	57 (79)	104 (83)	67 (77)	105 (76)	69 (73)	133 (81)	40 (91)	51 (82)	50 (83)	23 (82)
Not reported	2 (3)	1 (1)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)										
Current	30 (41)	50 (40)	16 (18)	38 (28)	30 (32)	46 (28)	14 (32)	18 (29)	22 (37)	9 (32)
Previous	15 (21)	34 (27)	19 (22)	32 (23)	18 (19)	53 (33)	14 (32)	26 (42)	17 (28)	6 (21)
Never	25 (35)	40 (32)	52 (60)	68 (49)	22 (23)	63 (39)	16 (36)	17 (27)	21 (35)	12 (43)
Not reported	2 (3)	1 (1)	0 (0)	0 (0)	24 (26)	1 (1)	0 (0)	1 (2)	0 (0)	1 (4)
History of other pharmacotherapy treatment (%)										
Current	--	--	--	--	--	2 (1)	0 (0)	8 (13)	5 (8)	3 (11)
Previous	--	--	--	--	--	14 (9)	5 (11)	7 (11)	10 (17)	4 (14)
Never	--	--	--	--	--	143 (88)	39 (89)	47 (76)	45 (75)	21 (75)
Not reported	--	--	--	--	--	4 (2)	0 (0)	0 (0)	0 (0)	0 (0)
ACT										
N° surveyed	2005 N=39	2006 N=52	2007 N=22	2008 N=31	2009 N=63	2010 N=97	2011 N=100	2012 N=78	2013 N=100	2014 N=2378
Ever any treatment/therapy for drug use (%)										
No	13 (33)	7 (13)	5 (23)	3 (10)	10 (16)	11 (11)	14 (14)	9 (12)	5 (5)	9 (9)
Yes	25 (64)	45 (87)	17 (77)	27 (87)	53 (84)	84 (87)	86 (86)	69 (88)	94 (94)	90 (91)
Not reported	1 (3)	0 (0)	0 (0)	1 (3)	0 (0)	2 (2)	0 (0)	0 (0)	1 (1)	0 (0)
History of methadone maintenance treatment (%)										
Current	14 (36)	20 (38)	5 (23)	11 (35)	23 (37)	45 (46)	43 (43)	34 (44)	47 (47)	37 (38)
Previous	9 (23)	11 (21)	9 (41)	10 (32)	18 (29)	16 (16)	20 (20)	27 (35)	31 (31)	29 (29)
Never	15 (38)	21 (40)	8 (36)	9 (29)	22 (35)	28 (29)	33 (33)	17 (22)	21 (21)	32 (32)
Not reported	1 (3)	0 (0)	0 (0)	1 (3)	0 (0)	8 (8)	4 (4)	0 (0)	1 (1)	1 (1)
History of other pharmacotherapy treatment (%)										
Current	4 (10)	6 (12)	4 (18)	6 (19)	8 (13)	9 (9)	13 (13)	10 (13)	15 (15)	15 (15)
Previous	6 (15)	17 (33)	6 (27)	6 (19)	11 (17)	27 (28)	31 (31)	18 (23)	37 (37)	29 (29)
Never	27 (69)	29 (56)	12 (55)	18 (58)	42 (67)	61 (63)	55 (55)	50 (64)	48 (48)	54 (55)
Not reported	2 (5)	0 (0)	0 (0)	1 (3)	2 (3)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)

HIV antibody prevalence

Table 2.2.1 HIV antibody prevalence by gender and year

Aust. Capital Territory	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995	38	2 (5.3)	23	0 (0.0)	62	2 (2.8)
1996	69	1 (1.5)	55	0 (0.0)	125	1 (0.8)
1997	53	0 (0.0)	27	0 (0.0)	80	0 (0.0)
1998	87	0 (0.0)	50	0 (0.0)	137	0 (0.0)
1999	50	0 (0.0)	42	1 (2.4)	92	1 (1.1)
2000	120	0 (0.0)	42	0 (0.0)	162	0 (0.0)
2001	33	0 (0.0)	8	0 (0.0)	41	0 (0.0)
2002	40	0 (0.0)	21	0 (0.0)	61	0 (0.0)
2003	41	0 (0.0)	19	0 (0.0)	60	0 (0.0)
2004	18	0 (0.0)	5	0 (0.0)	28	0 (0.0)
2005	29	0 (0.0)	9	0 (0.0)	38	0 (0.0)
2006	30	0 (0.0)	18	0 (0.0)	49	0 (0.0)
2007	10	0 (0.0)	8	0 (0.0)	18	0 (0.0)
2008	18	0 (0.0)	8	0 (0.0)	26	0 (0.0)
2009	36	0 (0.0)	22	0 (0.0)	58	0 (0.0)
2010	72	0 (0.0)	25	0 (0.0)	97	0 (0.0)
2011	64	0 (0.0)	31	0 (0.0)	95	0 (0.0)
2012	53	0 (0.0)	25	0 (0.0)	78	0 (0.0)
2013	67	0 (0.0)	32	0 (0.0)	100	0 (0.0)
2014	73	0 (0.0)	23	0 (0.0)	96	0 (0.0)
X^2 p trend: 1995-2014		0.015		0.491		0.015
X^2 p trend: 2010-2014		--		--		--

HCV antibody prevalence

Table 2.3.1 HCV antibody prevalence by gender and year

Aust. Capital Territory	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995	32	18 (56)	21	14 (67)	54	33 (61)
1996	69	46 (67)	55	34 (62)	125	81 (65)
1997	53	21 (40)	27	11 (41)	80	32 (40)
1998	87	46 (53)	50	22 (44)	137	68 (50)
1999	48	30 (63)	42	24 (57)	90	54 (60)
2000	120	65 (54)	42	27 (64)	162	92 (57)
2001	33	20 (61)	8	5 (63)	41	25 (61)
2002	40	30 (75)	21	18 (86)	61	48 (79)
2003	41	30 (73)	19	18 (95)	60	48 (80)
2004	18	12 (67)	5	4 (80)	23	16 (70)
2005	30	20 (67)	9	9 (100)	39	29 (74)
2006	29	23 (79)	16	10 (63)	46	33 (72)
2007	10	10 (100)	8	6 (75)	18	16 (89)
2008	18	12 (67)	8	6 (75)	26	18 (69)
2009	36	21 (58)	22	13 (59)	58	34 (59)
2010	70	48 (69)	25	15 (60)	95	63 (66)
2011	62	44 (71)	31	12 (39)	93	56 (60)
2012	53	34 (64)	25	16 (64)	78	50 (64)
2013	67	49 (73)	32	18 (56)	100	67 (67)
2014	71	49 (69)	23	12 (52)	94	61 (65)
X ² p trend: 1995-2014		0.081		0.940		0.166
X ² p trend: 2010-2014		0.940		0.912		0.906

Table 2.3.2 HCV antibody prevalence by age group, gender and year

Aust. Capital Territory	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	7	4 (57)	4	2 (50)	11	6 (55)
25-34 years	15	8 (53)	12	8 (67)	27	16 (59)
35-44 years	10	6 (60)	5	4 (80)	15	10 (67)
45+ years	0	0 (0)	0	0 (0)	0	0 (0)
1996						
<25 years	16	4 (25)	17	8 (47)	33	12 (36)
25-34 years	28	20 (71)	24	15 (63)	52	35 (67)
35-44 years	22	20 (91)	14	11 (79)	36	31 (86)
45+ years	2	2 (100)	0	0 (0)	2	2 (100)
1997						
<25 years	32	9 (28)	16	4 (25)	48	13 (27)
25-34 years	15	7 (47)	6	3 (50)	21	10 (48)
35-44 years	5	5 (100)	5	4 (80)	10	9 (90)
45+ years	1	0 (0)	0	0 (0)	1	0 (0)
1998						
<25 years	36	6 (17)	27	7 (26)	63	13 (21)
25-34 years	29	20 (69)	14	6 (43)	43	26 (60)
35-44 years	20	18 (90)	9	9 (100)	29	27 (93)
45+ years	2	2 (100)	0	0 (0)	2	2 (100)
1999						
<25 years	22	7 (32)	19	7 (37)	41	14 (34)
25-34 years	16	13 (81)	16	10 (63)	32	23 (72)
35-44 years	8	8 (100)	7	7 (100)	15	15 (100)
45+ years	2	2 (100)	0	0 (0)	2	2 (100)
2000						
<25 years	43	11 (26)	21	12 (57)	64	23 (36)
25-34 years	50	31 (62)	13	9 (69)	63	40 (63)
35-44 years	23	20 (87)	8	6 (75)	31	26 (84)
45+ years	4	3 (75)	0	0 (0)	4	3 (75)
2001						
<25 years	8	1 (13)	4	1 (25)	12	2 (17)
25-34 years	13	8 (62)	2	2 (100)	15	10 (67)
35-44 years	12	11 (92)	1	1 (100)	13	12 (92)
45+ years	0	0 (0)	1	1 (100)	1	1 (100)
2002						
<25 years	5	4 (80)	9	6 (67)	14	10 (71)
25-34 years	18	13 (72)	8	8 (100)	26	21 (81)
35-44 years	10	6 (60)	4	4 (100)	14	10 (71)
45+ years	7	7 (100)	0	0 (0)	7	7 (100)
2003						
<25 years	4	2 (50)	6	5 (83)	10	7 (70)
25-34 years	20	14 (70)	7	7 (100)	27	21 (78)
35-44 years	11	8 (73)	3	3 (100)	14	11 (79)
45+ years	6	6 (100)	3	3 (100)	9	9 (100)
2004						
<25 years	2	1 (50)	3	3 (100)	5	4 (80)
25-34 years	6	3 (50)	1	1 (100)	7	4 (57)
35-44 years	6	4 (67)	0	0 (0)	6	4 (67)
45+ years	4	4 (100)	1	0 (0)	5	4 (80)

Table 2.3.2 HCV antibody prevalence by age group, gender and year (continued)

Aust. Capital Territory	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<25 years	5	0 (0)	1	1 (100)	6	1 (17)
25-34 years	5	4 (80)	7	7 (100)	12	11 (92)
35-44 years	10	9 (90)	1	1 (100)	11	10 (91)
45+ years	10	7 (70)	0	0 (0)	10	7 (70)
2006						
<25 years	3	1 (33)	3	1 (33)	6	2 (33)
25-34 years	12	9 (75)	8	5 (63)	20	14 (70)
35-44 years	4	3 (75)	2	2 (100)	6	5 (83)
45+ years	9	9 (100)	3	2 (67)	12	11 (92)
2007						
<25 years	1	1 (100)	4	4 (100)	5	5 (100)
25-34 years	7	7 (100)	2	1 (50)	9	8 (89)
35-44 years	0	0 (0)	2	1 (50)	2	1 (50)
45+ years	2	2 (100)	0	0 (0)	2	2 (100)
2008						
<25 years	1	0 (0)	1	1 (100)	2	1 (50)
25-34 years	4	2 (50)	3	3 (100)	7	5 (71)
35-44 years	7	5 (71)	2	0 (0)	9	5 (56)
45+ years	6	5 (83)	2	2 (100)	8	7 (88)
2009						
<25 years	8	3 (38)	5	4 (80)	13	7 (54)
25-34 years	15	12 (80)	5	3 (60)	20	15 (75)
35-44 years	7	5 (71)	9	5 (56)	16	10 (63)
45+ years	6	1 (17)	3	1 (33)	9	2 (22)
2010						
<25 years	3	2 (67)	0	0 (0)	3	2 (67)
25-34 years	29	19 (66)	10	6 (60)	39	25 (64)
35-44 years	23	17 (74)	9	6 (67)	32	23 (72)
45+ years	14	9 (64)	6	3 (50)	20	12 (60)
2011						
<25 years	1	1 (100)	3	0 (0)	4	1 (25)
25-34 years	26	17 (65)	14	5 (38)	40	22 (55)
35-44 years	20	14 (70)	7	2 (29)	27	16 (59)
45+ years	15	12 (80)	7	5 (71)	22	17 (77)
2012						
<25 years	4	1 (25)	0	0 (0)	4	1 (25)
25-34 years	7	3 (42)	7	3 (43)	14	6 (43)
35-44 years	26	19 (73)	11	7 (64)	37	26 (70)
45+ years	16	11 (69)	7	6 (86)	23	17 (74)
2013						
<25 years	3	1 (33)	1	0 (0)	4	1 (25)
25-34 years	12	7 (58)	15	8 (53)	27	15 (56)
35-44 years	27	21 (78)	10	7 (70)	37	28 (76)
45+ years	25	20 (80)	6	3 (50)	31	23 (74)
2014						
<25 years	4	1 (25)	2	0 (0)	6	1 (17)
25-34 years	11	5 (45)	5	3 (60)	16	8 (50)
35-44 years	29	22 (76)	10	9 (90)	39	31 (79)
45+ years	26	20 (79)	6	0 (0)	32	20 (63)
2014 p value		0.050		0.002		0.010

Table 2.3.3 HCV antibody prevalence by drug last injected, years of injection and year

Aust. Capital Territory	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heroin	5	3 (60)	29	20 (69)	34	23 (68)
Methamphetamine	1	0 (0)	5	4 (80)	6	4 (67)
Other opioids	0	0 (0)	8	5 (63)	8	5 (63)
Other drugs	1	0 (0)	5	1 (20)	6	1 (17)
1996						
Heroin	0	4 (31)	76	53 (70)	89	57 (64)
Methamphetamine	2	0 (0)	7	3 (43)	9	3 (33)
Other opioids	1	0 (0)	10	9 (90)	11	9 (82)
Other drugs	1	0 (0)	14	11 (79)	15	11 (73)
1997						
Heroin	24	4 (17)	39	23 (59)	63	27 (43)
Methamphetamine	4	2 (50)	4	1 (25)	8	3 (38)
Other opioids	1	0 (0)	3	1 (33)	4	1 (25)
Other drugs	2	0 (0)	2	1 (50)	4	1 (25)
1998						
Heroin	33	7 (21)	84	45 (54)	117	52 (44)
Methamphetamine	2	0 (0)	6	5 (83)	8	5 (63)
Other opioids	1	1 (100)	4	4 (100)	5	5 (100)
Other drugs	2	1 (50)	5	5 (100)	7	6 (86)
1999						
Heroin	22	5 (23)	46	39 (85)	68	44 (65)
Methamphetamine	6	1 (17)	9	4 (44)	15	5 (33)
Other opioids	0	0 (0)	1	1 (100)	1	1 (100)
Other drugs	0	0 (0)	6	4 (67)	6	4 (67)
2000						
Heroin	40	12 (30)	89	62 (70)	129	74 (57)
Methamphetamine	3	0 (0)	7	4 (57)	10	4 (40)
Other opioids	1	0 (0)	5	5 (100)	6	5 (83)
Other drugs	3	1 (33)	13	8 (62)	16	9 (56)
2001						
Heroin	1	1 (100)	11	7 (64)	12	8 (67)
Methamphetamine	2	0 (0)	14	7 (50)	16	7 (44)
Other opioids	0	0 (0)	10	9 (90)	10	9 (90)
Other drugs	0	0 (0)	2	1 (50)	2	1 (50)
2002						
Heroin	4	3 (75)	36	27 (75)	40	30 (75)
Methamphetamine	1	1 (100)	9	7 (78)	10	8 (80)
Other opioids	0	0 (0)	5	5 (100)	5	5 (100)
Other drugs	2	1 (100)	4	3 (75)	6	5 (83)
2003						
Heroin	3	3 (100)	27	22 (81)	30	25 (83)
Methamphetamine	2	1 (50)	15	13 (87)	17	14 (83)
Other opioids	0	0 (0)	6	5 (83)	6	5 (83)
Other drugs	0	0 (0)	7	4 (57)	7	4 (57)
2004						
Heroin	0	0 (0)	12	9 (75)	12	9 (75)
Methamphetamine	2	1 (50)	4	2 (50)	6	3 (50)
Other opioids	0	0 (0)	4	3 (75)	4	3 (75)
Other drugs	0	0 (0)	1	1 (100)	1	1 (100)

Table 2.3.3 HCV antibody prevalence by drug last injected, years of injection and year

Aust. Capital Territory	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	0	0 (0)	14	14 (100)	14	14 (100)
Methamphetamine	1	0 (0)	9	7 (78)	10	7 (70)
Other opioids	0	0 (0)	5	5 (100)	5	5 (100)
Other drugs	0	0 (0)	2	2 (100)	2	2 (100)
2006						
Heroin	0	0 (0)	17	14 (82)	17	14 (83)
Methamphetamine	1	0 (0)	19	11 (58)	20	11 (55)
Other opioids	0	0 (0)	8	7 (88)	8	7 (88)
Other drugs	0	0 (0)	1	1 (100)	1	1 (100)
2007						
Heroin	0	0 (0)	7	5 (71)	7	5 (71)
Methamphetamine	1	1 (100)	7	7 (100)	8	8 (100)
Other opioids	0	0 (0)	2	2 (100)	2	2 (100)
Other drugs	0	0 (0)	1	1 (100)	1	1 (100)
2008						
Heroin	0	0 (0)	12	10 (83)	12	10 (83)
Methamphetamine	1	0 (0)	7	4 (57)	8	4 (50)
Other opioids	0	0 (0)	5	3 (60)	5	3 (60)
Other drugs	0	0 (0)	0	0 (0)	0	0 (0)
2009						
Heroin	2	1 (100)	22	13 (59)	24	15 (63)
Methamphetamine	0	0 (0)	15	6 (40)	15	6 (40)
Other opioids	3	0 (0)	13	11 (85)	16	11 (69)
Other drugs	1	0 (0)	1	1 (100)	2	1 (50)
2010						
Heroin	0	0 (0)	27	19 (70)	27	19 (70)
Methamphetamine	1	0 (0)	26	13 (50)	26	13 (50)
Other opioids	0	0 (0)	29	23 (79)	29	23 (79)
Other drugs	0	0 (0)	12	8 (67)	13	8 (62)
2011						
Heroin	0	0 (0)	41	20 (49)	41	20 (49)
Methamphetamine	1	0 (0)	23	13 (57)	24	14 (58)
Other opioids	1	1 (100)	18	15 (83)	19	16 (84)
Other drugs	3	2 (67)	6	4 (67)	9	6 (67)
2012						
Heroin	1	0 (0)	29	22 (76)	30	22 (73)
Methamphetamine	1	1 (100)	22	12 (55)	23	13 (57)
Other opioids	0	0 (0)	15	11 (73)	15	11 (73)
Other drugs	1	0 (0)	8	4 (50)	9	4 (44)
2013						
Heroin	1	1 (100)	55	36 (65)	56	37 (66)
Methamphetamine	2	1 (50)	28	18 (64)	30	19 (63)
Other opioids	0	0 (0)	11	9 (82)	11	9 (82)
Other drugs	1	0 (0)	2	2 (100)	3	2 (67)
2014						
Heroin	2	0 (0)	40	25 (63)	42	27 (64)
Methamphetamine	0	0 (0)	27	15 (56)	29	15 (52)
Other opioids	2	1 (50)	13	12 (80)	15	12 (80)
Other drugs	1	0 (0)	7	7 (88)	8	7 (88)
2014 p value		1.000		0.059		0.159

3. NEW SOUTH WALES


3.1 New South Wales sample

Four NSP services in New South Wales (NSW) participated in the ANSPS in all 20 survey years 1995 to 2014 (Kirketon Road Centre; Parramatta NSP; Blacktown NSP and St George NSP, now known as Central Access Service). A further 11 of the current participating NSP services (Albury; Redfern; Mt Druitt; Murwillumbah/Tweed; Nimbin/Lismore; Byron/Ballina; Newcastle; South Court Primary Care, First Step Port Kembla, NUAA and K2/Clinic 180) participated in the ANSPS in ten or more survey years. Representation of regional/rural NSP services increased over time, with just under half of the 19 participating services in 2014 located in regional/rural locations. NSW sample sizes ranged from 433 (in 1995) to 1,001 (in 1998). Response rates ranged between 29% (in 2002) and 66% (in 1997).

3.2 Demographic Characteristics

As observed nationally, around two thirds of NSW ANSPS respondents were male in all survey years over the period 1995 to 2014. The majority of respondents (74% to 82%) identified as heterosexual, with between 7% and 13% of respondents identifying as bisexual and 4% to 8% identifying as homosexual. The proportion of Indigenous respondents in NSW increased significantly over the survey period in NSW, from 6% in 1995 to 18% in 2014 (χ^2 trend $p < 0.001$). The proportion of respondents born outside Australia and those reporting that their parents spoke a language other than English at home varied over the past 20 years, an observation largely due to site variation. In 2014, 85% of NSW respondents were born in Australia and 92% reported that their parents spoke English at home (Table 3.1.1).

Figure 3.2.1 NSW proportion of younger and older PWID by year



The proportion of young people (those aged less than 25 years) increased between 1995 and 1998, but declined significantly in subsequent years (Figure 3.2.1). There was a concomitant increase in the median age of respondents, from a low of 30 years over the period 1998 to 2002, to a high of 40 years in 2014. In 1995 around 10% of NSW ANSPS respondents were aged 40 years or older, increasing to 50% in 2014 (Figure 3.2.1). The median age at first injection remained stable at 17-19 years across all years.

3.3 Injecting behaviour

Drug last injected

Heroin and methamphetamine were the most commonly reported drugs last injected in NSW in all survey years. Heroin was reported as the drug most recently injected by the majority of NSW ANSPS respondents in all survey years except 2013 and 2014. As shown in Figure 3.3.1, prevalence of heroin injection declined significantly over the past decade, from 41% in 2005 to 28% in 2014 (χ^2 trend $p < 0.001$). Despite the observation that methamphetamine was the most common drug last injected in 2013 and 2014, methamphetamine injection in NSW was stable over the five year period 2010 to 2014, ranging from 26% in 2012 to 34% in 2014 (χ^2 trend $p = 0.096$).

Figure 3.3.1 NSW prevalence of heroin and methamphetamine as the drug last injected by year





Figure 3.3.2 NSW prevalence of pharmaceutical opioids and PIEDs as the drug last injected by year




Prevalence of pharmaceutical opioids as the class of drugs most recently injected increased over the period following changes to Australian heroin markets in 2001 (Maher et al., 2007; Degenhardt et al., 2006; Topp et al., 2003). In 2001, less than 1% of NSW ANSPS respondents reported last injecting pharmaceutical opioids, however prevalence increased in subsequent years, to a high of 11% in 2012 (χ^2 trend $p < 0.001$). Over the most recent five year period, prevalence of pharmaceutical opioid injection declined from 9% in 2010 to 5% in 2014 (χ^2 trend $p = 0.006$), with the decline in prevalence commencing in 2013.

Reports of steroids and other performance and image-enhancing drugs (PIEDs) as the drug last injected were stable at 1% to 2% in all survey years over the period 1995 to 2008 in NSW. Over the five year period 2010 to 2014, reports of PIEDs as the last drug injected increased from 4% to 19% (χ^2 trend $p < 0.001$), although increases in prevalence were not observed in 2013 or 2014.

Injection risk behaviour

There was a significant reduction in self-reported blood borne viral transmission risk behaviours among NSW respondents over the 20 year survey period. The proportion of respondents reporting re-use of needles and syringes (including re-use of one's own used syringe) in the previous month declined from around one in three respondents (30% to 35%) over the period 1997 to 2002, to one in four respondents (24% to 28%) over the period 2003 to 2010, with a further decline to one in five respondents (19% to 23%) reporting syringe re-use over the period 2011 to 2014 (Figure 3.3.3). Similarly, prevalence of recent receptive syringe sharing (use of someone else's used needle/syringe) declined from around one third of respondents in 1995 to between 13% and 18% in all survey years since 1997. Reports of receptive sharing of drug preparation equipment also declined from more than half of respondents (54%) in 1999 to one quarter of respondents (25%) in 2014.

Figure 3.3.3 NSW re-use of syringes and receptive sharing (RS) of syringes and drug preparation equipment by year




As occurred nationally and in other jurisdictions, prevalence of public injecting in NSW in the month preceding survey participation declined significantly from a high of 60% in 2000 to 36% in 2014 (χ^2 trend $p = 0.001$, Table 3.1.3).

3.4 Imprisonment, OST and BBV testing


The proportion of NSW ANSPS respondents with a history of imprisonment was relatively stable, with just over half of ANSPS respondents reporting a history of imprisonment in all survey years except 2014 (Figure 3.4.1). The proportion of respondents reporting incarceration in the 12 months preceding survey participation declined from 21% in 1995 to 13% in 2014 (χ^2 trend $p < 0.001$). The proportion of respondents reporting recent imprisonment was stable over the past five years, 2010 to 2014 (χ^2 trend $p = 0.350$). Among NSW respondents who were recently incarcerated, between one fifth (22%) and one half (47%) reported injecting in prison over the 20 year period 1995 to 2014 (Table 3.1.1).

Figure 3.4.1 NSW prison history and proportion of respondents who reported injecting in prison in the last 12 months by year




More than 60% of NSW ANSPS respondents reported a history of OST in all survey years over the period 1995 to 2014 (Figure 3.4.2, Table 3.1.7). The proportion of respondents who reported current OST was high at around 50% in all survey years except over the period 1999 to 2002 and in 2013 and 2014 when around 40% of NSW respondents reported currently receiving OST.

Figure 3.4.2 NSW current and history of OST by year



More than 80% of NSW ANSPS respondents reported a lifetime history of testing for HCV and/or HIV in all survey years (Table 3.1.5). The proportion of respondents who reported a recent HCV antibody test (last 12 months) declined significantly over the 20 year survey period, from 77% in 1998 to 51% in 2014 (χ^2 trend $p < 0.001$). The proportion of NSW respondents reporting a recent HIV test also declined significantly, from 78% in 1995 to 49% in 2014 (χ^2 trend $p < 0.001$, Figure 3.4.3).

Figure 3.4.3 NSW HCV and HIV testing in the last 12 months by year




3.5 Blood borne viral infections

HIV antibody prevalence


HIV antibody prevalence in NSW remained low at 3.5% or less in all survey years (Figure 3.5.1, Table 3.2.1), however prevalence among men increased over the period 2010 to 2014, from 1.9% (n=8) in 2010 to 3.0% (n=18) in 2014 (χ^2 trend $p = 0.019$). It is important to note that this increase could be due to sample variation.

Figure 3.5.1 NSW and National HIV antibody prevalence by year



As shown in Figure 3.5.2, HIV antibody prevalence was highest among respondents reporting male homosexual identity, with this group comprising between 4% and 8% of NSW samples and HIV prevalence ranging from 7% (in 1998) to 52% (in 2013) among this sub-population (Figure 3.5.2, Table 3.2.2).

Figure 3.5.2 NSW HIV antibody prevalence by sexual identity, gender and survey year




In 2014, the median age of HIV antibody positive respondents in NSW was 42 years and half (50%) reported last injecting methamphetamine (Table 3.2.4).

HCV antibody prevalence

Over the period 1995 to 2008, HCV antibody prevalence was consistently higher in NSW than observed nationally, with prevalence of around 70% in most years between 1995 and 2008 (Figure 3.5.1). As occurred nationally and in most other jurisdictions, HCV antibody prevalence declined to 58% in 2009 in NSW, with a further decline in subsequent years, to a low of 50% in 2012 (Table 3.3.1). HCV antibody prevalence was stable at 50% to 55% over the past five years, 2010 to 2014 (χ^2 trend $p=0.805$).

Figure 3.5.3 NSW and National HCV antibody prevalence by year



In NSW in 2014, the median age of HCV antibody positive respondents was 41 years, with one third (34%) reporting last injecting heroin and a further third (35%) reporting last injecting methamphetamine (Table 3.3.3). HCV antibody prevalence was higher among older respondents (Table 3.3.2) and those with longer injection histories (Figure 3.5.4)

Among new initiates to injection in NSW, HCV antibody prevalence was high in the period following changes to Australian heroin markets, with one in two NSW respondents exposed to HCV in 2001 and 2002. In NSW, the proportion of new initiates exposed to HCV declined over the period 2002 to 2004 (χ^2 trend $p < 0.001$), with a significant decline also occurring over the past five years, from 20% in 2010 to 6% in 2014 (χ^2 trend $p = 0.006$).

Figure 3.5.4 NSW HCV antibody prevalence by time since first injection and year




Table 3.1.1 Number (percentage) of respondents by demographic characteristic and year

New South Wales	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Number of sites	4	4	7	11	13	13	14	16	18	18
N° surveyed	N=433	N=499	N=682	N=1001	N=907	N=911	N=691	N=760	N=785	N=646
Response rate	40%	47%	66%	37%	41%	43%	40%	29%	39%	40%
Gender (%)										
Male	267 (62)	324 (65)	414 (61)	597 (60)	575 (63)	570 (63)	430 (62)	485 (64)	543 (69)	436 (67)
Female	159 (37)	170 (34)	267 (39)	398 (40)	326 (36)	336 (37)	252 (36)	267 (35)	233 (30)	205 (32)
Transgender	2 (<1)	1 (<1)	11 (<1)	3 (<1)	5 (1)	2 (<1)	5 (1)	6 (1)	4 (<1)	2 (<1)
Not reported	5 (1)	4 (1)	0 (0)	3 (<1)	1 (<1)	3 (<1)	4 (1)	2 (<1)	5 (<1)	3 (<1)
Sexual identity (%)										
Heterosexual	352 (81)	380 (76)	529 (78)	808 (81)	671 (74)	693 (76)	536 (78)	578 (76)	610 (78)	523 (81)
Bisexual	44 (10)	53 (11)	78 (11)	92 (9)	116 (13)	93 (10)	77 (11)	83 (11)	66 (8)	49 (8)
Homosexual	24 (6)	39 (8)	47 (7)	44 (4)	38 (4)	54 (6)	31 (4)	38 (5)	38 (5)	27 (4)
Not reported	13 (3)	27 (5)	28 (4)	57 (6)	82 (9)	71 (8)	47 (7)	61 (8)	71 (9)	47 (7)
Age and time since first injection (years)										
<i>Median age</i>	31	31	31	30	30	30	30	30	32	33
<i>Age range</i>	17-54	15-59	15-58	15-63	16-69	15-61	16-62	16-63	15-64	16-65
<i>Age group (%)</i>										
≤24 years	84 (19)	96 (19)	154 (23)	283 (28)	223 (25)	247 (27)	168 (24)	169 (22)	163 (21)	106 (16)
25+ years	344 (79)	402 (81)	528 (77)	717 (72)	683 (75)	664 (73)	521 (75)	590 (78)	622 (79)	539 (83)
Not reported	5 (1)	1 (<1)	0 (0)	1 (<1)	1 (<1)	0 (0)	2 (<1)	1 (<1)	0 (0)	1 (<1)
<i>Median age 1st injection</i>	17	17	18	18	18	18	18	18	18	18
<i>Age range</i>	10-40	11-48	10-49	10-46	10-55	10-54	10-52	10-59	10-50	10-50
<i>N° not reported</i>	6	18	20	24	19	23	22	26	21	14
<i>Median years injection</i>	13	12	11	10	10	9	10	10	11	12
<i>Range</i>	<1-33	<1-34	<1-37	<1-37	<1-35	<1-41	<1-44	<1-43	<1-45	<1-45
<i>Time since first injection</i>										
≤3 years	37 (9)	55 (11)	98 (14)	174 (19)	174 (19)	158 (17)	135 (20)	115 915)	119 (15)	68 (11)
4+ years	387 (89)	424 (85)	562 (82)	802 (80)	701 (77)	720 (79)	528 (76)	617 (81)	644 (82)	561 (87)
Not reported	9 (2)	20 (4)	22 (3)	25 (3)	32 (4)	33 (4)	28 (4)	29 (4)	22 (3)	17 (3)

Table 3.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
New South Wales										
Number of sites	19	18	21	22	20	21	20	20	20	19
N° surveyed	N=729	N=683	N=701	N=899	N=830	N=680	N=694	N=712	N=686	N=761
Response rate	44%	41%	37%	36%	39%	40%	36%	47%	38%	45%
Gender (%)										
Male	464 (64)	434 (64)	450 (64)	582(65)	500 (60)	427 (63)	463 (67)	476 (67)	475 (69)	539 (71)
Female	259 (36)	242 (35)	247 (35)	310 (34)	322 (39)	247 (36)	228 (33)	227 (32)	206 (30)	212 (28)
Transgender	6 (1)	6 (<1)	3 (<1)	4 (<1)	7 (<1)	5 (1)	3 (<1)	6 (1)	5 (<1)	9 (1)
Not reported	0 (0)	1 (<1)	1 (<1)	3 (<1)	1 (<1)	1 (<1)	0 (0)	3 (<1)	0 (0)	1 (<1)
Sexual identity (%)										
Heterosexual	590 (81)	553 (81)	575 (82)	715 (80)	669 (81)	545 (80)	563 (81)	576 (81)	548 (80)	610 (80)
Bisexual	58 (8)	65 (10)	64 (9)	93 (10)	77 (9)	76 (11)	61 (9)	60 (8)	50 (7)	69 (9)
Homosexual	48 (7)	45 (7)	45 (6)	56 (6)	40 (5)	25 (4)	38 (5)	25 (4)	45 (7)	44 (6)
Not reported	33 (5)	20 (3)	17 (2)	35 (4)	44 (5)	34 (5)	32 (5)	51 (7)	43 (6)	38 (5)
Age and time since first injection (years)										
<i>Median age</i>	34	36	37	37	38	39	38	39	39	40
<i>Age range</i>	17-66	15-65	16 – 69	17-70	18-64	18-69	18-63	18-64	18-65	17-67
Age group (%)										
≤24 years	89 (12)	61 (9)	59 (8)	81 (9)	66 (8)	54 (8)	51 (7)	55 (8)	52 (8)	57 (7)
25+ years	640 (88)	619 (91)	642 (92)	815 (91)	764 (92)	626 (92)	640 (92)	657 (92)	634 (92)	702 (92)
Not reported	0 (0)	3 (<1)	0 (0)	3 (<1)	0 (0)	0 (0)	3 (<1)	0 (0)	0 (0)	2 (<1)
<i>Median age 1st injection</i>	18	18	18	18	18	18	19	19	19	19
<i>Age range</i>	10-55	10-52	10-56	10-60	10-57	10-63	10-47	10-64	10-54	10-47
<i>N° not reported</i>	26	3	21	18	17	22	23	20	25	25
<i>Median years injection</i>	13	15	16	17	17	18	17	18	19	18.5
<i>Range</i>	<1-46	<1-43	<1-49	<1-48	<1-45	<1-45	<1-46	<1-46	<1-48	<1-47
Time since first injection										
≤3 years	47 (6)	52 (8)	33 (5)	65 (7)	53 (6)	62 (9)	83 (12)	91 (13)	77 (11)	85 (11)
4+ years	654 (90)	604 (88)	647 (92)	814 (91)	760 (92)	596 (88)	587 (85)	601 (84)	584 (85)	651 (86)
Not reported	28 (4)	27 (4)	21 (3)	20 (2)	17 (2)	22 (3)	24 (3)	20 (3)	25 (4)	35 (3)

Table 3.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
N° surveyed	N=433	N=499	N=682	N=1001	N=907	N=911	N=691	N=760	N=785	N=646
New South Wales										
Aboriginal and Torres Strait Islander origin (%)										
No	390 (91)	417 (83)	620 (91)	888 (89)	793 (87)	798 (88)	606 (88)	652 (86)	677 (86)	546 (84)
Yes	28 (6)	34 (7)	46 (7)	80 (8)	80 (9)	93 (10)	63 (9)	76 (10)	91 (12)	81 (13)
Not reported	15 (3)	48 (10)	16 (2)	33 (3)	34 (4)	20 (2)	22 (3)	32 (4)	17 (2)	19 (3)
Region/country of birth (%)										
Australia	--	--	--	--	775 (86)	691 (76)	352 (51)	542 (51)	547 (70)	454 (70)
Other Oceania	--	--	--	--	--	42 (5)	17 (2)	18 (2)	33 (4)	16 (2)
Asia	--	--	--	--	22 (2)	72 (8)	75 (11)	92 (12)	131 (17)	114 (18)
UK & Ireland	--	--	--	--	--	34 (3)	17 (2)	26 (4)	27 (3)	17 (3)
Other	--	--	--	--	75 (8)	42 (5)	28 (4)	33 (4)	42 (5)	31 (5)
Not reported	--	--	--	--	35 (4)	30 (3)	202 (30)	50 (7)	5 (1)	14 (2)
Main language spoken at home by parents (%)										
English	--	--	--	--	773 (85)	739 (81)	517 (75)	576 (76)	553 (70)	344 (53)
Non-English	--	--	--	--	87 (10)	137 (15)	156 (22)	159 (21)	197 (25)	143 (22)
Not reported	--	--	--	--	47 (5)	35 (4)	18 (3)	25 (3)	35 (4)	159 (25)
Imprisonment last year (%)										
No	335 (78)	384 (77)	543 (80)	746 (74)	721 (79)	671 (74)	520 (75)	582 (77)	599 (76)	493 (76)
Yes	93 (21)	94 (19)	137 (20)	240 (24)	170 (19)	211 (23)	147 (21)	160 (21)	169 (22)	148 (23)
Not reported	5 (1)	21 (4)	2 (<1)	15 (2)	16 (2)	29 (3)	24 (4)	18 (2)	17 (2)	5 (1)
Injected in prison last year (%)										
N° in prison	N=93	N=94	N=137	N=240	N=170	N=211	N=147	N=160	N=169	N=148
Injected in prison	33 (35)	40 (43)	49 (36)	110 (46)	80 (47)	99 (47)	58 (39)	61 (38)	60 (36)	67 (45)
Frequency of injection last month (%)										
Not last month	23 (5)	28 (6)	44 (6)	52 (5)	60 (7)	45 (5)	83 (12)	86 (11)	84 (11)	40 (6)
Less than weekly	71 (16)	83 (17)	169 (25)	90 (9)	115 (13)	85 (9)	107 (15)	108 (14)	160 (20)	118 (18)
Weekly not daily	146 (34)	165 (33)	93 (14)	197 (20)	178 (20)	182 (20)	150 (22)	162 (21)	168 (21)	167 (26)
Daily or more	191 (45)	219 (44)	369 (54)	660 (66)	548 (60)	585 (64)	336 (49)	393 (53)	359 (46)	312 (48)
Not reported	2 (<1)	4 (1)	7 (1)	2 (<1)	6 (1)	14 (2)	15 (2)	11 (1)	14 (2)	9 (2)

Table 3.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
New South Wales										
N° surveyed	N=729	N=683	N=701	N=899	N=830	N=680	N=694	N=712	N=686	N=761
Aboriginal and Torres Strait Islander origin (%)										
No	590 (81)	571 (84)	575 (82)	736 (82)	682 (82)	565 (83)	582 (84)	609 (86)	543 (79)	609 (80)
Yes	115 (16)	87 (13)	105 (15)	131 (15)	122 (15)	96 (14)	91 (13)	90 (13)	124 (18)	136 (18)
Not reported	24 (3)	25 (4)	21 (3)	32 (4)	26 (3)	19 (3)	21 (3)	13 (2)	19 (3)	16 (2)
Region/country of birth (%)										
Australia	628 (86)	575 (84)	592 (84)	781 (87)	726 (87)	581 (85)	588 (85)	621 (87)	602 (88)	646 (85)
Other Oceania	25 (3)	29 (4)	18 (3)	31 (3)	18 (2)	24 (4)	21 (3)	22 (3)	19 (3)	30 (4)
Asia	4 (1)	5 (<1)	10 (1)	8 (1)	4 (<1)	10 (1)	12 (2)	8 (1)	9 (1)	11 (1)
UK & Ireland	31 (4)	35 (5)	26 (4)	38 (4)	37 (4)	23 (3)	27 (4)	30 (4)	22 (3)	27 (4)
Other	33 (5)	28 (4)	38 (5)	28 (3)	28 (3)	24 (4)	33 (5)	21 (3)	32 (5)	37 (5)
Not reported	8 (1)	11 (2)	17 (2)	13 (1)	17 (2)	18 (3)	13 (2)	10 (1)	2 (<1)	10 (1)
Main language spoken at home by parents (%)										
English	629 (86)	593 (87)	648 (92)	844 (94)	787 (95)	645 (95)	643 (93)	675 (95)	636 (93)	698 (92)
Non-English	100 (14)	60 (9)	37 (5)	40 (4)	33 (4)	23 (3)	40 (6)	32 (4)	48 (7)	56 (7)
Not reported	0	30 (4)	16 (2)	15 (2)	10 (1)	12 (2)	11 (2)	5 (1)	2 (<1)	7 (1)
Imprisonment last year (%)										
No	568 (78)	556 (81)	566 (81)	687 (76)	684 (82)	492 (72)	567 (82)	603 (85)	569 (83)	601 (79)
Yes	130 (18)	94 (14)	103 (15)	137 (15)	103 (12)	77 (11)	82 (12)	75 (11)	85 (12)	99 (13)
Not reported	31 (4)	33 (5)	32 (5)	75 (8)	43 (5)	111 (16)	45 (2)	34 (5)	32 (5)	61 (8)
Injected in prison last year (%)										
N° in prison	N=130	N=94	N=103	N=137	N=103	N=77	N=82	N=75	N=85	N=99
Injected in prison	38 (29)	40 (43)	37 (36)	46 (34)	30 (29)	20 (26)	18 (22)	27 (36)	31 (36)	38 (38)
Frequency of injection last month (%)										
Not last month	71 (10)	88 (13)	81 (12)	126 (14)	129 (16)	119 (18)	105 (15)	110 (15)	102 (15)	89 (12)
Less than weekly	121 (17)	131 (19)	136 (19)	146 (16)	150 (18)	128 (19)	119 (17)	144 (20)	150 (22)	138 (18)
Weekly not daily	176 (24)	169 (25)	167 (24)	229 (25)	200 (24)	134 (20)	167 (24)	178 (25)	161 (23)	186 (24)
Daily or more	357 (49)	285 (42)	298 (43)	392 (44)	337 (41)	284 (42)	285 (41)	271 (38)	251 (37)	339 (44)
Not reported	4 (1)	10 (1)	19 (3)	6 (1)	14 (2)	15 (2)	18 (3)	9 (1)	22 (3)	9 (1)
Experienced overdose in the previous 12 months										
Yes	--	--	--	--	--	--	--	--	63 (9)	122 (16)

Table 3.1.2 Number (percentage) of respondents by drug last injected and year

New South Wales N° surveyed	1995 N=433	1996 N=499	1997 N=682	1998 N=1001	1999 N=907	2000 N=911	2001 N=691	2002 N=760	2003 N=785	2004 N=646
Drug last injected (%)										
Cocaine	15 (3)	26 (5)	31 (5)	55 (5)	52 (6)	25 (3)	146 (21)	26 (3)	17 (2)	41 (6)
Methamphetamine	35 (8)	44 (9)	59 (9)	74 (7)	110 (12)	113 (12)	115 (16)	173 (23)	140 (18)	148 (23)
Heroin	136 (31)	196 (39)	318 (46)	483 (48)	534 (59)	534 (59)	221 (32)	367 (48)	416 (53)	320 (50)
Pharm. opioids	3 (1)	8 (2)	1 (<1)	5 (1)	3 (<1)	5 (1)	4 (1)	14 (2)	16 (2)	21 (3)
Methadone	183 (42)	141 (28)	168 (24)	182 (18)	54 (6)	65 (7)	56 (8)	66 (9)	66 (8)	50 (8)
Buprenorphine	--	--	--	--	--	--	--	0 (0)	1 (<1)	3 (<1)
Buprenorphine/naloxone	--	--	--	--	--	--	--	--	--	--
PIEDs	3 (1)	8 (2)	11 (2)	16 (2)	24 (3)	12 (1)	14 (2)	17 (2)	37 (5)	11 (2)
More than one	56 (13)	72 (14)	85 (12)	174 (17)	120 (13)	138 (15)	110 (16)	82 (11)	66 (8)	39 (6)
Other	0 (0)	2 (<1)	4 (1)	5 (<1)	2 (<1)	8 (1)	11 (1)	5 (<1)	12 (2)	6 (1)
Not reported	2 (<1)	2 (<1)	5 (1)	7 (1)	8 (1)	11 (1)	14 (2)	10 (1)	14 (2)	7 (1)

New South Wales N° surveyed	2005 N=729	2006 N=683	2007 N=701	2008 N=899	2009 N=830	2010 N=680	2011 N=694	2012 N=712	2013 N=686	2014 N=761
Drug last injected (%)										
Cocaine	45 (6)	36 (5)	30 (4)	45 (5)	51 (6)	19 (3)	12 (2)	16 (2)	22 (3)	19 (3)
Methamphetamine	183 (25)	197 (29)	185 (26)	230 (26)	181 (22)	201 (30)	198 (29)	187 (26)	218 (32)	259 (34)
Heroin	296 (41)	231 (34)	254 (36)	346 (39)	306 (37)	236 (35)	211 (30)	216 (30)	178 (26)	216 (28)
Pharm. opioids	23 (3)	45 (7)	57 (8)	80 (9)	80 (10)	62 (9)	70 (10)	80 (11)	57 (8)	40 (5)
Methadone	105 (14)	96 (14)	88 (13)	107 (12)	116 (14)	59 (9)	79 (11)	69 (10)	75 (11)	70 (9)
Buprenorphine	2 (<1)	16 (2)	20 (3)	27 (3)	16 (2)	16 (2)	16 (2)	10 (1)	11 (2)	9 (1)
Buprenorphine/naloxone	--	--	--	--	6 (<1)	2 (<1)	1 (<1)	7 (1)	2 (<1)	3 (<1)
PIEDs	20 (3)	16 (2)	12 (2)	20 (2)	30 (4)	29 (4)	64 (9)	83 (12)	73 (11)	77 (10)
More than one	24 (3)	17 (2)	26 (4)	21 (2)	23 (3)	36 (5)	27 (4)	33 (5)	33 (5)	33 (4)
Other	6 (1)	9 (1)	18 (3)	8 (1)	0 (0)	16 (2)	15 (2)	4 (<1)	9 (1)	32 (4)
Not reported	25 (3)	20 (3)	11 (2)	15 (2)	21 (3)	4 (<1)	1 (<1)	7 (1)	8 (1)	3 (<1)

Table 3.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
New South Wales										
N° injected last month	N=408	N=467	N=631	N=947	N=841	N=852	N=593	N=667	N=687	N=597
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	--	--	--	--	352 (42)	293 (34)	192 (32)	174 (26)	211 (31)	181 (30)
Water	--	--	--	--	223 (27)	193 (23)	140 (24)	138 (21)	147 (21)	125 (21)
Filter	--	--	--	--	172 (20)	147 (17)	98 (17)	102 (15)	121 (18)	89 (15)
Drug mix	--	--	--	--	120 (14)	110 (13)	79 (13)	95 (14)	87 (13)	59 (10)
None	--	--	--	--	--	--	--	--	--	--
Public injecting in last month (%)										
Any public	--	--	237 (38)	465 (49)	471 (56)	512 (60)	310 (52)	324 (49)	309 (45)	218 (36)
All private	--	--	362 (57)	433 (46)	317 (38)	294 (35)	282 (48)	318 (48)	348 (51)	338 (51)
Not reported	--	--	32 (5)	49 (5)	53 (6)	46 (5)	1 (<1)	23 (3)	30 (4)	41 (7)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	--	--	--	--	781 (93)	783 (92)	544 (92)	604 (91)	586 (85)	530 (89)
Pharmacy	--	--	--	--	485 (58)	532 (62)	367 (62)	373 (56)	307 (45)	278 (47)
New South Wales										
N° injected last month	N=654	N=585	N=601	N=767	N=687	N=548	N=571	N=593	N=562	N=663
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	152 (23)	114 (20)	134 (25)	160 (23)	127 (20)	93 (17)	94 (16)	95 (16)	118 (21)	128 (19)
Water	107 (16)	68 (12)	101 (19)	114 (16)	81 (13)	64 (12)	64 (11)	75 (13)	86 (15)	99 (15)
Filter	66 (10)	36 (6)	62 (11)	78 (11)	52 (8)	36 (7)	39 (7)	47 (8)	51 (9)	63 (10)
Drug mix	67 (10)	45 (8)	45 (8)	50 (7)	52 (8)	29 (5)	35 (6)	34 (6)	47 (8)	47 (7)
None	--	358 (62)	353 (65)	457 (66)	420 (68)	370 (68)	432 (76)	428 (72)	418 (74)	480 (72)
Public injecting in last month (%)										
Any public	265 (41)	235 (40)	268 (46)	308 (40)	249 (36)	176 (32)	169 (30)	166 (28)	166 (30)	212 (32)
All private	337 (52)	326 (56)	317 (53)	446 (58)	430 (63)	331 (60)	388 (68)	412 (69)	393 (70)	447 (67)
Not reported	54 (8)	24 (4)	16 (3)	13 (1)	8 (1)	41 (7)	14 (2)	15 (3)	3 (<1)	4 (<1)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	602 (92)	539 (92)	435 (72)	687 (90)	474 (69)	491 (90)	521 (91)	527 (89)	518 (92)	585 (88)
Pharmacy	268 (41)	267 (46)	130 (22)	334 (44)	139 (20)	114 (21)	96 (17)	101 (17)	96 (17)	132 (20)

Table 3.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

New South Wales N° injected last month	1995 N=408	1996 N=467	1997 N=631	1998 N=947	1999 N=841	2000 N=852	2001 N=593	2002 N=667	2003 N=687	2004 N=597
Use of sterile needles and syringes last month (%)										
All injections	--	--	412 (61)	593 (59)	527 (58)	537 (59)	393 (66)	453 (68)	509 (74)	416 (70)
Most of the time	--	--	175 (26)	249 (25)	234 (26)	248 (27)	157 (27)	148 (23)	138 (20)	137 (23)
Half of the time	--	--	16 (2)	26 (3)	36 (4)	31 (3)	16 (3)	22 (3)	13 (2)	10 (2)
Some of the time	--	--	9 (1)	44 (4)	13 (1)	19 (2)	12 (2)	14 (2)	12 (2)	18 (3)
Not last month	--	--	0 (0)	2 (<1)	3 (<1)	6 (1)	2 (<1)	12 (2)	4 (<1)	4 (<1)
Not reported	--	--	70 (10)	87 (9)	94 (10)	70 (8)	13 (2)	14 (2)	11 (1)	12 (2)
Re-used someone else's used needle & syringe last month (%)										
None	266 (65)	319 (68)	510 (81)	736 (78)	623 (74)	667 (78)	481 (81)	520 (78)	561 (82)	473 (79)
Once	39 (10)	54 (12)	27 (4)	56 (6)	60 (7)	60 (7)	33 (6)	39 (6)	39 (6)	41 (7)
Twice	52 (13)	52 (11)	24 (3)	54 (6)	38 (5)	37 (5)	12 (2)	30 (5)	23 (3)	28 (5)
3-5 times	29 (7)	22 (5)	16 (3)	49 (5)	28 (3)	43 (5)	26 (4)	21 (3)	29 (4)	27 (4)
>5 times	22 (5)	18 (4)	16 (3)	20 (2)	27 (3)	16 (2)	19 (3)	17 (3)	14 (2)	10 (2)
Not reported	0 (0)	2 (1)	38 (6)	32 (3)	65 (8)	29 (3)	22 (4)	37 (6)	21 (3)	18 (3)
Number of people needle & syringe was re-used after last month (%)										
None	266 (65)	319 (68)	510 (81)	736 (78)	623 (74)	667 (78)	481 (81)	520 (78)	551 (80)	473 (79)
One	99 (24)	102 (22)	83 (13)	137 (14)	139 (17)	119 (14)	52 (9)	65 (10)	66 (10)	58 (10)
Two	34 (8)	38 (8)	14 (2)	30 (3)	23 (3)	16 (2)	10 (2)	12 (2)	7 (1)	10 (2)
Three to five	3 (1)	0 (0)	2 (<1)	8 (1)	11 (1)	8 (1)	5 (1)	5 (1)	8 (1)	3 (<1)
More than five	5 (1)	6 (1)	4 (1)	4 (1)	10 (1)	9 (1)	8 (1)	8 (1)	5 (<1)	3 (<1)
Don't know	0 (0)	0 (0)	0 (0)	0 (0)	4 (<1)	4 (1)	4 (1)	19 (3)	9 (1)	13 (2)
Not reported	1 (1)	2 (1)	18 (3)	32 (3)	31 (4)	29 (3)	33 (5)	35 (5)	41 (6)	37 (6)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	--	--	60 (10)	88 (9)	101 (12)	81 (10)	45 (8)	53 (8)	50 (7)	43 (7)
Casual sex partner	--	--	4 (1)	10 (1)	12 (1)	6 (1)	8 (1)	4 (1)	7 (1)	4 (1)
Close friend	--	--	23 (4)	60 (6)	70 (8)	50 (6)	23 (4)	36 (5)	31 (5)	24 (4)
Acquaintance	--	--	7 (1)	25 (3)	16 (2)	19 (2)	12 (2)	11 (2)	13 (2)	16 (3)
Other	--	--	3 (<1)	8 (1)	11 (1)	11 (1)	2 (<1)	8 (1)	6 (1)	6 (1)

Table 3.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
New South Wales										
N° injected last month	N=654	N=585	N=601	N=767	N=687	N=548	N=571	N=593	N=562	N=663
Use of sterile needles and syringes last month (%)										
All injections	472 (72)	407 (70)	431 (72)	544 (71)	500 (73)	368 (67)	439 (77)	439 (74)	445 (79)	527 (79)
Most of the time	146 (22)	129 (22)	130 (22)	174 (23)	157 (23)	108 (20)	95 (17)	112 (19)	87 (15)	103 (16)
Half of the time	15 (2)	12 (2)	17 (3)	22 (3)	10 (1)	14 (3)	9 (2)	10 (2)	11 (2)	10 (2)
Some of the time	6 (1)	10 (2)	9 (2)	11 (1)	9 (1)	11 (2)	7 (1)	6 (1)	11 (2)	4 (<1)
Not last month	1 (<1)	11 (2)	0 (0)	7 (1)	2 (<1)	6 (1)	1 (<1)	6 (1)	2 (<1)	6 (1)
Not reported	14 (2)	16 (3)	14 (2)	9 (1)	9 (1)	41 (7)	20 (4)	20 (3)	6 (1)	13 (2)
Re-used someone else's used needle & syringe last month (%)										
None	532 (82)	477 (82)	485 (81)	604 (79)	560 (82)	400 (73)	486 (85)	491 (83)	485 (86)	548 (83)
Once	26 (4)	31 (5)	42 (7)	50 (7)	44 (6)	33 (6)	25 (4)	35 (6)	24 (4)	45 (7)
Twice	24 (4)	20 (3)	19 (3)	42 (5)	33 (5)	19 (3)	16 (3)	12 (2)	27 (5)	27 (4)
3-5 times	26 (4)	17 (3)	17 (3)	26 (3)	18 (3)	16 (3)	12 (2)	20 (3)	11 (2)	20 (3)
>5 times	16 (2)	14 (2)	6 (1)	22 (3)	17 (2)	15 (3)	5 (1)	15 (3)	13 (2)	13 (2)
Not reported	27 (4)	26 (4)	32 (5)	23 (3)	15 (2)	65 (12)	27 (5)	20 (3)	2 (<1)	10 (2)
Number of people needle & syringe was re-used after last month (%)										
None	504 (77)	477 (82)	485 (81)	604 (79)	560 (82)	400 (73)	486 (85)	491 (83)	485 (86)	548 (83)
One	65 (10)	43 (7)	42 (7)	66 (9)	53 (8)	33 (6)	27 (5)	41 (7)	28 (5)	45 (7)
Two	5 (1)	7 (1)	7 (1)	11 (1)	6 (1)	7 (1)	4 (<1)	9 (2)	8 (1)	8 (1)
Three to five	5 (1)	2 (<1)	5 (<1)	10 (1)	3 (<1)	8 (1)	2 (<1)	1 (<1)	2 (<1)	4 (<1)
More than five	3 (<1)	2 (<1)	2 (<1)	3 (<1)	2 (<1)	4 (<1)	0 (0)	4 (<1)	5 (1)	6 (1)
Don't know	28 (4)	16 (3)	12 (2)	30 (4)	18 (3)	11 (2)	16 (3)	9 (2)	16 (3)	18 (3)
Not reported	44 (7)	38 (7)	48 (8)	43 (6)	45 (7)	85 (16)	36 (6)	38 (6)	18 (3)	34 (5)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	60 (9)	30 (5)	36 (6)	56 (7)	39 (6)	53 (10)	48 (8)	33 (6)	26 (5)	44 (7)
Casual sex partner	3 (<1)	5 (<1)	2 (<1)	7 (1)	3 (<1)	6 (1)	1 (<1)	1 (<1)	5 (1)	7 (1)
Close friend	29 (4)	15 (3)	27 (4)	39 (5)	16 (2)	23 (4)	21 (4)	25 (4)	22 (4)	16 (2)
Acquaintance	10 (2)	12 (2)	12 (2)	12 (2)	13 (2)	11 (2)	11 (2)	9 (2)	11 (2)	14 (2)
Other	4 (1)	4 (<1)	4 (<1)	8 (1)	11 (2)	13 (2)	12 (2)	0 (0)	8 (1)	7 (1)

Table 3.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

New South Wales N° surveyed	1995 N=433	1996 N=499	1997 N=682	1998 N=1001	1999 N=907	2000 N=911	2001 N=691	2002 N=760	2003 N=785	2004 N=646
Sex last month (%)										
No	97 (22)	128 (26)	250 (37)	352 (35)	291 (32)	347 (38)	231 (33)	224 (30)	216 (28)	204 (31)
Yes	307 (71)	357 (71)	431 (63)	637 (64)	609 (67)	553 (61)	448 (65)	515 (67)	558 (71)	431 (67)
Not reported	29 (7)	14 (3)	1 (<1)	12 (1)	7 (1)	11 (1)	12 (2)	21 (3)	11 (1)	11 (2)
Condom use at last sex (%)										
No	259 (60)	236 (48)	441 (65)	658 (66)	531 (58)	525 (58)	435 (63)	459 (60)	504 (64)	413 (67)
Yes	107 (25)	107 (21)	225 (33)	315 (31)	344 (38)	350 (38)	235 (34)	279 (37)	261 (33)	220 (34)
Not reported	67 (15)	156 (31)	16 (2)	28 (3)	32 (4)	36 (4)	21 (3)	22 (3)	20 (3)	13 (2)
Condom use with regular sex partner(s) last month (%)										
No	--	233 (73)	257 (64)	357 (66)	333 (64)	296 (64)	189 (62)	209 (59)	225 (62)	177 (68)
Sometimes	--	26 (8)	46 (12)	71 (13)	58 (11)	43 (9)	49 (16)	54 (15)	46 (13)	32 (12)
Always	--	60 (19)	95 (24)	113 (21)	127 (25)	124 (27)	69 (22)	90 (26)	91 (25)	52 (20)
Condom use with new sex partner(s) last month (%)										
No	--	43 (33)	57 (31)	51 (31)	85 (33)	66 (32)	95 (39)	93 (36)	85 (39)	80 (46)
Sometimes	--	14 (11)	23 (12)	26 (16)	37 (14)	23 (11)	46 (19)	36 (14)	34 (16)	29 (17)
Always	--	72 (56)	107 (57)	86 (53)	134 (53)	117 (57)	105 (42)	129 (50)	98 (45)	64 (37)
Condom use with casual sex partner(s) last month (%)										
No	--	--	--	58 (28)	83 (29)	71 (29)	93 (42)	86 (36)	108 (47)	63 (39)
Sometimes	--	--	--	34 (17)	60 (21)	31 (13)	47 (21)	54 (23)	33 (14)	31 (19)
Always	--	--	--	114 (55)	147 (50)	142 (58)	83 (37)	100 (41)	91 (39)	68 (42)
Sex work last month (%)										
No	393 (91)	414 (83)	592 (87)	890 (89)	771 (85)	775 (85)	577 (84)	647 (85)	693 (88)	568 (88)
Yes	27 (6)	52 (10)	74 (11)	84 (8)	110 (12)	105 (12)	85 (12)	85 (11)	62 (8)	65 (10)
Not reported	13 (3)	33 (7)	16 (2)	27 (3)	26 (3)	31 (3)	29 (4)	28 (4)	30 (4)	13 (2)
Condom used at last sex work (%)										
Yes	23 (100)	46 (94)	59 (95)	73 (94)	98 (93)	72 (94)	53 (91)	57 (95)	50 (89)	59 (94)

Table 3.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

New South Wales N° surveyed	2005 N=729	2006 N=683	2007 N=701	2008 N=899	2009 N=830	2010 N=680	2011 N=694	2012 N=712	2013 N=686	2014 N=761
Sex with a regular partner last month (%)										
No	314 (43)	288 (42)	300 (43)	392 (44)	369 (44)	280 (41)	307 (44)	324 (46)	320 (47)	355 (47)
Yes	397 (54)	376 (55)	375 (54)	481 (54)	439 (53)	370 (54)	334 (48)	360 (51)	348 (51)	377 (50)
Not reported	18 (2)	19 (3)	26 (4)	26 (3)	22 (3)	30 (4)	53 (8)	28 (4)	18 (3)	29 (4)
Condom used with regular partner last month (%)										
Never	N=397	N=376	N=375	N=481	N=439	N=370	N=334	N=360	N=348	N=377
Sometimes	277 (70)	259 (69)	275 (73)	330 (69)	378 (86)	273 (74)	238 (71)	254 (71)	232 (67)	265 (70)
Every time	59 (15)	51 (14)	38 (10)	61 (13)	43 (10)	42 (11)	32 (10)	47 (13)	62 (18)	49 (13)
Not reported	46 (12)	28 (7)	49 (13)	69 (14)	2 (<1)	35 (9)	46 (14)	39 (11)	42 (12)	43 (11)
	15 (4)	38 (10)	13 (3)	21 (4)	16 (4)	20 (5)	18 (5)	20 (6)	12 (3)	20 (5)
Sex with other partner(s) last month (%)										
No	583 (80)	525 (77)	570 (81)	705 (78)	665 (80)	532 (78)	557 (80)	584 (82)	540 (79)	588 (77)
Yes	125 (17)	124 (18)	100 (14)	165 (18)	126 (15)	103 (15)	102 (15)	94 (13)	120 (17)	133 (17)
Not reported	21 (3)	34 (5)	31 (4)	29 (3)	39 (5)	45 (7)	35 (5)	34 (5)	26 (4)	40 (5)
Condom used with other partner(s) last month (%)										
Never	N=125	N=124	N=100	N=165	N=126	N=103	N=102	N=94	N=120	N=133
Sometimes	31 (25)	26 (21)	28 (28)	38 (23)	47 (37)	44 (43)	27 (26)	28 (30)	38 (32)	45 (34)
Every time	34 (27)	38 (31)	17 (17)	39 (24)	22 (17)	17 (17)	28 (27)	29 (31)	35 (29)	34 (26)
Not reported	56 (45)	53 (43)	47 (47)	79 (48)	55 (44)	39 (38)	46 (45)	32 (34)	40 (33)	43 (32)
	4 (3)	7 (6)	8 (8)	9 (5)	2 (2)	3 (3)	1 (1)	5 (5)	7 (6)	11 (8)
Sex work last month (%)										
No	660 (91)	586 (86)	618 (88)	771 (86)	740 (89)	568 (84)	618 (89)	637 (89)	607 (88)	642 (84)
Yes	52 (7)	59 (9)	50 (7)	78 (9)	57 (7)	51 (8)	38 (5)	42 (6)	33 (5)	51 (7)
Not reported	17 (2)	38 (6)	33 (5)	50 (6)	33 (4)	61 (9)	38 (5)	33 (5)	46 (7)	68 (9)
Condom used at last sex work (%)										
Yes	72 (94)	49 (88)	47 (98)	57 (84)	52 (91)	39 (80)	30 (83)	35 (85)	27 (93)	35 (76)

Table 3.1.5 Number (percentage) of respondents by testing for HIV and HCV infection by year

New South Wales N° surveyed	1995 N=433	1996 N=499	1997 N=682	1998 N=1001	1999 N=907	2000 N=911	2001 N=691	2002 N=760	2003 N=785	2004 N=646
Previous HIV test (%)										
Yes, ever	415 (96)	470 (94)	644 (94)	876 (88)	801 (88)	800 (88)	600 (87)	659 (87)	700 (89)	587 (91)
Yes, last year	319 (74)	398 (80)	536 (79)	797 (80)	604 (67)	618 (68)	437 (63)	491 (65)	501 (64)	411 (64)
>1 year ago	79 (18)	85 (17)	118 (17)	185 (18)	197 (22)	182 (20)	163 (24)	168 (22)	199 (25)	176 (27)
Never tested	30 (7)	14 (3)	23 (3)	9 (1)	92 (10)	98 (11)	78 (11)	90 (12)	81 (10)	54 (8)
Not reported	5 (1)	2 (<1)	5 (1)	10 (1)	14 (1)	13 (1)	13 (2)	11 (1)	4 (<1)	5 (1)
Previous HCV test (%)										
Yes, ever	365 (84)	443 (89)	622 (91)	855 (85)	797 (88)	815 (89)	626 (91)	673 (88)	691 (88)	594 (92)
Yes, last year	--	--	528 (77)	694 (69)	610 (67)	667 (73)	479 (69)	510 (68)	492 (63)	429 (66)
>1 year ago	--	--	94 (14)	161 (16)	187 (21)	148 (16)	147 (21)	163 (21)	199 (25)	165 (26)
Never tested	59 (14)	48 (10)	55 (8)	139 (14)	97 (11)	83 (9)	55 (8)	79 (10)	90 (11)	45 (7)
Not reported	9 (2)	8 (2)	5 (1)	7 (1)	13 (1)	13 (1)	10 (2)	9 (1)	4 (<1)	7 (1)
New South Wales										
N° surveyed	2005 N=729	2006 N=683	2007 N=701	2008 N=899	2009 N=830	2010 N=680	2011 N=694	2012 N=712	2013 N=686	2014 N=761
Previous HIV test (%)										
Yes, ever	662 (91)	608 (89)	620 (88)	777 (86)	727 (88)	564 (83)	575 (83)	582 (82)	576 (84)	610 (80)
Yes, last year	436 (60)	409 (60)	392 (56)	443 (49)	423 (51)	337 (50)	331 (48)	310 (44)	336 (49)	374 (49)
>1 year ago	226 (31)	199 (29)	228 (33)	334 (37)	304 (37)	227 (33)	244 (35)	272 (38)	240 (35)	236 (31)
Never tested	64 (9)	60 (9)	65 (9)	73 (8)	69 (8)	69 (10)	92 (13)	96 (13)	100 (15)	116 (15)
Not reported	3 (0)	15 (2)	16 (2)	49 (5)	34 (4)	47 (7)	27 (4)	34 (5)	10 (1)	35 (5)
Previous HCV test (%)										
Yes, ever	663 (91)	623 (91)	635 (91)	821 (91)	762 (92)	573 (84)	583 (84)	607 (85)	571 (83)	648 (85)
Yes, last year	452 (62)	420 (61)	420 (60)	494 (55)	497 (60)	357 (53)	354 (51)	364 (51)	342 (50)	389 (51)
>1 year ago	211 (29)	203 (30)	215 (31)	327 (36)	265 (32)	216 (32)	229 (33)	243 (34)	229 (33)	259 (34)
Never tested	64 (9)	47 (7)	52 (7)	45 (5)	39 (5)	59 (9)	67 (10)	64 (9)	62 (9)	80 (11)
Not reported	2 (0)	13 (2)	14 (2)	33 (4)	29 (3)	48 (7)	44 (6)	41 (6)	53 (8)	33 (4)

Table 3.1.6 Number (percentage) of respondents by HCV treatment by year

	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
New South Wales					N=401	N=451	N=337	N=390	N=389	N=341
Self-report HCV diagnosis	--	--	--	--	--	--	--	--	--	--
Any treatment for HCV (%)										
Interferon+/Ribavirin	--	--	--	--	10 (3)	24 (5)	11 (3)	16 (4)	16 (4)	16 (5)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	17 (4)	17 (4)	6 (2)	9 (2)	5 (1)	13 (4)
No treatment	--	--	--	--	367 (92)	402 (89)	315 (93)	356 (92)	357 (92)	302 (88)
Not reported	--	--	--	--	7 (2)	8 (2)	5 (1)	9 (2)	12 (3)	10 (3)
Current treatment for HCV (%)										
Interferon +/-or Ribavirin	--	--	--	--	4	4	3	2	2	3
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	4	9	2	2	4	3
New South Wales					N=508	N=368	N=364	N=375	N=364	N=378
Self-report HCV diagnosis										
Any treatment for HCV (%)										
Interferon +/-or Ribavirin	19 (5)	17 (5)	12 (3)	53 (10)	50 (10)	47 (13)	36 (10)	46 (12)	39 (11)	42 (11)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	3 (1)	4 (1)
Other	4 (1)	8 (2)	4 (1)	5 (1)	3 (<1)	5 (1)	4 (1)	3 (1)	8 (2)	4 (1)
No treatment	346 (93)	327 (90)	312 (91)	470 (86)	432 (85)	301 (82)	296 (81)	304 (81)	299 (82)	309 (82)
Not reported	3 (1)	11 (3)	16 (5)	18 (3)	23 (5)	15 (4)	28 (8)	22 (6)	15 (4)	12 (3)
Current treatment for HCV (%)										
Interferon +/-or Ribavirin	3	3	2	9	5	11	7	5	3	5
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	2	4
Other	0	4	1	4	1	3	3	2	2	3

Table 3.1.7 Number (percentage) of respondents by drug treatment by year

New South Wales N° surveyed	1995 N=433	1996 N=499	1997 N=682	1998 N=1001	1999 N=907	2000 N=911	2001 N=691	2002 N=760	2003 N=785	2004 N=646
Ever any treatment/therapy for drug use (%)										
No	45 (10)	77 (15)	111 (16)	200 (20)	238 (26)	211 (23)	165 (24)	189 (25)	208 (27)	80 (12)
Yes	387 (89)	419 (84)	569 (83)	798 (80)	667 (74)	666 (73)	520 (75)	559 (73)	575 (73)	555 (86)
Not reported	1 (1)	3 (1)	2 (1)	3 (<1)	2 (<1)	34 (4)	6 (1)	12 (2)	2 (<1)	11 (2)
History of methadone maintenance treatment (%)										
Current	300 (69)	279 (56)	382 (56)	500 (50)	369 (40)	304 (33)	294 (43)	266 (35)	331 (42)	285 (44)
Previous	55 (13)	110 (22)	120 (18)	190 (19)	178 (20)	253 (28)	134 (19)	199 (26)	173 (22)	153 (24)
Never	77 (18)	107 (21)	178 (26)	308 (31)	359 (40)	347 (38)	256 (37)	281 (37)	279 (35)	198 (31)
Not reported	1 (<1)	3 (1)	2 (<1)	3 (<1)	1 (<1)	7 (1)	7 (1)	15 (2)	2 (<1)	10 (1)
History of other pharmacotherapy treatment (%)										
Current	--	--	--	--	--	8 (1)	31 (4)	29 (4)	83 (11)	70 (11)
Previous	--	--	--	--	--	79 (9)	50 (7)	82 (11)	145 (18)	141 (22)
Never	--	--	--	--	--	824 (90)	598 (87)	627 (82)	544 (69)	413 (64)
Not reported	--	--	--	--	--	0 (0)	12 (2)	22 (3)	13 (2)	22 (3)
New South Wales N° surveyed										
2005 N=729										
2006 N=683										
2007 N=701										
2008 N=899										
2009 N=830										
2010 N=680										
2011 N=694										
2012 N=712										
2013 N=686										
2014 N=2378										
Ever any treatment/therapy for drug use (%)										
No	123 (17)	97 (14)	106 (15)	128 (14)	112 (13)	111 (16)	138 (20)	174 (24)	162 (24)	200 (26)
Yes	599 (82)	565 (82)	578 (82)	754 (84)	704 (85)	551 (81)	525 (76)	526 (74)	512 (75)	543 (71)
Not reported	7 (1)	21 (3)	17 (2)	17 (2)	14 (2)	18 (3)	31 (4)	12 (2)	12 (2)	18 (2)
History of methadone maintenance treatment (%)										
Current	320 (44)	298 (44)	286 (41)	379 (42)	396 (48)	279 (41)	273 (39)	289 (41)	263 (38)	251 (33)
Previous	153 (21)	169 (25)	182 (26)	219 (24)	177 (21)	143 (21)	128 (18)	143 (20)	146 (21)	158 (21)
Never	250 (34)	201 (29)	218 (31)	281 (31)	236 (28)	218 (32)	245 (35)	275 (39)	269 (39)	336 (44)
Not reported	6 (1)	15 (2)	15 (2)	20 (2)	21 (3)	40 (6)	48 (7)	5 (<1)	8 (1)	16 (2)
History of other pharmacotherapy treatment (%)										
Current	76 (10)	62 (9)	63 (9)	133 (15)	109 (13)	81 (12)	81 (12)	92 (13)	59 (9)	70 (9)
Previous	160 (22)	147 (22)	159 (23)	188 (21)	206 (25)	165 (24)	152 (22)	160 (22)	170 (25)	187 (25)
Never	481 (66)	455 (67)	458 (65)	557 (62)	493 (59)	426 (61)	437 (63)	454 (64)	449 (65)	491 (65)
Not reported	12 (2)	19 (3)	21 (3)	21 (2)	22 (3)	8 (1)	24 (3)	6 (1)	8 (1)	13 (2)

HIV antibody prevalence

Table 3.2.1 HIV antibody prevalence by gender and year

New South Wales	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995	259	6 (2.3)	155	4 (2.6)	420	11 (2.6)
1996	317	8 (2.5)	162	5 (3.1)	484	13 (2.7)
1997	384	6 (1.6)	254	1 (0.4)	639	7 (1.1)
1998	542	5 (0.9)	368	1 (0.3)	916	6 (0.7)
1999	536	8 (1.5)	312	1 (0.3)	854	9 (1.1)
2000	535	11 (2.1)	326	0 (0.0)	866	11 (1.3)
2001	406	6 (1.5)	241	0 (0.0)	656	6 (0.9)
2002	469	13 (2.8)	261	1 (0.4)	738	15 (2.0)
2003	533	12 (2.3)	230	0 (0.0)	772	13 (1.7)
2004	407	6 (1.5)	194	1 (0.5)	606	7 (1.2)
2005	437	6 (1.4)	243	0 (0.0)	686	6 (0.9)
2006	424	12 (2.8)	232	1 (0.4)	663	14 (2.1)
2007	439	12 (2.7)	240	2 (0.8)	683	15 (2.2)
2008	563	15 (2.7)	297	3 (1.0)	860	18 (2.1)
2009	488	12 (2.5)	320	0 (0.0)	816	13 (1.6)
2010	422	8 (1.9)	243	0 (0.0)	671	8 (1.2)
2011	455	5 (1.1)	224	1 (0.5)	682	7 (1.0)
2012	465	7 (1.5)	223	0 (0.0)	697	8 (1.2)
2013	456	20 (4.4)	204	0 (0.0)	665	21 (3.2)
2014	505	15 (3.0)	202	0 (0.0)	714	18 (2.5)
X^2 p trend: 1995-2014		0.038		0.003		0.066
X^2 p trend: 2010-2014		0.019		0.522		0.004

Table 3.2.2 HIV antibody prevalence by sexual identity, gender and year

New South Wales	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
Heterosexual	225	1 (0.4)	113	2 (1.7)	341	4 (1.2)
Bisexual	11	0 (0.0)	31	1 (3.2)	43	1 (2.3)
Homosexual	14	5 (35.7)	9	1 (11.1)	24	6 (25.0)
1996						
Heterosexual	256	0 (0.0)	113	3 (2.7)	371	3 (0.8)
Bisexual	23	2 (8.7)	26	0 (0.0)	49	2 (4.1)
Homosexual	23	6 (26.1)	14	1 (7.1)	37	7 (18.9)
1997						
Heterosexual	319	1 (0.3)	173	1 (0.6)	492	2 (0.4)
Bisexual	30	0 (0.0)	44	0 (0.0)	74	0 (0.0)
Homosexual	17	5 (29.4)	28	0 (0.0)	45	5 (11.1)
1998						
Heterosexual	459	2 (0.4)	274	0 (0.0)	735	2 (0.3)
Bisexual	30	2 (6.7)	60	1 (1.7)	90	3 (3.3)
Homosexual	14	1 (7.1)	23	0 (0.0)	37	1 (2.7)
1999						
Heterosexual	424	3 (0.7)	208	1 (0.5)	632	4 (0.6)
Bisexual	34	0 (0.0)	69	0 (0.0)	107	0 (0.0)
Homosexual	26	5 (19.2)	11	0 (0.0)	37	5 (13.5)
2000						
Heterosexual	451	6 (1.3)	204	0 (0.0)	656	6 (0.9)
Bisexual	18	1 (5.6)	69	0 (0.0)	88	1 (1.1)
Homosexual	22	4 (18.2)	31	0 (0.0)	53	4 (7.6)
2001						
Heterosexual	342	1 (0.3)	168	0 (0.0)	512	1 (0.2)
Bisexual	21	1 (4.8)	49	0 (0.0)	72	1 (1.4)
Homosexual	15	4 (26.7)	14	0 (0.0)	29	4 (13.8)
2002						
Heterosexual	388	3 (0.8)	175	1 (0.6)	566	4 (0.7)
Bisexual	24	1 (4.2)	51	0 (0.0)	79	2 (2.5)
Homosexual	20	8 (40.0)	14	0 (0.0)	34	8 (23.5)
2003						
Heterosexual	460	6 (1.3)	138	0 (0.0)	600	6 (1.0)
Bisexual	16	0 (0.0)	47	0 (0.0)	65	1 (1.5)
Homosexual	17	6 (35.3)	19	0 (0.0)	37	6 (16.2)
2004						
Heterosexual	345	0 (0.0)	141	1 (0.7)	487	1 (0.2)
Bisexual	15	0 (0.0)	33	0 (0.0)	48	0 (0.0)
Homosexual	14	6 (42.9)	11	0 (0.0)	25	6 (24.0)

Table 3.2.2 HIV antibody prevalence by sexual identity, gender and year (continued)

New South Wales	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Heterosexual	386	1 (0.3)	171	0 (0.0)	557	1 (0.2)
Bisexual	10	0 (0.0)	44	0 (0.0)	55	0 (0.0)
Homosexual	24	5 (20.8)	16	0 (0.0)	44	5 (11.4)
2006						
Heterosexual	366	2 (0.6)	170	1 (0.6)	537	3 (0.6)
Bisexual	23	3 (13.0)	38	0 (0.0)	64	4 (6.3)
Homosexual	27	7 (25.9)	16	0 (0.0)	44	7 (15.9)
2007						
Heterosexual	383	4 (1.0)	174	2 (1.2)	558	6 (1.1)
Bisexual	21	0 (0.0)	42	0 (0.0)	64	1 (1.6)
Homosexual	25	8 (32.0)	19	0 (0.0)	44	8 (18.2)
2008						
Heterosexual	488	2 (0.4)	202	1 (0.5)	691	3 (0.4)
Bisexual	25	0 (0.0)	63	2 (3.2)	89	3 (3.4)
Homosexual	31	13 (41.9)	21	0 (0.0)	54	13 (24.1)
2009						
Heterosexual	424	2 (0.5)	232	0 (0.0)	658	2 (0.3)
Bisexual	21	0 (0.0)	53	0 (0.0)	76	1 (1.3)
Homosexual	22	10 (45.5)	15	0 (0.0)	39	10 (25.6)
2010						
Heterosexual	371	1 (0.3)	166	0 (0.0)	539	1 (0.2)
Bisexual	14	0 (0.0)	58	0 (0.0)	74	0 (0.0)
Homosexual	15	7 (46.7)	8	0 (0.0)	24	7 (29.2)
2011						
Heterosexual	397	1 (0.3)	158	0 (0.0)	555	1 (0.2)
Bisexual	17	1 (5.6)	40	1 (2.5)	59	3 (5.1)
Homosexual	21	3 (14.3)	15	0 (0.0)	37	3 (8.1)
2012						
Heterosexual	410	1 (0.2)	153	0 (0.0)	565	1 (0.2)
Bisexual	14	0 (0.0)	42	0 (0.0)	58	1 (1.7)
Homosexual	15	5 (33.3)	7	0 (0.0)	24	5 (20.8)
2013						
Heterosexual	384	2 (0.5)	143	0 (0.0)	528	2 (0.4)
Bisexual	21	1 (4.8)	28	0 (0.0)	50	2 (4.0)
Homosexual	31	16 (51.6)	11	0 (0.0)	45	16 (35.6)
2014						
Heterosexual	434	3 (0.7)	135	0 (0.0)	571	3 (0.5)
Bisexual	17	2 (11.8)	44	0 (0.0)	65	5 (7.7)
Homosexual	31	10 (32.3)	10	0 (0.0)	42	10 (23.8)
2014 p value		<0.001		--		<0.001

Table 3.2.3 HIV antibody prevalence by age group, gender and year

New South Wales	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
<25 years	37	3 (8.1)	41	1 (2.4)	78	4 (5.0)
25-34 years	130	1 (0.8)	71	2 (2.8)	201	3 (1.5)
35-44 years	82	1 (1.2)	39	1 (2.6)	121	2 (2.4)
45+ years	6	1 (16.7)	3	0 (0.0)	9	1 (10.0)
1996						
<25 years	55	0 (0.0)	36	2 (5.6)	91	2 (2.2)
25-34 years	139	4 (2.9)	90	1 (1.1)	229	5 (2.2)
35-44 years	112	4 (3.6)	31	2 (6.5)	143	6 (4.2)
45+ years	10	0 (0.0)	5	0 (0.0)	15	0 (0.0)
1997						
<25 years	77	0 (0.0)	65	0 (0.0)	142	0 (0.0)
25-34 years	162	4 (2.5)	123	1 (0.8)	285	5 (1.8)
35-44 years	129	1 (0.8)	61	0 (0.0)	190	1 (0.5)
45+ years	16	1 (6.3)	5	0 (0.0)	21	1 (4.8)
1998						
<25 years	144	0 (0.0)	118	0 (0.0)	262	0 (0.0)
25-34 years	203	4 (2.0)	147	0 (0.0)	350	4 (1.1)
35-44 years	156	1 (0.6)	92	1 (1.1)	248	2 (0.8)
45+ years	38	0 (0.0)	11	0 (0.0)	49	0 (0.0)
1999						
<25 years	127	0 (0.0)	83	1 (1.2)	210	1 (0.5)
25-34 years	236	5 (2.1)	144	0 (0.0)	380	5 (1.3)
35-44 years	138	1 (0.7)	71	0 (0.0)	209	1 (0.5)
45+ years	35	2 (5.7)	14	0 (0.0)	49	2 (4.1)
2000						
<25 years	127	0 (0.0)	112	0 (0.0)	240	0 (0.0)
25-34 years	218	2 (2.8)	135	0 (0.0)	355	6 (1.7)
35-44 years	147	2 (1.4)	57	0 (0.0)	206	2 (1.0)
45+ years	43	3 (7.0)	22	0 (0.0)	65	3 (4.6)
2001						
<25 years	82	0 (0.0)	73	0 (0.0)	155	0 (0.0)
25-34 years	157	2 (1.3)	95	0 (0.0)	252	2 (0.8)
35-44 years	134	4 (3.0)	57	0 (0.0)	191	4 (2.1)
45+ years	33	0 (0.0)	15	0 (0.0)	48	0 (0.0)
2002						
<25 years	90	0 (0.0)	76	0 (0.0)	166	0 (0.0)
25-34 years	187	8 (4.3)	104	1 (1.0)	291	10 (3.4)
35-44 years	133	2 (1.5)	61	0 (0.0)	194	2 (1.0)
45+ years	57	3 (5.3)	20	0 (0.0)	77	3 (3.9)
2003						
<25 years	111	4 (3.6)	52	0 (0.0)	163	4 (2.5)
25-34 years	199	2 (1.0)	94	0 (0.0)	293	2 (1.0)
35-44 years	172	4 (2.3)	70	0 (0.0)	242	4 (1.6)
45+ years	51	2 (3.9)	14	0 (0.0)	65	2 (3.1)
2004						
<25 years	63	0 (0.0)	36	1 (2.8)	99	1 (1.0)
25-34 years	0	2 (1.3)	72	0 (0.0)	72	2 (0.9)
35-44 years	134	3 (2.2)	59	0 (0.0)	193	3 (1.6)
45+ years	52	1 (2.0)	27	0 (0.0)	79	1 (1.2)

Table 3.2.3 HIV antibody prevalence by age group, gender and year (continued)

New South Wales	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
<25 years	42	1 (2.4)	39	0 (0.0)	81	1 (1.2)
25-34 years	154	2 (1.3)	109	0 (0.0)	263	2 (0.8)
35-44 years	164	1 (0.6)	68	0 (0.0)	232	1 (0.4)
45+ years	75	2 (2.7)	26	0 (0.0)	101	2 (1.9)
2006						
<25 years	34	1 (2.9)	25	0 (0.0)	59	1 (1.7)
25-34 years	136	2 (1.5)	86	1 (1.2)	222	3 (1.7)
35-44 years	170	5 (2.9)	78	0 (0.0)	248	5 (2.0)
45+ years	83	4 (4.8)	41	0 (0.0)	124	4 (3.2)
2007						
<25 years	28	0 (0.0)	28	0 (0.0)	56	0 (0.0)
25-34 years	142	4 (2.8)	74	0 (0.0)	216	4 (1.8)
35-44 years	166	2 (1.2)	91	1 (1.1)	257	3 (1.6)
45+ years	103	6 (5.8)	47	1 (2.1)	150	7 (4.6)
2008						
<25 years	45	0 (0.0)	34	0 (0.0)	79	0 (0.0)
25-34 years	167	4 (2.4)	101	3 (3.0)	268	7 (3.0)
35-44 years	216	7 (3.2)	109	0 (0.0)	325	7 (2.1)
45+ years	132	4 (3.0)	53	0 (0.0)	185	4 (2.1)
2009						
<25 years	26	0 (0.0)	38	0 (0.0)	64	0 (0.0)
25-34 years	136	2 (1.5)	109	0 (0.0)	245	2 (0.8)
35-44 years	186	7 (3.8)	121	0 (0.0)	307	7 (2.6)
45+ years	140	3 (2.1)	52	0 (0.0)	192	3 (1.5)
2010						
<25 years	27	1 (3.7)	25	0 (0.0)	52	1 (1.9)
25-34 years	107	1 (0.9)	85	0 (0.0)	192	1 (0.5)
35-44 years	165	3 (1.8)	72	0 (0.0)	237	3 (1.3)
45+ years	123	3 (2.4)	59	0 (0.0)	182	3 (1.6)
2011						
<25 years	40	1 (2.5)	10	0 (0.0)	50	1 (2.0)
25-34 years	123	0 (0.0)	88	1 (1.1)	211	1 (0.5)
35-44 years	150	2 (1.3)	70	0 (0.0)	220	2 (1.4)
45+ years	140	2 (1.4)	55	0 (0.0)	195	2 (1.0)
2012						
<25 years	42	0 (0.0)	10	0 (0.0)	52	0 (0.0)
25-34 years	117	0 (0.0)	65	0 (0.0)	182	0 (0.0)
35-44 years	157	3 (1.9)	88	0 (0.0)	245	3 (1.6)
45+ years	145	4 (2.7)	60	0 (0.0)	208	4 (1.9)
2013						
<25 years	38	1 (2.6)	11	0 (0.0)	49	1 (2.0)
25-34 years	105	3 (2.9)	50	0 (0.0)	155	3 (2.6)
35-44 years	173	8 (4.6)	77	0 (0.0)	250	8 (3.2)
45+ years	140	8 (5.7)	66	0 (0.0)	206	8 (3.9)
2014						
<25 years	42	1 (2.4)	7	0 (0.0)	50	1 (2.0)
25-34 years	105	3 (2.9)	59	0 (0.0)	167	4 (2.4)
35-44 years	187	3 (1.6)	81	0 (0.0)	271	5 (1.9)
45+ years	171	8 (4.7)	53	0 (0.0)	224	8 (3.6)
2014 p value		0.393		--		0.674

Table 3.2.4 HIV antibody prevalence by drug last injected, gender and year

New South Wales	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
Heroin	83	2 (2.4)	48	1 (2.1)	131	3 (2.3)
Methamphetamine	22	2 (9.1)	12	0 (0.0)	35	2 (5.7)
Other opioids	106	0 (0.0)	70	1 (1.4)	179	1 (0.6)
Other drugs	47	2 (4.3)	25	2 (8.0)	47	5 (6.8)
1996						
Heroin	129	5 (3.9)	58	3 (5.2)	187	8 (4.3)
Methamphetamine	28	3 (10.7)	15	0 (0.0)	43	3 (7.0)
Other opioids	85	0 (0.0)	57	1 (1.8)	145	1 (0.7)
Other drugs	74	0 (0.0)	31	1 (3.2)	107	1 (0.9)
1997						
Heroin	175	4 (2.3)	118	0 (0.0)	294	4 (1.4)
Methamphetamine	33	1 (3.0)	25	0 (0.0)	58	1 (1.7)
Other opioids	92	0 (0.0)	70	1 (1.4)	162	1 (0.6)
Other drugs	80	1 (1.3)	40	0 (0.0)	120	1 (0.8)
1998						
Heroin	266	3 (1.1)	167	0 (0.0)	435	3 (0.7)
Methamphetamine	36	1 (2.8)	27	0 (0.0)	63	1 (1.6)
Other opioids	92	1 (1.1)	86	1 (1.2)	178	2 (1.1)
Other drugs	144	0 (0.0)	86	0 (0.0)	233	0 (0.0)
1999						
Heroin	311	2 (0.6)	181	1 (0.6)	496	3 (0.6)
Methamphetamine	65	4 (6.2)	38	0 (0.0)	103	4 (3.9)
Other opioids	32	0 (0.0)	23	0 (0.0)	55	0 (0.0)
Other drugs	124	2 (1.6)	67	0 (0.0)	192	2 (1.0)
2000						
Heroin	309	5 (1.6)	195	0 (0.0)	504	5 (1.0)
Methamphetamine	75	3 (4.0)	29	0 (0.0)	105	3 (2.9)
Other opioids	33	0 (0.0)	33	0 (0.0)	67	0 (0.0)
Other drugs	116	3 (2.6)	64	0 (0.0)	180	3 (1.7)
2001						
Heroin	141	1 (0.7)	71	0 (0.0)	212	1 (0.5)
Methamphetamine	64	4 (6.3)	39	0 (0.0)	105	4 (3.8)
Other opioids	34	0 (0.0)	25	0 (0.0)	59	0 (0.0)
Other drugs	161	1 (0.6)	101	0 (0.0)	266	1 (0.4)
2002						
Heroin	227	3 (1.3)	129	1 (0.8)	359	5 (1.4)
Methamphetamine	103	8 (7.8)	60	0 (0.0)	164	8 (4.9)
Other opioids	50	0 (0.0)	28	0 (0.0)	78	0 (0.0)
Other drugs	86	2 (2.3)	40	0 (0.0)	129	2 (1.6)
2003						
Heroin	276	5 (1.8)	126	0 (0.0)	407	1 (1.5)
Methamphetamine	100	4 (4.0)	37	0 (0.0)	138	4 (2.9)
Other opioids	56	1 (1.8)	26	0 (0.0)	82	1 (1.2)
Other drugs	95	2 (2.1)	34	0 (0.0)	131	2 (1.5)
2004						
Heroin	216	2 (0.9)	86	0 (0.0)	304	2 (1.7)
Methamphetamine	82	3 (3.7)	54	1 (1.9)	136	4 (2.9)
Other opioids	40	0 (0.0)	27	0 (0.0)	68	0 (0.0)
Other drugs	66	1 (1.5)	25	0 (0.0)	92	1 (1.1)

Table 3.2.4 HIV antibody prevalence by drug last injected, gender and year (continued)

New South Wales	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Heroin	183	2 (1.1)	102	0 (0.0)	286	2 (0.7)
Methamphetamine	101	3 (3.0)	65	0 (0.0)	170	3 (1.8)
Other opioids	77	1 (1.3)	45	0 (0.0)	122	1 (0.8)
Other drugs	59	0 (0.0)	25	0 (0.0)	85	
2006						
Heroin	133	2 (1.5)	88	0 (0.0)	223	2 (0.9)
Methamphetamine	124	8 (6.5)	64	0 (0.0)	192	9 (4.7)
Other opioids	103	2 (1.9)	48	0 (0.0)	152	2 (1.3)
Other drugs	50	0 (0.0)	26	0 (0.0)	76	
2007						
Heroin	153	4 (2.6)	91	0 (0.0)	246	4 (1.6)
Methamphetamine	109	4 (3.7)	71	1 (1.4)	180	5 (2.8)
Other opioids	109	4 (3.7)	52	0 (0.0)	162	4 (2.5)
Other drugs	59	0 (0.0)	24	1 (4.2)	84	2 (2.4)
2008						
Heroin	218	1 (0.5)	116	1 (0.9)	335	2 (0.6)
Methamphetamine	138	11 (8.0)	75	1 (1.3)	217	13 (6.0)
Other opioids	135	2 (1.5)	72	0 (0.0)	207	2 (1.0)
Other drugs	62	0 (0.0)	29	1 (3.5)	93	1 (1.1)
2009						
Heroin	180	2 (1.1)	119	0 (0.0)	302	2 (0.6)
Methamphetamine	98	7 (7.1)	79	0 (0.0)	178	7 (3.9)
Other opioids	137	3 (2.2)	76	0 (0.0)	214	3 (1.4)
Other drugs	62	0 (0.0)	37	0 (0.0)	102	1 (1.0)
2010						
Heroin	136	1 (0.7)	93	0 (0.0)	231	1 (0.4)
Methamphetamine	121	4 (3.3)	75	0 (0.0)	198	4 (2.0)
Other opioids	97	3 (3.1)	41	0 (0.0)	138	3 (2.2)
Other drugs	66	0 (0.0)	32	0 (0.0)	100	0 (0.0)
2011						
Heroin	123	0 (0.0)	82	0 (0.0)	207	1 (0.5)
Methamphetamine	118	4 (3.4)	76	0 (0.0)	195	4 (2.1)
Other opioids	109	1 (0.9)	54	1 (1.9)	163	2 (1.2)
Other drugs	104	0 (0.0)	12	0 (0.0)	116	0 (0.0)
2012						
Heroin	144	0 (0.0)	67	0 (0.0)	214	1 (0.5)
Methamphetamine	103	4 (3.9)	74	0 (0.0)	181	4 (2.2)
Other opioids	106	2 (1.9)	59	0 (0.0)	165	2 (1.2)
Other drugs	108	1 (0.9)	20	0 (0.0)	130	1 (0.8)
2013						
Heroin	109	2 (1.8)	61	0 (0.0)	171	2 (1.2)
Methamphetamine	137	10 (7.3)	71	0 (0.0)	211	10 (4.7)
Other opioids	100	4 (4.0)	44	0 (0.0)	144	4 (2.8)
Other drugs	104	4 (3.9)	26	0 (0.0)	131	5 (3.8)
2014						
Heroin	130	1 (0.8)	70	0 (0.0)	202	2 (1.0)
Methamphetamine	164	9 (5.5)	80	0 (0.0)	245	9 (3.7)
Other opioids	81	2 (2.5)	33	0 (0.0)	115	2 (1.7)
Other drugs	129	3 (2.3)	18	0 (0.0)	150	5 (3.3)
2014 p value		0.120		--		0.260

Table 3.3.1 HCV antibody prevalence by gender and year

New South Wales	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995	254	219 (86)	152	124 (82)	412	348 (84)
1996	323	233 (72)	169	117 (69)	497	355 (71)
1997	386	260 (67)	254	176 (69)	641	437 (68)
1998	543	369 (68)	369	265 (72)	918	637 (69)
1999	537	322 (60)	312	198 (63)	854	524 (61)
2000	538	350 (65)	327	225 (69)	870	579 (67)
2001	412	321 (71)	244	183 (75)	655	476 (73)
2002	473	335 (71)	261	181 (69)	741	523 (71)
2003	535	359 (67)	230	161 (70)	774	526 (68)
2004	409	288 (70)	197	141 (72)	611	433 (71)
2005	440	302 (69)	243	168 (69)	689	474 (69)
2006	424	292 (69)	232	173 (75)	663	468 (71)
2007	428	289 (68)	231	169 (73)	663	460 (69)
2008	539	379 (70)	281	208 (74)	827	591 (71)
2009	485	272 (56)	320	193 (60)	813	468 (58)
2010	422	228 (54)	243	135 (56)	671	365 (54)
2011	448	220 (49)	219	129 (59)	670	350 (52)
2012	453	213 (47)	220	121 (55)	682	338 (50)
2013	453	232 (51)	204	120 (59)	661	354 (54)
2014	502	264 (53)	200	123 (62)	709	390 (55)
X ² p trend: 1995-2014		<0.001		0.006		<0.001
X ² p trend: 2010-2014		0.997		0.570		0.805

Table 3.3.2 HCV antibody prevalence by age group, gender and year

New South Wales	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	36	20 (56)	40	28 (70)	76	48 (63)
25-34 years	128	115 (90)	71	61 (86)	199	176 (88)
35-44 years	80	74 (93)	37	33 (89)	117	107 (91)
45+ years	6	6 (100)	3	2 (67)	9	8 (89)
1996						
<25 years	57	25 (44)	38	19 (50)	95	44 (46)
25-34 years	142	106 (75)	93	73 (78)	235	179 (76)
35-44 years	113	101 (89)	33	26 (79)	146	127 (87)
45+ years	10	8 (80)	5	4 (80)	15	12 (80)
1997						
<25 years	77	24 (31)	65	29 (45)	142	53 (37)
25-34 years	163	104 (64)	123	86 (70)	286	190 (66)
35-44 years	130	118 (91)	61	57 (93)	191	175 (92)
45+ years	15	14 (88)	5	4 (80)	20	18 (90)
1998						
<25 years	144	54 (38)	118	63 (53)	262	117 (45)
25-34 years	204	145 (71)	147	110 (75)	351	255 (73)
35-44 years	156	136 (87)	93	84 (90)	249	220 (88)
45+ years	38	34 (89)	11	8 (73)	49	42 (86)
1999						
<25 years	128	52 (41)	83	37 (45)	211	89 (42)
25-34 years	236	129 (55)	144	92 (64)	380	221 (58)
35-44 years	138	115 (83)	71	56 (79)	209	171 (82)
45+ years	35	26 (74)	14	13 (93)	49	39 (80)
2000						
<25 years	127	63 (50)	112	70 (63)	239	133 (56)
25-34 years	220	130 (59)	136	93 (69)	356	223 (63)
35-44 years	147	118 (80)	58	47 (81)	205	165 (80)
45+ years	44	39 (89)	21	15 (71)	65	54 (83)
2001						
<25 years	82	45 (55)	75	51 (68)	157	96 (61)
25-34 years	160	102 (64)	95	65 (68)	255	167 (65)
35-44 years	136	110 (81)	58	53 (91)	194	163 (84)
45+ years	34	30 (88)	15	13 (87)	49	43 (88)
2002						
<25 years	90	53 (59)	76	48 (63)	166	101 (61)
25-34 years	188	127 (68)	104	66 (63)	292	193 (66)
35-44 years	135	103 (76)	61	48 (79)	196	151 (77)
45+ years	57	51 (89)	20	19 (95)	77	70 (91)
2003						
<25 years	111	49 (44)	52	28 (54)	163	77 (47)
25-34 years	200	127 (64)	94	66 (70)	294	193 (66)
35-44 years	173	139 (80)	70	55 (78)	243	194 (80)
45+ years	51	44 (86)	14	12 (86)	65	56 (86)
2004						
<25 years	63	30 (48)	37	21 (57)	100	21 (21)
25-34 years	159	108 (68)	73	47 (64)	232	155 (67)
35-44 years	134	107 (80)	59	48 (81)	193	155 (80)
45+ years	52	42 (81)	28	25 (89)	80	67 (84)

Table 3.3.2 HCV antibody prevalence by age group, gender and year (continued)

New South Wales	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2005						
<25 years	42	13 (31)	39	26 (67)	81	39 (48)
25-34 years	155	96 (62)	109	70 (64)	264	166 (63)
35-44 years	165	125 (76)	68	50 (74)	233	175 (75)
45+ years	76	66 (87)	26	21 (81)	102	87 (85)
2006						
<25 years	34	17 (50)	25	18 (72)	59	35 (59)
25-34 years	136	81 (60)	86	64 (74)	222	145 (65)
35-44 years	170	122 (72)	78	60 (77)	248	182 (73)
45+ years	83	72 (87)	41	29 (71)	124	101 (81)
2007						
<25 years	25	6 (24)	27	16 (60)	52	22 (42)
25-34 years	139	85 (61)	72	51 (71)	211	136 (64)
35-44 years	164	117 (71)	88	68 (77)	252	185 (73)
45+ years	100	81 (81)	44	34 (77)	144	115 (80)
2008						
<25 years	43	15 (35)	34	22 (65)	77	37 (48)
25-34 years	157	99 (63)	98	70 (71)	255	169 (66)
35-44 years	209	157 (75)	100	76 (76)	309	233 (75)
45+ years	127	107 (84)	49	40 (82)	176	147 (84)
2009						
<25 years	26	2 (8)	38	17 (45)	64	19 (30)
25-34 years	135	66 (49)	109	67 (61)	244	133 (55)
35-44 years	184	110 (60)	121	84 (69)	305	194 (64)
45+ years	140	94 (67)	52	25 (48)	192	119 (62)
2010						
<25 years	27	4 (15)	25	16 (64)	52	20 (38)
25-34 years	107	49 (46)	85	39 (46)	192	88 (46)
35-44 years	165	94 (57)	72	41 (57)	237	135 (57)
45+ years	123	81 (66)	59	39 (64)	182	120 (66)
2011						
<25 years	40	4 (10)	10	5 (50)	50	9 (18)
25-34 years	120	49 (41)	86	46 (53)	206	95 (46)
35-44 years	149	79 (53)	69	49 (71)	218	128 (59)
45+ years	137	88 (64)	53	29 (55)	190	117 (62)
2012						
<25 years	41	0 (0)	10	5 (50)	51	5 (10)
25-34 years	114	34 (30)	65	38 (58)	179	72 (40)
35-44 years	153	84 (55)	86	49 (57)	239	133 (56)
45+ years	145	95 (66)	59	29 (49)	204	124 (61)
2013						
<25 years	38	2 (5)	11	4 (36)	49	6 (12)
25-34 years	105	38 (36)	50	25 (50)	155	63 (41)
35-44 years	172	102 (59)	77	47 (61)	249	149 (60)
45+ years	138	90 (65)	66	44 (67)	204	134 (66)
2014						
<25 years	42	5 (12)	7	2 (29)	50	7 (14)
25-34 years	104	39 (38)	59	38 (64)	166	79 (48)
35-44 years	187	116 (62)	79	44 (56)	269	161 (60)
45+ years	169	104 (62)	53	37 (70)	222	141 (64)
2014 p value		<0.001		<0.001		<0.001

Table 3.3.3 HCV antibody prevalence by drug last injected, years of injection and year

New South Wales	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heroin	12	6 (50)	117	105 (90)	129	111 (86)
Methamphetamine	10	7 (70)	25	19 (76)	35	26 (74)
Other opioids	6	3 (50)	168	150 (89)	174	153 (88)
Other drugs	7	4 (57)	66	53 (80)	73	57 (78)
1996						
Heroin	23	5 (22)	171	125 (73)	194	130 (67)
Methamphetamine	14	5 (36)	30	22 (73)	44	27 (61)
Other opioids	3	2 (67)	146	130 (89)	149	132 (89)
Other drugs	15	4 (27)	93	72 (77)	108	76 (70)
1997						
Heroin	41	9 (21)	253	190 (75)	294	199 (68)
Methamphetamine	20	3 (15)	38	18 (47)	58	21 (36)
Other opioids	9	3 (33)	154	135 (88)	163	138 (85)
Other drugs	23	6 (26)	98	70 (71)	121	76 (63)
1998						
Heroin	96	27 (28)	341	247 (72)	437	274 (63)
Methamphetamine	15	4 (27)	48	33 (69)	63	37 (59)
Other opioids	6	4 (67)	172	154 (89)	178	158 (89)
Other drugs	45	16 (36)	188	146 (78)	233	162 (70)
1999						
Heroin	101	42 (42)	395	278 (70)	496	320 (65)
Methamphetamine	22	0 (0)	81	33 (41)	103	33 (32)
Other opioids	2	1 (50)	53	45 (85)	55	46 (84)
Other drugs	38	11 (29)	154	111 (72)	192	122 (64)
2000						
Heroin	90	39 (43)	416	307 (74)	506	346 (68)
Methamphetamine	21	3 (14)	85	45 (53)	106	48 (45)
Other opioids	3	1 (33)	65	54 (83)	68	55 (81)
Other drugs	36	18 (50)	144	106 (74)	180	124 (69)
2001						
Heroin	42	23 (55)	170	136 (80)	212	159 (75)
Methamphetamine	23	11 (48)	84	59 (70)	107	70 (65)
Other opioids	4	3 (75)	55	47 (85)	59	50 (85)
Other drugs	59	28 (48)	214	163 (76)	273	191 (70)
2002						
Heroin	58	34 (59)	301	241 (80)	359	275 (77)
Methamphetamine	27	8 (30)	139	88 (63)	166	96 (58)
Other opioids	1	1 (100)	77	63 (82)	78	64 (82)
Other drugs	26	12 (46)	103	73 (71)	129	85 (66)
2003						
Heroin	69	29 (42)	339	262 (77)	408	291 (71)
Methamphetamine	16	6 (38)	122	82 (67)	138	88 (64)
Other opioids	2	0 (0)	80	68 (85)	82	68 (83)
Other drugs	31	6 (19)	101	68 (67)	132	74 (56)
2004						
Heroin	33	15 (45)	274	210 (77)	307	225 (73)
Methamphetamine	17	4 (24)	120	80 (67)	137	84 (61)
Other opioids	1	0 (0)	67	52 (78)	68	52 (76)
Other drugs	13	4 (31)	80	64 (80)	93	68 (73)

Table 3.3.3 HCV antibody prevalence by drug last injected, years of injection and year

New South Wales	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	14	4 (29)	272	203 (75)	286	207 (72)
Methamphetamine	13	1 (8)	158	97 (61)	171	98 (57)
Other opioids	5	3 (60)	119	98 (82)	124	101 (81)
Other drugs	10	1 (10)	75	55 (73)	85	56 (66)
2006						
Heroin	10	2 (20)	213	170 (80)	223	172 (77)
Methamphetamine	20	1 (5)	172	111 (65)	192	112 (58)
Other opioids	7	3 (43)	145	120 (83)	152	123 (81)
Other drugs	13	4 (31)	63	43 (68)	76	47 (62)
2007						
Heroin	15	3 (20)	226	164 (73)	241	167 (69)
Methamphetamine	8	4 (50)	164	112 (68)	172	116 (67)
Other opioids	1	1 (100)	156	119 (76)	157	120 (76)
Other drugs	5	0 (0)	77	49 (64)	82	49 (60)
2008						
Heroin	14	4 (29)	305	241 (79)	319	245 (77)
Methamphetamine	14	4 (29)	195	122 (63)	209	126 (60)
Other opioids	14	10 (71)	187	148 (79)	201	158 (79)
Other drugs	21	6 (29)	64	45 (70)	85	51 (60)
2009						
Heroin	10	3 (30)	291	187 (64)	301	190 (63)
Methamphetamine	13	3 (23)	164	87 (53)	177	90 (51)
Other opioids	10	2 (20)	204	131 (64)	214	133 (62)
Other drugs	19	0 (0)	83	44 (53)	102	44 (43)
2010						
Heroin	14	3 (21)	217	141 (65)	231	144 (62)
Methamphetamine	16	3 (19)	182	90 (49)	198	93 (47)
Other opioids	8	4 (50)	130	77 (59)	138	81 (59)
Other drugs	23	2 (9)	77	43 (56)	100	45 (45)
2011						
Heroin	7	3 (43)	199	106 (53)	206	109 (53)
Methamphetamine	12	5 (42)	178	95 (53)	190	100 (53)
Other opioids	10	2 (20)	149	103 (69)	159	105 (66)
Other drugs	49	2 (4)	65	34 (52)	114	36 (32)
2012						
Heroin	14	3 (21)	197	115 (58)	211	118 (56)
Methamphetamine	11	4 (36)	166	87 (52)	177	91 (51)
Other opioids	8	4 (50)	152	97 (64)	160	101 (63)
Other drugs	53	2 (4)	74	25 (34)	127	27 (21)
2013						
Heroin	6	2 (33)	165	117 (71)	171	119 (70)
Methamphetamine	11	1 (9)	198	110 (56)	209	111 (53)
Other opioids	6	0 (0)	137	87 (64)	143	87 (61)
Other drugs	47	0 (0)	83	35 (42)	130	35 (27)
2014						
Heroin	4	1 (25)	192	130 (68)	200	133 (67)
Methamphetamine	14	1 (7)	221	130 (59)	243	135 (56)
Other opioids	2	0 (0)	111	73 (66)	114	74 (65)
Other drugs	41	0 (0)	100	41 (41)	150	48 (32)
2014 p value		0.054		<0.000		<0.000

4. NORTHERN TERRITORY

4.1 Northern Territory sample


Darwin NSP, operated by the North Territory AIDS and Hepatitis Council (NTAHC), participated in the ANSPS in all survey years 1995 to 2014. Alice Springs and Palmerston NSPs, also under the auspice of NTAHC participated in 15 and 10 years respectively. All three NSPs participated in the ANSPS in all years from 2007. Northern Territory sample sizes ranged from 20 (in 2006) to 102 (in 1997 and 1998). Response rates varied between 16% (in 2004) and 78% (in 2003). The relatively small sample size in some survey years is likely to have contributed to variations in demographic and injecting characteristics observed over time in the Northern Territory.

4.2 Demographic Characteristics

Between two thirds and three quarters of Northern Territory ANSPS respondents were male all survey years 1995 to 2014, except in 2006 when more than half (55%) of Northern Territory respondents were female. The majority of respondents (65% to 100%) identified as heterosexual, with minorities identifying as bisexual (0% to 24%) or homosexual (0% to 10%). The proportion of Indigenous respondents ranged from 0% to 20%, with around one in five respondents identifying as Indigenous in all of the past five years, 2010 to 2014. The majority of respondents (84% to 96%) were born in Australia and reported that their parents spoke English at home (74% to 100%). In 2014, 87% of Northern Territory respondents were born in Australia and 94% reported that their parents spoke English at home (Table 4.1.1).

As occurred nationally and elsewhere, the proportion of young people (those aged less than 25 years) in Northern Territory samples increased in the late 1990s, but declined significantly in subsequent years (Figure 3.2.1). There was a concomitant increase in the median age of respondents, from a low of 30 years in 1996, to a high of 42 years in 2013 and 2014. In 1995 around 10% of Northern Territory ANSPS respondents were aged 40 years or older, increasing to half in 2014 (Figure 3.2.1). The median age at first injection remained relatively stable at 17-20 years across all survey years.

Figure 4.2.1 Northern Territory proportion of younger and older PWID by year




4.3 Injecting behaviour

Drug last injected

Pharmaceutical opioids were the most commonly reported class of drugs last injected in the Northern Territory in all survey years except 1996. As shown in Figure 4.3.1, prevalence of pharmaceutical opioids was high but relatively stable over the past decade, with between half and three quarters of Northern Territory respondents reporting last injecting this class of drugs over the period 2010 to 2014 (χ^2 trend $p=0.565$). Methamphetamine was the second most commonly reported drug last injected in most survey years (Figure 4.3.1, Table 4.1.2). Prevalence of methamphetamine injection was stable over the five year period 2010 to 2014, ranging from 11% in 2013 to 27% in 2014 (χ^2 trend $p=0.646$).

Figure 4.3.1 Northern Territory prevalence of pharmaceutical opioids, methamphetamine and heroin as the drug last injected by year




Reports of all other drugs, including heroin, OST (methadone, buprenorphine or buprenorphine-naloxone) and PIEDs were low at 10% or less in all survey years over the period 2010 to 2014.

Injection risk behaviour

Prevalence of re-use of syringes (including re-use of one's own used syringe) in the month preceding survey participation was relatively stable since data collection commenced in 1997, reported by less than 20% of Northern Territory respondents in most years (Figure 4.3.2). Receptive sharing of syringes varied, but was also reported by less than 20% of respondents in most years. Receptive sharing of drug preparation equipment was more commonly reported, with around one in three respondents reporting this behaviour in most years. Fluctuations are likely due to small sample size in some survey years.

Prevalence of public injecting in the month preceding survey participation was stable over the period 1997 to 2014, ranging from 20% in 2001 and 2006 to 40% in 1997 and 2009 (χ^2 trend $p=0.247$, Table 4.1.3).


Figure 4.3.2 Northern Territory re-use of syringes and receptive sharing (RS) of syringes and drug preparation equipment by year



4.4 Imprisonment, OST and BBV testing


The proportion of Northern Territory ANSPS respondents with a history of imprisonment varied from 20% in 2006 to 61% in 2010, likely due to small sample sizes in some years (Figure 4.4.1). The proportion of respondents reporting incarceration in the 12 months preceding survey participation declined from 10% to 20% over the period 1996 to 2004, to less than 10% in most years 2005 to 2014 (χ^2 trend $p=0.003$). Among respondents who were recently incarcerated, a maximum of one per annum reported injecting in prison over the ten year period 2005 to 2014 (Table 4.1.1).

Figure 4.4.1 Northern Territory prison history and proportion of respondents who reported injecting in prison in the last 12 months by year




As occurred nationally, the proportion of Northern Territory ANSPS respondents who reported a history of OST increased over the period 1995 to 2014 (χ^2 trend $p < 0.001$, Figure 4.4.2, Table 4.1.7). The proportion of Northern Territory respondents who reported currently receiving OST varied (likely due to small samples in some years), with between 11% (in 2014) and 30% (in 2013) of respondents reporting current OST over the five year period 2010 to 2014.

Figure 4.4.2 Northern Territory current and history of OST by year



More than three quarters of Northern Territory ANSPS respondents reported a lifetime history of testing for HCV and/or HIV in all survey years (Table 4.1.5). The proportion of respondents who reported a recent HCV antibody test (last 12 months) varied but was relatively stable over the survey period, ranging from 39% in 1998 to 75% in 2004 (χ^2 trend $p = 0.844$, Figure 4.4.3).

Figure 4.4.3 Northern Territory HCV and HIV testing in the last 12 months by year




4.5 Blood borne viral infections

HIV antibody prevalence

HIV antibody prevalence remained low at 5% or less in all survey years in the Northern Territory (Figure 4.5.1, Table 4.2.1), with a decline in HIV antibody prevalence observed over the period 1995 to 2014 (χ^2 trend $p=0.045$). There were two HIV positive ANSPS respondents in the Northern Territory sample in 2013 and no HIV positive respondents participated in 2014.

Figure 4.5.1 Northern Territory and National HIV antibody prevalence by year



HCV antibody prevalence

The proportion of Northern Territory ANSPS respondents exposed to HCV was broadly similar to that observed nationally, with around one in two respondents testing positive for HCV antibodies in most years (Figure 4.5.1, Table 4.3.1). HCV antibody prevalence was stable over the twenty year period 1995 to 2014 (range 29% to 63%, χ^2 trend $p=0.962$) and the most recent five year period, 2010 to 2014 (range 35% to 55%, χ^2 trend $p=0.668$). The median age of HCV antibody positive respondents was 44 years in the Northern Territory in 2014.

Figure 4.5.1 Northern Territory and National HCV antibody prevalence by year




Table 4.1.1 Number (percentage) of respondents by demographic characteristic and year

	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Northern Territory										
Number of sites	2	2	2	2	1	2	2	1	1	2
N° surveyed	N=30	N=19	N=102	N=102	N=93	N=95	N=94	N=47	N=62	N=23
Response rate	42%	17%	70%	58%	55%	65%	57%	42%	78%	16%
Gender (%)										
Male	20 (67)	13 (68)	76 (74)	77 (75)	73 (78)	75 (79)	75 (80)	35 (75)	44 (71)	16 (70)
Female	10 (33)	6 (32)	24 (24)	25 (25)	20 (22)	19 (20)	18 (19)	11 (23)	18 (29)	6 (26)
Transgender	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	0 (0)	1 (1)	1 (2)	0 (0)	1 (4)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)										
Heterosexual	23 (77)	19 (100)	85 (83)	80 (78)	83 (89)	69 (73)	69 (73)	41 (88)	48 (77)	19 (83)
Bisexual	3 (10)	0 (0)	7 (7)	11 (11)	7 (8)	10 (11)	8 (9)	1 (2)	6 (10)	4 (17)
Homosexual	3 (10)	0 (0)	8 (8)	6 (6)	2 (2)	9 (9)	4 (4)	2 (4)	2 (3)	0 (0)
Not reported	1 (3)	0 (0)	2 (2)	5 (5)	1 (1)	7 (7)	13 (14)	3 (6)	6 (10)	0 (0)
Age and time since first injection (years)										
<i>Median age</i>	34	30	30.5	31	33	34	35	37	37	38
<i>Age range</i>	21-48	21-43	16-50	16-56	16-57	18-58	16-52	19-55	20-53	21-50
Age group (%)										
≤24 years	7 (23)	3 (16)	25 (25)	27 (26)	21 (23)	17 (18)	21 (22)	8 (17)	3 (5)	2 (9)
25+ years	23 (77)	16 (84)	77 (75)	75 (74)	72 (77)	78 (82)	73 (78)	39 (83)	58 (93)	21 (91)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
<i>Median age 1st injection</i>	20	18	17	18	18	18	18.5	18	19	18
<i>Age range</i>	13-41	11-36	12-41	12-47	10-41	9-45	13-48	12-37	8-40	13-35
<i>N° not reported</i>	2	0	1	1	0	2	4	0	2	0
<i>Median years injection</i>	8	7	10	10	11	12	11	17	14	19
<i>Range</i>	1-28	1-27	<1-30	<1-35	<1-34	<1-35	<1-34	<1-36	1-36	3-32
Time since first injection										
≤3 years	7 (23)	3 (16)	19 (19)	21 (21)	13 (14)	16 (17)	16 (17)	6 (13)	5 (8)	2 (9)
4+ years	21 (70)	16 (84)	80 (78)	80 (78)	80 (86)	76 (80)	74 (79)	41 (87)	54 (87)	21 (91)
Not reported	2 (7)	0 (0)	1 (1)	1 (1)	0 (0)	3 (3)	4 (4)	0 (0)	3 (5)	0 (0)

Table 4.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Northern Territory										
Number of sites	3	1	3	3	3	3	3	3	3	3
N° surveyed	N=29	N=20	N=31	N=75	N=77	N=83	N=70	N=50	N=70	N=70
Response rate	39%	--	31%	43%	29%	31%	33%	21%	33%	39%
Gender (%)										
Male	19 (66)	9 (45)	22 (71)	48 (64)	52 (68)	59 (71)	46 (66)	33 (66)	49 (70)	54 (77)
Female	10 (34)	11 (55)	9 (29)	27 (36)	25 (32)	24 (29)	23 (33)	16 (32)	21 (30)	16 (23)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (2)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)										
Heterosexual	26 (90)	13 (65)	28 (90)	62 (83)	66 (86)	67 (81)	56 (80)	39 (78)	61 (87)	63 (90)
Bisexual	2 (7)	4 (20)	1 (3)	4 (5)	5 (6)	10 (12)	12 (17)	8 (16)	5 (7)	3 (4)
Homosexual	1 (3)	3 (15)	2 (6)	5 (7)	2 (3)	5 (6)	1 (1)	2 (4)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	4 (5)	4 (5)	1 (1)	1 (1)	1 (2)	3 (4)	4 (6)
Age and time since first injection (years)										
Median age	35	33	38	39	40	41	40	39	42	41.5
Age range	19-56	24-52	25-59	17-66	22-60	17-63	17-64	20-59	19-62	21-61
Age group (%)										
≤24 years	4 (14)	1 (5)	0 (0)	3 (4)	4 (5)	6 (7)	4 (6)	2 (4)	2 (3)	3 (4)
25+ years	25 (86)	19 (95)	31 (100)	72 (96)	73 (95)	77 (93)	66 (94)	48 (96)	68 (97)	67 (96)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Median age 1st injection	20	19.5	17	18	18	18	19	18	20	20
Age range	11-41	14-30	12-42	13-58	12-42	12-46	12-44	12-40	13-40	10-45
N° not reported	2	0	1	2	4	0	3	3	2	0
Median years injection	15	11.5	18	16	18	19	16	17	21	21
Range	1-36	5-36	3-36	<1-35	1-37	<1-43	1-46	1-41	3-46	0-45
Time since first injection										
≤3 years	5 (17)	0 (0)	2 (6)	3 (4)	4 (5)	8 (10)	7 (10)	3 (6)	1 (1)	4 (6)
4+ years	23 (79)	20 (100)	28 (90)	70 (93)	69 (90)	75 (91)	60 (86)	44 (88)	67 (96)	65 (93)
Not reported	1 (3)	0 (0)	1 (3)	2 (3)	4 (5)	0 (0)	3 (4)	3 (6)	2 (3)	1 (1)

Table 4.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	1995 N=30	1996 N=19	1997 N=102	1998 N=102	1999 N=93	2000 N=95	2001 N=94	2002 N=47	2003 N=62	2004 N=23
Northern Territory										
N° surveyed										
Aboriginal and Torres Strait Islander origin (%)										
No	27 (90)	18 (95)	92 (90)	89 (87)	83 (89)	87 (92)	81 (86)	44 (94)	54 (87)	21 (92)
Yes	1 (3)	1 (5)	10 (10)	13 (13)	10 (11)	7 (7)	11 (12)	3 (6)	6 (10)	1 (4)
Not reported	2 (7)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	0 (0)	2 (3)	1 (4)
Region/country of birth (%)										
Australia	--	--	--	--	86 (92)	80 (96)	83 (89)	38 (81)	52 (84)	20 (87)
Other Oceania	--	--	--	--	--	1 (1)	5 (5)	1 (2)	3 (5)	0 (0)
Asia	--	--	--	--	0 (0)	2 (2)	1 (1)	0 (0)	1 (1)	1 (4)
UK & Ireland	--	--	--	--	--	7 (8)	3 (3)	8 (17)	6 (10)	0 (0)
Other	--	--	--	--	7 (8)	2 (2)	1 (1)	0 (0)	0 (0)	1 (4)
Not reported	--	--	--	--	0 (0)	3 (3)	1 (1)	0 (0)	0 (0)	1 (4)
Main language spoken at home by parents (%)										
English	--	--	--	--	83 (90)	91 (96)	82 (87)	46 (98)	59 (95)	17 (74)
Non-English	--	--	--	--	5 (5)	1 (1)	5 (5)	0 (0)	1 (2)	0 (0)
Not reported	--	--	--	--	5 (5)	3 (3)	7 (8)	1 (2)	2 (3)	6 (26)
Imprisonment last year (%)										
No	29 (97)	16 (84)	92 (90)	90 (88)	84 (90)	81 (85)	72 (77)	41 (87)	56 (90)	17 (74)
Yes	1 (3)	2 (11)	10 (10)	11 (11)	9 (10)	11 (12)	17 (18)	4 (9)	6 (10)	5 (22)
Not reported	0 (0)	1 (5)	0 (0)	1 (1)	0 (0)	3 (3)	5 (5)	2 (4)	0 (0)	1 (4)
Injected in prison last year (%)										
N° in prison	N=1	N=2	N=10	N=11	N=9	N=11	N=17	N=4	N=6	N=5
Injected in prison	0 (0)	1 (50)	4 (40)	5 (45)	1 (11)	5 (45)	2 (12)	2 (50)	2 (33)	3 (60)
Frequency of injection last month (%)										
Not last month	1 (3)	1 (5)	8 (8)	2 (2)	1 (1)	8 (8)	4 (4)	0 (0)	1 (2)	0 (0)
Less than weekly	7 (23)	6 (32)	24 (24)	12 (12)	10 (11)	14 (15)	7 (7)	6 (13)	4 (7)	4 (18)
Weekly not daily	5 (17)	1 (5)	13 (13)	14 (14)	11 (12)	15 (16)	13 (14)	8 (17)	9 (14)	1 (4)
Daily or more	17 (57)	11 (58)	57 (55)	74 (72)	71 (76)	55 (58)	69 (74)	33 (70)	48 (77)	18 (78)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)	1 (1)	0 (0)	0 (0)	0 (0)

Table 4.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Northern Territory										
N° surveyed	N=29	N=20	N=31	N=75	N=77	N=83	N=70	N=50	N=70	N=70
Aboriginal and Torres Strait Islander origin (%)										
No	27 (93)	17 (85)	30 (97)	61 (81)	65 (84)	64 (77)	56 (80)	37 (74)	55 (79)	55 (79)
Yes	1 (3)	3 (15)	0 (0)	13 (17)	10 (13)	18 (22)	13 (19)	12 (24)	13 (19)	14 (20)
Not reported	1 (3)	0 (0)	1 (3)	1 (1)	2 (3)	1 (1)	1 (1)	1 (2)	2 (3)	1 (1)
Region/country of birth (%)										
Australia	28 (97)	19 (95)	28 (90)	65 (87)	65 (84)	71 (86)	60 (86)	44 (88)	59 (84)	61 (87)
Other Oceania	0 (0)	1 (5)	1 (3)	2 (3)	2 (3)	3 (4)	0 (0)	1 (2)	1 (1)	2 (3)
Asia	0 (0)	0 (0)	0 (0)	0 (0)	2 (3)	0 (0)	2 (3)	0 (0)	0 (0)	1 (1)
UK & Ireland	0 (0)	0 (0)	1 (3)	3 (4)	2 (3)	6 (7)	8 (11)	2 (4)	7 (10)	3 (4)
Other	0 (0)	0 (0)	0 (0)	2 (3)	4 (5)	2 (2)	0 (0)	3 (6)	3 (4)	3 (4)
Not reported	1 (3)	0 (0)	1 (3)	3 (4)	2 (3)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Main language spoken at home by parents (%)										
English	25 (86)	18 (90)	29 (94)	75 (100)	70 (91)	77 (93)	65 (93)	48 (96)	68 (97)	66 (94)
Non-English	4 (14)	0 (0)	1 (3)	0 (0)	6 (7)	6 (7)	5 (7)	2 (4)	2 (3)	4 (6)
Not reported	0 (0)	2 (10)	1 (3)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Imprisonment last year (%)										
No	26 (90)	19 (95)	29 (94)	69 (92)	72 (94)	65 (78)	65 (93)	45 (90)	62 (89)	63 (90)
Yes	2 (7)	1 (5)	1 (3)	3 (4)	2 (3)	2 (2)	3 (4)	4 (8)	7 (14)	2 (3)
Not reported	1 (3)	0 (0)	1 (3)	3 (4)	3 (4)	16 (19)	2 (3)	1 (2)	1 (1)	5 (7)
Injected in prison last year (%)										
N° in prison	N=2	N=1	N=1	N=3	N=2	N=2	N=3	N=4	N=7	N=2
Injected in prison	1 (50)	0 (0)	1 (100)	0 (0)	1 (50)	1 (50)	1 (33)	0 (0)	1 (14)	0 (0)
Frequency of injection last month (%)										
Not last month	0 (0)	0 (0)	2 (6)	4 (5)	7 (9)	10 (12)	10 (14)	5 (10)	8 (11)	3 (4)
Less than weekly	5 (17)	5 (25)	3 (10)	8 (11)	13 (17)	13 (16)	7 (10)	3 (6)	11 (16)	9 (13)
Weekly not daily	2 (7)	4 (20)	6 (19)	11 (15)	15 (19)	13 (16)	7 (10)	10 (20)	12 (17)	9 (13)
Daily or more	22 (76)	11 (55)	20 (65)	52 (69)	42 (55)	45 (54)	46 (66)	32 (64)	39 (56)	48 (69)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	0 (0)	1 (1)
Experienced overdose in the previous 12 months										
Yes	--	--	--	--	--	--	--	--	10 (14)	2 (3)

Table 4.1.2 Number (percentage) of respondents by drug last injected and year

Northern Territory N° surveyed	1995 N=30	1996 N=19	1997 N=102	1998 N=102	1999 N=93	2000 N=95	2001 N=94	2002 N=47	2003 N=62	2004 N=23
Drug last injected (%)										
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	6 (20)	4 (21)	11 (11)	19 (19)	21 (22)	26 (27)	34 (36)	7 (15)	15 (24)	7 (30)
Heroin	6 (20)	7 (37)	19 (19)	10 (10)	11 (12)	12 (13)	5 (5)	2 (4)	2 (3)	0 (0)
Pharm. opioids	10 (34)	3 (16)	59 (57)	71 (69)	56 (61)	43 (46)	40 (43)	37 (79)	33 (53)	13 (57)
Methadone	4 (13)	3 (16)	6 (6)	1 (1)	3 (3)	0 (0)	8 (9)	0 (0)	5 (8)	1 (4)
Buprenorphine	--	--	--	--	--	--	--	0 (0)	0 (0)	0 (0)
Buprenorphine/naloxone	--	--	--	--	--	--	--	--	--	--
PIEDs	1 (3)	2 (10)	3 (3)	1 (1)	1 (1)	2 (2)	1 (1)	0 (0)	1 (2)	0 (0)
More than one	3 (10)	0 (0)	3 (3)	0 (0)	0 (0)	9 (9)	6 (6)	0 (0)	3 (5)	2 (9)
Other	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	2 (3)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)	0 (0)	0 (0)	1 (2)	0 (0)

Northern Territory N° surveyed	2005 N=29	2006 N=20	2007 N=31	2008 N=75	2009 N=77	2010 N=83	2011 N=70	2012 N=50	2013 N=70	2014 N=70
Drug last injected (%)										
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)
Methamphetamine	8 (28)	7 (35)	5 (16)	13 (17)	20 (26)	21 (25)	16 (23)	9 (18)	8 (11)	19 (27)
Heroin	0 (0)	0 (0)	0 (0)	2 (3)	2 (3)	3 (4)	2 (3)	2 (4)	7 (10)	6 (9)
Pharm. opioids	14 (48)	12 (60)	16 (52)	47 (63)	38 (49)	50 (60)	44 (63)	35 (70)	43 (61)	35 (50)
Methadone	4 (14)	0 (0)	5 (16)	4 (5)	7 (9)	3 (4)	2 (3)	1 (2)	1 (1)	6 (9)
Buprenorphine	1 (3)	0 (0)	4 (13)	1 (1)	1 (1)	1 (1)	0 (0)	0 (0)	1 (1)	1 (1)
Buprenorphine/naloxone	--	--	--	--	1 (1)	4 (5)	2 (3)	1 (2)	0 (0)	1 (1)
PIEDs	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	1 (1)	1 (2)	3 (4)	1 (1)
More than one	0 (0)	1 (5)	0 (0)	2 (3)	1 (1)	0 (0)	1 (1)	1 (2)	5 (7)	0 (0)
Other	1 (3)	0 (0)	0 (0)	4 (5)	1 (1)	0 (0)	2 (3)	0 (0)	1 (1)	0 (0)
Not reported	1 (3)	0 (0)	1 (3)	2 (3)	4 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Table 4.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

	1995 N=29	1996 N=18	1997 N=94	1998 N=100	1999 N=92	2000 N=84	2001 N=89	2002 N=47	2003 N=61	2004 N=23
Northern Territory										
N° injected last month										
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	--	--	--	--	4 (4)	29 (35)	21 (24)	7 (15)	16 (26)	7 (30)
Water	--	--	--	--	11 (12)	11 (13)	11 (12)	0 (0)	6 (10)	2 (9)
Filter	--	--	--	--	2 (2)	15 (18)	11 (12)	3 (6)	7 (11)	5 (22)
Drug mix	--	--	--	--	2 (2)	11 (13)	6 (7)	2 (4)	5 (8)	0 (0)
None	--	--	--	--	--	--	--	--	--	--
Public injecting in last month (%)										
Any public	--	--	38 (40)	37 (37)	28 (30)	32 (38)	18 (20)	14 (30)	18 (30)	5 (22)
All private	--	--	56 (60)	63 (63)	64 (70)	48 (57)	71 (80)	32 (68)	42 (69)	18 (78)
Not reported	--	--	0 (0)	0 (0)	0 (0)	4 (5)	0 (0)	1 (2)	1 (2)	0 (0)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	--	--	--	--	84 (91)	68 (81)	78 (88)	46 (98)	57 (93)	22 (96)
Pharmacy	--	--	--	--	36 (39)	26 (31)	34 (38)	14 (30)	19 (31)	5 (22)
Northern Territory										
N° injected last month										
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	8 (28)	3 (16)	4 (17)	18 (26)	12 (18)	19 (27)	17 (28)	10 (22)	22 (35)	11 (17)
Water	4 (14)	0 (0)	1 (4)	5 (7)	4 (6)	4 (6)	8 (13)	3 (7)	7 (11)	2 (3)
Filter	3 (10)	2 (11)	1 (4)	6 (9)	8 (12)	7 (10)	4 (7)	4 (9)	7 (11)	9 (14)
Drug mix	5 (17)	1 (5)	1 (4)	5 (7)	4 (6)	8 (11)	4 (7)	3 (7)	3 (5)	1 (2)
None	--	14 (74)	16 (67)	38 (56)	47 (71)	45 (63)	38 (63)	32 (71)	39 (63)	55 (83)
Public injecting in last month (%)										
Any public	6 (21)	4 (20)	7 (24)	14 (20)	28 (40)	26 (37)	18 (30)	16 (36)	18 (29)	14 (21)
All private	19 (66)	13 (65)	21 (72)	57 (80)	42 (60)	42 (37)	39 (65)	29 (64)	43 (69)	52 (79)
Not reported	4 (14)	3 (15)	1 (3)	0 (0)	0 (0)	3 (4)	3 (5)	0 (0)	1 (2)	0 (0)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	28 (97)	19 (95)	20 (69)	60 (85)	46 (66)	59 (83)	58 (97)	43 (96)	58 (94)	62 (94)
Pharmacy	5 (17)	6 (30)	0 (0)	16 (23)	7 (10)	9 (13)	8 (13)	9 (20)	6 (10)	7 (11)

Table 4.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

Northern Territory N° injected last month	1995 N=29	1996 N=18	1997 N=94	1998 N=100	1999 N=92	2000 N=84	2001 N=89	2002 N=47	2003 N=61	2004 N=23
Use of sterile needles and syringes last month (%)										
All injections	--	--	62 (66)	78 (78)	82 (89)	64 (77)	67 (75)	41 (87)	53 (86)	21 (92)
Most of the time	--	--	30 (32)	18 (18)	9 (10)	15 (18)	13 (15)	6 (13)	6 (10)	1 (4)
Half of the time	--	--	2 (2)	4 (4)	1 (1)	2 (2)	3 (3)	0 (0)	0 (0)	1 (4)
Some of the time	--	--	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)	0 (0)	1 (2)	0 (0)
Not last month	--	--	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Not reported	--	--	0 (0)	0 (0)	0 (0)	1 (1)	4 (5)	0 (0)	1 (2)	0 (0)
Re-used someone else's used needle & syringe last month (%)										
None	21 (72)	13 (72)	85 (91)	94 (94)	73 (80)	70 (84)	73 (82)	46 (98)	52 (84)	23 (100)
Once	3 (10)	1 (6)	0 (0)	5 (5)	3 (3)	1 (1)	1 (1)	1 (2)	3 (5)	0 (0)
Twice	3 (10)	3 (16)	2 (2)	0 (0)	3 (3)	10 (12)	1 (1)	0 (0)	1 (2)	0 (0)
3-5 times	1 (4)	1 (6)	3 (3)	1 (1)	0 (0)	1 (1)	4 (5)	0 (0)	1 (2)	0 (0)
>5 times	1 (4)	0 (0)	4 (4)	0 (0)	0 (0)	1 (1)	4 (5)	0 (0)	3 (5)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	13 (14)	1 (1)	6 (6)	0 (0)	1 (2)	0 (0)
Number of people needle & syringe was re-used after last month (%)										
None	21 (72)	13 (72)	85 (91)	94 (94)	73 (80)	70 (84)	73 (82)	46 (98)	52 (85)	23 (100)
One	6 (21)	4 (22)	9 (9)	6 (6)	5 (5)	5 (5)	5 (6)	0 (0)	3 (5)	0 (0)
Two	2 (7)	1 (6)	0 (0)	0 (0)	1 (1)	4 (5)	1 (1)	0 (0)	2 (3)	0 (0)
Three to five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (5)	2 (2)	1 (2)	0 (0)	0 (0)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Don't know	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	13 (14)	1 (1)	7 (8)	0 (0)	4 (7)	0 (0)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	--	--	5 (5)	5 (5)	0 (0)	6 (7)	5 (6)	0 (0)	3 (5)	0 (0)
Casual sex partner	--	--	1 (1)	0 (0)	2 (2)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)
Close friend	--	--	1 (1)	1 (1)	2 (2)	3 (4)	3 (3)	1 (2)	4 (7)	0 (0)
Acquaintance	--	--	0 (0)	0 (0)	2 (2)	1 (1)	2 (2)	1 (2)	1 (2)	0 (0)
Other	--	--	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (2)	0 (0)	0 (0)

Table 4.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

Northern Territory N° injected last month	2005 N=29	2006 N=17	2007 N=29	2008 N=71	2009 N=70	2010 N=71	2011 N=60	2012 N=45	2013 N=62	2014 N=66
Use of sterile needles and syringes last month (%)										
All injections	26 (90)	15 (75)	26 (90)	61 (86)	59 (84)	57 (80)	49 (82)	33 (73)	51 (82)	56 (85)
Most of the time	1 (3)	4 (20)	2 (7)	9 (13)	9 (13)	10 (14)	9 (15)	9 (20)	9 (15)	7 (11)
Half of the time	2 (7)	0 (0)	1 (3)	0 (0)	1 (1)	2 (3)	0 (0)	0 (0)	0 (0)	1 (2)
Some of the time	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)	1 (2)	1 (2)	2 (3)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	2 (3)	2 (3)	2 (4)	1 (2)	0 (0)
Re-used someone else's used needle & syringe last month (%)										
None	27 (93)	18 (90)	26 (90)	65 (92)	62 (89)	62 (87)	48 (80)	39 (87)	55 (89)	62 (94)
Once	0 (0)	0 (0)	0 (0)	1 (1)	5 (7)	1 (1)	3 (5)	1 (2)	3 (5)	2 (3)
Twice	0 (0)	0 (0)	0 (0)	2 (3)	0 (0)	1 (1)	4 (7)	4 (9)	2 (3)	1 (2)
3-5 times	1 (3)	0 (0)	1 (3)	3 (4)	1 (1)	1 (1)	1 (2)	1 (2)	0 (0)	1 (2)
>5 times	0 (0)	1 (5)	0 (0)	0 (0)	1 (1)	0 (0)	1 (2)	0 (0)	1 (2)	0 (0)
Not reported	1 (3)	1 (5)	2 (7)	0 (0)	1 (1)	6 (8)	3 (5)	0 (0)	1 (2)	0 (0)
Number of people needle & syringe was re-used after last month (%)										
None	27 (93)	18 (90)	26 (90)	65 (92)	62 (89)	62 (87)	48 (80)	39 (87)	55 (89)	62 (94)
One	0 (0)	0 (0)	0 (0)	2 (3)	2 (3)	2 (3)	6 (10)	4 (9)	1 (2)	1 (2)
Two	1 (3)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	1 (2)	0 (0)	0 (0)	2 (3)
Three to five	0 (0)	1 (5)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	2 (4)	0 (0)	0 (0)
More than five	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Don't know	0 (0)	0 (0)	0 (0)	1 (1)	2 (3)	0 (0)	2 (5)	0 (0)	2 (3)	0 (0)
Not reported	1 (3)	1 (5)	3 (10)	0 (0)	4 (6)	6 (8)	2 (5)	0 (0)	4 (6)	1 (2)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	0 (0)	1 (5)	0 (0)	3 (4)	1 (1)	1 (1)	8 (13)	5 (11)	1 (2)	0 (0)
Casual sex partner	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)
Close friend	1 (3)	0 (0)	0 (0)	2 (3)	0 (0)	2 (3)	5 (8)	1 (2)	0 (0)	0 (0)
Acquaintance	1 (3)	1 (5)	0 (0)	2 (3)	0 (0)	0 (0)	2 (3)	0 (0)	1 (2)	3 (5)
Other	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)	0 (0)	1 (2)

Table 4.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

Northern Territory N° surveyed	1995 N=30	1996 N=19	1997 N=102	1998 N=102	1999 N=93	2000 N=95	2001 N=94	2002 N=47	2003 N=62	2004 N=23
Sex last month (%)										
No	9 (30)	6 (32)	40 (39)	39 (38)	47 (51)	33 (35)	38 (40)	21 (45)	24 (39)	12 (52)
Yes	21 (70)	13 (68)	61 (60)	61 (60)	46 (49)	56 (59)	55 (59)	25 (53)	38 (61)	11 (48)
Not reported	0 (0)	0 (0)	1 (1)	2 (2)	0 (0)	6 (6)	1 (1)	1 (2)	0 (0)	0 (0)
Condom use at last sex (%)										
No	18 (60)	6 (32)	64 (63)	59 (58)	64 (69)	52 (55)	46 (49)	32 (68)	39 (63)	16 (70)
Yes	3 (10)	6 (32)	38 (37)	39 (38)	29 (31)	35 (37)	42 (45)	15 (32)	21 (34)	6 (26)
Not reported	9 (30)	7 (36)	0 (0)	4 (4)	0 (0)	8 (8)	6 (6)	0 (0)	2 (3)	1 (4)
Condom use with regular sex partner(s) last month (%)										
No	--	8 (67)	43 (86)	33 (94)	27 (84)	28 (64)	18 (53)	13 (81)	20 (69)	5 (71)
Sometimes	--	0 (0)	1 (2)	0 (0)	1 (3)	4 (9)	4 (12)	2 (13)	1 (3)	0 (0)
Always	--	4 (33)	6 (12)	2 (6)	4 (13)	12 (27)	12 (35)	1 (6)	8 (28)	2 (29)
Condom use with new sex partner(s) last month (%)										
No	--	1 (33)	6 (29)	0 (0)	0 (0)	3 (16)	11 (33)	2 (17)	6 (32)	6 (86)
Sometimes	--	0 (0)	0 (0)	0 (0)	0 (0)	9 (47)	6 (18)	1 (8)	2 (10)	0 (0)
Always	--	2 (67)	15 (71)	2 (100)	1 (100)	7 (37)	16 (49)	9 (75)	11 (58)	1 (14)
Condom use with casual sex partner(s) last month (%)										
No	--	--	--	10 (40)	7 (50)	7 (27)	10 (36)	2 (20)	5 (26)	6 (100)
Sometimes	--	--	--	3 (12)	1 (7)	7 (27)	3 (11)	0 (0)	2 (11)	0 (0)
Always	--	--	--	12 (48)	6 (43)	12 (46)	15 (53)	8 (80)	12 (63)	0 (0)
Sex work last month (%)										
No	28 (94)	18 (95)	93 (91)	99 (97)	91 (98)	80 (84)	82 (88)	44 (94)	57 (92)	23 (100)
Yes	1 (3)	1 (5)	4 (4)	3 (3)	2 (2)	9 (10)	6 (6)	3 (6)	3 (5)	0 (0)
Not reported	1 (3)	0 (0)	5 (5)	0 (0)	0 (0)	6 (6)	6 (6)	0 (0)	2 (3)	0 (0)
Condom used at last sex work (%)										
Yes	1 (100)	1 (100)	3 (75)	1 (50)	1 (100)	8 (89)	5 (100)	2 (67)	3 (100)	0 (0)

Table 4.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

Northern Territory N° surveyed	2005 N=29	2006 N=20	2007 N=31	2008 N=75	2009 N=77	2010 N=83	2011 N=70	2012 N=50	2013 N=70	2014 N=70
Sex with a regular partner last month (%)										
No	16 (55)	8 (40)	16 (52)	42 (56)	47 (61)	53 (64)	35 (50)	30 (60)	43 (61)	41 (59)
Yes	12 (41)	12 (60)	13 (42)	33 (44)	26 (34)	26 (31)	34 (49)	19 (38)	26 (37)	29 (41)
Not reported	1 (3)	0 (0)	2 (6)	0 (0)	4 (5)	4 (5)	1 (1)	1 (2)	1 (1)	0 (0)
Condom used with regular partner last month (%)										
Never	N=12 8 (67)	N=12 9 (75)	N=13 10 (77)	N=33 24 (73)	N=26 19 (73)	N=26 20 (77)	N=34 23 (68)	N=19 12 (63)	N=26 24 (92)	N=29 16 (55)
Sometimes	1 (8)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	1 (5)	0 (0)	5 (17)
Every time	1 (8)	1 (8)	3 (23)	8 (24)	3 (12)	4 (15)	8 (24)	5 (26)	1 (4)	4 (14)
Not reported	2 (17)	2 (17)	0 (0)	1 (3)	3 (12)	2 (8)	3 (9)	1 (5)	1 (4)	4 (14)
Sex with other partner(s) last month (%)										
No	25 (86)	16 (80)	24 (77)	66 (88)	65 (84)	65 (78)	64 (91)	40 (80)	57 (81)	60 (86)
Yes	4 (14)	4 (20)	6 (19)	7 (9)	6 (8)	12 (14)	6 (9)	10 (20)	13 (19)	10 (14)
Not reported	0 (0)	0 (0)	1 (3)	2 (3)	6 (8)	6 (7)	0 (0)	0 (0)	0 (0)	0 (0)
Condom used with other partner(s) last month (%)										
Never	N=4 3 (75)	N=4 1 (25)	N=6 2 (33)	N=7 2 (29)	N=6 2 (33)	N=12 5 (42)	N=6 1 (17)	N=10 5 (50)	N=13 5 (38)	N=10 1 (10)
Sometimes	0 (0)	1 (25)	0 (0)	3 (43)	1 (17)	2 (17)	1 (17)	2 (20)	2 (15)	6 (60)
Every time	1 (25)	2 (50)	4 (67)	2 (29)	3 (50)	4 (33)	3 (50)	3 (30)	5 (38)	3 (30)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)	1 (17)	0 (0)	1 (8)	0 (0)
Sex work last month (%)										
No	28 (97)	15 (75)	28 (90)	69 (92)	71 (92)	72 (87)	66 (94)	46 (92)	64 (91)	64 (91)
Yes	0 (0)	4 (20)	1 (3)	4 (5)	3 (4)	5 (6)	4 (6)	4 (8)	3 (4)	6 (9)
Not reported	1 (3)	1 (5)	2 (6)	2 (3)	3 (4)	6 (7)	0 (0)	0 (0)	3 (4)	0 (0)
Condom used at last sex work (%)										
Yes	0 (0)	4 (100)	1 (100)	4 (100)	3 (100)	4 (80)	4 (100)	3 (75)	2 (67)	4 (67)

Table 4.1.5 Number (percentage) of respondents by testing for HIV and HCV infection by year

Northern Territory N° surveyed	1995 N=30	1996 N=19	1997 N=102	1998 N=102	1999 N=93	2000 N=95	2001 N=94	2002 N=47	2003 N=62	2004 N=23
Previous HIV test (%)										
Yes, ever	25 (83)	16 (84)	85 (83)	91 (89)	87 (94)	73 (77)	81 (86)	39 (83)	54 (87)	20 (87)
Yes, last year	17 (57)	11 (58)	45 (44)	52 (51)	61 (66)	44 (46)	55 (58)	27 (57)	33 (53)	13 (57)
>1 year ago	8 (27)	5 (26)	40 (39)	39 (38)	26 (28)	29 (31)	26 (28)	12 (26)	21 (34)	7 (30)
Never tested	3 (10)	3 (16)	17 (17)	11 (11)	6 (6)	20 (21)	10 (11)	7 (15)	7 (11)	3 (13)
Not reported	2 (6)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	3 (3)	1 (2)	1 (2)	0 (0)
Previous HCV test (%)										
Yes, ever	16 (53)	13 (68)	87 (85)	87 (85)	82 (88)	71 (75)	85 (90)	41 (87)	50 (81)	23 (100)
Yes, last year	--	--	50 (49)	40 (39)	47 (50)	52 (55)	65 (69)	28 (61)	32 (52)	18 (78)
>1 year ago	--	--	37 (36)	47 (46)	35 (38)	19 (20)	20 (21)	13 (28)	18 (29)	5 (22)
Never tested	14 (47)	6 (32)	15 (15)	15 (15)	11 (12)	22 (23)	7 (8)	5 (11)	11 (18)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	2 (2)	1 (2)	1 (1)	0 (0)
Northern Territory N° surveyed										
2005 N=29										
2006 N=20										
2007 N=31										
2008 N=75										
2009 N=77										
2010 N=83										
2011 N=70										
2012 N=50										
2013 N=70										
2014 N=70										
Previous HIV test (%)										
Yes, ever	27 (93)	19 (95)	28 (90)	61 (81)	65 (84)	66 (80)	64 (91)	44 (88)	60 (86)	60 (86)
Yes, last year	15 (52)	15 (75)	16 (52)	36 (48)	32 (42)	38 (46)	32 (46)	29 (58)	35 (50)	28 (40)
>1 year ago	12 (41)	4 (20)	12 (39)	25 (33)	33 (43)	28 (34)	32 (46)	15 (30)	25 (36)	32 (46)
Never tested	2 (7)	0 (0)	2 (6)	9 (12)	9 (12)	12 (14)	6 (9)	5 (10)	10 (14)	10 (14)
Not reported	0 (0)	1 (5)	1 (3)	5 (7)	3 (4)	5 (6)	0 (0)	1 (2)	0 (0)	0 (0)
Previous HCV test (%)										
Yes, ever	28 (97)	20 (100)	29 (94)	65 (87)	72 (94)	69 (83)	67 (96)	46 (92)	60 (86)	66 (94)
Yes, last year	14 (48)	15 (75)	19 (61)	38 (51)	40 (52)	46 (55)	37 (53)	30 (60)	36 (51)	31 (44)
>1 year ago	14 (48)	5 (25)	10 (32)	27 (36)	32 (42)	23 (28)	30 (43)	16 (32)	24 (34)	35 (50)
Never tested	1 (3)	0 (0)	1 (3)	5 (7)	3 (4)	8 (10)	2 (3)	3 (6)	7 (10)	4 (6)
Not reported	0 (0)	0 (0)	1 (3)	5 (7)	2 (3)	6 (7)	1 (1)	1 (2)	3 (4)	0 (0)

Table 4.1.6 Number (percentage) of respondents by HCV treatment by year

	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Northern Territory										
Self-report HCV diagnosis	--	--	--	--	N=33	N=27	N=31	N=22	N=24	N=12
Any treatment for HCV (%)										
Interferon+/Ribavirin	--	--	--	--	1 (3)	1 (4)	3 (10)	1 (4)	1 (4)	0 (0)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)
No treatment	--	--	--	--	30 (91)	25 (92)	28 (90)	22 (96)	23 (96)	11 (92)
Not reported	--	--	--	--	2 (6)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)
Current treatment for HCV (%)										
Interferon +/- Ribavirin	--	--	--	--	0	0	0	0	1	0
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	0	1	0	0	0	0

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Northern Territory										
Self-report HCV diagnosis	N=13	N=4	N=17	N=36	N=32	N=46	N=33	N=24	N=36	N=40
Any treatment for HCV (%)										
Interferon +/- Ribavirin	0 (0)	0 (0)	0 (0)	3 (9)	2 (6)	2 (4)	1 (3)	1 (4)	2 (6)	11 (28)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	0 (0)	1 (3)
Other	1 (8)	0 (0)	2 (12)	2 (6)	0 (0)	1 (2)	2 (6)	0 (0)	0 (0)	0 (0)
No treatment	12 (92)	3 (75)	12 (71)	31 (86)	30 (94)	44 (96)	29 (88)	22 (92)	33 (92)	28 (70)
Not reported	0 (0)	1 (25)	3 (18)	0 (0)	0 (0)	0 (0)	1 (3)	1 (4)	1 (3)	0 (0)
Current treatment for HCV (%)										
Interferon +/- Ribavirin	0	0	1	1	0	1	0	0	1	0
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	0	0
Other	0	0	0	1	0	1	1	0	0	0

Table 4.1.7 Number (percentage) of respondents by drug treatment by year

Northern Territory N° surveyed	1995 N=30	1996 N=19	1997 N=102	1998 N=102	1999 N=93	2000 N=95	2001 N=94	2002 N=47	2003 N=62	2004 N=23
Ever any treatment/therapy for drug use (%)										
No	15 (50)	6 (32)	48 (47)	49 (48)	44 (47)	47 (50)	44 (47)	15 (32)	29 (47)	9 (39)
Yes	15 (50)	13 (68)	54 (53)	53 (52)	49 (53)	45 (47)	49 (52)	32 (68)	33 (53)	14 (61)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)	1 (1)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)										
Current	1 (3)	2 (10)	4 (4)	2 (2)	6 (7)	8 (8)	8 (9)	5 (11)	10 (16)	5 (22)
Previous	9 (30)	2 (10)	29 (28)	29 (28)	18 (19)	18 (19)	22 (23)	14 (30)	12 (19)	3 (13)
Never	20 (67)	15 (80)	69 (68)	71 (70)	69 (74)	67 (71)	63 (67)	28 (59)	40 (65)	15 (65)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)	0 (0)	0 (0)	0 (0)
History of other pharmacotherapy treatment (%)										
Current	--	--	--	--	--	0 (0)	2 (2)	2 (4)	6 (10)	4 (17)
Previous	--	--	--	--	--	5 (5)	6 (6)	9 (19)	8 (13)	4 (17)
Never	--	--	--	--	--	88 (93)	84 (90)	36 (77)	48 (77)	15 (66)
Not reported	--	--	--	--	--	2 (2)	2 (2)	0 (0)	0 (0)	0 (0)
Northern Territory N° surveyed										
2005 N=29										
2006 N=20										
2007 N=31										
2008 N=75										
2009 N=77										
2010 N=83										
2011 N=70										
2012 N=50										
2013 N=70										
2014 N=2378										
Ever any treatment/therapy for drug use (%)										
No	13 (45)	12 (60)	13 (42)	22 (29)	21 (27)	24 (29)	22 (31)	14 (28)	29 (41)	24 (34)
Yes	16 (55)	8 (40)	17 (55)	53 (71)	55 (71)	56 (67)	47 (67)	36 (72)	41 (59)	45 (64)
Not reported	0 (0)	0 (0)	1 (3)	0 (0)	1 (1)	3 (4)	1 (1)	0 (0)	0 (0)	1 (1)
History of methadone maintenance treatment (%)										
Current	4 (14)	1 (5)	4 (13)	12 (16)	12 (16)	7 (8)	7 (10)	6 (12)	11 (16)	2 (3)
Previous	10 (34)	2 (10)	10 (32)	18 (24)	14 (18)	25 (30)	22 (31)	11 (22)	18 (26)	15 (21)
Never	15 (52)	17 (85)	16 (52)	45 (60)	49 (64)	46 (55)	39 (56)	32 (64)	41 (59)	48 (69)
Not reported	0 (0)	0 (0)	1 (3)	0 (0)	2 (3)	5 (6)	2 (3)	1 (2)	0 (0)	5 (7)
History of other pharmacotherapy treatment (%)										
Current	2 (7)	0 (0)	0 (0)	15 (20)	5 (6)	11 (13)	7 (10)	9 (18)	10 (14)	6 (9)
Previous	6 (21)	4 (20)	7 (23)	20 (27)	17 (22)	17 (20)	21 (30)	15 (30)	14 (20)	24 (34)
Never	21 (72)	16 (80)	23 (74)	40 (53)	54 (70)	54 (65)	42 (60)	26 (52)	45 (64)	39 (56)
Not reported	0 (0)	0 (0)	1 (3)	0 (0)	1 (1)	1 (1)	0 (0)	0 (0)	1 (1)	1 (1)

HIV antibody prevalence

Table 4.2.1 HIV antibody prevalence by gender and year

Northern Territory	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995	20	0 (0.0)	10	0 (0.0)	30	0 (0.0)
1996	13	0 (0.0)	6	0 (0.0)	19	0 (0.0)
1997	76	5 (6.6)	24	0 (0.0)	102	5 (4.9)
1998	65	4 (6.2)	22	0 (0.0)	87	4 (4.6)
1999	64	3 (4.7)	15	0 (0.0)	79	3 (3.8)
2000	70	1 (1.4)	19	0 (0.0)	90	1 (1.1)
2001	60	0 (0.0)	18	0 (0.0)	79	0 (0.0)
2002	35	0 (0.0)	11	0 (0.0)	47	0 (0.0)
2003	43	1 (2.3)	18	0 (0.0)	61	1 (1.6)
2004	11	0 (0.0)	4	0 (0.0)	16	0 (0.0)
2005	15	0 (0.0)	9	0 (0.0)	24	0 (0.0)
2006	9	0 (0.0)	11	0 (0.0)	20	0 (0.0)
2007	20	0 (0.0)	9	0 (0.0)	29	0 (0.0)
2008	46	1 (2.2)	27	0 (0.0)	73	1 (1.4)
2009	51	0 (0.0)	25	0 (0.0)	76	0 (0.0)
2010	55	0 (0.0)	23	0 (0.0)	78	0 (0.0)
2011	46	1 (2.2)	21	0 (0.0)	68	1 (1.5)
2012	30	1 (3.3)	15	0 (0.0)	46	1 (2.2)
2013	47	2 (4.3)	19	0 (0.0)	66	2 (3.0)
2014	54	0 (0.0)	16	0 (0.0)	70	0 (0.0)
X ² p trend: 1995-2014		0.065		--		0.045
X ² p trend: 2010-2014		0.737		--		0.682

HCV antibody prevalence

Table 4.3.1 HCV antibody prevalence by gender and year

Northern Territory	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995	19	14 (74)	8	3 (38)	27	17 (63)
1996	13	5 (38)	6	2 (33)	19	7 (37)
1997	76	41 (54)	24	10 (42)	102	52 (51)
1998	65	28 (43)	23	7 (30)	88	35 (40)
1999	64	36 (56)	15	3 (20)	79	39 (49)
2000	71	32 (45)	19	6 (32)	91	38 (42)
2001	65	41 (63)	18	8 (44)	84	50 (60)
2002	35	24 (69)	11	5 (45)	47	29 (62)
2003	44	20 (45)	18	9 (50)	62	29 (47)
2004	11	6 (55)	4	3 (75)	16	9 (56)
2005	15	6 (40)	9	6 (67)	24	12 (50)
2006	7	4 (57)	10	1 (10)	17	5 (29)
2007	20	13 (65)	9	5 (56)	29	18 (62)
2008	46	23 (50)	26	15 (58)	72	38 (53)
2009	50	20 (40)	25	9 (36)	75	29 (39)
2010	55	29 (53)	23	8 (35)	78	37 (47)
2011	40	22 (50)	21	10 (48)	61	32 (52)
2012	30	11 (37)	15	5 (33)	46	16 (35)
2013	46	21 (46)	19	12 (63)	65	33 (51)
2014	53	30 (57)	16	8 (50)	69	38 (55)
X ² p trend: 1995-2014		0.610		0.266		0.962
X ² p trend: 2010-2014		0.999		0.411		0.668

Table 4.3.2 HCV antibody prevalence by age group, gender and year

Northern Territory	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	0	0 (0)	5	1 (20)	5	1 (20)
25-34 years	7	4 (57)	1	0 (0)	8	4 (50)
35-44 years	11	9 (82)	2	2 (100)	13	11 (85)
45+ years	1	1 (100)	0	0 (0)	1	1 (100)
1996						
<25 years	1	0 (0)	2	0 (0)	3	0 (0)
25-34 years	6	1 (17)	4	2 (50)	10	3 (30)
35-44 years	6	4 (67)	0	0 (0)	6	4 (67)
45+ years	0	0 (0)	0	0 (0)	0	0 (0)
1997						
<25 years	18	2 (11)	7	1 (14)	25	3 (12)
25-34 years	30	19 (63)	11	4 (36)	41	24 (59)
35-44 years	27	19 (70)	4	3 (75)	31	23 (74)
45+ years	1	1 (100)	2	2 (100)	3	3 (100)
1998						
<25 years	11	0 (0)	13	0 (0)	24	0 (0)
25-34 years	26	8 (31)	4	1 (25)	30	9 (30)
35-44 years	20	13 (65)	5	5 (100)	25	18 (72)
45+ years	8	7 (88)	1	1 (100)	9	8 (89)
1999						
<25 years	9	1 (11)	8	0 (0)	17	1 (6)
25-34 years	24	11 (46)	3	0 (0)	27	11 (41)
35-44 years	21	15 (71)	2	2 (100)	23	17 (74)
45+ years	10	9 (90)	2	1 (50)	12	10 (83)
2000						
<25 years	10	0 (0)	7	2 (29)	17	2 (12)
25-34 years	23	10 (43)	7	3 (43)	30	13 (43)
35-44 years	31	18 (58)	3	0 (0)	34	18 (53)
45+ years	7	4 (57)	2	1 (50)	9	5 (56)
2001						
<25 years	11	4 (36)	5	3 (60)	16	7 (44)
25-34 years	17	8 (47)	6	3 (50)	23	11 (48)
35-44 years	25	19 (76)	6	1 (17)	31	20 (65)
45+ years	12	10 (83)	1	1 (100)	13	11 (85)
2002						
<25 years	3	0 (0)	5	2 (40)	8	2 (25)
25-34 years	10	4 (40)	2	0 (0)	12	4 (33)
35-44 years	10	9 (90)	4	3 (75)	14	12 (86)
45+ years	12	11 (92)	0	0 (0)	12	11 (92)
2003						
<25 years	2	0 (0)	1	1 (100)	3	1 (33)
25-34 years	13	6 (46)	11	5 (45)	24	11 (46)
35-44 years	20	7 (35)	6	3 (50)	26	10 (38)
45+ years	8	6 (75)	0	0 (0)	8	6 (75)
2004						
<25 years	1	0 (0)	0	0 (0)	1	0 (0)
25-34 years	4	3 (75)	0	0 (0)	4	3 (75)
35-44 years	2	0 (0)	2	1 (50)	4	1 (25)
45+ years	4	3 (75)	2	2 (100)	6	5 (83)

Table 4.3.2 HCV antibody prevalence by age group, gender and year (continued)

Northern Territory	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<25 years	0	0 (0)	2	2 (100)	2	2 (100)
25-34 years	7	2 (29)	1	0 (0)	8	2 (25)
35-44 years	5	1 (20)	2	0 (0)	7	1 (14)
45+ years	3	3 (100)	4	4 (4)	7	7 (100)
2006						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	5	2 (40)	6	1 (17)	11	3 (27)
35-44 years	1	1 (100)	3	0 (0)	4	1 (25)
45+ years	1	1 (100)	1	0 (0)	2	1 (50)
2007						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	7	3 (43)	3	2 (67)	10	5 (50)
35-44 years	7	5 (71)	4	1 (25)	11	6 (55)
45+ years	6	5 (83)	2	2 (100)	8	7 (88)
2008						
<25 years	1	0 (0)	2	1 (50)	3	1 (33)
25-34 years	13	4 (31)	8	3 (38)	21	7 (33)
35-44 years	18	8 (44)	8	6 (75)	26	14 (54)
45+ years	14	11 (79)	8	5 (63)	22	16 (73)
2009						
<25 years	2	0 (0)	2	1 (50)	4	1 (25)
25-34 years	7	1 (14)	7	2 (29)	14	3 (21)
35-44 years	21	9 (43)	9	4 (44)	30	13 (43)
45+ years	20	10 (50)	7	2 (29)	27	12 (44)
2010						
<25 years	4	1 (25)	2	0 (0)	6	1 (17)
25-34 years	5	0 (0)	7	2 (29)	12	2 (17)
35-44 years	17	7 (41)	8	3 (38)	25	10 (40)
45+ years	29	21 (72)	6	3 (50)	35	24 (69)
2011						
<25 years	1	1 (100)	2	0 (0)	3	1 (33)
25-34 years	9	3 (33)	7	4 (57)	16	7 (44)
35-44 years	15	7 (73)	9	3 (33)	24	10 (42)
45+ years	15	11 (73)	3	3 (100)	18	14 (78)
2012						
<25 years	2	1 (50)	0	0 (0)	2	1 (50)
25-34 years	5	0 (0)	6	2 (33)	11	2 (18)
35-44 years	16	6 (38)	5	2 (40)	21	8 (38)
45+ years	7	4 (57)	4	1 (25)	11	5 (45)
2013						
<25 years	1	0 (0)	1	0 (0)	2	0 (0)
25-34 years	9	4 (44)	3	0 (0)	12	4 (33)
35-44 years	17	8 (47)	8	7 (88)	25	15 (60)
45+ years	19	9 (47)	7	5 (71)	26	14 (54)
2014						
<25 years	1	0 (0)	2	1 (50)	3	1 (33)
25-34 years	10	4 (40)	3	2 (67)	13	6 (46)
35-44 years	20	11 (55)	5	3 (60)	25	14 (56)
45+ years	22	15 (68)	6	2 (33)	28	17 (61)
2014 p value		0.311		0.814		0.722

Table 4.3.3 HCV antibody prevalence by drug last injected, years of injection and year

Northern Territory	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Pharm. opioids	4	2 (50)	6	5 (83)	10	7 (70)
Methadone	1	0 (0)	3	2 (67)	4	2 (50)
Methamphetamine	2	0 (0)	4	2 (50)	6	2 (33)
Other drugs	0	0 (0)	7	6 (86)	7	6 (86)
1996						
Pharm. opioids	0	0 (0)	3	3 (100)	3	3 (100)
Methadone	0	0 (0)	3	1 (33)	3	1 (33)
Methamphetamine	2	0 (0)	2	0 (0)	4	0 (0)
Other drugs	1	0 (0)	8	3 (38)	9	3 (33)
1997						
Pharm. opioids	8	1 (13)	51	34 (67)	59	35 (59)
Methadone	2	0 (0)	4	3 (75)	6	3 (50)
Methamphetamine	2	0 (0)	9	2 (22)	11	2 (18)
Other drugs	7	2 (29)	19	10 (53)	26	12 (46)
1998						
Pharm. opioids	8	2 (25)	51	29 (57)	59	31 (53)
Methadone	0	0 (0)	0	0 (0)	0	0 (0)
Methamphetamine	9	0 (0)	10	2 (20)	19	2 (11)
Other drugs	1	0 (0)	8	2 (25)	10	2 (20)
1999						
Pharm. opioids	4	0 (0)	43	32 (74)	47	32 (68)
Methadone	0	0 (0)	2	0 (0)	2	0 (0)
Methamphetamine	6	0 (0)	12	2 (17)	18	2 (11)
Other drugs	1	0 (0)	11	5 (45)	12	5 (42)
2000						
Pharm. opioids	5	0 (0)	38	25 (66)	43	25 (58)
Methadone	0	0 (0)	0	0 (0)	0	0 (0)
Methamphetamine	9	2 (22)	14	2 (14)	23	4 (17)
Other drugs	2	1 (50)	20	8 (40)	22	9 (41)
2001						
Pharm. opioids	4	1 (25)	33	23 (70)	37	24 (65)
Methadone	0	0 (0)	7	5 (71)	7	5 (71)
Methamphetamine	11	4 (36)	19	10 (53)	30	14 (47)
Other drugs	0	0 (0)	10	7 (70)	10	7 (70)
2002						
Pharm. opioids	2	0 (0)	35	26 (74)	37	26 (70)
Methadone	0	0 (0)	0	0 (0)	0	0 (0)
Methamphetamine	3	0 (0)	4	2 (50)	7	2 (29)
Other drugs	1	0 (0)	2	1 (50)	3	1 (33)
2003						
Pharm. opioids	1	0 (0)	32	17 (53)	33	17 (52)
Methadone	0	0 (0)	5	3 (60)	5	3 (60)
Methamphetamine	3	0 (0)	12	3 (25)	15	2 (30)
Other drugs	1	0 (0)	7	5 (71)	8	5 (63)
2004						
Pharm. opioids	0	0 (0)	9	4 (44)	9	4 (44)
Methadone	0	0 (0)	0	0 (0)	0	0 (0)
Methamphetamine	2	0 (0)	4	1 (100)	6	4 (67)
Other drugs	0	0 (0)	1	1 (100)	1	1 (100)

Table 4.3.3 HCV antibody prevalence by drug last injected, years of injection and year

Northern Territory	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Pharm. opioids	2	0 (0)	9	3 (33)	11	3 (27)
Methadone	0	0 (0)	4	4 (100)	4	4 (100)
Methamphetamine	2	0 (0)	4	3 (75)	6	3 (50)
Other drugs	0	0 (0)	2	2 (100)	2	2 (100)
2006						
Pharm. opioids	0	0 (0)	10	3 (30)	10	3 (30)
Methadone	0	0 (0)	0	0 (0)	0	0 (0)
Methamphetamine	0	0 (0)	6	1 (17)	6	1 (17)
Other drugs	0	0 (0)	1	1 (100)	1	1 (100)
2007						
Pharm. opioids	1	1 (100)	14	9 (64)	15	10 (67)
Methadone	1	1 (100)	5	2 (40)	5	2 (40)
Methamphetamine	0	0 (0)	4	1 (25)	5	2 (40)
Other drugs	0	0 (0)	4	4 (100)	4	4 (100)
2008						
Pharm. opioids	1	0 (0)	45	29 (69)	46	29 (63)
Methadone	0	0 (0)	4	3 (75)	4	3 (75)
Methamphetamine	1	0 (0)	11	2 (18)	12	2 (17)
Other drugs	1	1 (100)	8	3 (38)	9	4 (44)
2009						
Pharm. opioids	2	1 (50)	36	19 (53)	38	20 (53)
Methadone	0	0 (0)	6	2 (33)	6	2 (33)
Methamphetamine	2	0 (0)	17	3 (18)	19	3 (16)
Other drugs	0	0 (0)	8	2 (25)	8	2 (25)
2010						
Pharm. opioids	2	0 (0)	46	25 (54)	48	25 (52)
Methadone	1	0 (0)	2	1 (50)	3	1 (33)
Methamphetamine	3	0 (0)	15	7 (47)	18	7 (39)
Other drugs	2	0 (0)	7	4 (57)	9	4 (44)
2011						
Pharm. opioids	1	0 (0)	35	23 (66)	36	23 (64)
Methadone	0	0 (0)	2	2 (100)	2	2 (100)
Methamphetamine	2	0 (0)	13	5 (38)	15	5 (33)
Other drugs	3	1 (33)	5	1 (20)	8	2 (25)
2012						
Pharm. opioids	1	0 (0)	32	12 (38)	33	12 (37)
Methadone	0	0 (0)	1	0 (0)	1	0 (0)
Methamphetamine	1	0 (0)	6	2 (33)	7	2 (29)
Other drugs	1	0 (0)	4	2 (50)	5	2 (40)
2013						
Pharm. opioids	1	0 (0)	42	24 (57)	43	24 (56)
Methadone	0	0 (0)	1	1 (100)	1	1 (100)
Methamphetamine	0	0 (0)	6	2 (33)	6	2 (33)
Other drugs	0	0 (0)	15	6 (40)	15	6 (40)
2014						
Pharm. opioids	0	0 (0)	33	25 (76)	34	25 (74)
Methadone	0	0 (0)	6	2 (33)	6	2 (33)
Methamphetamine	3	0 (0)	16	8 (50)	19	8 (42)
Other drugs	0	0 (0)	9	3 (33)	10	3 (30)
2014 p value		--		0.031		0.019

5. QUEENSLAND


5.1 Queensland sample

Three Queensland NSPs participated in the ANSPS in all 20 survey years (Queensland Injectors Health Network [QulHN] NSPs in Brisbane and the Gold Coast [formerly QulVAA and DUNES] and Biala). A further two NSP services (Kobi House, Toowoomba and Cairns NSP) participated in all years except 1995 and three additional NSP services (QulHN Sunshine Coast, Townsville ATODs and West Moreton NSP) participated in most survey years since 2007. Queensland sample sizes ranged from 344 (in 1995) to 834 (in 1999). Response rates ranged between 31% (in 2005) and 74% (in 1997).

5.2 Demographic Characteristics

As occurred nationally, between two thirds and three quarters of Queensland ANSPS respondents were male in all survey years 1995 to 2014. The majority of respondents (74% to 86%) identified as heterosexual, with between 7% and 13% of respondents identifying as bisexual and 1% to 8% identifying as homosexual. The proportion of Indigenous respondents increased significantly over the survey period in Queensland, from 3% in 1995 to 10% in 2014 (χ^2 trend $p < 0.001$). Between 10% and 20% of Queensland ANSPS respondents were born outside Australia and a minority (11% or less) reported that their parents spoke a language other than English at home in all survey years since collection of this indicator commenced in 1999. In 2014, 85% of Queensland respondents were born in Australia and 92% reported that their parents spoke English at home (Table 5.1.1).

Figure 5.2.1 Queensland proportion of younger and older PWID by year



Around one in two Queensland ANSPS respondents were young people (aged less than 25 years) in the late 1990s, however the proportion of young people participating in the ANSPS declined significantly in subsequent years (Figure 5.2.1). The proportion of young people participating in the ANSPS in Queensland was stable, at around one in ten respondents in all years over the period 2005 to 2010 (χ^2 trend $p = 0.512$). There was an increase in the median age of respondents, from 24 to 26 years in the late 1990s


to a high of 37 years in 2013 and 2014. In 1995 less than 10% of Queensland respondents were aged 40 years or older, increasing to around 40% in 2014 (Figure 5.2.1). The median age at first injection remained stable at 18-19 years across all survey years. However, Queensland ANSPS respondents were typically younger than ANSPS respondents nationally, including in 2014 ($p < 0.001$).

5.3 Injecting behaviour

Drug last injected

Heroin, methamphetamine and more recently, pharmaceutical opioids, were the most commonly reported drugs last injected in Queensland. Methamphetamine was the most common drug last injected in all years since 2001, although prevalence declined significantly from 52% in 2001 to 31% in 2014 (χ^2 trend $p < 0.001$). Prevalence of methamphetamine injection was stable over the period 2010 to 2014, ranging from 26% in 2012 to 31% in 2014 (χ^2 trend $p = 0.335$). Heroin was reported as the drug most recently injected by half of Queensland ANSPS respondents in 1995 and 1996, with a significant decline in prevalence commensurate with changes in Australian heroin markets in 2001 (Maher et al., 2007; Degenhardt et al., 2006; Topp et al., 2003). As shown in Figure 5.3.1, prevalence of heroin injection has continued to decline in recent years, from 22% in 2010 to 15% in 2014 (χ^2 trend $p = 0.005$).


Figure 5.3.1 Queensland prevalence of heroin and methamphetamine as the drug last injected by year



Prevalence of pharmaceutical opioids as the class of drugs most recently injected in Queensland increased over the period 2001 to 2007 (χ^2 trend $p < 0.001$, Figure 5.3.2), however prevalence declined in more recent years, from 26% in 2010 to 19% in 2014 (χ^2 trend $p = 0.026$).

Reports of PIEDs were stable at 1% to 2% in all survey years over the period 1995 to 2009 (Figure 5.3.2). In 2010, reports of PIEDs as the last drug injected in Queensland increased to 4%, with further increases observed each subsequent year, to a high of 14% in 2014 (χ^2 trend $p < 0.001$).


Figure 5.3.2 Queensland prevalence of pharmaceutical opioids and PIEDs as the drug last injected by year



Injection risk behaviour

There was a significant reduction in self-reported blood borne viral transmission risk behaviours among Queensland respondents over the 20 year survey period. The proportion of respondents reporting re-use of needles and syringes (including re-use of one's own used syringe) in the month preceding ANSPS participation declined from one in four respondents in 1997, to one in five respondents in 2014 (χ^2 trend $p < 0.001$, Figure 5.3.3). Similarly, prevalence of recent receptive syringe sharing (use of someone else's used needle/syringe) declined from around 29% in 1995 to 16% in 2014 (χ^2 trend $p = 0.007$). Reports of receptive sharing of drug preparation equipment also declined from more than half (53%) in 1999 to 29% of respondents in 2014 (χ^2 trend $p < 0.001$). In more recent years, prevalence of receptive sharing of syringes and drug preparation equipment increased from 9% in 2010 to 16% in 2014 (χ^2 trend $p = 0.032$) and from 25% in 2010 to 29% in 2014 (χ^2 trend $p = 0.042$) respectively.

Figure 5.3.3 Queensland re-use of syringes and receptive sharing (RS) of syringes and drug preparation equipment by year



Prevalence of public injecting in the month preceding survey participation was stable at between one third and one half of Queensland ANSPS respondents in all years 1999 to 2014 (χ^2 trend $p=0.241$, Table 5.1.3).

5.4 Imprisonment, OST and BBV testing

The proportion of Queensland ANSPS respondents with a history of imprisonment was relatively stable, with just under half of respondents reporting a history of imprisonment in all survey years (χ^2 trend $p=0.593$, Figure 5.4.1). The proportion of respondents reporting incarceration in the 12 months preceding survey participation was also stable at around 10% (χ^2 trend $p=0.114$). Among Queensland respondents who were recently incarcerated, between one quarter and two thirds reported injecting in prison over the 20 year period 1995 to 2014 (Table 5.1.1).

Figure 5.4.1 Queensland prison history and proportion of respondents who reported injecting in prison in the last 12 months by year






Figure 5.4.2 Queensland current and history of OST by year



As occurred nationally, the proportion of Queensland ANSPS respondents who reported a history of OST increased over the period 1995 to 2014 (χ^2 trend $p < 0.001$, Figure 5.4.2, Table 5.1.7), with more than half of ANSPS respondents reporting a history of OST in all years since 2004. The proportion of respondents who reported current OST also increased over the same period, from around 20% in the late 1990's, to around 30% in more recent years (χ^2 trend $p < 0.001$). The proportion of respondents reporting a history or current OST was stable over the most recent period, 2010 to 2014 (χ^2 trend $p = 0.068$ and $p = 0.113$ respectively). In 2014, 50% of respondents reported a history of OST and 28% reported currently receiving OST.

Figure 5.4.3 Queensland HCV and HIV testing in the last 12 months by year



More than 80% of Queensland ANSPS respondents reported a lifetime history of testing for HCV and/or HIV in all survey years (Table 5.1.5). The proportion of respondents who reported a recent HCV antibody test (last 12 months) significantly declined over the survey period, from 71% in 1998 to 56% in 2014 (χ^2 trend $p < 0.001$). The proportion of Queensland respondents reporting a recent HIV test also declined significantly, from around 60% over the period 1995 to 2006, to 52% in 2014 (χ^2 trend $p < 0.001$, Figure 5.4.3).

5.5 Blood borne viral infections

HIV antibody prevalence

HIV antibody prevalence remained low at less than 2.5% in all survey years in Queensland (Figure 5.5.1, Table 5.2.1) and was stable over the period 1995 to 2014 (χ^2 trend $p = 0.207$) and the more recent period from 2010 to 2014 (χ^2 trend $p = 0.934$). As shown in Figure 5.5.2, HIV prevalence was highest among respondents reporting male homosexual identity, with this group comprising between 1% and 8% of Queensland samples and HIV prevalence ranged from 14% (in 1998) to 67% (in 2009) among this sub-population (Table 5.2.2).

Figure 5.5.1 Queensland and National HIV antibody prevalence by year





Figure 5.5.2 Queensland HIV antibody prevalence by sexual identity, gender and survey year




The median age of HIV antibody positive respondents in Queensland in 2014 was 45 years (Table 5.2.3) and three quarters (73%) reported last injecting methamphetamine (Table 5.2.4).

HCV antibody prevalence

In Queensland HCV antibody prevalence was consistently lower than observed nationally in all survey years, 1995 to 2014 (Figure 3.5.3). HCV antibody increased over the period 1997 to 2008, with prevalence of 50% or higher observed between 2003 and 2008 (χ^2 trend $p < 0.001$, Figure 5.5.3, Table 5.3.1). As occurred nationally and in most other jurisdictions, HCV antibody prevalence declined over the period 2007 (60%) to 2009 (43%) in Queensland and was stable at between 37% and 47% over the period 2010 to 2014 (χ^2 trend $p = 0.317$).

Figure 5.5.3 Queensland and National HCV antibody prevalence by year



In Queensland in 2014, the median age of HCV antibody positive respondents was 41 years, with around one third (30%) reporting last injecting pharmaceutical opioids (30%) and one quarter reporting last injecting methamphetamine (27%) or heroin (25%, Table 5.2.3). HCV antibody prevalence was higher among respondents with longer injection histories (Figure 5.5.4) and among older respondents (Table 5.3.2).

As observed nationally and elsewhere, HCV antibody prevalence among new initiates to injection was highest in the period following changes to Australian heroin markets in 2001, with around one in four new initiates exposed to HCV between 2002 and 2004. The proportion of new initiates in Queensland exposed to HCV declined from 26% in 2004 to 11% in 2010 (χ^2 trend $p=0.047$) and was stable at around 10% over the period 2010 to 2014 (χ^2 trend $p=0.929$).

Figure 5.5.4 Queensland HCV antibody prevalence by time since first injection and year




Table 5.1.1 Number (percentage) of respondents by demographic characteristic and year

Queensland	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Number of sites	4	5	5	6	6	6	6	9	10	7
N° surveyed	N=344	N=513	N=520	N=694	N=834	N=750	N=817	N=715	N=745	N=587
Response rate	56%	69%	74%	50%	51%	57%	50%	48%	50%	58%
Gender (%)										
Male	247 (72)	374 (73)	358 (69)	490 (71)	552 (66)	487 (65)	562 (69)	504 (70)	512 (69)	407 (69)
Female	92 (27)	132 (26)	160 (31)	202 (29)	277 (33)	257 (34)	247 (30)	205 (29)	226 (30)	179 (30)
Transgender	0 (0)	0 (0)	2 (<1)	2 (<1)	4 (<1)	4 (<1)	6 (1)	5 (1)	5 (<1)	1 (<1)
Not reported	5 (1)	7 (1)	0 (0)	0 (0)	1 (<1)	2 (<1)	2 (<1)	1 (<1)	2 (<1)	0 (0)
Sexual identity (%)										
Heterosexual	264 (77)	395 (77)	419 (81)	561 (81)	621 (74)	573 (76)	626 (76)	529 (74)	577 (77)	492 (84)
Bisexual	42 (12)	65 (13)	55 (10)	67 (10)	106 (13)	80 (11)	71 (9)	71 (10)	70 (9)	46 (8)
Homosexual	27 (8)	38 (7)	26 (5)	50 (7)	51 (6)	45 (6)	48 (6)	36 (5)	42 (6)	27 (4)
Not reported	11 (3)	15 (3)	20 (4)	16 (2)	56 (7)	52 (7)	72 (9)	79 (11)	56 (8)	22 (4)
Age and time since first injection (years)										
<i>Median age</i>	25	24	24	25	26	28	28	29	31	31
<i>Age range</i>	16-49	15-51	16-55	16-57	14-52	15-56	16-57	14-58	15-55	16-61
<i>Age group (%)</i>										
≤24 years	165 (48)	263 (51)	269 (52)	308 (44)	339 (41)	266 (35)	242 (30)	199 (28)	170 (23)	117 (20)
25+ years	177 (51)	248 (48)	251 (48)	385 (55)	493 (59)	482 (64)	572 (70)	513 (72)	573 (77)	468 (80)
Not reported	2 (<1)	2 (<1)	0 (0)	1 (<1)	2 (<1)	2 (<1)	3 (<1)	3 (<1)	2 (<1)	2 (<1)
<i>Median age 1st injection</i>	18	18	18	19	18	18	18	18	18	18
<i>Age range</i>	10-48	10-47	10-50	12-47	10-47	10-51	10-52	10-56	10-49	10-56
<i>N° not reported</i>	10	17	11	14	26	18	32	24	37	11
<i>Median years injection</i>	5	4	5	5	6	7	8	9	10	11
<i>Range</i>	0-31	0-28	0-30	0-40	0-36	0-37	<1-38	<1-38	<1-40	<1-37
<i>Time since first injection</i>										
≤3 years	118 (34)	190 (37)	197 (38)	241 (35)	232 (28)	166 (22)	161 (20)	118 (17)	93 (12)	69 (12)
4+ years	216 (63)	306 (60)	312 (60)	438 (63)	573 (69)	565 (75)	621 (76)	572 (80)	611 (82)	506 (86)
Not reported	10 (3)	17 (3)	11 (2)	15 (2)	29 (3)	19 (3)	35 (4)	25 (4)	41 (6)	12 (2)

Table 5.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

Queensland	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Number of sites	7	7	7	8	8	8	8	8	8	7
N° surveyed	N=291	N=501	N=417	N=508	N=801	N=550	N=552	N=624	N=565	N=490
Response rate	31%	33%	34%	35%	54%	34%	40%	45%	45%	51%
Gender (%)										
Male	198 (68)	353 (70)	282 (68)	341 (67)	585 (73)	419 (76)	394 (71)	454 (73)	397 (70)	356 (73)
Female	91 (31)	145 (29)	131 (31)	165 (32)	211 (26)	126 (23)	154 (28)	168 (27)	167 (30)	133 (27)
Transgender	1 (0)	2 (<1)	3 (<1)	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)	1 (<1)	1 (<1)
Not reported	1 (0)	1 (<1)	1 (<1)	1 (<1)	4 (<1)	4 (<1)	2 (<1)	1 (<1)	0 (0)	0 (0)
Sexual identity (%)										
Heterosexual	236 (81)	411 (82)	350 (84)	436 (86)	686 (86)	457 (83)	467 (85)	529 (85)	471 (83)	398 (81)
Bisexual	23 (8)	37 (7)	32 (8)	40 (8)	63 (8)	39 (7)	44 (8)	49 (8)	42 (7)	36 (7)
Homosexual	19 (7)	39 (8)	25 (6)	21 (4)	10 (1)	28 (5)	20 (4)	18 (3)	19 (3)	22 (4)
Not reported	13 (4)	14 (3)	10 (2)	11 (2)	42 (5)	26 (5)	21 (4)	28 (4)	33 (6)	34 (7)
Age and time since first injection (years)										
<i>Median age</i>	32	33	35	34	34	35	35	36	37	37
<i>Age range</i>	16-63	13-57	17-60	16-60	15-66	15-73	17-62	16-71	16-65	14-64
Age group (%)										
≤24 years	43 (15)	75 (15)	49 (12)	68 (13)	117 (15)	61 (11)	59 (11)	73 (12)	68 (12)	52 (11)
25+ years	248 (85)	425 (85)	367 (88)	438 (86)	684 (85)	487 (86)	492 (89)	551 (88)	495 (88)	436 (89)
Not reported	0 (0)	1 (<1)	1 (<1)	2 (<1)	0 (0)	2 (<1)	1 (<1)	0 (0)	2 (<1)	2 (<1)
<i>Median age 1st injection</i>	18	18	18	18	18	18	18	18	19	19
<i>Age range</i>	11-50	10-52	11-44	10-57	10-58	10-59	11-56	10-70	11-61	10-49
<i>N° not reported</i>	9	1	12	7	19	13	12	15	15	15
Median years injection	13	13	14	14	14	15	15	16	15	16
<i>Range</i>	<1-37	<1-43	<1-38	<1-40	<1-46	<1-60	<1-47	<1-53	<1-46	<1-47
Time since first injection										
≤3 years	33 (11)	50 (10)	38 (9)	52 (10)	73 (9)	50 (9)	67 (12)	79 (13)	89 (16)	70 (14)
4+ years	249 (86)	431 (86)	367 (88)	448 (88)	709 (89)	484 (88)	474 (86)	530 (85)	461 (82)	405 (83)
Not reported	9 (3)	20 (4)	12 (3)	8 (2)	19 (2)	16 (3)	11 (2)	15 (2)	15 (3)	15 (3)

Table 5.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

Queensland N° surveyed	1995 N=344	1996 N=513	1997 N=520	1998 N=694	1999 N=834	2000 N=750	2001 N=817	2002 N=715	2003 N=745	2004 N=587
Aboriginal and Torres Strait Islander origin (%)										
No	322 (94)	465 (91)	489 (94)	662 (95)	755 (91)	669 (90)	735 (90)	636 (89)	669 (90)	541 (92)
Yes	10 (3)	16 (3)	22 (4)	23 (3)	41 (5)	49 (6)	51 (6)	49 (7)	51 (7)	33 (6)
Not reported	12 (3)	32 (6)	9 (2)	9 (1)	38 (4)	32 (4)	31 (4)	30 (4)	25 (3)	13 (2)
Region/country of birth (%)										
Australia	--	--	--	--	758 (91)	604 (81)	686 (84)	605 (85)	645 (87)	492 (84)
Other Oceania	--	--	--	--	--	41 (5)	48 (6)	32 (4)	37 (5)	31 (5)
Asia	--	--	--	--	1 (<1)	2 (<1)	5 (<1)	3 (<1)	7 (1)	7 (1)
UK & Ireland	--	--	--	--	--	31 (4)	24 (3)	23 (3)	26 (3)	29 (5)
Other	--	--	--	--	29 (3)	23 (3)	22 (3)	25 (4)	17 (2)	16 (3)
Not reported	--	--	--	--	46 (6)	49 (7)	32 (4)	27 (4)	13 (2)	12 (2)
Main language spoken at home by parents (%)										
English	--	--	--	--	758 (91)	678 (91)	715 (87)	628 (88)	692 (93)	453 (77)
Non-English	--	--	--	--	23 (3)	25 (3)	40 (5)	37 (5)	27 (4)	12 (2)
Not reported	--	--	--	--	53 (6)	47 (6)	62 (8)	50 (7)	26 (3)	122 (21)
Imprisonment last year (%)										
No	306 (89)	462 (90)	482 (93)	624 (90)	713 (85)	639 (85)	670 (82)	595 (83)	636 (85)	499 (85)
Yes	31 (9)	37 (7)	36 (7)	63 (9)	107 (13)	98 (13)	115 (14)	109 (15)	96 (13)	83 (14)
Not reported	7 (2)	14 (3)	2 (<1)	7 (1)	14 (2)	13 (2)	32 (4)	11 (2)	13 (2)	5 (1)
Injected in prison last year (%)										
N° in prison	N=31	N=37	N=36	N=63	N=107	N=98	N=115	N=109	N=96	N=83
Injected in prison	7 (23)	16 (43)	23 (64)	26 (41)	43 (40)	39 (40)	41 (36)	43 (39)	30 (31)	55 (66)
Frequency of injection last month (%)										
Not last month	29 (9)	39 (8)	53 (10)	53 (8)	70 (8)	67 (9)	84 (10)	85 (12)	88 (12)	59 (10)
Less than weekly	63 (18)	124 (24)	157 (30)	144 (17)	145 (18)	132 (18)	180 (22)	120 (17)	149 (20)	119 (20)
Weekly not daily	111 (32)	164 (32)	92 (18)	204 (29)	203 (24)	202 (27)	207 (25)	165 (23)	196 (26)	141 (24)
Daily or more	137 (40)	183 (35)	217 (42)	292 (42)	402 (48)	343 (46)	333 (41)	339 (47)	297 (40)	265 (45)
Not reported	4 (1)	3 (1)	1 (<1)	1 (<1)	14 (2)	6 (1)	13 (2)	6 (1)	15 (2)	3 (1)

Table 5.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

Queensland N° surveyed	2005 N=291	2006 N=501	2007 N=417	2008 N=508	2009 N=801	2010 N=550	2011 N=552	2012 N=624	2013 N=565	2014 n=490
Aboriginal and Torres Strait Islander origin (%)										
No	273 (94)	438 (87)	375 (90)	459 (90)	675 (84)	479 (87)	481 (87)	537 (86)	493 (87)	428 (87)
Yes	14 (5)	49 (10)	38 (10)	32 (6)	105 (13)	62 (11)	55 (10)	78 (13)	58 (10)	49 (10)
Not reported	4 (1)	14 (3)	4 (<1)	17 (3)	21 (3)	9 (2)	16 (3)	9 (1)	14 (2)	13 (3)
Region/country of birth (%)										
Australia	259 (89)	436 (87)	374 (90)	431 (85)	698 (87)	490 (89)	465 (84)	549 (88)	504 (89)	421 (86)
Other Oceania	11 (4)	21 (4)	15 (4)	25 (5)	40 (5)	20 (4)	29 (5)	35 (6)	29 (5)	30 (6)
Asia	2 (1)	4 (<1)	1 (<1)	5 (1)	5 (<1)	5 (1)	4 (1)	1 (<1)	0 (0)	2 (<1)
UK & Ireland	13 (4)	18 (4)	14 (3)	22 (4)	24 (3)	17 (3)	22 (4)	22 (4)	13 (2)	15 (3)
Other	5 (2)	12 (2)	10 (2)	14 (3)	21 (3)	15 (3)	22 (4)	14 (2)	17 (3)	17 (3)
Not reported	1 (<1)	10 (2)	3 (<1)	11 (2)	13 (2)	3 (<1)	10 (2)	3 (<1)	2 (<1)	5 (1)
Main language spoken at home by parents (%)										
English	259 (89)	465 (93)	395 (95)	489 (96)	768 (96)	535 (97)	530 (96)	606 (97)	544 (96)	468 (96)
Non-English	32 (11)	17 (3)	17 (4)	13 (3)	24 (3)	9 (2)	15 (3)	16 (3)	19 (3)	17 (3)
Not reported	0 (0)	19 (4)	5 (1)	6 (1)	9 (1)	6 (1)	7 (1)	2 (<1)	2 (<1)	5 (1)
Imprisonment last year (%)										
No	250 (86)	412 (82)	363 (87)	418 (82)	656 (82)	410 (75)	474 (86)	543 (88)	497 (88)	415 (85)
Yes	34 (12)	67 (13)	43 (10)	56 (11)	111 (14)	51 (9)	49 (9)	64 (10)	45 (8)	48 (10)
Not reported	7 (2)	22 (4)	11 (3)	34 (7)	34 (4)	89 (16)	29 (5)	17 (3)	23 (4)	27 (6)
Injected in prison last year (%)										
N° in prison	N=34	N=67	N=43	N=56	N=111	N=51	N=49	N=64	N=45	n=48
Injected in prison	14 (41)	27 (40)	22 (51)	20 (36)	51 (46)	25 (49)	26 (53)	30 (47)	17 (38)	18 (38)
Frequency of injection last month (%)										
Not last month	35 (12)	61 (12)	32 (8)	50 (10)	74 (9)	59 (11)	51 (9)	67 (11)	41 (7)	47 (10)
Less than weekly	45 (15)	100 (20)	70 (17)	80 (16)	123 (15)	103 (19)	99 (18)	112 (18)	107 (19)	64 (13)
Weekly not daily	89 (31)	96 (19)	119 (29)	137 (27)	173 (22)	131 (24)	136 (25)	133 (21)	153 (27)	134 (27)
Daily or more	120 (41)	243 (49)	188 (45)	234 (46)	426 (53)	252 (46)	260 (47)	305 (49)	254 (45)	238 (49)
Not reported	2 (1)	1 (<1)	8 (2)	7 (1)	5 (<1)	5 (1)	6 (1)	7 (1)	10 (2)	7 (1)
Experienced overdose in the previous 12 months										
Yes	--	--	--	--	--	--	--	--	65 (12)	65 (13)

Table 5.1.2 Number (percentage) of respondents by drug last injected and year

Queensland N° surveyed	1995 N=344	1996 N=513	1997 N=520	1998 N=694	1999 N=834	2000 N=750	2001 N=817	2002 N=715	2003 N=745	2004 N=587
Drug last injected (%)										
Cocaine	1 (<1)	5 (1)	2 (<1)	2 (<1)	2 (<1)	3 (<1)	2 (<1)	2 (<1)	2 (<1)	5 (1)
Methamphetamine	126 (37)	173 (34)	212 (41)	318 (46)	361 (43)	283 (38)	422 (52)	320 (45)	345 (46)	256 (44)
Heroin	169 (49)	264 (51)	238 (46)	290 (42)	360 (43)	337 (45)	217 (26)	214 (30)	194 (26)	165 (28)
Pharm. opioids	4 (1)	15 (3)	5 (1)	13 (2)	13 (2)	18 (2)	50 (6)	61 (9)	83 (11)	67 (11)
Methadone	9 (3)	5 (1)	14 (3)	7 (1)	10 (1)	12 (1)	32 (4)	25 (3)	25 (3)	24 (4)
Buprenorphine	--	--	--	--	--	--	--	4 (1)	2 (<1)	14 (2)
Buprenorphine/naloxone	--	--	--	--	--	--	--	--	--	--
PIEDs	5 (1)	15 (3)	17 (3)	12 (2)	14 (2)	22 (3)	14 (2)	17 (2)	11 (2)	8 (1)
More than one	23 (7)	31 (6)	27 (5)	47 (7)	53 (6)	61 (8)	66 (8)	62 (9)	49 (7)	36 (6)
Other	6 (2)	5 (1)	2 (<1)	4 (<1)	6 (<1)	4 (<1)	6 (1)	5 (1)	14 (2)	5 (1)
Not reported	1 (<1)	0 (0)	3 (<1)	1 (<1)	15 (2)	10 (1)	8 (1)	5 (1)	20 (3)	7 (1)

Queensland N° surveyed	2005 N=291	2006 N=501	2007 N=417	2008 N=508	2009 N=801	2010 N=550	2011 N=552	2012 N=624	2013 N=565	2014 N=490
Drug last injected (%)										
Cocaine	1 (<1)	2 (<1)	1 (<1)	2 (<1)	7 (<1)	2 (<1)	6 (1)	3 (<1)	3 (<1)	3 (<1)
Methamphetamine	116 (40)	197 (39)	145 (35)	171 (34)	232 (29)	149 (27)	162 (29)	165 (26)	162 (29)	155 (31)
Heroin	85 (29)	115 (23)	106 (25)	124 (24)	218 (27)	123 (22)	112 (20)	129 (21)	91 (16)	75 (15)
Pharm. opioids	41 (14)	90 (18)	96 (23)	120 (24)	177 (22)	141 (26)	130 (24)	124 (20)	117 (21)	94 (19)
Methadone	10 (3)	24 (5)	19 (5)	32 (6)	38 (5)	36 (7)	22 (4)	45 (7)	36 (6)	22 (4)
Buprenorphine	10 (3)	30 (6)	28 (7)	26 (5)	53 (7)	32 (6)	39 (7)	41 (7)	32 (6)	20 (4)
Buprenorphine/naloxone	--	--	--	--	10 (1)	13 (2)	10 (2)	17 (3)	16 (3)	14 (3)
PIEDs	6 (2)	13 (3)	5 (1)	11 (2)	9 (1)	24 (4)	41 (7)	70 (11)	71 (13)	71 (14)
More than one	9 (3)	6 (1)	2 (<1)	11 (2)	30 (4)	19 (3)	24 (4)	20 (3)	35 (6)	16 (3)
Other	4 (1)	9 (2)	6 (1)	6 (1)	10 (1)	9 (2)	6 (1)	8 (1)	1 (<1)	16 (3)
Not reported	9 (3)	15 (3)	9 (2)	5 (1)	17 (2)	2 (<1)	0 (0)	2 (<1)	1 (<1)	4 (<1)

Table 5.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

Queensland N° injected last month	1995 N=311	1996 N=471	1997 N=466	1998 N=640	1999 N=750	2000 N=677	2001 N=720	2002 N=624	2003 N=642	2004 N=525
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	--	--	--	--	281 (38)	188 (28)	177 (25)	179 (29)	180 (28)	129 (25)
Water	--	--	--	--	220 (30)	134 (20)	143 (20)	151 (24)	145 (23)	109 (21)
Filter	--	--	--	--	165 (22)	111 (16)	98 (14)	125 (20)	117 (18)	76 (14)
Drug mix	--	--	--	--	119 (16)	86 (13)	84 (12)	97 (16)	76 (12)	56 (11)
None	--	--	--	--	--	--	--	--	--	--
Public injecting in last month (%)										
Any public	--	--	154 (33)	249 (39)	364 (49)	314 (46)	315 (44)	324 (52)	280 (44)	227 (43)
All private	--	--	286 (61)	352 (55)	329 (44)	325 (48)	405 (56)	277 (44)	335 (52)	256 (49)
Not reported	--	--	26 (6)	39 (6)	57 (8)	38 (6)	0 (0)	23 (4)	27 (4)	42 (8)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	--	--	--	--	682 (91)	616 (91)	643 (89)	560 (90)	586 (91)	477 (91)
Pharmacy	--	--	--	--	495 (66)	413 (61)	397 (55)	374 (60)	355 (55)	298 (57)
Queensland										
N° injected last month	2005 N=254	2006 N=439	2007 N=377	2008 N=451	2009 N=722	2010 N=487	2011 N=495	2012 N=550	2013 N=514	2014 N=436
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	68 (27)	83 (20)	80 (23)	85 (21)	187 (28)	97 (20)	111 (22)	114 (21)	104 (20)	75 (17)
Water	45 (18)	67 (16)	50 (15)	61 (15)	132 (20)	74 (15)	77 (16)	73 (13)	85 (17)	82 (19)
Filter	38 (15)	51 (12)	53 (15)	48 (12)	100 (15)	56 (12)	54 (11)	58 (11)	55 (11)	36 (8)
Drug mix	32 (13)	35 (8)	33 (10)	32 (8)	65 (10)	41 (8)	42 (8)	51 (9)	45 (9)	38 (9)
None	--	268 (63)	239 (69)	280 (68)	389 (59)	317 (65)	318 (64)	387 (70)	379 (74)	305 (70)
Public injecting in last month (%)										
Any public	106 (42)	187 (43)	164 (44)	164 (36)	347 (49)	174 (36)	174 (35)	193 (35)	163 (32)	140 (32)
All private	127 (50)	229 (52)	209 (55)	285 (63)	367 (51)	280 (57)	303 (61)	347 (63)	347 (68)	294 (67)
Not reported	20 (8)	23 (5)	4 (1)	2 (<1)	8 (1)	33 (7)	18 (4)	10 (2)	4 (1)	2 (<1)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	238 (94)	391 (89)	263 (70)	411 (91)	461 (64)	430 (88)	444 (90)	500 (91)	487 (95)	394 (90)
Pharmacy	121 (48)	221 (50)	95 (25)	187 (41)	234 (32)	112 (23)	118 (24)	159 (29)	109 (21)	107 (25)

Table 5.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

Queensland N° injected last month	1995 N=311	1996 N=471	1997 N=466	1998 N=640	1999 N=750	2000 N=677	2001 N=720	2002 N=624	2003 N=642	2004 N=525
Use of sterile needles and syringes last month (%)										
All injections	--	--	328 (71)	455 (71)	534 (71)	506 (75)	535 (74)	469 (75)	484 (75)	392 (75)
Most of the time	--	--	103 (22)	127 (20)	170 (23)	134 (20)	154 (21)	130 (21)	129 (20)	104 (20)
Half of the time	--	--	10 (2)	21 (3)	16 (2)	12 (2)	10 (1)	8 (1)	13 (2)	6 (1)
Some of the time	--	--	5 (1)	15 (2)	4 (<1)	5 (1)	2 (<1)	8 (1)	7 (1)	7 (1)
Not last month	--	--	5 (1)	4 (1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)	1 (<1)	5 (1)
Not reported	--	--	15 (3)	18 (3)	25 (3)	18 (3)	16 (3)	8 (1)	8 (1)	11 (2)
Re-used someone else's used needle & syringe last month (%)										
None	220 (71)	340 (72)	367 (79)	523 (82)	562 (75)	560 (83)	578 (80)	500 (80)	535 (83)	417 (79)
Once	31 (10)	56 (12)	18 (4)	39 (6)	61 (8)	34 (5)	40 (6)	36 (6)	34 (5)	33 (6)
Twice	30 (9)	39 (8)	21 (5)	22 (3)	35 (5)	30 (4)	31 (4)	31 (5)	25 (4)	19 (4)
3-5 times	24 (8)	26 (6)	20 (4)	22 (3)	36 (4)	16 (2)	22 (3)	25 (4)	20 (3)	25 (5)
>5 times	5 (1)	9 (2)	14 (3)	17 (3)	25 (4)	12 (2)	20 (3)	18 (3)	9 (2)	12 (2)
Not reported	1 (1)	1 (<1)	26 (3)	17 (3)	31 (4)	25 (4)	29 (4)	14 (2)	19 (3)	19 (4)
Number of people needle & syringe was re-used after last month (%)										
None	220 (71)	340 (72)	367 (79)	523 (82)	562 (75)	560 (83)	578 (80)	500 (80)	535 (83)	417 (79)
One	49 (16)	91 (19)	68 (15)	79 (12)	119 (16)	74 (11)	66 (9)	65 (10)	46 (7)	48 (9)
Two	32 (10)	34 (7)	9 (2)	10 (1)	8 (1)	5 (1)	8 (1)	10 (2)	9 (1)	9 (2)
Three to five	3 (1)	1 (<1)	3 (<1)	3 (<1)	10 (1)	8 (1)	5 (1)	8 (1)	3 (<1)	4 (1)
More than five	6 (2)	4 (1)	3 (<1)	4 (1)	13 (2)	5 (1)	5 (1)	5 (1)	2 (<1)	1 (<1)
Don't know	0 (0)	0 (0)	1 (<1)	4 (1)	13 (2)	1 (<1)	14 (2)	10 (2)	15 (2)	10 (2)
Not reported	1 (<1)	1 (<1)	15 (3)	17 (3)	25 (3)	24 (3)	44 (6)	26 (4)	32 (5)	36 (7)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	--	--	51 (11)	65 (10)	91 (12)	62 (9)	64 (9)	47 (8)	47 (6)	34 (6)
Casual sex partner	--	--	2 (<1)	6 (1)	8 (1)	11 (2)	8 (1)	10 (2)	11 (2)	4 (1)
Close friend	--	--	18 (4)	28 (4)	43 (6)	32 (5)	34 (5)	28 (4)	29 (5)	20 (4)
Acquaintance	--	--	8 (1)	6 (1)	14 (2)	14 (2)	10 (1)	11 (2)	18 (3)	12 (2)
Other	--	--	2 (<1)	2 (<1)	10 (1)	11 (2)	6 (1)	5 (1)	0 (0)	1 (<1)

Table 5.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

Queensland N° injected last month	2005 N=254	2006 N=439	2007 N=377	2008 N=451	2009 N=722	2010 N=487	2011 N=495	2012 N=550	2013 N=514	2014 N=436
Use of sterile needles and syringes last month (%)										
All injections	187 (74)	332 (76)	282 (75)	329 (73)	532 (74)	348 (71)	368 (74)	426 (77)	391 (76)	340 (78)
Most of the time	55 (22)	85 (19)	71 (19)	107 (24)	151 (21)	91 (19)	92 (19)	85 (15)	101 (20)	84 (19)
Half of the time	5 (2)	9 (2)	9 (2)	7 (2)	10 (1)	8 (2)	12 (2)	12 (2)	12 (2)	3 (1)
Some of the time	4 (2)	2 (<1)	2 (<1)	2 (<1)	14 (2)	5 (1)	6 (1)	2 (<1)	5 (1)	3 (1)
Not last month	1 (0)	1 (<1)	3 (<1)	2 (<1)	5 (<1)	1 (<1)	2 (<1)	4 (<1)	1 (<1)	0 (0)
Not reported	2 (1)	10 (2)	10 (3)	4 (1)	10 (1)	34 (7)	15 (3)	21 (4)	4 (1)	6 (1)
Re-used someone else's used needle & syringe last month (%)										
None	206 (82)	349 (80)	316 (84)	388 (86)	579 (80)	377 (77)	379 (77)	463 (84)	437 (85)	361 (83)
Once	10 (4)	29 (7)	16 (4)	24 (5)	37 (5)	13 (3)	29 (6)	31 (6)	21 (4)	24 (6)
Twice	9 (4)	18 (4)	12 (3)	14 (3)	23 (5)	9 (2)	15 (3)	12 (2)	18 (4)	18 (4)
3-5 times	11 (4)	16 (4)	16 (4)	7 (2)	32 (4)	11 (2)	19 (4)	12 (2)	13 (3)	15 (3)
>5 times	8 (3)	9 (2)	9 (2)	13 (3)	31 (4)	10 (2)	18 (4)	21 (4)	19 (4)	11 (3)
Not reported	9 (4)	18 (4)	8 (2)	5 (1)	20 (3)	67 (14)	35 (7)	11 (2)	6 (1)	7 (2)
Number of people needle & syringe was re-used after last month (%)										
None	196 (77)	349 (80)	316 (84)	388 (86)	579 (80)	377 (77)	379 (77)	463 (84)	437 (85)	361 (83)
One	22 (9)	33 (8)	28 (7)	35 (8)	63 (9)	26 (5)	43 (9)	36 (7)	39 (8)	27 (6)
Two	1 (<1)	3 (<1)	5 (1)	0 (0)	11 (2)	1 (<1)	6 (1)	4 (<1)	7 (1)	6 (1)
Three to five	5 (2)	2 (<1)	2 (<1)	3 (1)	7 (1)	7 (1)	3 (<1)	1 (<1)	3 (<1)	4 (1)
More than five	1 (<1)	2 (<1)	1 (<1)	3 (1)	5 (<1)	3 (<1)	4 (1)	6 (1)	2 (<1)	2 (<1)
Don't know	14 (6)	12 (3)	8 (2)	9 (2)	16 (2)	10 (2)	9 (2)	10 (2)	15 (3)	13 (3)
Not reported	15 (6)	38 (9)	17 (5)	13 (3)	41 (6)	63 (13)	51 (10)	30 (5)	11 (2)	23 (5)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	21 (8)	29 (7)	26 (7)	26 (6)	52 (7)	29 (6)	45 (9)	27 (5)	33 (6)	27 (6)
Casual sex partner	0 (0)	4 (<1)	2 (<1)	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)	4 (1)	0 (0)
Close friend	8 (3)	12 (3)	13 (3)	13 (3)	43 (6)	17 (3)	28 (6)	19 (3)	20 (4)	10 (2)
Acquaintance	6 (2)	1 (<1)	0 (0)	7 (2)	8 (1)	7 (1)	11 (2)	8 (1)	12 (2)	5 (1)
Other	3 (1)	2 (<1)	5 (1)	3 (1)	6 (<1)	6 (1)	10 (2)	7 (1)	6 (1)	3 (1)

Table 5.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

Queensland N° surveyed	1995 N=344	1996 N=513	1997 N=520	1998 N=694	1999 N=834	2000 N=750	2001 N=817	2002 N=715	2003 N=745	2004 N=587
Sex last month (%)										
No	81 (23)	131 (25)	175 (34)	191 (27)	232 (28)	206 (28)	214 (26)	194 (27)	195 (26)	161 (27)
Yes	260 (76)	379 (74)	341 (65)	499 (72)	585 (70)	537 (72)	584 (72)	502 (70)	535 (72)	410 (70)
Not reported	3 (1)	3 (1)	4 (1)	4 (1)	17 (2)	7 (1)	19 (2)	19 (3)	15 (2)	16 (3)
Condom use at last sex (%)										
No	181 (53)	227 (44)	319 (61)	411 (59)	516 (62)	481 (64)	503 (62)	459 (65)	499 (67)	407 (69)
Yes	110 (32)	138 (27)	196 (38)	272 (39)	288 (34)	243 (33)	271 (33)	246 (34)	223 (30)	171 (29)
Not reported	53 (15)	148 (29)	5 (1)	11 (2)	30 (4)	26 (3)	43 (5)	10 (1)	23 (3)	9 (2)
Condom use with regular sex partner(s) last month (%)										
No	--	191 (57)	196 (61)	247 (59)	337 (67)	316 (67)	239 (61)	212 (61)	217 (62)	194 (68)
Sometimes	--	57 (17)	56 (17)	56 (13)	68 (14)	57 (12)	61 (16)	41 (12)	54 (15)	34 (12)
Always	--	86 (26)	71 (22)	115 (28)	95 (19)	98 (21)	90 (23)	92 (27)	81 (23)	57 (20)
Condom use with new sex partner(s) last month (%)										
No	--	46 (31)	47 (34)	41 (34)	92 (47)	77 (43)	162 (48)	127 (46)	119 (48)	101 (48)
Sometimes	--	20 (13)	27 (20)	13 (11)	23 (12)	21 (12)	55 (16)	428 (15)	40 (16)	33 (16)
Always	--	84 (56)	63 (46)	67 (55)	81 (41)	80 (45)	124 (36)	109 (39)	88 (36)	74 (36)
Condom use with casual sex partner(s) last month (%)										
No	--	--	--	48 (29)	95 (43)	108 (47)	115 (44)	116 (46)	85 (42)	87 (50)
Sometimes	--	--	--	28 (17)	32 (14)	23 (10)	52 (20)	40 (16)	36 (18)	26 (15)
Always	--	--	--	91 (54)	96 (43)	100 (43)	96 (36)	94 (38)	82 (40)	61 (35)
Sex work last month (%)										
No	323 (93)	485 (94)	484 (93)	660 (95)	755 (91)	682 (91)	724 (89)	658 (92)	681 (91)	535 (91)
Yes	12 (3)	15 (3)	25 (5)	23 (3)	51 (6)	38 (5)	54 (7)	44 (6)	48 (6)	35 (6)
Not reported	9 (3)	13 (2)	11 (2)	11 (2)	28 (3)	30 (4)	39 (4)	13 (2)	16 (2)	17 (3)
Condom used at last sex work (%)										
Yes	10 (83)	12 (80)	16 (76)	18 (90)	38 (88)	32 (94)	41 (89)	36 (83)	36 (86)	31 (94)

Table 5.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

Queensland N° surveyed	2005 N=291	2006 N=501	2007 N=417	2008 N=508	2009 N=801	2010 N=550	2011 N=552	2012 N=624	2013 N=565	2014 N=490
Sex with a regular partner last month (%)										
No	135 (46)	200 (40)	178 (43)	228 (45)	358 (45)	241 (44)	250 (45)	280 (45)	255 (45)	229 (47)
Yes	154 (53)	284 (57)	224 (54)	261 (51)	414 (52)	284 (52)	280 (51)	334 (54)	304 (54)	250 (51)
Not reported	2 (1)	17 (3)	15 (4)	19 (4)	29 (4)	25 (5)	22 (4)	10 (2)	6 (1)	11 (2)
Condom used with regular partner last month (%)										
Never	N=154	N=284	N=224	N=261	N=414	N=284	N=280	N=334	N=304	N=250
Sometimes	110 (71)	191 (67)	165 (74)	191 (73)	293 (71)	194 (68)	199 (71)	256 (77)	221 (73)	174 (70)
Every time	18 (12)	49 (17)	31 (14)	25 (10)	58 (14)	42 (15)	34 (12)	39 (12)	40 (13)	39 (16)
Not reported	21 (14)	29 (10)	21 (9)	27 (10)	41 (10)	33 (12)	30 (11)	31 (9)	27 (9)	25 (10)
Not reported	5 (3)	15 (5)	7 (3)	18 (7)	22 (5)	15 (5)	17 (6)	8 (2)	16 (5)	12 (5)
Sex with other partner(s) last month (%)										
No	246 (85)	410 (82)	347 (83)	417 (82)	653 (82)	440 (80)	449 (81)	526 (84)	461 (82)	398 (81)
Yes	38 (13)	68 (14)	61 (15)	68 (13)	117 (15)	79 (14)	81 (15)	77 (12)	83 (15)	74 (15)
Not reported	7 (2)	23 (5)	9 (2)	23 (5)	31 (4)	31 (6)	22 (4)	21 (3)	21 (4)	18 (4)
Condom used with other partner(s) last month (%)										
Never	N=38	N=68	N=61	N=68	N=117	N=79	N=81	N=77	N=83	N=74
Sometimes	9 (24)	17 (25)	20 (33)	21 (31)	40 (34)	25 (32)	30 (37)	24 (31)	26 (31)	23 (31)
Every time	9 (24)	15 (22)	22 (36)	16 (24)	40 (34)	20 (25)	20 (25)	20 (26)	22 (37)	25 (34)
Not reported	18 (47)	32 (47)	16 (26)	28 (41)	36 (31)	31 (39)	24 (30)	23 (30)	34 (41)	13 (18)
Not reported	2 (5)	4 (6)	3 (5)	3 (4)	1 (<1)	3 (4)	7 (9)	10 (13)	1 (1)	13 (18)
Sex work last month (%)										
No	275 (95)	458 (91)	387 (93)	455 (90)	740 (92)	489 (89)	509 (92)	593 (95)	525 (93)	439 (90)
Yes	9 (3)	20 (4)	20 (5)	14 (3)	30 (4)	14 (3)	19 (3)	17 (3)	9 (2)	19 (4)
Not reported	7 (2)	23 (5)	10 (2)	39 (8)	31 (4)	47 (9)	24 (4)	14 (2)	31 (5)	32 (7)
Condom used at last sex work (%)										
Yes	32 (94)	17 (85)	11 (65)	12 (86)	18 (69)	10 (83)	12 (80)	13 (76)	6 (86)	10 (59)

Table 5.1.5 Number (percentage) of respondents by testing for HIV and HCV infection by year

Queensland N° surveyed	1995 N=344	1996 N=513	1997 N=520	1998 N=694	1999 N=834	2000 N=750	2001 N=817	2002 N=715	2003 N=745	2004 N=587
Yes, ever										
Previous HIV test (%)	289 (84)	430 (84)	427 (82)	578 (83)	686 (82)	644 (86)	683 (84)	617 (86)	650 (87)	518 (88)
Yes, last year	197 (57)	331 (66)	327 (64)	436 (63)	517 (62)	493 (66)	496 (61)	476 (67)	466 (62)	364 (62)
>1 year ago	74 (22)	93 (18)	95 (18)	137 (20)	170 (20)	151 (20)	187 (23)	141 (20)	184 (25)	154 (26)
Never tested	70 (20)	88 (16)	95 (17)	117 (17)	133 (16)	96 (13)	120 (14)	89 (12)	88 (12)	58 (10)
Not reported	3 (1)	1 (<1)	3 (1)	4 (<1)	14 (2)	10 (1)	14 (2)	9 (1)	7 (1)	11 (2)
Previous HCV test (%)										
Yes, ever	240 (70)	380 (74)	388 (75)	521 (75)	668 (80)	652 (87)	687 (84)	598 (84)	628 (84)	525 (89)
Yes, last year	--	--	317 (71)	403 (58)	527 (63)	507 (68)	522 (64)	470 (66)	468 (63)	383 (65)
>1 year ago	--	--	71 (14)	118 (17)	141 (17)	145 (19)	165 (20)	128 (18)	160 (21)	142 (24)
Never tested	95 (28)	126 (25)	127 (24)	166 (24)	153 (18)	87 (12)	112 (14)	109 (15)	105 (14)	54 (9)
Not reported	9 (2)	7 (1)	5 (1)	7 (1)	13 (2)	11 (1)	18 (2)	8 (1)	12 (2)	8 (2)
Queensland N° surveyed	2005 N=291	2006 N=501	2007 N=417	2008 N=508	2009 N=801	2010 N=550	2011 N=552	2012 N=624	2013 N=565	2014 N=490
Previous HIV test (%)										
Yes, ever	262 (90)	456 (91)	374 (90)	434 (85)	649 (81)	444 (81)	474 (86)	517 (83)	477 (84)	408 (83)
Yes, last year	179 (62)	297 (59)	239 (57)	258 (51)	410 (51)	239 (43)	281 (51)	291 (47)	277 (49)	253 (52)
>1 year ago	83 (29)	159 (32)	135 (32)	176 (35)	239 (30)	205 (37)	193 (35)	226 (36)	200 (35)	155 (32)
Never tested	29 (10)	37 (7)	40 (10)	49 (10)	126 (16)	73 (13)	63 (11)	87 (14)	82 (15)	68 (14)
Not reported	0 (0)	8 (2)	3 (<1)	25 (5)	26 (3)	33 (6)	15 (3)	20 (3)	6 (1)	14 (3)
Previous HCV test (%)										
Yes, ever	262 (90)	451 (90)	381 (91)	449 (88)	695 (88)	468 (85)	472 (86)	533 (85)	466 (82)	414 (84)
Yes, last year	185 (64)	297 (59)	258 (62)	289 (57)	446 (56)	281 (51)	290 (53)	328 (53)	269 (48)	273 (56)
>1 year ago	77 (26)	154 (31)	123 (30)	160 (32)	249 (31)	187 (34)	182 (33)	205 (33)	197 (35)	141 (29)
Never tested	28 (10)	38 (8)	32 (8)	36 (7)	85 (11)	44 (8)	47 (9)	60 (10)	56 (10)	52 (11)
Not reported	1 (<1)	12 (2)	4 (1)	23 (5)	21 (9)	38 (7)	33 (6)	31 (5)	43 (8)	24 (5)

Table 5.1.6 Number (percentage) of respondents by HCV treatment by year

Queensland	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Self-report HCV diagnosis	--	--	--	--	N=246	N=233	N=281	N=275	N=291	N=248
Any treatment for HCV (%)										
Interferon+/Ribavirin	--	--	--	--	8 (3)	8 (3)	11 (4)	12 (4)	13 (4)	15 (6)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	10 (4)	7 (3)	10 (4)	11 (4)	16 (6)	7 (3)
No treatment	--	--	--	--	226 (92)	211 (90)	253 (90)	245 (88)	255 (88)	217 (87)
Not reported	--	--	--	--	2 (1)	7 (3)	7 (2)	7 (3)	7 (2)	9 (4)
Current treatment for HCV (%)										
Interferon +/-or Ribavirin	--	--	--	--	0	1	1	1	4	4
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	6	3	6	0	0	4

Queensland	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Self-report HCV diagnosis	N=129	N=207	N=188	N=238	N=351	N=263	N=255	N=289	N=257	N=202
Any treatment for HCV (%)										
Interferon +/-or Ribavirin	7 (5)	12 (6)	12 (6)	18 (8)	25 (7)	27 (10)	20 (8)	24 (8)	25 (10)	24 (12)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	5 (2)	5 (2)
Other	7 (5)	3 (1)	5 (3)	2 (1)	6 (2)	2 (1)	5 (2)	1 (<1)	1 (<1)	2 (1)
No treatment	112 (87)	187 (90)	163 (87)	211 (89)	300 (85)	222 (84)	217 (85)	257 (89)	218 (85)	159 (79)
Not reported	3 (2)	5 (2)	8 (4)	7 (3)	20 (6)	12 (5)	13 (5)	7 (2)	8 (3)	6 (3)
Current treatment for HCV (%)										
Interferon +/-or Ribavirin	3	3	4	1	6	2	2	6	3	3
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	3	0
Other	3	2	0	0	2	0	2	0	0	1

Table 5.1.7 Number (percentage) of respondents by drug treatment by year

Queensland N° surveyed	1995 N=344	1996 N=513	1997 N=520	1998 N=694	1999 N=834	2000 N=750	2001 N=817	2002 N=715	2003 N=745	2004 N=587
Ever any treatment/therapy for drug use (%)										
No	182 (53)	269 (52)	261 (50)	359 (52)	376 (45)	303 (40)	321 (39)	271 (38)	308 (41)	174 (30)
Yes	161 (47)	241 (47)	258 (50)	332 (47)	446 (54)	440 (59)	485 (59)	433 (60)	432 (58)	407 (69)
Not reported	1 (<1)	3 (1)	1 (<1)	3 (1)	12 (1)	7 (1)	11 (1)	11 (2)	5 (1)	6 (1)
History of methadone maintenance treatment (%)										
Current	59 (17)	110 (21)	112 (21)	144 (21)	159 (19)	191 (25)	164 (20)	142 (20)	157 (21)	141 (24)
Previous	53 (15)	63 (12)	76 (15)	79 (11)	173 (21)	153 (20)	177 (22)	143 (20)	165 (22)	120 (21)
Never	231 (67)	337 (66)	331 (64)	468 (67)	502 (60)	403 (54)	461 (56)	418 (58)	417 (56)	318 (54)
Not reported	1 (1)	3 (1)	1 (<1)	3 (1)	0 (0)	3 (<1)	15 (2)	12 (2)	6 (1)	8 (1)
History of other pharmacotherapy treatment (%)										
Current	--	--	--	--	--	18 (2)	24 (3)	54 (8)	73 (10)	81 (14)
Previous	--	--	--	--	--	81 (11)	74 (9)	86 (12)	108 (14)	93 (16)
Never	--	--	--	--	--	638 (85)	686 (84)	557 (77)	550 (74)	396 (67)
Not reported	--	--	--	--	--	12 (2)	33 (4)	18 (3)	14 (2)	17 (3)
Queensland N° surveyed										
2005 N=291										
2006 N=501										
2007 N=417										
2008 N=508										
2009 N=801										
2010 N=550										
2011 N=552										
2012 N=624										
2013 N=565										
2014 N=2378										
Ever any treatment/therapy for drug use (%)										
No	73 (25)	115 (23)	86 (21)	124 (24)	182 (23)	119 (22)	152 (28)	176 (28)	188 (33)	168 (34)
Yes	215 (74)	374 (75)	323 (77)	374 (74)	606 (76)	410 (75)	380 (69)	442 (71)	373 (66)	308 (63)
Not reported	3 (1)	12 (2)	8 (2)	10 (2)	13 (2)	21 (4)	20 (4)	6 (1)	4 (1)	14 (3)
History of methadone maintenance treatment (%)										
Current	62 (21)	91 (18)	94 (23)	92 (18)	143 (18)	98 (18)	92 (17)	106 (17)	95 (17)	80 (16)
Previous	87 (30)	140 (28)	132 (32)	129 (25)	189 (24)	133 (24)	121 (22)	151 (24)	114 (20)	94 (19)
Never	137 (47)	253 (51)	189 (45)	272 (54)	453 (57)	292 (53)	322 (58)	362 (58)	354 (63)	303 (62)
Not reported	5 (2)	17 (3)	2 (<1)	15 (3)	16 (2)	27 (5)	17 (3)	5 (1)	2 (1)	13 (3)
History of other pharmacotherapy treatment (%)										
Current	47 (16)	81 (16)	81 (19)	88 (17)	142 (18)	100 (18)	89 (16)	110 (18)	83 (15)	67 (14)
Previous	61 (21)	110 (22)	87 (21)	120 (24)	180 (22)	126 (23)	128 (23)	147 (24)	147 (26)	110 (22)
Never	180 (62)	300 (60)	241 (58)	292 (57)	470 (59)	320 (58)	320 (58)	364 (58)	333 (59)	302 (62)
Not reported	3 (1)	10 (2)	8 (2)	8 (2)	9 (1)	4 (1)	15 (3)	3 (<1)	2 (<1)	11 (2)

HIV antibody prevalence

Table 5.2.1 HIV antibody prevalence by gender and year

Queensland	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995	225	4 (1.8)	83	1 (1.2)	313	5 (1.6)
1996	374	7 (1.9)	132	1 (0.8)	513	8 (1.6)
1997	327	7 (2.1)	150	2 (1.3)	479	9 (1.9)
1998	472	4 (0.9)	196	1 (0.5)	670	5 (0.8)
1999	531	11 (2.1)	268	2 (0.8)	804	13 (1.6)
2000	464	7 (1.5)	250	0 (0.0)	720	8 (1.1)
2001	550	8 (1.5)	240	0 (0.0)	798	8 (1.0)
2002	479	10 (2.1)	200	2 (1.0)	685	13 (1.9)
2003	504	7 (1.4)	219	0 (0.0)	730	7 (1.0)
2004	379	10 (2.6)	165	1 (0.6)	544	11 (2.0)
2005	188	4 (2.1)	88	0 (0.0)	278	4 (1.4)
2006	350	11 (3.1)	142	1 (0.7)	495	12 (2.4)
2007	279	10 (3.6)	130	0 (0.0)	413	10 (2.4)
2008	335	9 (2.7)	161	0 (0.0)	498	9 (1.8)
2009	581	10 (1.7)	209	0 (0.0)	795	10 (1.3)
2010	407	11 (2.1)	123	0 (0.0)	535	11 (2.1)
2011	376	8 (2.1)	148	0 (0.0)	528	8 (1.5)
2012	415	7 (1.7)	153	2 (1.3)	570	9 (1.6)
2013	372	7 (1.9)	160	0 (0.0)	533	7 (1.3)
2014	349	11 (3.2)	131	0 (0.0)	481	11 (2.3)
X^2 p trend: 1995-2014		0.088		0.078		0.207
X^2 p trend: 2010-2014		0.853		0.968		0.934

Table 5.2.2 HIV antibody prevalence by sexual identity, gender and year

Queensland	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
Heterosexual	184	1 (0.5)	59	1 (1.7)	244	2 (0.8)
Bisexual	19	0 (0.0)	17	0 (0.0)	38	0 (0.0)
Homosexual	17	3 (17.7)	6	0 (0.0)	24	3 (12.5)
1996						
Heterosexual	303	0 (0.0)	88	2 (1.1)	395	1 (0.3)
Bisexual	32	1 (3.1)	32	0 (0.0)	65	1 (1.5)
Homosexual	26	6 (23.0)	12	0 (0.0)	38	6 (15.8)
1997						
Heterosexual	278	1 (0.4)	105	1 (1.0)	384	2 (0.5)
Bisexual	18	0 (0.0)	34	1 (2.9)	52	1 (1.9)
Homosexual	16	6 (37.5)	10	0 (0.0)	26	6 (23.1)
1998						
Heterosexual	401	0 (0.0)	142	0 (0.0)	544	0 (0.0)
Bisexual	29	0 (0.0)	35	1 (2.9)	64	1 (1.6)
Homosexual	29	4 (13.8)	17	0 (0.0)	47	4 (8.5)
1999						
Heterosexual	422	4 (1.0)	177	2 (1.1)	599	6 (1.0)
Bisexual	42	0 (0.0)	59	0 (0.0)	103	0 (0.0)
Homosexual	29	5 (17.2)	17	0 (0.0)	48	5 (10.4)
2000						
Heterosexual	378	1 (0.3)	167	0 (0.0)	547	1 (0.2)
Bisexual	26	1 (3.9)	53	0 (0.0)	79	1 (1.3)
Homosexual	26	5 (19.2)	15	0 (0.0)	44	6 (13.6)
2001						
Heterosexual	440	2 (0.5)	167	0 (0.0)	611	2 (0.3)
Bisexual	25	0 (0.0)	44	0 (0.0)	70	0 (0.0)
Homosexual	33	6 (18.2)	13	0 (0.0)	47	6 (12.8)
2002						
Heterosexual	337	3 (0.8)	129	1 (0.8)	507	4 (0.8)
Bisexual	19	1 (5.3)	47	1 (2.1)	68	2 (2.9)
Homosexual	24	6 (25.0)	8	0 (0.0)	34	7 (20.6)
2003						
Heterosexual	414	1 (0.2)	152	0 (0.0)	567	1 (0.2)
Bisexual	17	1 (5.9)	50	0 (0.0)	69	1 (1.5)
Homosexual	32	4 (12.5)	6	0 (0.0)	40	4 (10.0)
2004						
Heterosexual	335	1 (0.3)	121	0 (0.0)	456	1 (0.2)
Bisexual	13	1 (7.7)	30	1 (3.3)	43	2 (4.7)
Homosexual	16	7 (43.8)	8	0 (0.0)	24	7 (29.2)

Table 5.2.2 HIV antibody prevalence by sexual identity, gender and year (continued)

Queensland	Male		Female		Total	
	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)	N ^o tested	N ^o with HIV (%)
2005						
Heterosexual	159	1 (0.6)	67	0 (0.0)	227	1 (0.4)
Bisexual	8	0 (0.0)	14	0 (0.0)	22	0 (0.0)
Homosexual	12	3 (25.0)	5	0 (0.0)	17	3 (17.7)
2006						
Heterosexual	303	0 (0.0)	104	0 (0.0)	408	0 (0.0)
Bisexual	11	0 (0.0)	22	1 (4.5)	34	1 (2.9)
Homosexual	26	11 (42.3)	12	0 (0.0)	39	11 (28.2)
2007						
Heterosexual	249	1 (0.4)	98	0 (0.0)	347	1 (0.3)
Bisexual	7	1 (14.3)	22	0 (0.0)	31	1 (3.2)
Homosexual	18	8 (44.4)	6	0 (0.0)	25	8 (32.0)
2008						
Heterosexual	3022	0 (0.0)	127	0 (0.0)	430	0 (0.0)
Bisexual	10	2 (20.0)	27	0 (0.0)	37	2 (5.4)
Homosexual	17	17 (41.0)	4	0 (0.0)	21	7 (33.0)
2009						
Heterosexual	519	1 (0.2)	162	0 (0.0)	682	1 (0.2)
Bisexual	24	2 (8.3)	37	0 (0.0)	62	2 (3.2)
Homosexual	9	6 (67.0)	1	0 (0.0)	10	6 (60.0)
2010						
Heterosexual	345	2 (0.6)	97	0 (0.0)	445	2 (0.5)
Bisexual	21	2 (9.5)	16	0 (0.0)	37	2 (5.4)
Homosexual	21	7 (33)	6	0 (0.0)	27	87(25.9)
2011						
Heterosexual	340	2 (0.6)	109	0 (0.0)	451	2 (0.4)
Bisexual	13	0 (0.0)	29	0 (0.0)	43	0 (0.0)
Homosexual	11	6 (54.6)	6	0 (0.0)	17	6 (35.3)
2012						
Heterosexual	368	1 (0.3)	112	2 (1.8)	480	3 (0.6)
Bisexual	20	2 (10.0)	27	0 (0.0)	48	2 (4.2)
Homosexual	11	2 (18.2)	6	0 (0.0)	17	2 (11.8)
2013						
Heterosexual	322	1 (0.3)	119	0 (0.0)	442	1 (0.2)
Bisexual	13	1 (7.7)	28	0 (0.0)	41	1 (2.4)
Homosexual	17	5 (29.4)	2	0 (0.0)	19	5 (26.3)
2014						
Heterosexual	297	1 (0.3)	95	0 (0.0)	392	1 (0.3)
Bisexual	11	1 (9.1)	24	0 (0.0)	35	1 (2.9)
Homosexual	17	8 (47.1)	3	0 (0.0)	20	9 (40.0)
2014 p value		<0.001		--		<0.001

Table 5.2.3 HIV antibody prevalence by age group, gender and year

Queensland	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
<25 years	99	1 (1.0)	44	0 (0.0)	147	1 (0.7)
25-34 years	86	2 (2.3)	26	1 (3.9)	113	3 (2.7)
35-44 years	29	1 (3.5)	13	0 (0.0)	42	1 (2.4)
45+ years	9	0 (0.0)	0	0 (0.0)	9	0 (0.0)
1996						
<25 years	190	2 (1.1)	70	0 (0.0)	263	2 (0.8)
25-34 years	122	2 (1.6)	37	1 (2.7)	161	3 (1.9)
35-44 years	56	3 (5.4)	23	0 (0.0)	79	3 (3.8)
45+ years	6	0 (0.0)	45	0 (0.0)	8	0 (0.0)
1997						
<25 years	159	1 (0.63)	89	0 (0.0)	249	1 (0.4)
25-34 years	107	3 (2.8)	41	2 (4.9)	149	5 (3.4)
35-44 years	52	3 (5.8)	19	0 (0.0)	71	3 (4.2)
45+ years	9	0 (0.0)	1	0 (0.0)	10	0 (0.0)
1998						
<25 years	201	0 (0.0)	95	0 (0.0)	296	0 (0.0)
25-34 years	186	3 (1.6)	58	1 (1.7)	245	4 (1.6)
35-44 years	69	1 (1.5)	37	0 (0.0)	107	1 (0.9)
45+ years	15	0 (0.0)	6	0 (0.0)	21	0 (0.0)
1999						
<25 years	194	2 (1.0)	123	0 (0.0)	319	2 (0.6)
25-34 years	226	4 (1.8)	87	1 (1.2)	315	5 (1.6)
35-44 years	83	4 (4.8)	52	1 (1.9)	135	5 (3.7)
45+ years	27	1 (3.7)	6	0 (0.0)	33	1 (3.0)
2000						
<25 years	138	1 (0.7)	112	0 (0.0)	252	1 (0.4)
25-34 years	195	4 (2.1)	78	0 (0.0)	275	4 (1.5)
35-44 years	98	2 (2.0)	51	0 (0.0)	150	3 (2.0)
45+ years	32	0 (0.0)	9	0 (0.0)	41	0 (0.0)
2001						
<25 years	145	0 (0.0)	94	0 (0.0)	241	
25-34 years	226	3 (1.3)	92	0 (0.0)	321	3 (0.9)
35-44 years	132	4 (3.0)	47	0 (0.0)	181	4 (2.2)
45+ years	45	1 (2.2)	7	0 (0.0)	53	1 (1.9)
2002						
<25 years	119	0 (0.0)	69	1 (1.5)	188	1 (0.5)
25-34 years	229	6 (2.6)	73	0 (0.0)	304	6 (2.0)
35-44 years	94	3 (3.2)	48	1 (2.1)	145	5 (3.5)
45+ years	0	1 (2.9)	9	0 (0.0)	45	1 (2.2)
2003						
<25 years	111	2 (1.8)	56	0 (0.0)	169	2 (1.2)
25-34 years	189	1 (0.5)	86	0 (0.0)	277	1 (0.4)
35-44 years	138	3 (2.2)	61	0 (0.0)	201	3 (1.5)
45+ years	64	1 (1.6)	16	0 (0.0)	81	1 (1.2)
2004						
<25 years	68	1 (1.5)	42	0 (0.0)	110	1 (0.9)
25-34 years	162	3 (1.9)	60	1 (2.0)	222	3 (1.4)
35-44 years	99	5 (5.1)	49	0 (0.0)	148	6 (4.1)
45+ years	49	0 (0.0)	14	0 (0.0)	63	0 (0.0)

Table 5.2.3 HIV antibody prevalence by age group, gender and year (continued)

Queensland	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
<25 years	29	0 (0.0)	14	0 (0.0)	43	0 (0.0)
25-34 years	79	0 (0.0)	37	0 (0.0)	116	0 (0.0)
35-44 years	56	4 (7.1)	27	0 (0.0)	85	4 (4.7)
45+ years	24	0 (0.0)	10	0 (0.0)	34	0 (0.0)
2006						
<25 years	46	1 (2.2)	28	0 (0.0)	74	1 (1.4)
25-34 years	149	2 (1.3)	58	0 (0.0)	209	2 (1.0)
35-44 years	98	6 (6.1)	41	1 (2.4)	139	7 (5.0)
45+ years	56	2 (3.6)	15	0 (0.0)	72	2 (2.8)
2007						
<25 years	34	0 (0.0)	15	0 (0.0)	49	0 (0.0)
25-34 years	107	1 (0.9)	45	0 (0.0)	154	1 (0.7)
35-44 years	93	7 (7.5)	45	0 (0.0)	138	7 (5.1)
45+ years	44	2 (4.6)	25	0 (0.0)	71	2 (2.8)
2008						
<25 years	38	0 (0.0)	26	0 (0.0)	64	0 (0.0)
25-34 years	127	2 (1.6)	60	0 (0.0)	187	2 (1.1)
35-44 years	114	4 (3.5)	43	0 (0.0)	158	4 (2.5)
45+ years	55	3 (3.5)	31	0 (0.0)	87	3 (3.5)
2009						
<25 years	75	0 (0.0)	39	0 (0.0)	116	0 (0.0)
25-34 years	220	3 (1.6)	85	0 (0.0)	307	3 (1.0)
35-44 years	195	5 (2.6)	52	0 (0.0)	247	5 (2.0)
45+ years	91	2 (2.2)	33	0 (0.0)	125	2 (1.6)
2010						
<25 years	44	0 (0.0)	13	0 (0.0)	58	0 (0.0)
25-34 years	154	2 (1.3)	50	0 (0.0)	204	2 (1.0)
35-44 years	118	5 (2.4)	32	0 (0.0)	153	5 (3.3)
45+ years	85	3 (3.5)	27	0 (0.0)	113	3 (2.7)
2011						
<25 years	45	0 (0.0)	9	0 (0.0)	56	0 (0.0)
25-34 years	129	0 (0.0)	67	0 (0.0)	197	0 (0.0)
35-44 years	122	4 (3.3)	45	0 (0.0)	168	4 (2.4)
45+ years	79	4 (5.1)	27	0 (0.0)	106	4 (3.8)
2012						
<25 years	56	0 (0.0)	13	0 (0.0)	69	0 (0.0)
25-34 years	128	1 (0.8)	63	0 (0.0)	192	1 (0.5)
35-44 years	144	1 (0.7)	46	1 (2.2)	190	2 (1.0)
45+ years	87	5 (5.8)	31	1 (3.2)	119	6 (5.0)
2013						
<25 years	43	0 (0.0)	20	0 (0.0)	63	0 (0.0)
25-34 years	111	0 (0.0)	49	0 (0.0)	160	0 (0.0)
35-44 years	106	5 (4.7)	52	0 (0.0)	158	5 (3.2)
45+ years	110	2 (1.8)	39	0 (0.0)	150	2 (1.3)
2014						
<25 years	35	0 (0.0)	16	0 (0.0)	51	0 (0.0)
25-34 years	110	1 (0.9)	45	0 (0.0)	155	1 (0.7)
35-44 years	107	4 (3.7)	45	0 (0.0)	152	4 (2.6)
45+ years	95	6 (6.3)	25	0 (0.0)	121	6 (5.0)
2014 p value		0.119		--		0.091

Table 5.2.4 HIV antibody prevalence by drug last injected, gender and year

Queensland	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995						
Heroin	116	3 (2.6)	45	1 (2.2)	161	4 (2.5)
Methamphetamine	75	1 (1.3)	30	0 (0.0)	108	1 (0.9)
Other opioids	10	0 (0.0)	2	0 (0.0)	13	0 (0.0)
Other drugs	23	0 (0.0)	6	0 (0.0)	30	0 (0.0)
1996						
Heroin	174	2 (1.2)	86	0 (0.0)	264	2 (0.8)
Methamphetamine	135	3 (2.2)	36	1 (2.8)	173	4 (2.3)
Other opioids	17	0 (0.0)	3	0 (0.0)	20	0 (0.0)
Other drugs	48	0 (0.0)	7	0 (0.0)	56	2 (3.6)
1997						
Heroin	144	5 (3.5)	83	0 (0.0)	227	5 (2.2)
Methamphetamine	136	1 (0.7)	53	0 (0.0)	191	1 (0.5)
Other opioids	11	1 (9.1)	5	2 (40.0)	16	3 (18.8)
Other drugs	34	0 (0.0)	9	0 (0.0)	43	0 (0.0)
1998						
Heroin	182	1 (0.6)	98	0 (0.0)	281	1 (0.4)
Methamphetamine	227	2 (0.9)	77	1 (1.3)	304	3 (1.0)
Other opioids	12	0 (0.0)	8	0 (0.0)	20	0 (0.0)
Other drugs	50	1 (2.0)	13	0 (0.0)	64	1 (1.6)
1999						
Heroin	205	1 (0.5)	141	0 (0.0)	349	1 (0.3)
Methamphetamine	237	7 (3.0)	106	2 (1.9)	344	9 (2.6)
Other opioids	18	2 (11.1)	5	0 (0.0)	23	2 (8.7)
Other drugs	61	1 (1.6)	12	0 (0.0)	73	1 (1.4)
2000						
Heroin	187	2 (1.1)	140	0 (0.0)	328	2 (0.6)
Methamphetamine	183	3 (1.6)	85	0 (0.0)	270	3 (1.1)
Other opioids	18	0 (0.0)	9	0 (0.0)	28	0 (0.0)
Other drugs	70	1 (1.4)	13	0 (0.0)	84	2 (2.4)
2001						
Heroin	144	1 (0.7)	68	0 (0.0)	212	1 (0.5)
Methamphetamine	285	5 (1.8)	123	0 (0.0)	413	5 (1.2)
Other opioids	52	0 (0.0)	28	0 (0.0)	82	0 (0.0)
Other drugs	65	2 (3.1)	19	0 (0.0)	84	2 (2.4)
2002						
Heroin	137	0 (0.0)	68	0 (0.0)	206	1 (0.5)
Methamphetamine	217	6 (2.8)	85	0 (0.0)	304	6 (2.0)
Other opioids	60	1 (1.7)	28	1 (3.6)	89	2 (2.3)
Other drugs	62	3 (4.8)	18	1 (5.6)	82	4 (4.9)
2003						
Heroin	122	2 (1.6)	70	0 (0.0)	193	2 (1.0)
Methamphetamine	236	4 (1.7)	95	0 (0.0)	335	4 (1.2)
Other opioids	76	0 (0.0)	30	0 (0.0)	107	0 (0.0)
Other drugs	56	1 (1.8)	18	0 (0.0)	75	1 (1.3)
2004						
Heroin	109	2 (1.8)	45	0 (0.0)	154	2 (1.3)
Methamphetamine	161	6 (3.7)	73	0 (0.0)	234	6 (2.6)
Other opioids	66	1 (1.5)	29	0 (0.0)	95	1 (1.1)
Other drugs	36	1 (2.8)	18	1 (5.6)	54	2 (3.7)

Table 5.2.4 HIV antibody prevalence by drug last injected, gender and year (continued)

Queensland	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Heroin	50	0 (0.0)	28	0 (0.0)	79	0 (0.0)
Methamphetamine	74	1 (1.4)	39	0 (0.0)	114	1 (0.9)
Other opioids	44	2 (4.6)	15	0 (0.0)	59	2 (3.4)
Other drugs	15	1 (6.7)	3	0 (0.0)	18	1 (5.6)
2006						
Heroin	71	1 (1.4)	41	0 (0.0)	113	1 (0.9)
Methamphetamine	139	7 (5.0)	56	1 (1.8)	195	8 (4.1)
Other opioids	100	2 (2.0)	42	0 (0.0)	143	2 (1.4)
Other drugs	27	1 (3.7)	1	0 (0.0)	29	1 (3.5)
2007						
Heroin	64	0 (0.0)	41	0 (0.0)	106	0 (0.0)
Methamphetamine	97	4 (4.1)	46	0 (0.0)	143	4 (2.8)
Other opioids	100	5 (5.0)	38	0 (0.0)	141	5 (3.6)
Other drugs	12	1 (8.3)	2	0 (0.0)	14	1 (7.1)
2008						
Heroin	83	1 (1.2)	41	0 (0.0)	124	1 (0.8)
Methamphetamine	107	4 (3.7)	56	0 (0.0)	163	4 (2.5)
Other opioids	121	3 (2.5)	54	0 (0.0)	177	3 (1.7)
Other drugs	21	1 (4.8)	8	0 (0.0)	29	1 (3.5)
2009						
Heroin	158	1 (0.6)	57	0 (0.0)	216	1 (0.5)
Methamphetamine	169	7 (4.1)	60	0 (0.0)	231	7 (3.0)
Other opioids	201	2 (1.0)	73	0 (0.0)	276	2 (0.7)
Other drugs	43	0 (0.0)	13	0 (0.0)	56	0 (0.0)
2010						
Heroin	93	3 (3.2)	30	0 (0.0)	123	3 (2.4)
Methamphetamine	106	6 (5.7)	33	0 (0.0)	142	6 (4.2)
Other opioids	163	2 (1.2)	52	0 (0.0)	217	2 (0.9)
Other drugs	44	0 (0.0)	7	0 (0.0)	51	0 (0.0)
2011						
Heroin	75	0 (0.0)	32	0 (0.0)	107	0 (0.0)
Methamphetamine	102	4 (3.9)	54	0 (0.0)	156	4 (2.6)
Other opioids	141	4 (2.8)	49	0 (0.0)	193	4 (2.1)
Other drugs	58	0 (0.0)	13	0 (0.0)	72	0 (0.0)
2012						
Heroin	70	0 (0.0)	48	1 (2.1)	118	1 (0.9)
Methamphetamine	103	2 (1.9)	46	0 (0.0)	149	2 (1.3)
Other opioids	158	5 (3.2)	50	1 (2.0)	209	6 (2.9)
Other drugs	82	0 (0.0)	9	0 (0.0)	92	0 (0.0)
2013						
Heroin	58	0 (0.0)	30	0 (0.0)	88	0 (0.0)
Methamphetamine	91	6 (6.6)	62	0 (0.0)	153	6 (3.9)
Other opioids	133	1 (0.8)	60	0 (0.0)	194	1 (0.5)
Other drugs	89	0 (0.0)	8	0 (0.0)	97	0 (0.0)
2014						
Heroin	53	1 (1.9)	21	0 (0.0)	74	1 (1.4)
Methamphetamine	98	8 (8.2)	54	0 (0.0)	152	8 (5.3)
Other opioids	103	1 (1.0)	44	0 (0.0)	148	1 (0.7)
Other drugs	92	1 (1.1)	12	0 (0.0)	104	1 (1.0)
2014 p value		0.019		--		0.050

Table 5.3.1 HCV antibody prevalence by gender and year

Queensland	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995	223	84 (38)	82	37 (45)	309	124 (40)
1996	358	107 (30)	125	54 (43)	489	162 (33)
1997	327	86 (26)	150	51 (34)	479	138 (29)
1998	472	114 (24)	196	76 (39)	670	192 (29)
1999	531	191 (36)	268	115 (43)	804	307 (38)
2000	467	172 (37)	250	110 (44)	723	285 (39)
2001	556	238 (43)	243	121 (50)	807	363 (45)
2002	479	231 (48)	198	93 (47)	683	329 (48)
2003	505	241 (48)	219	123 (56)	731	366 (50)
2004	381	188 (49)	166	94 (57)	547	282 (52)
2005	188	105 (56)	86	40 (47)	276	146 (53)
2006	349	185 (53)	142	88 (62)	494	276 (56)
2007	278	158 (57)	129	85 (66)	411	247 (60)
2008	333	182 (55)	159	91 (57)	494	275 (56)
2009	576	244 (42)	209	94 (45)	790	339 (43)
2010	403	180 (45)	121	58 (48)	529	241 (46)
2011	368	158 (43)	146	63 (43)	518	221 (43)
2012	409	183 (45)	154	83 (54)	565	267 (47)
2013	372	167 (45)	160	79 (49)	533	247 (46)
2014	327	120 (37)	123	49 (40)	451	169 (37)
X ² p trend: 1995-2014		<0.001		0.067		<0.001
X ² p trend: 2010-2014		0.315		0.723		0.317

Table 5.3.2 HCV antibody prevalence by age group, gender and year

Queensland	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	98	16 (16)	43	10 (23)	144	28 (19)
25-34 years	86	41 (48)	26	16 (62)	113	58 (51)
35-44 years	28	23 (82)	13	11 (85)	41	34 (83)
45+ years	9	4 (44)	0	0 (0)	9	4 (44)
1996						
<25 years	184	16 (9)	64	15 (23)	251	32 (13)
25-34 years	113	43 (38)	36	20 (56)	150	63 (42)
35-44 years	55	46 (84)	23	19 (83)	78	65 (83)
45+ years	6	6 (100)	2	1 (50)	8	7 (88)
1997						
<25 years	159	9 (6)	89	16 (18)	249	25 (10)
25-34 years	107	29 (27)	41	18 (44)	149	48 (32)
35-44 years	52	40 (77)	19	16 (84)	71	56 (79)
45+ years	9	8 (89)	1	1 (100)	10	9 (90)
1998						
<25 years	201	14 (7)	95	9 (9)	296	23 (8)
25-34 years	186	41 (22)	58	35 (60)	245	77 (31)
35-44 years	69	47 (68)	37	28 (76)	107	76 (71)
45+ years	15	12 (80)	6	4 (67)	21	16 (76)
1999						
<25 years	194	29 (15)	123	32 (26)	319	61 (19)
25-34 years	226	72 (32)	87	38 (44)	315	111 (35)
35-44 years	83	67 (81)	52	39 (75)	135	106 (79)
45+ years	27	23 (85)	6	6 (100)	33	29 (88)
2000						
<25 years	138	24 (17)	112	28 (25)	252	54 (21)
25-34 years	196	53 (27)	78	44 (56)	276	97 (35)
35-44 years	100	68 (68)	51	32 (63)	152	100 (66)
45+ years	32	27 (84)	9	6 (67)	41	33 (80)
2001						
<25 years	145	33 (23)	94	30 (32)	241	63 (26)
25-34 years	231	77 (33)	94	44 (47)	328	123 (38)
35-44 years	133	88 (66)	48	41 (85)	183	130 (71)
45+ years	45	39 (87)	7	6 (86)	53	46 (87)
2002						
<25 years	119	45 (38)	69	29 (42)	188	74 (39)
25-34 years	228	102 (45)	72	29 (40)	302	132 (44)
35-44 years	95	57 (60)	47	28 (60)	145	88 (61)
45+ years	35	26 (74)	9	7 (78)	45	34 (76)
2003						
<25 years	111	29 (26)	56	15 (27)	169	45 (27)
25-34 years	189	65 (34)	86	51 (59)	277	116 (42)
35-44 years	139	97 (70)	61	45 (74)	202	143 (71)
45+ years	64	50 (78)	16	12 (75)	81	62 (77)
2004						
<25 years	69	17 (25)	42	19 (45)	111	36 (32)
25-34 years	163	59 (36)	60	22 (37)	223	81 (36)
35-44 years	99	71 (72)	50	42 (84)	149	113 (76)
45+ years	49	40 (82)	14	11 (79)	63	51 (81)

Table 5.3.2 HCV antibody prevalence by age group, gender and year (continued)

Queensland	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<25 years	29	5 (17)	14	1 (7)	43	6 (14)
25-34 years	80	37 (46)	63	13 (36)	116	50 (43)
35-44 years	55	46 (84)	26	22 (85)	83	69 (83)
45+ years	24	17 (71)	10	4 (40)	34	21 (62)
2006						
<25 years	46	11 (24)	28	12 (43)	74	23 (31)
25-34 years	149	64 (43)	58	27 (47)	209	93 (45)
35-44 years	98	64 (65)	41	35 (85)	139	99 (71)
45+ years	55	45 (82)	15	14 (93)	71	60 (85)
2007						
<25 years	34	9 (26)	14	6 (43)	48	15 (31)
25-34 years	107	55 (51)	45	23 (51)	154	80 (52)
35-44 years	92	59 (64)	45	35 (78)	137	94 (69)
45+ years	44	31 (77)	25	21 (84)	71	57 (80)
2008						
<25 years	38	10 (26)	26	13 (50)	64	23 (36)
25-34 years	125	56 (45)	58	32 (55)	183	88 (48)
35-44 years	114	70 (61)	43	25 (58)	158	96 (61)
45+ years	55	45 (82)	31	21 (68)	87	67 (77)
2009						
<25 years	75	17 (23)	39	15 (38)	116	32 (28)
25-34 years	218	75 (34)	85	39 (46)	305	114 (37)
35-44 years	193	96 (50)	52	22 (42)	245	118 (48)
45+ years	90	56 (62)	33	18 (55)	124	75 (60)
2010						
<25 years	43	7 (16)	13	3 (23)	57	10 (18)
25-34 years	153	54 (35)	50	25 (50)	203	79 (39)
35-44 years	118	65 (55)	31	14 (45)	152	81 (53)
45+ years	83	49 (59)	26	16 (62)	110	66 (60)
2011						
<25 years	45	3 (7)	9	3 (33)	56	6 (11)
25-34 years	128	44 (34)	65	24 (37)	194	68 (35)
35-44 years	119	64 (54)	45	19 (42)	165	83 (50)
45+ years	75	46 (61)	27	17 (63)	102	63 (62)
2012						
<25 years	55	6 (11)	13	4 (31)	68	10 (15)
25-34 years	129	49 (38)	64	38 (59)	194	88 (45)
35-44 years	139	73 (52)	46	23 (50)	185	96 (52)
45+ years	86	55 (64)	31	18 (58)	118	73 (62)
2013						
<25 years	43	5 (12)	20	5 (25)	63	10 (16)
25-34 years	111	38 (34)	49	24 (49)	160	62 (39)
35-44 years	106	57 (54)	52	24 (46)	158	81 (52)
45+ years	110	66 (60)	39	26 (67)	150	93 (62)
2014						
<25 years	35	2 (6)	16	2 (13)	51	4 (8)
25-34 years	105	25 (24)	42	18 (43)	147	43 (29)
35-44 years	97	44 (45)	44	16 (36)	141	60 (43)
45+ years	88	49 (56)	21	13 (62)	110	62 (56)
2014 p value		<0.001		0.020		<0.001

Table 5.3.3 HCV antibody prevalence by drug last injected, years of injection and year

Queensland	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heroin	37	9 (24)	122	65 (53)	159	74 (47)
Methamphetamine	55	3 (5)	51	25 (49)	106	28 (26)
Other opioids	1	0 (0)	12	9 (75)	13	9 (69)
Other drugs	13	3 (23)	17	10 (59)	30	13 (43)
1996						
Heroin	59	5 (8)	194	112 (58)	253	117 (46)
Methamphetamine	98	6 (6)	70	18 (26)	168	24 (14)
Other opioids	4	1 (25)	15	11 (73)	19	12 (63)
Other drugs	16	1 (6)	33	13 (39)	49	14 (29)
1997						
Heroin	57	7 (12)	170	87 (51)	227	94 (41)
Methamphetamine	104	4 (4)	87	19 (22)	191	23 (12)
Other opioids	21	0 (0)	16	10 (63)	16	10 (63)
Other drugs	0	0 (0)	22	11 (50)	43	11 (26)
1998						
Heroin	61	8 (13)	220	115 (52)	281	123 (44)
Methamphetamine	143	5 (4)	161	36 (22)	304	41 (13)
Other opioids	6	0 (0)	14	11 (79)	20	11 (55)
Other drugs	22	1 (5)	42	16 (38)	64	17 (27)
1999						
Heroin	51	20 (39)	298	174 (58)	349	194 (56)
Methamphetamine	145	9 (6)	199	65 (33)	344	74 (22)
Other opioids	2	1 (50)	21	15 (71)	23	16 (70)
Other drugs	25	3 (12)	48	19 (40)	73	22 (30)
2000						
Heroin	44	13 (30)	284	163 (57)	328	176 (54)
Methamphetamine	90	8 (9)	180	53 (29)	270	61 (23)
Other opioids	1	0 (0)	27	16 (59)	28	16 (57)
Other drugs	23	2 (9)	64	16 (41)	87	28 (32)
2001						
Heroin	22	8 (36)	193	118 (61)	215	126 (59)
Methamphetamine	109	11 (10)	308	123 (40)	417	134 (32)
Other opioids	6	2 (33)	76	60 (79)	82	62 (76)
Other drugs	18	0 (0)	68	40 (59)	86	40 (47)
2002						
Heroin	17	7 (41)	189	106 (56)	206	113 (55)
Methamphetamine	68	24 (35)	234	96 (41)	302	120 (40)
Other opioids	11	2 (18)	78	45 (58)	89	47 (53)
Other drugs	16	7 (43)	66	41 (62)	82	48 (59)
2003						
Heroin	13	4 (31)	180	126 (70)	193	130 (67)
Methamphetamine	62	12 (19)	274	116 (42)	336	128 (38)
Other opioids	6	2 (33)	101	73 (72)	107	75 (70)
Other drugs	9	0 (0)	66	29 (44)	75	29 (39)
2004						
Heroin	7	2 (29)	149	87 (58)	156	89 (57)
Methamphetamine	39	12 (31)	196	82 (42)	235	94 (40)
Other opioids	7	2 (29)	88	74 (84)	95	76 (80)
Other drugs	9	1 (11)	45	22 (49)	54	23 (43)

Table 5.3.3 HCV antibody prevalence by drug last injected, years of injection and year

Queensland	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	3	0 (0)	75	44 (59)	78	44 (56)
Methamphetamine	19	1 (5)	94	39 (41)	113	40 (35)
Other opioids	2	1 (50)	57	48 (84)	59	49 (83)
Other drugs	6	0 (0)	12	10 (83)	18	10 (56)
2006						
Heroin	4	1 (25)	109	77 (71)	113	78 (69)
Methamphetamine	28	1 (7)	167	71 (43)	195	73 (37)
Other opioids	9	4 (44)	133	102 (77)	142	106 (75)
Other drugs	8	0 (0)	21	9 (43)	29	9 (31)
2007						
Heroin	5	1 (20)	101	66 (65)	106	67 (63)
Methamphetamine	26	5 (19)	117	63 (54)	143	68 (48)
Other opioids	4	1 (25)	135	101 (75)	139	102 (73)
Other drugs	3	0 (0)	11	4 (36)	14	4 (29)
2008						
Heroin	4	2 (50)	119	82 (69)	123	84 (68)
Methamphetamine	27	3 (11)	135	62 (46)	162	65 (40)
Other opioids	13	4 (31)	163	108 (66)	176	112 (64)
Other drugs	7	1 (14)	21	9 (43)	28	10 (36)
2009						
Heroin	18	5 (28)	198	112 (57)	216	117 (54)
Methamphetamine	29	1 (3)	202	64 (32)	231	65 (28)
Other opioids	16	3 (19)	256	122 (48)	272	125 (46)
Other drugs	6	0 (0)	49	23 (53)	55	26 (47)
2010						
Heroin	6	0 (0)	116	70 (60)	122	70 (57)
Methamphetamine	14	1 (7)	128	46 (36)	142	47 (33)
Other opioids	10	1 (10)	202	106 (52)	212	107 (50)
Other drugs	15	0 (0)	36	17 (47)	51	17 (33)
2011						
Heroin	8	3 (38)	98	52 (53)	106	55 (52)
Methamphetamine	14	1 (7)	138	51 (37)	152	52 (34)
Other opioids	9	2 (22)	180	96 (53)	189	98 (52)
Other drugs	32	1 (3)	39	15 (38)	71	16 (23)
2012						
Heroin	4	1 (25)	114	74 (65)	118	75 (64)
Methamphetamine	13	3 (23)	133	53 (40)	146	56 (38)
Other opioids	6	2 (33)	202	116 (57)	208	118 (57)
Other drugs	45	1 (2)	46	17 (37)	91	18 (20)
2013						
Heroin	8	1 (13)	80	52 (65)	88	53 (60)
Methamphetamine	16	5 (31)	137	55 (40)	153	60 (39)
Other opioids	13	2 (15)	181	108 (60)	194	110 (57)
Other drugs	44	0 (0)	53	23 (43)	97	23 (24)
2014						
Heroin	1	1 (100)	64	41 (64)	66	42 (64)
Methamphetamine	17	2 (12)	123	43 (35)	141	46 (33)
Other opioids	4	1 (25)	135	71 (53)	141	72 (51)
Other drugs	32	0 (0)	59	7 (12)	100	7 (7)
2014 p value		0.003		<0.001		<0.001

6. SOUTH AUSTRALIA


6.1 South Australia sample

In South Australia (SA), one NSP participated in the ANSPS in all 20 survey years 1995 to 2014 (SAVIVE Shopfront Clean Needle Program). Of the six services that participated in 2014, four participated in the ANSPS in 15 or more years (Hindmarsh Centre, SAVIVE Noarlunga, Parks and Port Adelaide). Nunkuwarrin Yunti is the only Aboriginal Community Controlled Health Organisation that participates in the ANSPS nationally and this service has participated annually in most years since 2004. SA sample sizes ranged from 37 (in 1995) to 355 (in 2003), with samples of 200 respondents or more in all of the past 5 years, 2010 to 2014. Response rates ranged between 26% (in 1997) and 70% (in 1999).

6.2 Demographic Characteristics

Although men outnumbered women in all survey years 1995 to 2014, the proportion of men was higher (at 60% to 68% of samples) in the most recent period (2010 to 2014) than in most previous survey years (1995 to 2009). The majority of respondents (73% to 86%) identified as heterosexual, with between 2% and 16% identifying as bisexual and 2% to 12% identifying as homosexual. The proportion of Indigenous respondents in SA increased significantly over the survey period from 3% in 1995 to 12% in 2014 (χ^2 trend $p < 0.001$). This increase was not due to the inclusion of respondents from Nunkuwarrin Yunti as the trend remained statistically significant when these respondents were excluded (χ^2 trend $p < 0.001$). The majority of respondents from SA were born in Australia (82% to 88%) and reported that their parents spoke English at home (80% to 93%). In 2014, 87% of South Australian respondents were born in Australia and 93% reported that their parents spoke English at home (Table 6.1.1).

Figure 6.2.1 South Australia proportion of younger and older PWID by year



The proportion of young people (those aged less than 25 years) in SA increased between 1995 and 1998, but declined significantly in subsequent years (Figure 6.2.1). In 2014, 3% of ANSPS respondents in SA were aged less than 25 years. There was a

concomitant increase in the median age of respondents, from a low of 29 years in 1998 and 2000, to a high of 40 years in each of the past three years (2012 to 2014). Between 1995 and 2000, around 15% of South Australian ANSPS respondents were aged 40 years or older, increasing to more than half in 2012 (Figure 6.2.1). The median age at first injection remained stable at 18 to 19 years across all survey years.


6.3 Injecting behaviour

Drug last injected

Methamphetamine and heroin were the most commonly reported drugs last injected in SA in all 20 survey years. Methamphetamine was reported as the drug most recently injected by the majority of ANSPS respondents in most survey years, including between 2000 and 2009 and in 2013 and 2014 (Figure 6.3.1). Prevalence of heroin injection varied over the past two decades, from a high of 70% in 1995 to less than 30% in the period following changes in the Australian heroin market in 2001 (Maher et al., 2007; Degenhardt et al., 2006; Topp et al., 2003).

As occurred nationally and elsewhere, prevalence of pharmaceutical opioids as the class of drugs most recently injected increased from 2001. In 2001, 3% of SA ANSPS respondents reported last injecting pharmaceutical opioids, however prevalence increased to a high of 17% in 2013 (χ^2 trend $p < 0.001$). Reports of all other drugs, including cocaine and PIEDs were rare in SA in all survey years 1995 to 2014.

Figure 6.3.1 South Australia prevalence of heroin, methamphetamine and pharmaceutical opioids as the drug last injected by year




Injection risk behaviour

There was a significant reduction in self-reported blood borne viral transmission risk behaviours among South Australian respondents over the 20 year survey period. The proportion of respondents reporting re-use of needles and syringes (including re-use of one's own syringe) in the month preceding ANSPS participation declined from around one in four respondents over the period 1997 to 2008 to around one in five over the

period 2011 to 2014 (χ^2 trend $p < 0.001$, Figure 6.3.3). Prevalence of recent receptive syringe sharing (use of someone else's used needle/syringe) was stable over the period 1996 to 2014, with between 9% and 20% of ANSPS respondents in SA reporting this practice (χ^2 trend $p = 0.066$). Reports of receptive sharing of drug preparation equipment declined significantly, from more than half of respondents in 1999 to less than one third of respondents in 2014 (χ^2 trend $p < 0.001$).


As occurred nationally and in other jurisdictions, prevalence of public injecting in the month preceding survey participation declined significantly in SA from a high of 58% in 2000 to 32% in 2014 (χ^2 trend $p = 0.001$, Table 6.1.3).

Figure 6.3.3 South Australia re-use of syringes and receptive sharing (RS) of syringes and drug preparation equipment by year




6.4 Imprisonment, OST and BBV testing

Figure 6.4.1 South Australia prison history and proportion of respondents who reported injecting in prison in the last 12 months by year




The proportion of South Australian ANSPS respondents who reported a history of imprisonment was stable at between 38% and 54% all years over the period 2002 and 2014 (χ^2 trend $p=0.344$). The proportion of respondents reporting incarceration in the 12 months preceding survey participation declined from around 24% in 1997 to 8% in 2014 (χ^2 trend $p<0.001$). Among South Australian respondents who were recently incarcerated, the proportion who reported injecting in prison also declined, from a high of 83% in 1995 to 5% in 2014 (χ^2 trend $p<0.001$, Table 6.1.1).

Figure 6.4.2 South Australia current and history of OST by year



As occurred nationally and elsewhere, the proportion of South Australian ANSPS respondent who reported a history of OST increased significantly over the period 1995 to 2014 (χ^2 trend $p<0.001$), from around one in three respondents in the late 1990s to more than half in all years since 2007 (Figure 6.4.2, Table 6.1.7). The proportion of respondents in SA who reported current OST also increased, from around one in five respondents in the late 1990s to more than one third in all survey years since 2009 (χ^2 trend $p<0.001$).

Figure 6.4.3 South Australia HCV and HIV testing in the last 12 months by year




More than three quarters of South Australian ANSPS respondents reported a lifetime history of testing for HCV and/or HIV in all survey years (Table 6.7.1). The proportion of respondents who reported a recent HCV antibody test (last 12 months) declined significantly over the survey period, from 88% in 1997 to 51% in 2014 (χ^2 trend $p < 0.001$). The proportion of South Australian respondents reporting a recent HIV test also declined significantly, from 75% in 1997 to less than half in 2014 (χ^2 trend $p < 0.001$, Figure 6.4.3).

6.5 Blood borne viral infections

HIV antibody prevalence

HIV antibody prevalence remained low at 3.5% or less in all survey years in SA (Figure 6.5.1, Table 6.2.1), however prevalence increased over the 20 year period 1995 to 2014 (χ^2 trend $p = 0.034$). Unlike most other jurisdictions, HIV prevalence was higher among women compared to men in some years, including over the period 2011 to 2013, when prevalence among women ranged between 4% and 5.5%. In 2014, only two South Australian ANSPS respondents tested HIV positive and neither were women.

Figure 6.5.1 South Australia HIV antibody prevalence by year



HCV antibody prevalence

HCV antibody prevalence was consistently lower in South Australia than observed nationally in all survey years over the period 1997 to 2014, with less than half of ANSPS respondents exposed to HCV in most years (Figure 6.5.2, Table 6.3.1). HCV antibody prevalence was stable at between 41% and 52% over the period 2010 to 2014 (χ^2 trend $p = 0.321$). As observed in other jurisdictions, HCV antibody prevalence was higher among respondents with longer injection histories (Figure 6.5.3).

In South Australia in 2014, the median age of HCV antibody positive respondents was 42 years, with almost half reporting last injecting methamphetamine (47%) and a further one third reporting last injecting heroin (33%, Table 6.3.3).

Figure 6.5.2 South Australia and National HCV antibody prevalence by year




Figure 6.5.3 South Australia HCV antibody prevalence by time since first injection and year




Table 6.1.1 Number (percentage) of respondents by demographic characteristic and year

	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
South Australia										
Number of sites	2	2	2	5	6	8	6	6	6	6
N° surveyed	N=37	N=45	N=59	N=230	N=250	N=312	N=276	N=318	N=355	N=255
Response rate	46%	36%	26%	46%	70%	64%	60%	49%	50%	42%
Gender (%)										
Male	21 (57)	30 (67)	39 (66)	134 (58)	152 (61)	212 (68)	174 (63)	199 (63)	221 (62)	161 (63)
Female	13 (35)	14 (31)	20 (34)	95 (41)	98 (39)	97 (31)	100 (36)	117 (37)	129 (36)	89 (35)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (1)	2 (1)	1 (<1)	4 (1)	3 (1)
Not reported	3 (8)	1 (2)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	1 (<1)	1 (<1)	2 (1)
Sexual identity (%)										
Heterosexual	27 (73)	36 (80)	47 (80)	178 (78)	187 (75)	231 (74)	208 (76)	240 (76)	265 (75)	203 (80)
Bisexual	6 (16)	1 (2)	4 (7)	17 (7)	33 (13)	40 (13)	28 (10)	41 (13)	45 (13)	34 (13)
Homosexual	1 (3)	5 (11)	3 (5)	28 (12)	17 (7)	33 (11)	26 (9)	11 (3)	25 (7)	8 (3)
Not reported	3 (8)	3 (7)	5 (8)	7 (3)	13 (5)	8 (3)	14 (5)	26 (8)	20 (5)	10 (4)
Age and time since first injection (years)										
Median age	31	30	30	29	30	29	30	30	31	30
Age range	16-45	18-48	16-50	16-53	17-50	14-52	14-53	15-54	16-60	16-56
Age group (%)										
≤24 years	7 (19)	10 (22)	15 (25)	73 (32)	68 (27)	96 (31)	75 (27)	72 (23)	58 (16)	65 (26)
25+ years	29 (78)	35 (78)	43 (73)	157 (68)	181 (72)	215 (69)	201 (73)	246 (77)	296 (83)	187 (73)
Not reported	1 (3)	0 (0)	1 (2)	0 (0)	1 (<1)	1 (<1)	0 (0)	0 (0)	1 (<1)	3 (1)
Median age 1st injection	18	18	18	18	18	18	18	18	18	18
Age range	14-33	14-40	12-43	10-43	10-47	11-40	11-53	11-50	11-48	11-52
N° not reported	1	1	2	2	4	2	2	8	10	13
Median years injection	10	11	7	7	9.5	8	9	11	12	10
Range	<1-23	<1-25	<1-24	<1-33	<1-36	<1-35	<1-31	<1-37	<1-38	<1-71
Time since first injection										
≤3 years	3 (8)	7 (16)	17 (29)	64 (28)	52 (21)	59 (19)	53 (19)	49 (15)	39 (11)	45 (18)
4+ years	33 (89)	37 (82)	39 (66)	164 (71)	194 (78)	250 (80)	221 (80)	261 (82)	304 (86)	196 (77)
Not reported	1 (3)	1 (2)	3 (5)	2 (1)	4 (2)	3 (1)	2 (1)	8 (3)	12 (3)	14 (6)

Table 6.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

South Australia	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Number of sites	7	6	7	7	7	7	7	7	7	7
N° surveyed	N=211	N=200	N=220	N=196	N=248	N=216	N=213	N=203	N=248	N=228
Response rate	47%	36%	39%	45%	53%	41%	51%	42%	56%	51%
Gender (%)										
Male	126 (60)	114 (57)	127 (58)	101 (52)	156 (63)	129 (60)	133 (62)	127 (63)	169 (68)	143 (63)
Female	84 (40)	86 (43)	91 (41)	93 (47)	92 (37)	86 (40)	78 (37)	75 (37)	78 (31)	83 (36)
Transgender	1 (0)	0 (0)	2 (1)	1 (1)	0 (0)	1 (<1)	2 (1)	1 (<1)	1 (<1)	2 (1)
Not reported	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)										
Heterosexual	166 (79)	160 (80)	175 (80)	146 (74)	204 (82)	185 (86)	178 (84)	155 (76)	193 (78)	177 (78)
Bisexual	27 (13)	17 (9)	23 (10)	29 (15)	23 (9)	11 (5)	22 (10)	18 (9)	26 (10)	28 (12)
Homosexual	9 (4)	10 (5)	15 (7)	13 (7)	13 (5)	12 (6)	6 (3)	12 (6)	8 (3)	5 (2)
Not reported	9 (4)	13 (7)	7 (3)	8 (4)	8 (3)	8 (4)	7 (3)	18 (9)	21 (8)	18 (8)
Age and time since first injection (years)										
<i>Median age</i>	33	34	34	36	38	38	39	40	40	40
<i>Age range</i>	18-59	16-58	19-58	17-56	16-61	18-62	17-61	18-60	17-60	18-68
Age group (%)										
≤24 years	30 (14)	27 (14)	25 (11)	19 (10)	25 (10)	18 (8)	13 (6)	14 (7)	21 (8)	6 (3)
25+ years	181 (86)	172 (86)	193 (88)	177 (90)	222 (90)	198 (92)	200 (94)	189 (93)	225 (91)	222 (97)
Not reported	0 (0)	1 (<1)	2 (1)	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)
<i>Median age 1st injection</i>	18	18	18	18	18	18	19	18	18	18
<i>Age range</i>	12-50	10-44	10-47	11-45	12-46	12-44	11-45	10-55	12-48	10-57
<i>N° not reported</i>	4	1	5	4	5	2	4	3	8	1
<i>Median years injection</i>	13	14	13	15	17	17	20	20	18	20
<i>Range</i>	<1-38	<1-41	<1-41	1-41	<1-44	<1-45	<1-37	<1-43	<1-46	<1-41
Time since first injection										
≤3 years	23 (11)	17 (9)	21 (10)	16 (8)	22 (9)	7 (3)	13 (6)	14 (7)	14 (6)	12 (5)
4+ years	184 (87)	178 (89)	194 (88)	176 (90)	221 (89)	207 (96)	196 (92)	186 (92)	226 (91)	214 (94)
Not reported	4 (2)	5 (3)	5 (2)	4 (2)	5 (2)	2 (1)	4 (2)	3 (2)	8 (3)	2 (1)

Table 6.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
South Australia										
N° surveyed	N=37	N=45	N=59	N=230	N=250	N=312	N=276	N=318	N=355	N=255
Aboriginal and Torres Strait Islander origin (%)										
No	34 (92)	42 (93)	56 (95)	209 (91)	237 (95)	267 (85)	246 (89)	295 (92)	317 (89)	228 (90)
Yes	1 (3)	0 (0)	2 (3)	17 (7)	10 (4)	40 (13)	24 (9)	18 (6)	25 (7)	21 (8)
Not reported	2 (5)	3 (7)	1 (2)	4 (2)	3 (1)	5 (2)	6 (2)	5 (2)	13 (4)	6 (2)
Region/country of birth (%)										
Australia	--	--	--	--	215 (86)	--	238 (86)	273 (86)	314 (88)	218 (85)
Other Oceania	--	--	--	--	--	--	4 (1)	2 (<1)	2 (1)	3 (1)
Asia	--	--	--	--	2 (1)	--	2 (1)	6 (2)	1 (<1)	8 (3)
UK & Ireland	--	--	--	--	--	--	20 (7)	25 (8)	20 (6)	13 (5)
Other	--	--	--	--	13 (5)	--	7 (3)	9 (3)	14 (4)	9 (4)
Not reported	--	--	--	--	20 (8)	--	5 (2)	3 (1)	4 (1)	4 (2)
Main language spoken at home by parents (%)										
English	--	--	--	--	215 (86)	251 (80)	243 (88)	256 (80)	290 (82)	179 (70)
Non-English	--	--	--	--	11 (4)	36 (12)	18 (7)	40 (13)	22 (6)	24 (10)
Not reported	--	--	--	--	24 (10)	25 (8)	15 (5)	22 (7)	43 (12)	52 (20)
Imprisonment last year (%)										
No	30 (81)	38 (84)	46 (78)	200 (87)	209 (84)	247 (79)	239 (87)	265 (83)	304 (86)	197 (77)
Yes	6 (16)	4 (9)	13 (22)	30 (13)	38 (15)	60 (19)	34 (12)	44 (14)	48 (13)	43 (17)
Not reported	1 (3)	3 (7)	0 (0)	0 (0)	3 (1)	5 (2)	3 (1)	9 (3)	3 (1)	15 (6)
Injected in prison last year (%)										
N° in prison	N=6	N=4	N=13	N=30	N=38	N=60	N=34	N=44	N=48	N=43
Injected in prison	5 (83)	1 (25)	3 (23)	10 (33)	16 (42)	20 (33)	16 (47)	12 (27)	17 (35)	22 (51)
Frequency of injection last month (%)										
Not last month	0 (0)	4 (9)	4 (7)	12 (5)	13 (5)	18 (6)	11 (4)	11 (3)	25 (7)	17 (7)
Less than weekly	6 (16)	6 (13)	13 (22)	38 (16)	38 (15)	39 (12)	56 (20)	58 (18)	60 (17)	34 (13)
Weekly not daily	12 (32)	20 (45)	12 (20)	61 (27)	82 (33)	70 (22)	88 (32)	89 (28)	94 (27)	68 (27)
Daily or more	18 (49)	15 (33)	29 (49)	119 (52)	116 (46)	183 (59)	120 (43)	156 (49)	171 (48)	129 (50)
Not reported	1 (3)	0 (0)	1 (2)	0 (0)	1 (1)	2 (1)	1 (1)	4 (1)	5 (1)	7 (3)

Table 6.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
South Australia										
N° surveyed	N=211	N=200	N=220	N=196	N=248	N=216	N=213	N=203	N=248	N=228
Aboriginal and Torres Strait Islander origin (%)										
No	186 (88)	176 (88)	202 (92)	158 (81)	206 (83)	185 (86)	183 (86)	183 (90)	201 (81)	197 (86)
Yes	17 (8)	18 (9)	16 (7)	28 (14)	31 (13)	23 (11)	29 (14)	17 (8)	35 (14)	28 (11)
Not reported	8 (4)	6 (3)	2 (1)	10 (5)	11 (4)	8 (4)	1 (<1)	3 (1)	12 (5)	3 (1)
Region/country of birth (%)										
Australia	183 (87)	167 (84)	186 (85)	160 (82)	219 (88)	191 (88)	185 (87)	178 (88)	214 (86)	202 (87)
Other Oceania	2 (1)	1 (<1)	3 (1)	4 (2)	5 (2)	3 (1)	4 (2)	1 (<1)	4 (2)	4 (2)
Asia	2 (1)	5 (3)	2 (<1)	5 (3)	1 (<1)	4 (2)	4 (2)	1 (<1)	3 (1)	2 (1)
UK & Ireland	16 (8)	18 (9)	18 (8)	17 (9)	17 (7)	11 (5)	9 (4)	10 (5)	18 (7)	11 (5)
Other	7 (3)	8 (4)	8 (4)	7 (4)	5 (2)	4 (2)	9 (4)	12 (6)	9 (4)	8 (4)
Not reported	1 (0)	1 (<1)	3 (1)	3 (2)	1 (<1)	3 (1)	2 (1)	1 (<1)	0 (0)	1 (<1)
Main language spoken at home by parents (%)										
English	174 (82)	166 (83)	195 (89)	179 (91)	224 (90)	198 (92)	193 (91)	182 (90)	230 (93)	213 (93)
Non-English	37 (18)	19 (10)	23 (10)	12 (6)	19 (8)	16 (7)	18 (8)	21 (10)	18 (7)	133 (6)
Not reported	0 (0)	15 (8)	2 (1)	5 (3)	5 (2)	2 (1)	2 (1)	0 (0)	0 (0)	2 (1)
Imprisonment last year (%)										
No	179 (85)	174 (87)	173 (79)	158 (81)	199 (80)	168 (78)	175 (82)	184 (92)	200 (81)	195 (86)
Yes	24 (11)	18 (9)	32 (15)	21 (11)	37 (15)	16 (7)	19 (9)	15 (8)	25 (10)	19 (8)
Not reported	8 (4)	8 (4)	15 (7)	17 (9)	12 (5)	32 (15)	19 (9)	4 (2)	23 (9)	14 (6)
Injected in prison last year (%)										
N° in prison	N=24	N=18	N=32	N=21	N=37	N=16	N=19	N=15	N=25	N=19
Injected in prison	8 (33)	4 (22)	8 (25)	7 (33)	5 (14)	1 (6)	4 (21)	2 (13)	4 (16)	1 (5)
Frequency of injection last month (%)										
Not last month	20 (9)	7 (4)	14 (6)	20 (10)	22 (9)	13 (6)	12 (6)	10 (5)	10 (4)	9 (4)
Less than weekly	42 (20)	37 (19)	40 (18)	30 (15)	38 (15)	42 (19)	41 (19)	41 (20)	41 (17)	42 (18)
Weekly not daily	51 (24)	58 (29)	54 (25)	51 (26)	59 (24)	61 (28)	49 (23)	57 (28)	70 (28)	66 (29)
Daily or more	98 (46)	96 (48)	112 (51)	93 (47)	127 (51)	99 (46)	108 (51)	95 (47)	121 (49)	106 (46)
Not reported	0 (0)	2 (1)	0 (0)	2 (1)	2 (1)	1 (<1)	3 (1)	0 (0)	6 (2)	5 (2)
Experienced overdose in the previous 12 months										
Yes	--	--	--	--	--	--	--	--	22 (9)	25 (11)

Table 6.1.2 Number (percentage) of respondents by drug last injected and year

South Australia N° surveyed	1995 N=37	1996 N=45	1997 N=59	1998 N=230	1999 N=250	2000 N=312	2001 N=276	2002 N=318	2003 N=355	2004 N=255
Drug last injected (%)										
Cocaine	0 (0)	2 (4)	1 (2)	8 (3)	4 (2)	4 (1)	9 (3)	1 (<1)	4 (1)	4 (2)
Methamphetamine	8 (21)	14 (31)	26 (43)	87 (38)	104 (42)	93 (30)	143 (52)	144 (45)	169 (48)	101 (40)
Heroin	26 (70)	24 (54)	23 (38)	104 (45)	113 (45)	175 (56)	68 (25)	78 (25)	83 (23)	74 (29)
Pharm. opioids	1 (3)	2 (4)	1 (2)	5 (2)	10 (4)	10 (3)	20 (7)	27 (8)	33 (9)	18 (7)
Methadone	0 (0)	2 (4)	4 (7)	7 (3)	3 (1)	7 (2)	10 (4)	13 (4)	14 (4)	12 (5)
Buprenorphine	--	--	--	--	--	--	--	3 (1)	0 (0)	2 (1)
Buprenorphine/naloxone	--	--	--	--	--	--	--	--	--	--
PIEDs	0 (0)	0 (0)	1 (2)	0 (0)	1 (<1)	2 (1)	0 (0)	4 (1)	3 (1)	1 (<1)
More than one	1 (3)	0 (0)	1 (2)	15 (7)	12 (5)	18 (6)	21 (8)	34 (11)	37 (10)	18 (7)
Other	0 (0)	0 (0)	1 (2)	2 (1)	1 (<1)	0 (0)	0 (0)	1 (<1)	2 (1)	1 (<1)
Not reported	1 (3)	1 (2)	1 (2)	2 (1)	2 (1)	3 (1)	5 (2)	13 (4)	8 (2)	24 (9)

South Australia N° surveyed	2005 N=211	2006 N=200	2007 N=220	2008 N=196	2009 N=248	2010 N=216	2011 N=213	2012 N=203	2013 N=248	2014 N=228
Drug last injected (%)										
Cocaine	2 (1)	1 (<1)	2 (1)	4 (2)	3 (1)	2 (1)	2 (1)	0 (0)	1 (<1)	0 (0)
Methamphetamine	88 (42)	101 (51)	95 (43)	100 (51)	91 (37)	87 (40)	75 (35)	72 (35)	93 (38)	116 (51)
Heroin	77 (36)	40 (20)	62 (28)	49 (25)	84 (34)	86 (40)	77 (36)	74 (36)	83 (33)	65 (29)
Pharm. opioids	16 (8)	24 (12)	24 (11)	20 (10)	34 (14)	26 (12)	28 (13)	26 (13)	41 (17)	14 (6)
Methadone	5 (2)	7 (4)	11 (5)	10 (5)	8 (3)	7 (3)	13 (6)	9 (4)	8 (3)	9 (4)
Buprenorphine	4 (2)	14 (7)	10 (5)	7 (4)	14 (6)	2 (1)	3 (1)	4 (2)	0 (0)	2 (1)
Buprenorphine/naloxone	--	--	--	--	3 (1)	3 (1)	2 (1)	1 (<1)	3 (1)	1 (<1)
PIEDs	2 (1)	3 (2)	2 (1)	1 (1)	0 (0)	0 (0)	1 (<1)	4 (2)	1 (<1)	1 (<1)
More than one	8 (4)	3 (2)	6 (3)	2 (1)	5 (2)	3 (1)	8 (4)	11 (5)	16 (6)	18 (8)
Other	2 (1)	2 (1)	6 (3)	0 (0)	0 (0)	0 (0)	4 (2)	1 (<1)	2 (1)	2 (1)
Not reported	7 (3)	5 (2)	2 (1)	3 (2)	6 (2)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)

Table 6.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

South Australia N° injected last month	1995 N=36	1996 N=41	1997 N=54	1998 N=218	1999 N=236	2000 N=292	2001 N=264	2002 N=303	2003 N=325	2004 N=231
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	--	--	--	--	101 (43)	121 (41)	52 (20)	66 (22)	73 (22)	59 (26)
Water	--	--	--	--	71 (30)	98 (34)	56 (21)	64 (21)	73 (22)	56 (24)
Filter	--	--	--	--	70 (30)	80 (27)	45 (17)	49 (16)	57 (18)	40 (17)
Drug mix	--	--	--	--	56 (24)	60 (21)	19 (19)	53 (17)	67 (21)	36 (16)
None	--	--	--	--	--	--	--	--	--	--
Public injecting in last month (%)										
Any public	--	--	15 (28)	77 (35)	121 (51)	168 (58)	114 (43)	137 (45)	145 (45)	116 (50)
All private	--	--	35 (65)	140 (64)	100 (42)	109 (37)	150 (57)	155 (51)	175 (54)	104 (45)
Not reported	--	--	4 (7)	1 (<1)	15 (6)	15 (5)	0 (0)	11 (4)	5 (2)	11 (5)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	--	--	--	--	213 (90)	272 (93)	248 (94)	263 (87)	303 (93)	207 (90)
Pharmacy	--	--	--	--	139 (59)	138 (47)	112 (42)	123 (41)	151 (46)	112 (48)
South Australia N° injected last month										
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	35 (18)	35 (19)	47 (24)	25 (16)	36 (18)	46 (23)	33 (17)	21 (11)	51 (22)	32 (15)
Water	37 (19)	32 (17)	39 (20)	36 (23)	28 (14)	42 (21)	27 (14)	22 (11)	43 (19)	28 (13)
Filter	20 (10)	19 (10)	29 (15)	16 (10)	19 (9)	24 (12)	19 (10)	13 (7)	26 (11)	12 (6)
Drug mix	24 (13)	14 (8)	15 (8)	9 (6)	20 (10)	16 (8)	17 (9)	15 (8)	21 (9)	12 (6)
None	--	112 (60)	118 (60)	100 (63)	141 (69)	121 (60)	131 (66)	134 (69)	147 (63)	155 (72)
Public injecting in last month (%)										
Any public	99 (52)	73 (38)	102 (50)	83 (48)	82 (37)	94 (47)	91 (46)	91 (47)	103 (44)	69 (32)
All private	78 (41)	109 (57)	97 (47)	89 (51)	141 (63)	97 (48)	98 (50)	91 (47)	128 (55)	143 (67)
Not reported	13 (7)	9 (5)	7 (4)	2 (1)	1 (<1)	11 (5)	9 (5)	11 (6)	1 (<1)	2 (1)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	175 (92)	166 (87)	139 (67)	144 (83)	150 (67)	183 (91)	176 (89)	159 (82)	211 (91)	191 (89)
Pharmacy	80 (42)	79 (41)	37 (18)	66 (38)	36 (16)	26 (13)	30 (15)	41 (21)	41 (18)	34 (16)

Table 6.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

South Australia N° injected last month	1995 N=36	1996 N=41	1997 N=54	1998 N=218	1999 N=236	2000 N=292	2001 N=264	2002 N=303	2003 N=325	2004 N=231
Use of sterile needles and syringes last month (%)										
All injections	--	--	41 (76)	151 (69)	169 (72)	206 (71)	214 (81)	223 (74)	253 (78)	162 (70)
Most of the time	--	--	8 (15)	51 (23)	53 (22)	65 (22)	41 (16)	61 (20)	57 (18)	57 (25)
Half of the time	--	--	1 (2)	7 (3)	4 (2)	7 (2)	3 (1)	9 (3)	7 (2)	6 (3)
Some of the time	--	--	0 (0)	8 (4)	3 (1)	6 (2)	3 (1)	3 (1)	2 (1)	2 (1)
Not last month	--	--	1 (2)	1 (<1)	1 (<1)	0 (0)	2 (1)	1 (<1)	1 (<1)	1 (<1)
Not reported	--	--	3 (5)	0 (0)	6 (3)	8 (3)	1 (<1)	6 (2)	5 (1)	3 (1)
Re-used someone else's used needle & syringe last month (%)										
None	24 (67)	32 (78)	47 (87)	182 (83)	186 (79)	240 (82)	229 (87)	250 (82)	278 (86)	181 (78)
Once	3 (8)	4 (10)	2 (4)	15 (7)	16 (7)	11 (4)	14 (5)	11 (4)	12 (4)	8 (3)
Twice	5 (14)	2 (5)	3 (5)	10 (5)	7 (3)	12 (3)	5 (2)	13 (4)	7 (2)	15 (7)
3-5 times	4 (11)	2 (5)	0 (0)	5 (2)	4 (2)	8 (3)	3 (1)	9 (3)	16 (5)	12 (5)
>5 times	0 (0)	1 (2)	1 (2)	6 (3)	10 (4)	5 (2)	9 (3)	8 (3)	5 (1)	11 (5)
Not reported	0 (0)	0 (0)	1 (2)	0 (0)	13 (6)	16 (5)	4 (2)	12 (4)	7 (2)	4 (2)
Number of people needle & syringe was re-used after last month (%)										
None	24 (67)	32 (78)	47 (87)	182 (83)	186 (79)	240 (82)	229 (87)	250 (82)	272 (84)	181 (79)
One	7 (19)	6 (15)	5 (9)	34 (16)	33 (14)	31 (11)	18 (7)	25 (8)	30 (9)	21 (9)
Two	4 (11)	2 (5)	1 (2)	2 (1)	4 (2)	2 (1)	0 (0)	3 (1)	3 (1)	3 (1)
Three to five	1 (3)	1 (2)	0 (0)	0 (0)	4 (2)	4 (1)	2 (1)	1 (<1)	0 (0)	3 (1)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	3 (1)	3 (1)	1 (<1)	1 (<1)	0 (0)	2 (1)
Don't know	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)	5 (2)	3 (1)	5 (1)	7 (3)
Not reported	0 (0)	0 (0)	1 (2)	0 (0)	6 (2)	11 (4)	9 (3)	20 (7)	15 (5)	14 (6)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	--	--	2 (4)	25 (11)	27 (11)	23 (8)	19 (7)	19 (6)	25 (47)	13 (6)
Casual sex partner	--	--	1 (2)	1 (<1)	0 (0)	1 (<1)	2 (1)	2 (1)	2 (4)	3 (1)
Close friend	--	--	1 (2)	8 (4)	14 (6)	15 (5)	3 (1)	13 (94)	8 (15)	11 (5)
Acquaintance	--	--	0 (0)	4 (2)	5 (2)	5 (2)	6 (2)	0 (0)	4 (8)	6 (3)
Other	--	--	0 (0)	1 (<1)	2 (1)	1 (<1)	3 (1)	0 (0)	1 (2)	4 (2)

Table 6.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

South Australia N° injected last month	2005 N=191	2006 N=191	2007 N=206	2008 N=174	2009 N=224	2010 N=202	2011 N=198	2012 N=193	2013 N=232	2014 N=214
Use of sterile needles and syringes last month (%)										
All injections	134 (70)	143 (75)	147 (71)	126 (72)	184 (82)	151 (75)	146 (74)	149 (77)	187 (81)	174 (81)
Most of the time	48 (25)	27 (14)	45 (22)	34 (20)	31 (14)	32 (16)	36 (18)	28 (15)	35 (15)	30 (14)
Half of the time	6 (3)	10 (5)	4 (2)	6 (3)	4 (2)	4 (2)	3 (2)	0 (0)	3 (1)	4 (2)
Some of the time	3 (2)	3 (2)	3 (1)	5 (3)	3 (1)	4 (2)	1 (<1)	1 (<1)	2 (1)	2 (1)
Not last month	0 (0)	2 (1)	0 (0)	1 (1)	0 (0)	0 (0)	1 (<1)	1 (<1)	2 (1)	0 (0)
Not reported	0 (0)	6 (3)	7 (3)	2 (1)	2 (1)	11 (5)	11 (6)	14 (7)	3 (1)	4 (2)
Re-used someone else's used needle & syringe last month (%)										
None	163 (85)	157 (82)	166 (81)	138 (79)	197 (88)	154 (76)	163 (82)	162 (84)	197 (85)	183 (86)
Once	8 (4)	5 (3)	11 (5)	7 (4)	7 (3)	8 (4)	5 (3)	12 (6)	17 (7)	10 (5)
Twice	6 (3)	8 (4)	8 (4)	10 (6)	7 (3)	4 (2)	6 (3)	5 (3)	6 (3)	12 (6)
3-5 times	2 (1)	11 (6)	8 (4)	11 (6)	3 (1)	7 (3)	6 (3)	0 (0)	5 (2)	4 (2)
>5 times	4 (2)	5 (3)	4 (2)	2 (1)	4 (2)	5 (2)	5 (3)	1 (<1)	6 (3)	3 (1)
Not reported	8 (4)	5 (3)	9 (4)	6 (3)	6 (3)	24 (12)	13 (7)	13 (7)	1 (<1)	2 (1)
Number of people needle & syringe was re-used after last month (%)										
None	157 (82)	157 (82)	166 (81)	138 (79)	197 (88)	154 (76)	163 (82)	162 (84)	197 (85)	183 (86)
One	12 (6)	12 (6)	10 (5)	17 (10)	11 (5)	7 (3)	14 (7)	7 (4)	14 (6)	11 (5)
Two	1 (1)	5 (3)	5 (2)	3 (2)	3 (1)	3 (1)	2 (1)	1 (<1)	3 (1)	1 (<1)
Three to five	1 (1)	0 (0)	3 (1)	0 (0)	0 (0)	3 (1)	1 (<1)	1 (<1)	3 (1)	0 (0)
More than five	3 (2)	0 (0)	1 (<1)	0 (0)	0 (0)	3 (1)	0 (0)	0 (0)	3 (1)	2 (1)
Don't know	8 (4)	7 (4)	5 (2)	8 (5)	4 (2)	4 (2)	4 (2)	2 (1)	9 (4)	10 (5)
Not reported	9 (5)	10 (5)	16 (8)	8 (5)	9 (4)	28 (14)	14 (7)	20 (10)	3 (1)	7 (3)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	15 (8)	10 (5)	15 (7)	10 (6)	9 (4)	19 (9)	18 (9)	7 (4)	18 (8)	14 (7)
Casual sex partner	1 (<1)	2 (1)	4 (2)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)	2 (1)	1 (<1)
Close friend	5 (3)	7 (4)	2 (1)	7 (4)	3 (1)	13 (6)	7 (4)	3 (2)	9 (4)	9 (4)
Acquaintance	3 (2)	4 (2)	1 (<1)	3 (2)	2 (1)	2 (1)	3 (2)	2 (1)	5 (2)	2 (1)
Other	0 (0)	3 (2)	2 (1)	4 (2)	0 (0)	6 (3)	4 (2)	1 (<1)	5 (2)	3 (1)

Table 6.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

South Australia N° surveyed	1995 N=37	1996 N=45	1997 N=59	1998 N=230	1999 N=250	2000 N=312	2001 N=276	2002 N=318	2003 N=355	2004 N=255
Sex last month (%)										
No	13 (35)	10 (22)	13 (22)	57 (25)	62 (25)	106 (34)	77 (28)	77 (24)	104 (29)	82 (32)
Yes	22 (60)	34 (76)	46 (78)	171 (74)	185 (74)	205 (66)	192 (70)	234 (74)	241 (68)	167 (66)
Not reported	2 (5)	1 (2)	0 (0)	2 (1)	3 (1)	1 (<1)	7 (2)	7 (2)	10 (3)	6 (2)
Condom use at last sex (%)										
No	19 (52)	21 (47)	40 (68)	153 (67)	163 (65)	216 (69)	195 (71)	223 (70)	249 (70)	166 (65)
Yes	9 (24)	11 (24)	18 (30)	70 (30)	83 (33)	95 (30)	72 (26)	82 (26)	97 (27)	69 (27)
Not reported	9 (24)	13 (29)	1 (2)	7 (3)	4 (2)	1 (<1)	9 (3)	13 (4)	9 (3)	20 (8)
Condom use with regular sex partner(s) last month (%)										
No	--	18 (62)	31 (79)	94 (68)	108 (68)	113 (69)	98 (74)	97 (69)	121 (74)	74 (63)
Sometimes	--	3 (10)	3 (8)	17 (12)	14 (9)	18 (11)	19 (14)	14 (10)	11 (7)	20 (17)
Always	--	8 (28)	5 (13)	28 (20)	37 (23)	32 (20)	15 (12)	29 (21)	31 (19)	24 (20)
Condom use with new sex partner(s) last month (%)										
No	--	4 (36)	14 (58)	16 (36)	39 (48)	15 (23)	31 (43)	44 (43)	44 (43)	44 (49)
Sometimes	--	1 (9)	0 (0)	9 (21)	6 (7)	10 (15)	10 (14)	19 (18)	17 (16)	12 (13)
Always	--	6 (55)	10 (42)	19 (43)	37 (45)	40 (62)	31 (43)	40 (39)	42 (41)	34 (38)
Condom use with casual sex partner(s) last month (%)										
No	--	--	--	16 (27)	41 (44)	27 (29)	32 (44)	31 (33)	38 (42)	34 (42)
Sometimes	--	--	--	13 (22)	8 (9)	20 (21)	10 (14)	24 (26)	19 (21)	23 (28)
Always	--	--	--	31 (51)	44 (47)	47 (50)	31 (42)	39 (41)	33 (37)	25 (30)
Sex work last month (%)										
No	31 (84)	42 (93)	57 (96)	209 (91)	223 (89)	282 (90)	242 (88)	286 (90)	318 (90)	221 (87)
Yes	3 (8)	2 (5)	1 (2)	12 (5)	22 (9)	30 (10)	25 (9)	16 (5)	15 (4)	19 (7)
Not reported	3 (8)	1 (2)	1 (2)	9 (4)	5 (2)	0 (0)	9 (3)	16 (5)	22 (6)	15 (6)
Condom used at last sex work (%)										
Yes	3 (100)	2 (100)	1 (100)	8 (80)	17 (89)	24 (96)	15 (75)	13 (81)	15 (100)	17 (94)

Table 6.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

South Australia N° surveyed	2005 N=211	2006 N=200	2007 N=220	2008 N=196	2009 N=248	2010 N=216	2011 N=213	2012 N=203	2013 N=248	2014 N=228
Sex with a regular partner last month (%)										
No	98 (46)	88 (44)	88 (40)	81 (41)	112 (45)	100 (46)	96 (45)	91 (45)	124 (50)	102 (45)
Yes	107 (51)	111 (56)	122 (55)	107 (55)	124 (50)	106 (49)	102 (48)	108 (53)	118 (48)	119 (52)
Not reported	6 (3)	1 (<1)	10 (5)	8 (4)	12 (5)	10 (5)	15 (7)	4 (2)	6 (2)	7 (3)
Condom used with regular partner last month (%)										
Never	N=107	N=111	N=122	N=107	N=124	N=106	N=102	N=108	N=118	N=2119
Sometimes	82 (77)	81 (73)	97 (80)	78 (73)	80 (64)	71 (67)	69 (68)	73 (68)	86 (73)	89 (75)
Every time	15 (14)	14 (13)	17 (14)	17 (16)	23 (19)	13 (12)	10 (10)	11 (10)	14 (12)	14 (12)
Not reported	8 (7)	8 (7)	6 (5)	8 (7)	12 (10)	10 (9)	15 (15)	13 (12)	6 (5)	11 (9)
Not reported	2 (2)	8 (7)	2 (2)	4 (4)	9 (7)	12 (11)	8 (8)	11 (10)	12 (10)	5 (4)
Sex with other partner(s) last month (%)										
No	172 (82)	164 (82)	171 (78)	153 (78)	205 (83)	170 (79)	179 (84)	176 (87)	216 (87)	185 (81)
Yes	34 (16)	30 (15)	42 (19)	31 (16)	31 (13)	33 (15)	22 (10)	22 (11)	23 (9)	34 (15)
Not reported	5 (2)	6 (3)	7 (3)	12 (6)	12 (5)	13 (6)	12 (6)	5 (2)	9 (4)	9 (4)
Condom used with other partner(s) last month (%)										
Never	N=34	N=30	N=42	N=31	N=31	N=33	N=22	N=22	N=23	N=34
Sometimes	7 (21)	9 (30)	21 (50)	5 (16)	9 (29)	7 (21)	6 (27)	9 (41)	11 (48)	10 (29)
Every time	9 (26)	7 (23)	6 (14)	12 (39)	9 (29)	7 (21)	6 (27)	4 (18)	5 (22)	10 (29)
Not reported	17 (50)	12 (40)	14 (33)	14 (45)	13 (42)	16 (48)	10 (45)	8 (36)	6 (26)	11 (32)
Not reported	1 (3)	2 (7)	1 (2)	0 (0)	0 (0)	3 (9)	0 (0)	1 (5)	1 (4)	3 (9)
Sex work last month (%)										
No	195 (92)	182 (91)	194 (88)	170 (87)	229 (92)	184 (85)	194 (91)	192 (95)	217 (88)	207 (91)
Yes	10 (5)	12 (6)	21 (10)	13 (7)	10 (4)	20 (9)	9 (4)	6 (3)	20 (8)	10 (4)
Not reported	6 (3)	6 (3)	5 (2)	13 (7)	9 (4)	12 (6)	10 (5)	5 (2)	11 (4)	11 (5)
Condom used at last sex work (%)										
Yes	24 (96)	8 (80)	13 (72)	11 (85)	9 (90)	13 (68)	8 (89)	6 (100)	14 (70)	8 (80)

Table 6.1.5 Number (percentage) of respondents by testing for HIV and HCV infection by year

South Australia N° surveyed	1995 N=37	1996 N=45	1997 N=59	1998 N=230	1999 N=250	2000 N=312	2001 N=276	2002 N=318	2003 N=355	2004 N=255
Previous HIV test (%)										
Yes, ever	34 (92)	39 (87)	53 (90)	195 (85)	205 (82)	265 (85)	241 (87)	280 (88)	321 (90)	210 (82)
Yes, last year	24 (65)	28 (62)	44 (75)	128 (56)	144 (58)	183 (59)	161 (58)	199 (63)	225 (63)	134 (53)
>1 year ago	10 (27)	11 (25)	9 (15)	67 (29)	61 (24)	82 (26)	80 (29)	81 (25)	96 (27)	76 (30)
Never tested	2 (5)	6 (13)	6 (10)	35 (15)	45 (18)	47 (15)	35 (13)	35 (11)	28 (8)	31 (12)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (1)	6 (2)	14 (5)
Previous HCV test (%)										
Yes, ever	25 (68)	36 (80)	52 (88)	184 (80)	204 (82)	269 (86)	240 (87)	276 (87)	316 (89)	213 (84)
Yes, last year	--	--	46 (78)	134 (58)	150 (60)	197 (63)	153 (55)	198 (62)	223 (63)	138 (54)
>1 year ago	--	--	6 (10)	50 (22)	54 (21)	72 (23)	87 (32)	78 (25)	93(26)	75 (30)
Never tested	10 (27)	8 (18)	7 (12)	46 (20)	44 (18)	43 (14)	36 (13)	38 (12)	37 (10)	34 (13)
Not reported	2 (5)	1 (20)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)	4 (1)	2 (1)	8 (3)
South Australia N° surveyed										
2005 N=211										
2006 N=200										
2007 N=220										
2008 N=196										
2009 N=248										
2010 N=216										
2011 N=213										
2012 N=203										
2013 N=248										
2014 N=228										
Previous HIV test (%)										
Yes, ever	184 (87)	166 (83)	192 (87)	156 (80)	211 (85)	180 (83)	174 (82)	175 (86)	207 (83)	176 (77)
Yes, last year	107 (51)	99 (50)	116 (53)	94 (48)	130 (52)	88 (41)	93 (44)	101 (50)	132 (53)	98 (43)
>1 year ago	77 (36)	67 (34)	76 (35)	62 (32)	81 (33)	92 (43)	81 (38)	74 (36)	75 (30)	78 (34)
Never tested	26 (12)	34 (17)	27 (12)	30 (15)	28 (11)	25 (12)	29 (14)	21 (10)	34 (14)	45 (20)
Not reported	1 (<1)	0 (0)	1 (<1)	10 (5)	9 (4)	11 (5)	10 (5)	7 (3)	7 (3)	7 (3)
Previous HCV test (%)										
Yes, ever	183 (87)	168 (84)	196 (89)	161 (82)	206 (83)	172 (80)	182 (85)	182 (90)	214 (86)	183 (80)
Yes, last year	113 (54)	117 (59)	123 (56)	104 (53)	139 (56)	99 (46)	105 (49)	112 (55)	140 (56)	116 (51)
>1 year ago	70 (33)	51 (26)	73 (33)	57 (29)	67 (27)	73 (34)	77 (36)	70 (34)	74 (30)	67 (29)
Never tested	27 (13)	32 (16)	23 (10)	29 (15)	28 (11)	23 (11)	15 (7)	13 (6)	22 (9)	35 (15)
Not reported	1 (<1)	0 (0)	1 (<1)	6 (3)	14 (6)	21 (10)	16 (8)	8 (4)	12 (5)	10 (4)

Table 6.1.6 Number (percentage) of respondents by HCV treatment by year

South Australia	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Self-report HCV diagnosis	--	--	--	--	N=77	N=115	N=91	N=115	N=141	N=84
Any treatment for HCV (%)										
Interferon +/- Ribavirin	--	--	--	--	2 (3)	5 (4)	0 (0)	7 (6)	3 (2)	3 (4)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	4 (5)	2 (2)	4 (4)	3 (3)	5 (4)	2 (2)
No treatment	--	--	--	--	68 (88)	107 (93)	85 (94)	95 (82)	130 (92)	77 (93)
Not reported	--	--	--	--	3 (4)	1 (1)	2 (2)	10 (9)	3 (2)	2 (2)
Current treatment for HCV (%)										
Interferon +/- Ribavirin	--	--	--	--	2	6	0	0	1	1
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	0	0	0	0	3	1

South Australia	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Self-report HCV diagnosis	N=70	N=68	N=59	N=59	N=102	N=92	N=101	N=95	N=119	N=93
Any treatment for HCV (%)										
Interferon +/- Ribavirin	3 (4)	5 (7)	2 (3)	7 (12)	14 (14)	6 (7)	12 (12)	10 (11)	17 (14)	13 (14)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	0 (0)	1 (1)
Other	1 (1)	2 (3)	1 (2)	0 (0)	1 (1)	0 (0)	1 (1)	2 (2)	0 (0)	2 (2)
No treatment	65 (93)	53 (78)	53 (90)	50 (85)	81 (79)	83 (90)	80 (79)	78 (82)	89 (75)	71 (76)
Not reported	1 (1)	8 (12)	3 (5)	2 (3)	6 (6)	3 (3)	8 (8)	5 (5)	13 (11)	6 (6)
Current treatment for HCV (%)										
Interferon +/- Ribavirin	1	2	2	1	2	2	2	3	2	1
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	0	0
Other	1	1	0	0	1	0	0	0	0	1

Table 6.1.7 Number (percentage) of respondents by drug treatment by year

South Australia N° surveyed	1995 N=37	1996 N=45	1997 N=59	1998 N=230	1999 N=250	2000 N=312	2001 N=276	2002 N=318	2003 N=355	2004 N=255
Ever any treatment/therapy for drug use (%)										
No	15 (40)	16 (36)	33 (56)	122 (53)	119 (48)	121 (39)	119 (43)	129 (41)	147 (41)	51 (20)
Yes	21 (57)	29 (64)	26 (44)	108 (47)	131 (52)	190 (61)	157 (57)	189 (59)	206 (58)	162 (64)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)	2 (1)	42 (16)
History of methadone maintenance treatment (%)										
Current	5 (14)	17 (38)	14 (24)	42 (18)	57 (23)	66 (21)	59 (21)	71 (22)	72 (20)	47 (18)
Previous	7 (19)	5 (11)	5 (8)	37 (16)	40 (16)	54 (17)	53 (19)	79 (25)	90 (26)	41 (16)
Never	24 (64)	23 (51)	40 (68)	151 (66)	153 (61)	191 (61)	164 (60)	168 (53)	189 (53)	89 (35)
Not reported	1 (3)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)	4 (1)	78 (31)
History of other pharmacotherapy treatment (%)										
Current	--	--	--	--	--	15 (5)	14 (5)	20 (6)	32 (9)	35 (14)
Previous	--	--	--	--	--	26 (8)	25 (9)	33 (10)	55 (15)	39 (15)
Never	--	--	--	--	--	269 (86)	233 (84)	261 (83)	259 (73)	156 (61)
Not reported	--	--	--	--	--	2 (1)	4 (2)	4 (1)	9 (3)	25 (10)
South Australia N° surveyed										
2005 N=211										
2006 N=200										
2007 N=220										
2008 N=196										
2009 N=248										
2010 N=216										
2011 N=213										
2012 N=203										
2013 N=248										
2014 N=2378										
Ever any treatment/therapy for drug use (%)										
No	72 (34)	69 (35)	60 (27)	66 (34)	67 (27)	46 (21)	49 (23)	60 (30)	72 (29)	72 (33)
Yes	136 (64)	127 (64)	158 (72)	123 (63)	176 (71)	163 (75)	163 (77)	142 (70)	170 (69)	153 (67)
Not reported	3 (1)	4 (2)	2 (1)	7 (4)	5 (2)	7 (3)	1 (<1)	1 (<1)	6 (2)	3 (1)
History of methadone maintenance treatment (%)										
Current	45 (21)	25 (13)	51 (23)	39 (20)	61 (25)	57 (26)	48 (22)	58 (29)	65 (26)	57 (25)
Previous	48 (23)	64 (32)	57 (26)	40 (20)	46 (19)	53 (25)	61 (29)	44 (22)	41 (17)	46 (20)
Never	114 (54)	108 (54)	109 (50)	112 (57)	135 (54)	92 (42)	96 (45)	100 (49)	140 (56)	122 (54)
Not reported	4 (2)	3 (2)	3 (1)	5 (3)	6 (2)	14 (6)	8 (4)	1 (<1)	2 (1)	3 (1)
History of other pharmacotherapy treatment (%)										
Current	46 (22)	27 (14)	28 (13)	26 (13)	42 (17)	29 (13)	26 (12)	29 (14)	31 (13)	28 (12)
Previous	32 (15)	38 (19)	46 (21)	33 (17)	60 (24)	62 (29)	56 (26)	45 (22)	70 (28)	54 (24)
Never	128 (61)	130 (65)	143 (65)	130 (66)	145 (58)	124 (57)	126 (59)	129 (64)	147 (59)	145 (64)
Not reported	5 (2)	5 (3)	3 (1)	7 (4)	1 (<1)	1 (<1)	5 (2)	0 (0)	0	1 (<1)

HIV antibody prevalence

Table 6.2.1 HIV antibody prevalence by gender and year

South Australia	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995	19	0 (0.0)	11	0 (0.0)	32	0 (0.0)
1996	30	0 (0.0)	14	0 (0.0)	45	0 (0.0)
1997	25	1 (4.0)	14	0 (0.0)	39	0 (0.0)
1998	96	1 (1.0)	71	1 (1.4)	168	2 (1.2)
1999	142	2 (1.4)	96	4 (4.2)	238	6 (2.5)
2000	200	0 (0.0)	92	0 (0.0)	294	0 (0.0)
2001	173	3 (1.7)	99	1 (1.0)	274	4 (1.5)
2002	194	1 (0.5)	115	1 (0.9)	311	2 (0.6)
2003	190	1 (0.5)	115	1 (0.9)	308	2 (0.7)
2004	145	0 (0.0)	80	1 (1.3)	229	1 (0.4)
2005	122	1 (0.8)	82	0 (0.0)	205	1 (0.5)
2006	112	1 (0.9)	85	0 (0.0)	197	1 (0.5)
2007	120	2 (1.7)	89	0 (0.0)	211	2 (1.0)
2008	96	0 (0.0)	92	0 (0.0)	189	0 (0.0)
2009	155	2 (1.3)	91	1 (1.1)	246	3 (1.2)
2010	129	0 (0.0)	84	1 (1.2)	214	1 (0.5)
2011	129	2 (1.6)	76	3 (4.0)	207	5 (2.4)
2012	123	2 (1.6)	73	4 (5.5)	197	6 (3.1)
2013	154	4 (2.6)	74	3 (4.1)	229	7 (3.1)
2014	137	2 (1.5)	82	0 (0.0)	220	2 (0.9)
X ² p trend: 1995-2014		0.175		0.213		0.034
X ² p trend: 2010-2014		0.231		0.705		0.612

Table 6.3.1 HCV antibody prevalence by gender and year

South Australia	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995	19	14 (74)	11	4 (36)	32	19 (59)
1996	30	18 (60)	13	6 (46)	44	24 (55)
1997	25	9 (36)	14	8 (57)	39	17 (44)
1998	96	28 (29)	71	17 (24)	168	45 (27)
1999	142	61 (43)	96	37 (39)	238	98 (41)
2000	200	96 (48)	92	42 (46)	294	138 (47)
2001	174	89 (51)	99	51 (52)	275	142 (52)
2002	192	90 (47)	115	43 (37)	309	133 (43)
2003	190	86 (45)	115	53 (46)	308	142 (46)
2004	147	67 (46)	80	39 (49)	231	108 (47)
2005	122	54 (44)	82	40 (49)	205	95 (46)
2006	112	49 (44)	85	35 (41)	197	84 (43)
2007	120	50 (42)	89	31 (35)	211	82 (39)
2008	95	30 (32)	90	24 (27)	186	54 (29)
2009	155	65 (42)	91	36 (40)	246	101 (41)
2010	127	54 (43)	84	38 (45)	212	93 (44)
2011	128	67 (52)	75	31 (41)	205	98 (48)
2012	122	51 (42)	71	28 (39)	194	79 (41)
2013	153	78 (51)	74	32 (43)	228	111 (49)
2014	128	68 (53)	79	40 (51)	208	109 (52)
X ² p trend: 1995-2014		0.729		0.756		0.630
X ² p trend: 2010-2014		0.395		0.665		0.321

Table 6.3.2 HCV antibody prevalence by age group, gender and year

South Australia	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	5	2 (40)	1	0 (0)	6	2 (33)
25-34 years	9	7 (78)	8	3 (38)	17	10 (59)
35-44 years	4	4 (100)	2	1 (50)	6	5 (83)
45+ years	1	1 (100)	0	0 (0)	1	1 (100)
1996						
<25 years	6	2 (33)	4	0 (0)	10	2 (20)
25-34 years	14	10 (71)	5	3 (60)	19	13 (68)
35-44 years	9	6 (67)	4	3 (75)	13	9 (69)
45+ years	1	0 (0)	0	0 (0)	1	0 (0)
1997						
<25 years	7	2 (29)	1	0 (0)	8	2 (25)
25-34 years	11	3 (27)	8	6 (75)	19	9 (47)
35-44 years	6	3 (50)	3	2 (67)	9	5 (56)
45+ years	0	0 (0)	2	0 (0)	2	0 (0)
1998						
<25 years	30	0 (0)	21	0 (0)	51	0 (0)
25-34 years	38	11 (29)	30	9 (30)	68	20 (29)
35-44 years	26	16 (62)	18	8 (44)	44	24 (55)
45+ years	2	1 (50)	2	0 (0)	4	1 (25)
1999						
<25 years	37	6 (16)	28	3 (11)	65	9 (14)
25-34 years	61	25 (41)	45	23 (51)	106	48 (45)
35-44 years	32	24 (75)	21	9 (43)	53	33 (62)
45+ years	12	6 (50)	1	1 (100)	13	7 (54)
2000						
<25 years	60	13 (22)	31	13 (42)	91	26 (29)
25-34 years	81	41 (51)	41	16 (39)	122	57 (47)
35-44 years	45	30 (67)	17	11 (65)	62	41 (66)
45+ years	14	12 (86)	3	2 (67)	17	14 (82)
2001						
<25 years	52	20 (38)	23	10 (43)	75	30 (40)
25-34 years	70	33 (47)	43	23 (53)	113	56 (50)
35-44 years	44	32 (73)	30	15 (50)	74	47 (64)
45+ years	8	4 (50)	3	3 (100)	11	7 (64)
2002						
<25 years	41	8 (20)	29	3 (10)	70	11 (16)
25-34 years	87	40 (46)	52	20 (38)	139	50 (36)
35-44 years	48	33 (69)	25	15 (60)	73	48 (66)
45+ years	16	9 (56)	9	5 (56)	25	14 (56)
2003						
<25 years	28	7 (25)	25	9 (36)	53	16 (30)
25-34 years	99	41 (41)	53	20 (38)	152	61 (40)
35-44 years	52	32 (62)	30	20 (67)	82	52 (63)
45+ years	11	6 (55)	6	3 (50)	17	9 (53)
2004						
<25 years	33	6 (18)	24	10 (42)	57	16 (28)
25-34 years	64	32 (50)	26	10 (38)	90	42 (47)
35-44 years	31	15 (48)	23	15 (65)	54	30 (56)
45+ years	17	14 (82)	7	4 (57)	24	18 (75)

Table 6.3.2 HCV antibody prevalence by age group, gender and year (continued)

South Australia	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<25 years	13	3 (23)	15	5 (33)	28	8 (29)
25-34 years	51	18 (35)	37	13 (35)	88	31 (35)
35-44 years	39	23 (59)	21	14 (67)	60	39 (65)
45+ years	19	10 (53)	9	8 (89)	28	18 (64)
2006						
<25 years	9	0 (0)	17	2 (12)	26	2 (8)
25-34 years	48	18 (38)	34	13 (38)	82	52 (63)
35-44 years	38	20 (53)	23	12 (52)	61	32 (52)
45+ years	16	10 (63)	11	8 (73)	27	18 (67)
2007						
<25 years	7	4 (57)	14	4 (29)	21	8 (38)
25-34 years	45	14 (31)	37	10 (27)	82	24 (29)
35-44 years	53	23 (43)	25	10 (40)	78	33 (42)
45+ years	14	8 (57)	12	7 (58)	26	15 (58)
2008						
<25 years	6	0 (0)	11	2 (18)	17	2 (12)
25-34 years	23	5 (22)	37	7 (19)	60	12 (20)
35-44 years	50	17 (34)	26	7 (27)	76	24 (32)
45+ years	16	8 (50)	16	8 (50)	32	24 (75)
2009						
<25 years	14	1 (7)	10	4 (40)	24	5 (21)
25-34 years	37	13 (35)	30	11 (37)	67	24 (36)
35-44 years	65	29 (45)	37	10 (27)	102	39 (38)
45+ years	39	22 (56)	13	11 (85)	52	33 (63)
2010						
<25 years	8	0 (0)	10	2 (20)	18	2 (11)
25-34 years	30	8 (27)	23	11 (48)	53	19 (36)
35-44 years	52	22 (42)	38	15 (39)	90	37 (41)
45+ years	36	24 (67)	13	10 (77)	49	34 (69)
2011						
<25 years	5	0 (0)	8	1 (13)	13	1 (8)
25-34 years	25	9 (36)	13	3 (23)	39	12 (31)
35-44 years	63	35 (56)	31	15 (48)	94	50 (53)
45+ years	35	23 (66)	23	12 (52)	58	35 (60)
2012						
<25 years	9	0 (0)	5	1 (20)	14	1 (7)
25-34 years	22	7 (32)	18	5 (28)	40	12 (30)
35-44 years	50	18 (36)	26	9 (35)	76	27 (36)
45+ years	41	26 (63)	22	13 (59)	63	39 (62)
2013						
<25 years	7	1 (14)	11	1 (9)	18	2 (11)
25-34 years	25	11 (44)	19	9 (47)	44	20 (45)
35-44 years	56	26 (46)	27	12 (44)	83	38 (46)
45+ years	63	40 (63)	17	10 (59)	80	50 (63)
2014						
<25 years	5	1 (20)	1	0 (0)	6	1 (17)
25-34 years	22	7 (32)	19	8 (42)	41	15 (37)
35-44 years	56	28 (50)	41	18 (44)	97	46 (47)
45+ years	45	32 (71)	18	14 (78)	64	47 (73)
2014 p value		0.005		0.034		<0.001

Table 6.3.3 HCV antibody prevalence by drug last injected, years of injection and year

South Australia	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heroin	1	1 (100)	22	16 (73)	23	17 (74)
Methamphetamine	0	0 (0)	5	1 (20)	7	1 (14)
Other opioids	0	0 (0)	1	1 (100)	1	1 (100)
Other drugs	0	0 (0)	1	0 (0)	1	0 (0)
1996						
Heroin	2	1 (50)	21	14 (67)	23	15 (62)
Methamphetamine	4	1 (25)	10	4 (40)	14	5 (36)
Other opioids	1	1 (100)	3	2 (67)	4	3 (75)
Other drugs	0	0 (0)	2	2 (100)	2	2 (100)
1997						
Heroin	5	4 (80)	14	8 (57)	19	12 (63)
Methamphetamine	4	1 (25)	8	1 (13)	12	2 (17)
Other opioids	1	0 (0)	5	1 (20)	5	1 (20)
Other drugs	0	0 (0)	1	1 (100)	2	1 (50)
1998						
Heroin	13	3 (23)	58	28 (48)	71	31 (44)
Methamphetamine	31	0 (0)	36	6 (17)	67	6 (9)
Other opioids	0	0 (0)	12	6 (50)	12	6 (50)
Other drugs	4	0 (0)	13	2 (15)	17	2 (12)
1999						
Heroin	16	6 (38)	91	59 (65)	107	65 (61)
Methamphetamine	33	2 (6)	67	14 (21)	100	16 (16)
Other opioids	1	0 (0)	12	7 (58)	13	7 (54)
Other drugs	1	0 (0)	15	10 (67)	16	10 (63)
2000						
Heroin	23	8 (35)	142	85 (60)	165	93 (56)
Methamphetamine	31	4 (13)	58	19 (33)	89	23 (26)
Other opioids	0	0 (0)	16	12 (75)	16	12 (75)
Other drugs	2	1 (50)	20	8 (40)	22	9 (41)
2001						
Heroin	10	5 (50)	58	46 (76)	68	51 (75)
Methamphetamine	38	9 (24)	104	42 (40)	142	51 (36)
Other opioids	1	1 (100)	29	18 (62)	30	19 (63)
Other drugs	4	2 (50)	26	16 (62)	30	18 (60)
2002						
Heroin	5	2 (40)	70	42 (60)	75	44 (56)
Methamphetamine	30	5 (17)	112	40 (36)	142	45 (32)
Other opioids	5	3 (60)	37	18 (49)	42	21 (50)
Other drugs	4	1 (25)	33	19 (58)	37	20 (54)
2003						
Heroin	2	0 (0)	73	46 (63)	75	46 (61)
Methamphetamine	26	2 (8)	122	51 (42)	148	53 (36)
Other opioids	2	2 (100)	36	18 (50)	38	20 (53)
Other drugs	3	1 (33)	37	19 (51)	40	20 (50)
2004						
Heroin	10	5 (50)	55	37 (67)	65	42 (65)
Methamphetamine	21	2 (10)	122	24 (34)	92	26 (28)
Other opioids	3	1 (33)	36	20 (71)	31	21 (68)
Other drugs	2	0 (0)	37	9 (45)	22	9 (41)

Table 6.3.3 HCV antibody prevalence by drug last injected, gender and year (cont.)

South Australia	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	3	1 (33)	74	41 (55)	77	42 (55)
Methamphetamine	17	0 (0)	67	27 (40)	84	27 (32)
Other opioids	0	0 (0)	24	15 (63)	24	15 (63)
Other drugs	2	0 (0)	12	7 (58)	14	7 (50)
2006						
Heroin	1	0 (0)	39	23 (59)	40	23 (58)
Methamphetamine	10	1 (10)	89	21 (24)	99	22 (22)
Other opioids	1	1 (100)	43	32 (74)	44	33 (75)
Other drugs	4	0 (0)	5	2 (40)	9	2 (22)
2007						
Heroin	4	2 (50)	56	29 (52)	31	31 (52)
Methamphetamine	13	2 (15)	77	21 (27)	23	23 (26)
Other opioids	1	1 (100)	43	22 (51)	23	23 (52)
Other drugs	2	0 (0)	13	4 (31)	4	4 (27)
2008						
Heroin	3	1 (33)	45	22 (49)	23	23 (48)
Methamphetamine	9	0 (0)	83	12 (14)	12	12 (13)
Other opioids	2	0 (0)	35	15 (43)	15	15 (41)
Other drugs	0	0 (0)	6	4 (67)	4	4 (67)
2009						
Heroin	7	1 (14)	76	40 (53)	83	41 (49)
Methamphetamine	8	1 (13)	82	28 (34)	90	29 (32)
Other opioids	6	0 (0)	53	27 (51)	59	27 (46)
Other drugs	0	0 (0)	8	3 (38)	8	3 (38)
2010						
Heroin	3	0 (0)	82	41 (50)	85	41 (48)
Methamphetamine	4	0 (0)	82	26 (32)	86	26 (30)
Other opioids	0	0 (0)	37	23 (67)	37	23 (62)
Other drugs	0	0 (0)	4	3 (75)	4	3 (75)
2011						
Heroin	4	0 (0)	70	47 (67)	47	47 (64)
Methamphetamine	3	0 (0)	68	21 (31)	21	21 (30)
Other opioids	3	1 (33)	43	25 (58)	26	26 (57)
Other drugs	3	0 (0)	11	4 (36)	4	4 (29)
2012						
Heroin	2	0 (0)	69	31 (45)	31	31 (44)
Methamphetamine	5	1 (20)	61	14 (23)	15	15 (23)
Other opioids	2	1 (50)	38	22 (58)	23	23 (58)
Other drugs	4	0 (0)	12	9 (75)	9	9 (56)
2013						
Heroin	3	1 (33)	70	42 (60)	73	43 (59)
Methamphetamine	8	1 (13)	76	29 (38)	84	30 (36)
Other opioids	0	0 (0)	51	26 (51)	51	26 (51)
Other drugs	1	0 (0)	19	12 (63)	20	12 (60)
2014						
Heroin	2	0 (0)	59	36 (61)	62	36 (58)
Methamphetamine	3	0 (0)	103	52 (51)	106	52 (49)
Other opioids	1	1 (100)	19	9 (47)	21	11 (52)
Other drugs	1	0 (0)	18	10 (56)	19	10 (53)
2014 p value		0.286		0.570		0.720

7. TASMANIA

7.1 Tasmanian sample


One NSP service (Hobart NSP) participated in the ANSPS in all years 1995 to 2014, except in 2013. A further three NSPs participated in most years since 2002 (Clarence NSP, Launceston NSP and Glenorchy NSP). Tasmanian sample sizes ranged from 6 (in 1995) to 168 (in 2007), with samples of between 70 to 100 respondents in most of the past 5 years, 2010 to 2014. Response rates ranged between 7% (in 1995) and 85% (in 2004).

7.2 Demographic Characteristics

Although the gender distribution of Tasmanian ANSPS samples varied over the period 1995 to 2010, men outnumbered women in most survey years (range 49% in 2012 to 79% in 2001). The majority of respondents (67% to 91%) identified as heterosexual, with between 0% and 33% identifying as bisexual and between 0% and 22% identifying as homosexual. Although the proportion of Indigenous respondents increased nationally over time, this was not the case in Tasmania (χ^2 trend $p=0.087$). The proportion of Indigenous respondents ranged from a low of 0% in 1996 to a high of 16% in 2014. The majority of Tasmanian survey respondents were born in Australia (83% to 97%) and reported that their parents spoke English at home (66% to 100%) across all survey years in which these data were available (Table 7.1.1).

The proportion of young people (those aged less than 25 years) was high at around one in three in most years between 1995 and 2002, but declined significantly in subsequent years (Figure 7.2.1). There was a concomitant increase in the median age of respondents, from a low of 21 years in 1996 to 41 years in 2014. In 1995 none of the Tasmanian ANSPS respondents were aged 40 years or older, however this increased to more than half in 2014 (Figure 7.2.1). The median age at first injection remained relatively stable at 16-20 years across all survey years.

Figure 7.2.1 Tasmania proportion of younger and older PWID by year




7.3 Injecting behaviour

Drug last injected

Pharmaceutical opioids, methamphetamine and methadone were the most commonly reported drugs last injected in Tasmania, with around one third of respondents reporting last injecting these three drugs in most survey years (Figure 7.3.1). Prevalence of methadone and methamphetamine injection were stable over the 20 year period 1995 to 2014 (χ^2 trend $p=0.109$ and $p=0.833$ respectively) and over the period 2010 to 2014 (χ^2 trend $p=0.112$ and $p=0.664$). Prevalence of pharmaceutical opioids as the last drug injected increased over the period 1995 to 2014 (χ^2 trend $p<0.001$), most notably over the period 2008 to 2012 (Figure 7.3.1). Prevalence of pharmaceutical opioid injection was stable over the more recent period, 2010 to 2014 (χ^2 trend $p=0.790$).

Reports of all other drugs, including heroin, were rare in Tasmania.

Figure 7.3.1 Tasmania prevalence of heroin and methamphetamine as the drug last injected by year




Injection risk behaviour

There was a significant reduction in the proportion of Tasmanian respondents reporting re-use of needles and syringes (including re-use of one's own used syringe) in the month preceding ANSPS participation, from 36% in 1997 to 3% in 2014 (χ^2 trend $p=0.002$, Figure 7.3.2). Reports of receptive sharing of syringes were stable over the 20 year period 1995 to 2014 and over the more recent five year period 2010 to 2014 (χ^2 trend $p=0.306$ and $p=0.724$ respectively). Reports of receptive sharing of drug preparation equipment were stable over the period 1999 (when data collection commenced) to 2014 (χ^2 trend $p=0.077$), however reports increased in more recent years, from 8% in 2010 to 27% in 2014 (χ^2 trend $p=0.005$).

Prevalence of public injecting in the month preceding survey participation was stable in Tasmania over the 18 year period 1997 to 2014, ranging from 15% in 2001 to 45% in 2002 (χ^2 trend $p=0.159$, Table 7.1.3).


Figure 7.3.2 Tasmania re-use of syringes and receptive sharing (RS) of syringes and drug preparation equipment by year



7.4 Imprisonment, OST and BBV testing


The proportion of Tasmanian ANSPS respondents with a history of imprisonment was stable, with around 40% reporting a history of imprisonment in all survey years 2002 to 2014 (χ^2 trend $p=0.664$, Figure 7.4.1). The proportion of respondents reporting incarceration in the 12 months preceding survey participation was also stable over the 20 year survey period 1005 to 2014 (χ^2 trend $p=0.338$) and over the more recent survey period 2010 to 2014 (χ^2 trend $p=0.452$). In 2014, 39% of Tasmanian ANSPS respondents reported a history of imprisonment and 4% reported incarceration in the previous 12 months. The proportion of respondents who were recently incarcerated and who reported injecting in prison varied from none to 100% over the 20 year period 1995 to 2014 (Table 7.1.1), with substantial variation likely due to the relatively small sample size in most years.

Figure 7.4.1 Tasmania prison history and proportion of respondents who reported injecting in prison in the last 12 months by year




Around two in every three ANSPS respondents in Tasmania reported a history of OST in most years over the period 1995 to 2014 (Figure 7.4.2, Table 7.1.7). The proportion of respondents who reported current OST was high at just less than half in most survey years except over the period 2001 to 2003 when more than half the respondents reported currently receiving OST. In 2014, 64% of Tasmanian respondents reported a history of OST and 45% reported currently receiving OST.

Figure 7.4.2 Tasmania current and history of OST by year



The proportion of Tasmanian ANSPS respondents who reported a lifetime history of testing for HCV and/or HIV was high at 73% or more in all survey years (Table 7.1.5). Unlike most other jurisdictions, the proportion of Tasmanian respondents who reported a recent HCV antibody test (last 12 months) was stable over the survey period 1995 to 2014 (χ^2 trend $p=0.056$). However, there was a significant decline in the proportion of respondents who reported a recent HIV test from 78% in 1996 to 36% in 2014 (χ^2 trend $p<0.001$, Figure 7.4.3).

Figure 7.4.3 Tasmania HCV and HIV testing in the last 12 months by year



7.5 Blood borne viral infections


HIV antibody prevalence

HIV antibodies were rarely detected among Tasmanian ANSPS respondents, with no cases identified since 2002 (Table 7.2.1). Over the 20 year period, 1995 to 2014, HIV antibody prevalence declined from 5.0% in 1997 to 0% in 2014 (χ^2 trend $p < 0.001$).

HCV antibody prevalence

Although HCV antibody prevalence fluctuated in the Tasmania (most likely due to small sample sizes in some years), prevalence was lower than observed nationally in most years (Figure 7.5.1). HCV antibody prevalence in Tasmania was stable over the 20 year survey period 1995 to 2014 (χ^2 trend $p = 0.226$) and over the more recent survey period 2010 to 2014 (χ^2 trend $p = 0.334$). In 2014, 57% of Tasmanian ANSPS respondents had been exposed to HCV.

Figure 7.5.1 Tasmania and National HCV antibody prevalence by year



Despite fluctuations in HCV antibody prevalence in survey years with small sample sizes, prevalence was high among both males and females in recent survey years (2010 to 2014) when between 70 and 100 respondents were recruited (Figure 7.5.2).

Figure 7.5.2 Tasmania HCV antibody prevalence by gender and year




Table 7.1.1 Number (percentage) of respondents by demographic characteristic and year

Tasmania	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Number of sites	1	1	1	2	1	1	1	4	4	4
N° surveyed	N=6	N=18	N=23	N=51	N=25	N=27	N=28	N=151	N=118	N=107
Response rate	7%	11%	34%	29%	29%	30%	27%	58%	32%	85%
Gender (%)										
Male	4 (67)	11 (61)	17 (74)	40 (78)	19 (76)	18 (67)	22 (79)	97 (64)	70 (59)	66 (62)
Female	2 (33)	7 (39)	6 (26)	11 (22)	6 (24)	9 (33)	6 (21)	52 (34)	47 (40)	40 (37)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)
Sexual identity (%)										
Heterosexual	4 (67)	14 (78)	18 (79)	44 (86)	20 (80)	19 (71)	20 (71)	120 (79)	93 (79)	94 (88)
Bisexual	2 (33)	0 (0)	3 (13)	4 (8)	3 (12)	3 (11)	2 (7)	10 (7)	10 (8)	5 (5)
Homosexual	0 (0)	4 (22)	1 (4)	2 (4)	1 (4)	2 (7)	1 (4)	4 (3)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	1 (4)	1 (2)	1 (4)	3 (11)	5 (18)	17 (11)	14 (2)	8 (7)
Age and time since first injection (years)										
<i>Median age</i>	28.5	20.5	28	25	29	33	28	29	28	32
<i>Age range</i>	20-31	16-43	21-40	16-51	19-49	20-45	19-36	15-55	16-51	17-57
Age group (%)										
≤24 years	1 (16)	12 (67)	5 (22)	22 (43)	6 (24)	7 (26)	8 (29)	53 (35)	37 (31)	13 (12)
25+ years	5 (83)	6 (33)	18 (78)	29 (57)	19 (76)	20 (74)	20 (71)	98 (65)	81 (69)	93 (87)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
<i>Median age 1st injection</i>	16.5	16	17	17	18	19	17.5	17	17	19
<i>Age range</i>	14-18	13-22	13-30	12-31	14-31	13-40	10-25	12-42	10-45	10-46
<i>N° not reported</i>	0	0	0	1	0	0	0	2	1	4
<i>Median years injection</i>	11.5	5	10	6	8	8	9	9	9	12
<i>Range</i>	2-17	<1-24	1-27	<1-23	1-27	<1-26	2-19	<1-31	<1-32	<1-35
Time since first injection										
≤3 years	1 (17)	7 (39)	3 (13)	15 (29)	4 (16)	5 (19)	4 (14)	23 (15)	11 (9)	12 (11)
4+ years	5 (83)	11 (61)	20 (87)	35 (68)	21 (84)	22 (81)	24 (86)	126 (83)	106 (90)	90 (84)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (1)	1 (1)	5 (5)

Table 7.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

Tasmania	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Number of sites	3	2	4	4	4	4	4	4	3	4
N° surveyed	N=137	N=150	N=168	N=57	N=122	N=106	N=68	N=75	N=70	N=69
Response rate	--	50%	45%	25%	22%	39%	28%	28%	33%	36%
Gender (%)										
Male	86 (63)	94 (63)	111 (66)	33 (58)	74 (61)	68 (64)	43 (63)	37 (49)	42 (60)	37 (54)
Female	51 (37)	56 (37)	57 (34)	24 (42)	47 (39)	38 (36)	25 (37)	38 (51)	28 (40)	31 (45)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Sexual identity (%)										
Heterosexual	124 (91)	130 (87)	138 (82)	46 (81)	101 (83)	96 (91)	61 (90)	62 (83)	61 (87)	52 (75)
Bisexual	5 (4)	14 (9)	12 (7)	6 (11)	12 (10)	4 (4)	2 (3)	7 (9)	3 (4)	3 (4)
Homosexual	1 (1)	0 (0)	13 (8)	3 (5)	5 (4)	1 (1)	3 (4)	4 (5)	2 (3)	2 (3)
Not reported	7 (5)	6 (4)	5 (3)	2 (4)	4 (3)	5 (5)	2 (3)	2 (3)	4 (6)	12 (17)
Age and time since first injection (years)										
<i>Median age</i>	31	33	34	36	33	35	38	38	37	41
<i>Age range</i>	18-53	16-60	15-57	21-58	17-59	20-60	17-58	18-57	21-63	21-60
Age group (%)										
≤24 years	23 (17)	21 (14)	16 (10)	3 (5)	13 (11)	7 (7)	4 (6)	3 (4)	3 (4)	1 (1)
25+ years	114 (83)	129 (86)	152 (90)	54 (95)	109 (89)	99 (93)	64 (94)	72 (96)	66 (94)	68 (99)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
<i>Median age 1st injection</i>	19	18	18	18	19	19	19	18	19	20
<i>Age range</i>	11-49	11-47	10-44	11-38	11-44	12-42	13-49	13-45	12-40	12-53
N° not reported	7	0	3	1	5	0	3	3	3	2
Median years injection										
<i>Range</i>	<1-34	<1-40	<1-40	1-41	<1-39	<1-42	<1-40	<1-38	1-41	1-43
Time since first injection										
≤3 years	17 (12)	10 (7)	13 (8)	1 (2)	13 (11)	7 (7)	8 (12)	8 (11)	5 (7)	1 (1)
4+ years	113 (82)	136 (91)	152 (90)	55 (96)	104 (85)	98 (92)	57 (84)	64 (85)	62 (89)	66 (96)
Not reported	7 (5)	4 (3)	3 (2)	1 (2)	5 (4)	1 (1)	3 (4)	3 (4)	3 (4)	2 (3)

Table 7.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

Tasmania N° surveyed	1995 N=6	1996 N=18	1997 N=23	1998 N=51	1999 N=25	2000 N=27	2001 N=28	2002 N=151	2003 N=118	2004 N=107
Aboriginal and Torres Strait Islander origin (%)										
No	5 (83)	17 (94)	21 (91)	47 (92)	20 (80)	25 (92)	23 (83)	129 (84)	100 (85)	96 (90)
Yes	1 (17)	0 (0)	2 (9)	3 (6)	4 (16)	1 (4)	4 (14)	17 (11)	13 (11)	8 (7)
Not reported	0 (0)	1 (6)	0 (0)	1 (2)	1 (4)	1 (4)	1 (3)	5 (3)	5 (4)	3 (3)
Region/country of birth (%)										
Australia	--	--	--	--	24 (96)	24 (89)	23 (83)	137 (91)	111 (94)	95 (89)
Other Oceania	--	--	--	--	--	0 (0)	1 (4)	2 (1)	1 (<1)	2 (2)
Asia	--	--	--	--	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
UK & Ireland	--	--	--	--	--	0 (0)	2 (7)	6 (4)	3 (3)	3 (3)
Other	--	--	--	--	0 (0)	0 (0)	0 (0)	6 (4)	3 (3)	4 (3)
Not reported	--	--	--	--	1 (4)	3 (11)	2 (7)	0 (0)	0 (0)	3 (3)
Main language spoken at home by parents (%)										
English	--	--	--	--	24 (96)	26 (96)	25 (89)	142 (94)	114 (96)	71 (66)
Non-English	--	--	--	--	1 (4)	1 (4)	2 (7)	6 (4)	2 (2)	3 (3)
Not reported	--	--	--	--	0 (0)	0 (0)	1 (4)	3 (2)	2 (2)	33 (31)
Imprisonment last year (%)										
No	5 (83)	17 (94)	20 (87)	45 (88)	22 (88)	21 (78)	25 (89)	136 (90)	101 (86)	91 (85)
Yes	1 (17)	0 (0)	2 (9)	5 (10)	3 (12)	4 (15)	2 (7)	13 (9)	16 (13)	14 (13)
Not reported	0 (0)	1 (6)	1 (4)	1 (2)	0 (0)	2 (7)	1 (4)	2 (1)	1 (1)	2 (2)
Injected in prison last year (%)										
N° in prison	N=1	N=0	N=2	N=5	N=3	N=4	N=2	N=13	N=16	N=14
Injected in prison	1 (100)	0 (0)	1 (50)	2 (40)	0 (0)	0 (0)	1 (50)	5 (38)	6 (38)	10 (71)
Frequency of injection last month (%)										
Not last month	0 (0)	2 (11)	1 (4)	1 (2)	0 (0)	4 (15)	2 (7)	4 (3)	8 (7)	3 (3)
Less than weekly	1 (17)	5 (28)	5 (22)	4 (8)	5 (20)	2 (7)	4 (15)	20 (13)	20 (17)	20 (19)
Weekly not daily	1 (17)	7 (39)	8 (35)	24 (47)	7 (28)	6 (22)	11 (39)	55 (36)	45 (38)	38 (35)
Daily or more	4 (66)	4 (22)	9 (39)	22 (43)	13 (52)	15 (56)	11 (39)	72 (48)	45 (38)	45 (42)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)

Table 7.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

Tasmania N° surveyed	2005 N=137	2006 N=150	2007 N=168	2008 N=57	2009 N=122	2010 N=106	2011 N=68	2012 N=75	2013 N=70	2014 N=69
Aboriginal and Torres Strait Islander origin (%)										
No	121 (88)	121 (81)	141 (84)	50 (88)	100 (82)	94 (89)	59 (87)	64 (85)	60 (86)	56 (81)
Yes	12 (9)	25 (17)	25 (15)	5 (9)	15 (12)	12 (11)	8 (12)	10 (13)	9 (13)	11 (16)
Not reported	4 (3)	4 (3)	2 (1)	2 (4)	7 (6)	0 (0)	1 (1)	1 (1)	1 (1)	2 (3)
Region/country of birth (%)										
Australia	126 (92)	138 (92)	159 (95)	48 (84)	111 (91)	98 (92)	64 (94)	69 (92)	67 (96)	67 (97)
Other Oceania	0 (0)	1 (<1)	3 (2)	0 (0)	2 (2)	2 (2)	0 (0)	0 (0)	1 (1)	0 (0)
Asia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
UK & Ireland	6 (4)	6 (4)	3 (2)	6 (11)	2 (2)	4 (4)	2 (3)	1 (1)	2 (3)	2 (3)
Other	3 (2)	2 (1)	0 (0)	0 (0)	2 (2)	2 (2)	2 (3)	3 (4)	0 (0)	0 (0)
Not reported	2 (2)	3 (2)	3 (2)	3 (5)	5 (4)	0 (0)	0 (0)	2 (3)	0 (0)	0 (0)
Main language spoken at home by parents (%)										
English	115 (84)	136 (91)	165 (98)	55 (96)	119 (98)	105 (99)	68 (100)	73 (97)	70 (100)	69 (100)
Non-English	22 (16)	2 (1)	3 (2)	2 (4)	1 (1)	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)
Not reported	0 (0)	12 (8)	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Imprisonment last year (%)										
No	113 (82)	126 (84)	139 (83)	45 (79)	98 (80)	81 (76)	63 (93)	68 (91)	54 (77)	56 (81)
Yes	18 (13)	19 (13)	25 (15)	7 (12)	17 (14)	5 (5)	4 (6)	4 (5)	9 (13)	3 (4)
Not reported	6 (4)	5 (3)	4 (2)	5 (9)	7 (6)	20 (19)	1 (1)	3 (4)	7 (10)	10 (14)
Injected in prison last year (%)										
N° in prison	N=18	N=19	N=25	N=7	N=17	N=5	N=4	N=4	N=9	N=3
Injected in prison	3 (17)	3 (16)	11 (44)	3 (43)	6 (35)	0 (0)	1 (25)	2 (50)	1 (11)	1 (33)
Frequency of injection last month (%)										
Not last month	6 (4)	4 (3)	6 (4)	2 (4)	7 (6)	9 (8)	5 (7)	7 (9)	5 (7)	1 (1)
Less than weekly	31 (23)	31 (21)	48 (29)	8 (14)	18 (15)	21 (20)	10 (15)	14 (19)	13 (19)	7 (10)
Weekly not daily	46 (34)	41 (27)	55 (33)	23 (40)	47 (39)	45 (42)	27 (40)	19 (25)	26 (37)	24 (35)
Daily or more	54 (39)	73 (49)	58 (35)	24 (42)	46 (38)	31 (29)	26 (38)	35 (47)	24 (34)	36 (52)
Not reported	0 (0)	1 (<1)	1 (<1)	0 (0)	4 (3)	0 (0)	0 (0)	0 (0)	2 (3)	1 (1)
Experienced overdose in the previous 12 months										
Yes	--	--	--	--	--	--	--	--	6 (9)	4 (6)

Table 7.1.2 Number (percentage) of respondents by drug last injected and year

Tasmania N° surveyed	1995 N=6	1996 N=18	1997 N=23	1998 N=51	1999 N=25	2000 N=27	2001 N=28	2002 N=151	2003 N=118	2004 N=107
Drug last injected (%)										
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	1 (17)	4 (22)	8 (35)	16 (31)	5 (20)	6 (22)	6 (22)	45 (30)	33 (28)	33 (31)
Heroin	2 (33)	1 (6)	0 (0)	5 (10)	0 (0)	3 (11)	0 (0)	4 (3)	1 (1)	0 (0)
Pharm. opioids	2 (33)	6 (33)	4 (17)	10 (20)	5 (20)	6 (22)	8 (28)	25 (16)	28 (24)	20 (19)
Methadone	0 (0)	5 (28)	10 (44)	17 (33)	10 (40)	4 (15)	8 (28)	49 (32)	38 (32)	41 (38)
Buprenorphine	--	--	--	--	--	--	--	1 (1)	0 (0)	1 (1)
Buprenorphine/naloxone	--	--	--	--	--	--	--	--	--	--
PIEDs	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	1 (1)	0 (0)	1 (1)
More than one	1 (17)	0 (0)	1 (4)	2 (4)	4 (16)	7 (26)	5 (18)	20 (13)	15 (13)	9 (8)
Other	0 (0)	2 (11)	0 (0)	0 (0)	1 (4)	0 (0)	1 (4)	6 (4)	3 (3)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)

Tasmania N° surveyed	2005 N=137	2006 N=150	2007 N=168	2008 N=57	2009 N=122	2010 N=106	2011 N=68	2012 N=75	2013 N=70	2014 N=69
Drug last injected (%)										
Cocaine	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Methamphetamine	64 (47)	73 (49)	50 (30)	13 (23)	30 (25)	29 (27)	18 (26)	24 (32)	17 (24)	23 (33)
Heroin	2 (1)	3 (2)	3 (2)	4 (7)	4 (3)	1 (1)	1 (1)	1 (1)	2 (3)	2 (3)
Pharm. opioids	27 (20)	24 (16)	43 (26)	12 (21)	33 (27)	35 (33)	23 (34)	30 (40)	23 (33)	25 (36)
Methadone	30 (22)	35 (23)	54 (32)	24 (42)	40 (33)	30 (28)	21 (31)	13 (17)	19 (27)	10 (14)
Buprenorphine	1 (<1)	0 (0)	1 (<1)	1 (2)	2 (2)	0 (0)	1 (1)	2 (3)	3 (4)	1 (1)
Buprenorphine/naloxone	--	--	--	--	4 (3)	0 (0)	0 (0)	1 (1)	1 (1)	0 (0)
PIEDs	1 (<1)	1 (1)	0 (0)	0 (0)	1 (<1)	1 (1)	0 (0)	1 (1)	1 (1)	0 (0)
More than one	6 (4)	7 (5)	5 (3)	1 (2)	4 (3)	8 (8)	3 (4)	0 (0)	3 (4)	7 (10)
Other	2 (1)	1 (1)	9 (5)	1 (2)	1 (<1)	2 (2)	1 (1)	3 (4)	1 (1)	1 (1)
Not reported	4 (3)	5 (3)	3 (2)	1 (2)	3 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Table 7.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

Tasmania N° injected last month	1995 N=6	1996 N=16	1997 N=22	1998 N=50	1999 N=25	2000 N=23	2001 N=26	2002 N=147	2003 N=110	2004 N=103
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	--	--	--	--	4 (16)	2 (9)	6 (23)	17 (12)	13 (12)	6 (6)
Water	--	--	--	--	2 (8)	2 (9)	4 (15)	12 (8)	9 (8)	10 (10)
Filter	--	--	--	--	2 (8)	1 (4)	4 (15)	6 (4)	4 (4)	4 (4)
Drug mix	--	--	--	--	0 (0)	1 (4)	4 (15)	13 (9)	7 (6)	4 (4)
None	--	--	--	--	--	--	--	--	--	--
Public injecting in last month (%)										
Any public	--	--	8 (36)	22 (44)	5 (20)	5 (22)	4 (15)	66 (45)	40 (36)	30 (29)
All private	--	--	13 (59)	27 (54)	19 (76)	14 (61)	22 (85)	77 (52)	66 (60)	68 (66)
Not reported	--	--	1 (5)	1 (2)	1 (4)	4 (17)	0 (0)	4 (3)	4 (4)	5 (5)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	--	--	--	--	23 (92)	18 (78)	24 (92)	140 (95)	108 (98)	98 (95)
Pharmacy	--	--	--	--	4 (16)	7 (30)	8 (31)	55 (37)	34 (31)	27 (26)
Tasmania										
N° injected last month	2005 N=131	2006 N=145	2007 N=161	2008 N=55	2009 N=111	2010 N=97	2011 N=63	2012 N=68	2013 N=63	2014 N=67
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	9 (7)	11 (8)	16 (11)	4 (9)	6 (6)	9 (9)	9 (14)	9 (13)	6 (10)	7 (10)
Water	18 (14)	15 (11)	17 (11)	5 (11)	7 (7)	12 (12)	5 (8)	5 (7)	10 (16)	14 (21)
Filter	9 (7)	3 (2)	10 (7)	0 (0)	6 (6)	6 (6)	2 (3)	3 (4)	8 (13)	2 (3)
Drug mix	11 (8)	6 (4)	5 (3)	1 (2)	3 (3)	4 (4)	3 (5)	4 (6)	2 (3)	2 (3)
None	--	98 (69)	112 (75)	36 (82)	86 (84)	67 (69)	51 (81)	54 (79)	46 (73)	46 (69)
Public injecting in last month (%)										
Any public	43 (33)	59 (41)	58 (36)	20 (36)	43 (39)	32 (33)	23 (37)	17 (25)	16 (25)	15 (22)
All private	83 (63)	82 (57)	103 (64)	33 (60)	67 (60)	52 (54)	39 (62)	48 (71)	46 (73)	52 (78)
Not reported	5 (4)	4 (3)	0 (0)	2 (4)	1 (1)	13 (13)	1 (2)	3 (4)	1 (2)	0 (0)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	123 (94)	130 (90)	128 (80)	54 (98)	73 (66)	96 (99)	58 (92)	61 (90)	63 (100)	66 (99)
Pharmacy	50 (38)	72 (50)	18 (11)	15 (27)	21 (19)	9 (9)	10 (16)	18 (26)	6 (10)	7 (10)

Table 7.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

Tasmania N° injected last month	1995 N=6	1996 N=16	1997 N=22	1998 N=50	1999 N=25	2000 N=23	2001 N=26	2002 N=147	2003 N=110	2004 N=103
Use of sterile needles and syringes last month (%)										
All injections	--	--	14 (64)	37 (74)	21 (84)	20 (87)	18 (69)	118 (80)	90 (82)	88 (85)
Most of the time	--	--	7 (32)	11 (22)	2 (8)	2 (9)	7 (27)	25 (17)	18 (16)	10 (10)
Half of the time	--	--	0 (0)	1 (2)	2 (8)	0 (0)	0 (0)	3 (2)	0 (0)	0 (0)
Some of the time	--	--	1 (4)	1 (2)	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)	1 (1)
Not last month	--	--	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	--	--	0 (0)	0 (0)	0 (0)	1 (4)	1 (4)	0 (0)	1 (1)	4 (4)
Re-used someone else's used needle & syringe last month (%)										
None	5 (83)	11 (69)	19 (86)	42 (84)	23 (92)	19 (83)	23 (88)	130 (88)	102 (92)	86 (83)
Once	0 (0)	2 (12)	0 (0)	2 (4)	0 (0)	1 (4)	2 (8)	2 (1)	2 (2)	4 (4)
Twice	0 (0)	3 (19)	1 (5)	3 (6)	1 (4)	0 (0)	0 (0)	5 (4)	2 (2)	5 (5)
3-5 times	1 (17)	0 (0)	2 (9)	1 (2)	1 (4)	0 (0)	0 (0)	6 (5)	0 (0)	2 (2)
>5 times	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (1)	2 (2)	1 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (13)	1 (4)	2 (1)	2 (2)	5 (5)
Number of people needle & syringe was re-used after last month (%)										
None	5 (83)	11 (69)	19 (86)	42 (84)	23 (92)	19 (83)	23 (88)	130 (88)	99 (90)	86 (83)
One	0 (0)	2 (12)	3 (14)	5 (10)	2 (8)	0 (0)	1 (4)	10 (7)	4 (4)	5 (5)
Two	1 (17)	3 (19)	0 (0)	1 (2)	0 (0)	1 (4)	0 (0)	1 (1)	0 (0)	0 (0)
Three to five	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	1 (1)
More than five	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)
Don't know	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (13)	2 (8)	4 (3)	5 (4)	8 (8)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	--	--	2 (9)	4 (8)	1 (4)	0 (0)	1 (4)	9 (6)	5 (5)	5 (5)
Casual sex partner	--	--	0 (0)	1 (2)	0 (0)	0 (0)	1 (4)	1 (1)	1 (1)	0 (0)
Close friend	--	--	0 (0)	3 (6)	0 (0)	0 (0)	1 (4)	1 (1)	0 (0)	3 (3)
Acquaintance	--	--	0 (0)	2 (4)	0 (0)	1 (4)	0 (0)	2 (1)	0 (0)	0 (0)
Other	--	--	1 (5)	0 (0)	1 (4)	3 (13)	0 (0)	0 (0)	0 (0)	1 (1)

Table 7.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

Tasmania	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
N° injected last month	N=131	N=145	N=161	N=55	N=111	N=97	N=63	N=68	N=63	N=67
Use of sterile needles and syringes last month (%)										
All injections	112 (86)	114 (79)	131 (81)	40 (73)	93 (84)	75 (77)	55 (87)	53 (78)	55 (87)	64 (96)
Most of the time	19 (15)	26 (18)	27 (17)	13 (24)	15 (14)	10 (10)	7 (11)	11 (16)	6 (10)	2 (3)
Half of the time	0 (0)	1 (<1)	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)
Some of the time	0 (0)	1 (<1)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	3 (2)	2 (1)	2 (4)	1 (1)	12 (12)	1 (1)	4 (6)	1 (2)	1 (1)
Re-used someone else's used needle & syringe last month (%)										
None	121 (92)	127 (88)	132 (82)	44 (80)	94 (85)	82 (85)	51 (81)	54 (79)	61 (97)	61 (91)
Once	3 (2)	4 (3)	8 (5)	2 (4)	1 (1)	1 (1)	5 (8)	5 (7)	1 (2)	4 (6)
Twice	2 (2)	5 (3)	3 (2)	2 (4)	4 (4)	1 (1)	1 (1)	1 (1)	0 (0)	1 (1)
3-5 times	2 (2)	0 (0)	6 (4)	3 (5)	7 (6)	0 (0)	4 (6)	1 (1)	0 (0)	0 (0)
>5 times	0 (0)	2 (1)	2 (1)	2 (4)	2 (2)	0 (0)	0 (0)	3 (4)	1 (2)	0 (0)
Not reported	3 (2)	7 (5)	10 (6)	2 (4)	3 (3)	13 (13)	2 (3)	4 (6)	0 (0)	1 (1)
Number of people needle & syringe was re-used after last month (%)										
None	114 (87)	127 (88)	132 (82)	44 (80)	94 (85)	82 (85)	51 (81)	54 (79)	61 (97)	61 (91)
One	7 (5)	5 (3)	6 (4)	3 (5)	3 (3)	2 (2)	3 (5)	2 (3)	0 (0)	0 (0)
Two	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Three to five	0 (0)	1 (<1)	0 (0)	1 (2)	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
More than five	1 (1)	0 (0)	1 (<1)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Don't know	5 (4)	1 (<1)	4 (2)	1 (2)	3 (3)	0 (0)	6 (10)	2 (3)	0 (0)	0 (0)
Not reported	4 (3)	11 (8)	18 (11)	6 (11)	9 (8)	13 (13)	3 (5)	8 (12)	2 (3)	6 (9)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	5 (4)	5 (3)	7 (4)	4 (7)	4 (4)	5 (5)	3 (5)	1 (1)	0 (0)	0 (0)
Casual sex partner	0 (0)	1 (<1)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)
Close friend	4 (3)	2 (1)	2 (1)	2 (4)	1 (1)	1 (1)	3 (5)	3 (4)	0 (0)	0 (0)
Acquaintance	1 (1)	1 (<1)	2 (1)	0 (0)	1 (1)	0 (0)	3 (5)	1 (1)	0 (0)	0 (0)
Other	2 (2)	0 (0)	0 (0)	0 (0)	2 (2)	1 (1)	2 (3)	0 (0)	0 (0)	1 (1)

Table 7.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

Tasmania N° surveyed	1995 N=6	1996 N=18	1997 N=23	1998 N=51	1999 N=25	2000 N=27	2001 N=28	2002 N=151	2003 N=118	2004 N=107
Sex last month (%)										
No	1 (17)	4 (22)	7 (30)	12 (24)	7 (28)	6 (22)	9 (32)	36 (24)	28 (24)	32 (30)
Yes	5 (83)	14 (78)	16 (70)	39 (76)	18 (72)	20 (74)	19 (68)	113 (75)	90 (76)	70 (65)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	2 (1)	0 (0)	5 (5)
Condom use at last sex (%)										
No	3 (50)	12 (67)	19 (83)	41 (80)	20 (80)	19 (70)	21 (75)	110 (73)	87 (74)	72 (67)
Yes	2 (33)	2 (11)	4 (17)	10 (20)	4 (16)	7 (26)	7 (25)	38 (25)	31 (26)	30 (28)
Not reported	1 (17)	4 (22)	0 (0)	0 (0)	1 (4)	1 (4)	0 (0)	3 (2)	0 (0)	5 (5)
Condom use with regular sex partner(s) last month (%)										
No	--	--	--	--	--	--	--	51 (75)	44 (71)	37 (74)
Sometimes	--	--	--	--	--	--	--	7 (10)	4 (6)	3 (6)
Always	--	--	--	--	--	--	--	10 (15)	14 (23)	10 (20)
Condom use with new sex partner(s) last month (%)										
No	--	--	--	--	--	--	--	24 (59)	32 (65)	14 (52)
Sometimes	--	--	--	--	--	--	--	5 (13)	4 (8)	3 (11)
Always	--	--	--	--	--	--	--	11 (28)	13 (27)	10 (37)
Condom use with casual sex partner(s) last month (%)										
No	--	--	--	--	--	--	--	20 (47)	25 (66)	17 (68)
Sometimes	--	--	--	--	--	--	--	7 (17)	3 (8)	1 (4)
Always	--	--	--	--	--	--	--	15 (36)	10 (26)	7 (28)
Sex work last month (%)										
No	6 (100)	18 (100)	22 (96)	51 (100)	23 (92)	26 (96)	27 (96)	140 (93)	113 (96)	93 (87)
Yes	0 (0)	0 (0)	1 (4)	0 (0)	1 (4)	0 (0)	0 (0)	5 (3)	5 (4)	10 (9)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	1 (4)	1 (4)	6 (4)	0 (0)	4 (4)
Condom used at last sex work (%)										
Yes	--	--	--	--	--	--	--	--	2 (40)	5 (56)

Table 7.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

Tasmania N° surveyed	2005 N=137	2006 N=150	2007 N=168	2008 N=57	2009 N=122	2010 N=106	2011 N=68	2012 N=75	2013 N=70	2014 N=69
Sex with a regular partner last month (%)										
No	45 (33)	55 (37)	63 (38)	23 (40)	52 (43)	43 (41)	28 (41)	34 (45)	23 (33)	28 (41)
Yes	88 (64)	91 (61)	103 (61)	34 (60)	59 (48)	59 (56)	37 (54)	37 (49)	41 (59)	36 (52)
Not reported	4 (3)	4 (3)	2 (1)	0 (0)	11 (9)	4 (4)	3 (4)	4 (5)	6 (9)	5 (7)
Condom used with regular partner last month (%)										
Never	N=88 67 (76)	N=91 70 (77)	N=103 74 (72)	N=34 21 (62)	N=59 51 (86)	N=59 44 (75)	N=37 24 (65)	N=37 27 (73)	N=41 27 (66)	N=36 27 (75)
Sometimes	9 (10)	9 (10)	15 (15)	5 (15)	1 (2)	7 (12)	9 (24)	4 (11)	2 (5)	1 (3)
Every time	3 (3)	8 (9)	9 (9)	7 (21)	4 (7)	6 (10)	4 (11)	6 (16)	7 (17)	6 (17)
Not reported	9 (10)	4 (4)	5 (5)	1 (3)	3 (5)	2 (3)	0 (0)	0 (0)	5 (12)	2 (6)
Sex with other partner(s) last month (%)										
No	113 (82)	132 (88)	145 (86)	48 (84)	86 (70)	94 (89)	57 (84)	58 (77)	59 (84)	59 (86)
Yes	21 (15)	9 (6)	16 (10)	7 (12)	19 (16)	7 (7)	8 (12)	8 (11)	5 (7)	4 (6)
Not reported	3 (2)	9 (6)	7 (4)	2 (4)	17 (14)	5 (5)	3 (4)	9 (12)	6 (9)	6 (9)
Condom used with other partner(s) last month (%)										
Never	N=21 7 (33)	N=9 4 (44)	N=16 7 (44)	N=7 2 (29)	N=19 4 (21)	N=7 4 (57)	N=8 3 (28)	N=8 3 (38)	N=5 3 (60)	N=4 2 (50)
Sometimes	6 (29)	3 (33)	5 (31)	2 (29)	5 (26)	1 (14)	2 (25)	2 (25)	1 (20)	0 (0)
Every time	7 (33)	2 (22)	3 (19)	3 (43)	9 (47)	2 (29)	3 (38)	2 (25)	1 (20)	1 (25)
Not reported	1 (5)	0 (0)	1 (6)	0 (0)	1 (5)	0 (0)	0 (0)	1 (13)	0 (0)	1 (25)
Sex work last month (%)										
No	129 (94)	134 (89)	157 (93)	54 (95)	107 (88)	101 (95)	64 (94)	68 (91)	58 (83)	56 (81)
Yes	4 (3)	5 (3)	3 (2)	2 (4)	2 (2)	2 (2)	1 (1)	2 (3)	1 (1)	1 (1)
Not reported	4 (3)	11 (7)	8 (5)	1 (2)	13 (11)	3 (3)	3 (4)	5 (7)	11 (16)	12 (17)
Condom used at last sex work (%)										
Yes	0 (0)	4 (80)	3 (100)	1 (100)	1 (50)	1 (50)	1 (100)	2 (100)	1 (100)	1 (100)

Table 7.1.5 Number (percentage) of respondents by testing for HIV and HCV infection by year

Tasmania N° surveyed	1995 N=6	1996 N=18	1997 N=23	1998 N=51	1999 N=25	2000 N=27	2001 N=28	2002 N=151	2003 N=118	2004 N=107
Previous HIV test (%)										
Yes, ever	5 (83)	15 (83)	21 (91)	47 (92)	22 (88)	24 (89)	26 (93)	139 (92)	98 (83)	86 (80)
Yes, last year	4 (66)	14 (78)	13 (57)	36 (71)	12 (48)	18 (67)	17 (61)	103 (68)	76 (64)	58 (54)
>1 year ago	1 (17)	1 (6)	7 (30)	11 (21)	10 (40)	6 (22)	9 (32)	36 (24)	22 (19)	28 (26)
Never tested	0 (0)	0 (0)	1 (4)	3 (6)	3 (12)	2 (7)	2 (7)	12 (8)	20 (17)	18 (17)
Not reported	1 (17)	3 (17)	2 (9)	1 (2)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	3 (3)
Previous HCV test (%)										
Yes, ever	5 (83)	14 (78)	21 (91)	42 (82)	21 (84)	24 (89)	22 (79)	135 (89)	104 (88)	88 (82)
Yes, last year	--	--	15 (65)	34 (66)	15 (60)	17 (63)	14 (50)	98 (65)	82 (69)	65 (61)
>1 year ago	--	--	6 (26)	8 (16)	6 (24)	7 (26)	8 (29)	37 (24)	22 (19)	23 (21)
Never tested	1 (17)	4 (22)	2 (9)	8 (16)	4 (16)	2 (7)	6 (21)	15 (10)	14 (12)	17 (16)
Not reported	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	1 (4)	0 (0)	1 (1)	0 (0)	2 (2)
Tasmania										
N° surveyed	2005 N=137	2006 N=150	2007 N=168	2008 N=57	2009 N=122	2010 N=106	2011 N=68	2012 N=75	2013 N=70	2014 N=69
Previous HIV test (%)										
Yes, ever	110 (80)	121 (81)	146 (87)	51 (89)	91 (75)	85 (80)	54 (79)	55 (73)	61 (87)	56 (81)
Yes, last year	61 (45)	71 (47)	92 (55)	35 (61)	50 (41)	43 (41)	24 (35)	29 (39)	33 (47)	25 (36)
>1 year ago	49 (36)	50 (33)	54 (32)	16 (28)	41 (34)	42 (40)	30 (44)	26 (35)	28 (40)	31 (45)
Never tested	25 (18)	25 (17)	22 (13)	5 (9)	18 (15)	15 (14)	12 (18)	15 (20)	5 (7)	12 (17)
Not reported	2 (1)	4 (3)	0 (0)	1 (2)	13 (11)	6 (6)	2 (3)	5 (7)	4 (6)	1 (1)
Previous HCV test (%)										
Yes, ever	113 (82)	125 (83)	152 (90)	54 (95)	108 (89)	92 (87)	57 (84)	63 (84)	56 (80)	63 (91)
Yes, last year	70 (51)	81 (54)	99 (59)	37 (65)	71 (58)	56 (53)	30 (44)	36 (48)	33 (47)	38 (55)
>1 year ago	43 (31)	44 (29)	53 (32)	17 (30)	37 (30)	36 (34)	27 (40)	27 (36)	23 (33)	25 (36)
Never tested	23 (17)	22 (15)	16 (10)	3 (5)	8 (7)	10 (9)	7 (10)	7 (9)	6 (9)	3 (4)
Not reported	1 (1)	3 (2)	0 (0)	0 (0)	6 (5)	4 (4)	4 (6)	5 (7)	8 (11)	3 (4)

Table 7.1.6 Number (percentage) of respondents by HCV treatment by year

Tasmania	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Self-report HCV diagnosis	--	--	--	--	N=7	N=8	N=8	N=56	N=50	N=48
Any treatment for HCV (%)										
Interferon+/Ribavirin	--	--	--	--	0 (0)	0 (0)	0 (0)	1 (2)	2 (4)	1 (2)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	1 (14)	0 (0)	0 (0)	2 (4)	2 (4)	0 (0)
No treatment	--	--	--	--	6 (86)	8 (100)	8 (100)	53 (95)	46 (92)	47 (98)
Not reported	--	--	--	--	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Current treatment for HCV (%)										
Interferon +/-or Ribavirin	--	--	--	--	0	0	0	0	0	0
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	0	0	0	0	0	0

Tasmania	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Self-report HCV diagnosis	N=72	N=58	N=67	N=30	N=68	N=48	N=32	N=34	N=34	N=28
Any treatment for HCV (%)										
Interferon+/or Ribavirin	1 (1)	5 (8)	7 (10)	0 (0)	6 (9)	6 (12)	2 (6)	6 (18)	3 (9)	4 (14)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	0 (0)	0 (0)
Other	1 (1)	2 (3)	1 (1)	1 (3)	1 (1)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
No treatment	70 (97)	51 (88)	59 (88)	29 (97)	61 (90)	40 (83)	29 (91)	26 (76)	30 (88)	23 (82)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (3)	2 (6)	1 (3)	1 (4)
Current treatment for HCV (%)										
Interferon +/-or Ribavirin	0	0	0	0	0	0	3	0	0	0
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	0	0
Other	0	0	0	0	0	0	0	0	0	0

Table 7.1.7 Number (percentage) of respondents by drug treatment by year

Tasmania N° surveyed	1995 N=6	1996 N=18	1997 N=23	1998 N=51	1999 N=25	2000 N=27	2001 N=28	2002 N=151	2003 N=118	2004 N=107
Ever any treatment/therapy for drug use (%)										
No	3 (50)	10 (56)	4 (17)	16 (31)	9 (36)	9 (33)	5 (18)	26 (17)	32 (27)	34 (32)
Yes	3 (50)	8 (44)	19 (83)	35 (69)	16 (64)	17 (73)	23 (82)	125 (83)	86 (73)	73 (68)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)
History of methadone maintenance treatment (%)										
Current	2 (33)	4 (22)	14 (61)	23 (45)	12 (48)	12 (44)	20 (72)	79 (52)	57 (48)	48 (45)
Previous	1 (17)	2 (11)	3 (13)	7 (14)	3 (12)	3 (11)	2 (7)	26 (17)	29 (25)	15 (14)
Never	3 (50)	12 (67)	6 (26)	21 (41)	1 (4)	11 (41)	6 (21)	45 (30)	32 (27)	43 (40)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	9 (36)	1 (4)	0 (0)	1 (1)	0 (0)	1 (1)
History of other pharmacotherapy treatment (%)										
Current	--	--	--	--	--	1 (4)	1 (4)	6 (4)	6 (5)	2 (2)
Previous	--	--	--	--	--	0 (0)	3 (10)	12 (8)	10 (8)	9 (8)
Never	--	--	--	--	--	25 (92)	23 (82)	130 (86)	100 (85)	95 (89)
Not reported	--	--	--	--	--	1 (4)	1 (4)	3 (2)	2 (2)	1 (1)
Tasmania										
N° surveyed	2005 N=137	2006 N=150	2007 N=168	2008 N=57	2009 N=122	2010 N=106	2011 N=68	2012 N=75	2013 N=70	2014 N=2378
Ever any treatment/therapy for drug use (%)										
No	50 (37)	51 (34)	46 (27)	13 (23)	31 (25)	28 (26)	13 (19)	19 (25)	13 (19)	17 (25)
Yes	85 (62)	95 (63)	120 (71)	43 (75)	88 (72)	77 (73)	53 (78)	55 (73)	56 (80)	52 (75)
Not reported	2 (1)	4 (3)	2 (1)	1 (2)	3 (2)	1 (1)	2 (3)	1 (1)	1 (1)	0 (0)
History of methadone maintenance treatment (%)										
Current	49 (36)	52 (35)	66 (39)	24 (42)	47 (39)	44 (42)	20 (30)	22 (29)	27 (39)	21 (30)
Previous	19 (14)	24 (16)	41 (24)	12 (21)	24 (20)	19 (18)	18 (26)	21 (28)	14 (20)	16 (23)
Never	67 (49)	70 (47)	61 (36)	21 (37)	46 (38)	40 (38)	25 (37)	31 (41)	29 (41)	32 (46)
Not reported	2 (1)	4 (3)	0 (0)	0 (0)	5 (4)	3 (3)	5 (7)	1 (1)	0 (0)	0 (0)
History of other pharmacotherapy treatment (%)										
Current	6 (4)	3 (2)	10 (6)	5 (9)	8 (7)	7 (7)	5 (7)	10 (13)	7 (10)	11 (16)
Previous	10 (7)	14 (9)	14 (8)	10 (18)	28 (23)	25 (24)	20 (29)	15 (20)	18 (26)	12 (17)
Never	120 (88)	127 (85)	141 (84)	39 (68)	83 (68)	73 (69)	42 (62)	47 (63)	44 (63)	44 (64)
Not reported	1 (1)	6 (4)	3 (2)	3 (5)	3 (2)	1 (1)	1 (1)	3 (4)	1 (1)	2 (3)

HIV antibody prevalence

Table 7.2.1 HIV antibody prevalence by gender and year

Tasmania	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
1996	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)
1997	16	1 (6.3)	4	0 (0.0)	20	1 (5.0)
1998	35	1 (2.9)	8	0 (0.0)	43	1 (2.3)
1999	18	0 (0.0)	6	0 (0.0)	24	0 (0.0)
2000	17	1 (5.9)	8	0 (0.0)	25	1 (4.0)
2001	21	1 (4.8)	6	0 (0.0)	27	1 (3.7)
2002	96	0 (0.0)	50	0 (0.0)	148	0 (0.0)
2003	70	0 (0.0)	46	0 (0.0)	117	0 (0.0)
2004	65	0 (0.0)	39	0 (0.0)	105	0 (0.0)
2005	86	0 (0.0)	51	0 (0.0)	137	0 (0.0)
2006	94	0 (0.0)	56	0 (0.0)	150	0 (0.0)
2007	110	0 (0.0)	56	0 (0.0)	166	0 (0.0)
2008	33	0 (0.0)	24	0 (0.0)	57	0 (0.0)
2009	73	0 (0.0)	47	0 (0.0)	121	0 (0.0)
2010	68	0 (0.0)	38	0 (0.0)	106	0 (0.0)
2011	43	0 (0.0)	25	0 (0.0)	68	0 (0.0)
2012	36	0 (0.0)	38	0 (0.0)	74	0 (0.0)
2013	41	0 (0.0)	28	0 (0.0)	69	0 (0.0)
2014	32	0 (0.0)	30	0 (0.0)	63	0 (0.0)
X ² p trend: 1995-2014		0.001		--		<0.001
X ² p trend: 2010-2014		--		--		--

HCV antibody prevalence

Table 7.3.1 HCV antibody prevalence by gender and year

Tasmania	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995	2	2 (100)	2	1 (50)	4	3 (75)
1996	10	2 (20)	7	0 (0)	17	2 (12)
1997	16	7 (44)	5	4 (80)	21	11 (52)
1998	35	14 (40)	8	4 (50)	43	18 (42)
1999	18	7 (39)	6	4 (67)	24	11 (46)
2000	17	9 (53)	8	1 (13)	25	10 (40)
2001	22	8 (36)	6	2 (33)	28	10 (36)
2002	96	47 (49)	50	18 (36)	148	66 (45)
2003	70	36 (51)	46	31 (67)	117	67 (57)
2004	66	30 (45)	39	20 (51)	106	50 (47)
2005	86	51 (59)	51	30 (59)	137	81 (59)
2006	93	53 (57)	55	32 (58)	148	85 (57)
2007	91	52 (57)	43	30 (70)	134	82 (61)
2008	32	26 (81)	24	19 (79)	56	45 (80)
2009	73	38 (52)	45	24 (53)	119	63 (53)
2010	68	30 (44)	38	18 (47)	106	48 (45)
2011	42	17 (40)	25	14 (56)	67	31 (46)
2012	36	17 (47)	37	17 (46)	73	34 (47)
2013	41	19 (46)	28	18 (64)	69	37 (54)
2014	30	16 (53)	30	18 (60)	61	35 (57)
X^2 p trend: 1995-2014		0.549		0.324		0.226
X^2 p trend: 2010-2014		0.599		0.503		0.334

Table 7.3.2 HCV antibody prevalence by age group, gender and year

Tasmania	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	0	0 (0)	1	1 (100)	1	1 (100)
25-34 years	2	2 (100)	1	0 (0)	3	2 (67)
35-44 years	0	0 (0)	0	0 (0)	0	0 (0)
45+ years	0	0 (0)	0	0 (0)	0	0 (0)
1996						
<25 years	6	1 (17)	5	0 (0)	11	1 (9)
25-34 years	3	0 (0)	2	0 (0)	5	0 (0)
35-44 years	1	1 (100)	0	0 (0)	1	1 (100)
45+ years	0	0 (0)	0	0 (0)	0	0 (0)
1997						
<25 years	2	0 (0)	2	1 (50)	4	1 (25)
25-34 years	11	6 (55)	1	1 (100)	12	7 (58)
35-44 years	3	1 (33)	2	2 (100)	5	3 (60)
45+ years	0	0 (0)	0	0 (0)	0	0 (0)
1998						
<25 years	13	0 (0)	5	2 (40)	18	2 (11)
25-34 years	16	9 (56)	3	2 (67)	19	11 (58)
35-44 years	5	4 (80)	0	0 (0)	5	4 (80)
45+ years	1	1 (100)	0	0 (0)	1	1 (100)
1999						
<25 years	5	0 (0)	1	0 (0)	6	0 (0)
25-34 years	11	6 (55)	3	2 (67)	14	8 (57)
35-44 years	1	0 (0)	2	2 (100)	3	2 (67)
45+ years	1	1 (100)	0	0 (0)	1	1 (100)
2000						
<25 years	3	0 (0)	4	0 (0)	7	0 (0)
25-34 years	5	3 (60)	2	0 (0)	7	3 (43)
35-44 years	8	5 (63)	1	0 (0)	9	5 (56)
45+ years	1	1 (100)	1	1 (100)	2	2 (100)
2001						
<25 years	5	0 (0)	3	2 (67)	8	2 (25)
25-34 years	14	7 (50)	3	0 (0)	17	7 (41)
35-44 years	3	1 (33)	0	0 (0)	3	1 (33)
45+ years	0	0 (0)	0	0 (0)	0	0 (0)
2002						
<25 years	31	11 (35)	21	7 (33)	52	18 (35)
25-34 years	37	20 (54)	23	10 (43)	60	30 (50)
35-44 years	22	11 (50)	5	1 (20)	27	12 (44)
45+ years	6	5 (83)	1	0 (0)	7	5 (71)
2003						
<25 years	20	5 (25)	16	9 (56)	36	14 (39)
25-34 years	35	19 (54)	17	13 (76)	52	32 (62)
35-44 years	9	7 (78)	11	7 (64)	20	14 (70)
45+ years	6	5 (83)	2	2 (100)	8	7 (88)
2004						
<25 years	7	2 (29)	6	2 (33)	13	4 (31)
25-34 years	33	14 (42)	17	9 (53)	50	23 (46)
35-44 years	18	12 (67)	13	8 (62)	31	20 (65)
45+ years	8	2 (25)	3	1 (33)	11	3 (27)

Table 7.3.2 HCV antibody prevalence by age group, gender and year (continued)

Tasmania	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2005						
<25 years	12	6 (50)	11	4 (36)	23	10 (43)
25-34 years	44	25 (57)	24	15 (63)	68	40 (59)
35-44 years	23	14 (61)	11	7 (64)	34	21 (62)
45+ years	7	6 (86)	5	4 (80)	12	10 (83)
2006						
<25 years	8	2 (25)	12	5 (42)	20	7 (35)
25-34 years	41	21 (51)	24	14 (58)	65	35 (54)
35-44 years	34	23 (68)	15	10 (67)	49	33 (67)
45+ years	10	7 (70)	4	3 (75)	14	10 (71)
2007						
<25 years	3	3 (100)	7	3 (43)	10	6 (60)
25-34 years	39	21 (54)	18	14 (78)	57	35 (61)
35-44 years	37	20 (54)	16	11 (69)	53	31 (58)
45+ years	12	8 (67)	2	2 (100)	14	10 (71)
2008						
<25 years	2	2 (100)	1	1 (100)	3	3 (100)
25-34 years	10	8 (80)	14	11 (79)	24	19 (79)
35-44 years	9	8 (89)	5	4 (80)	14	12 (86)
45+ years	11	8 (73)	4	3 (75)	15	11 (73)
2009						
<25 years	9	4 (44)	3	0 (0)	12	4 (33)
25-34 years	29	12 (41)	30	18 (60)	59	30 (51)
35-44 years	26	19 (73)	9	4 (44)	35	23 (66)
45+ years	9	3 (33)	3	2 (67)	12	5 (42)
2010						
<25 years	2	0 (0)	5	2 (40)	7	2 (29)
25-34 years	30	12 (40)	13	7 (54)	43	19 (44)
35-44 years	20	10 (50)	13	5 (38)	33	15 (45)
45+ years	16	8 (50)	6	4 (67)	22	12 (55)
2011						
<25 years	2	0 (0)	2	1 (50)	4	1 (25)
25-34 years	12	3 (25)	10	6 (60)	22	9 (41)
35-44 years	19	9 (47)	8	5 (63)	27	14 (52)
45+ years	9	5 (56)	5	2 (40)	14	7 (50)
2012						
<25 years	1	0 (0)	2	0 (0)	3	0 (0)
25-34 years	11	5 (45)	13	7 (54)	24	12 (50)
35-44 years	14	8 (57)	17	7 (41)	31	15 (48)
45+ years	10	4 (40)	5	3 (60)	15	7 (47)
2013						
<25 years	2	0 (0)	1	1 (100)	3	1 (33)
25-34 years	11	3 (27)	9	4 (44)	20	7 (35)
35-44 years	17	9 (53)	12	9 (75)	29	18 (62)
45+ years	11	7 (64)	5	3 (60)	16	10 (63)
2014						
<25 years	0	0 (0)	0	0 (0)	0	0 (0)
25-34 years	2	1 (50)	8	5 (63)	10	6 (60)
35-44 years	18	9 (50)	12	6 (50)	31	16 (52)
45+ years	10	6 (60)	10	7 (70)	20	13 (65)
2014 p value		0.848		0.651		0.649

Table 7.3.3 HCV antibody prevalence by drug last injected, years of injection and year

Tasmania	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Pharm. opioids	0	0 (0)	1	0 (0)	1	0 (0)
Methadone	0	0 (0)	0	0 (0)	0	0 (0)
Methamphetamine	1	1 (100)	0	0 (0)	1	1 (100)
Other drugs	0	0 (0)	2	2 (100)	2	0 (0)
1996						
Pharm. opioids	3	1 (33)	3	0 (0)	6	1 (17)
Methadone	2	0 (0)	3	1 (33)	5	1 (20)
Methamphetamine	1	0 (0)	3	0 (0)	4	0 (0)
Other drugs	0	0 (0)	2	0 (0)	2	0 (0)
1997						
Pharm. opioids	0	0 (0)	4	2 (50)	4	2 (50)
Methadone	1	0 (0)	8	5 (63)	9	5 (56)
Methamphetamine	2	0 (0)	5	3 (60)	7	3 (43)
Other drugs	0	0 (0)	1	1 (100)	1	1 (100)
1998						
Pharm. opioids	5	0 (0)	4	3 (75)	9	3 (33)
Methadone	1	1 (100)	13	7 (54)	14	8 (57)
Methamphetamine	3	0 (0)	9	3 (33)	12	3 (25)
Other drugs	0	0 (0)	7	4 (57)	7	4 (57)
1999						
Pharm. opioids	1	0 (0)	4	2 (50)	5	2 (40)
Methadone	1	0 (0)	9	5 (56)	10	5 (50)
Methamphetamine	1	0 (0)	3	1 (33)	4	1 (25)
Other drugs	1	0 (0)	4	3 (75)	5	3 (60)
2000						
Pharm. opioids	2	0 (0)	4	2 (50)	6	2 (33)
Methadone	1	0 (0)	2	1 (50)	3	1 (33)
Methamphetamine	1	0 (0)	4	1 (25)	5	1 (20)
Other drugs	1	0 (0)	10	6 (60)	11	6 (55)
2001						
Pharm. opioids	1	1 (100)	7	4 (57)	8	5 (63)
Methadone	1	0 (0)	7	1 (14)	8	1 (13)
Methamphetamine	1	0 (0)	5	3 (60)	6	3 (50)
Other drugs	1	0 (0)	5	1 (20)	6	1 (17)
2002						
Pharm. opioids	4	2 (50)	20	10 (50)	24	12 (50)
Methadone	5	2 (40)	43	23 (53)	48	25 (52)
Methamphetamine	11	5 (45)	33	9 (27)	44	14 (32)
Other drugs	3	0 (0)	29	15 (52)	32	15 (47)
2003						
Pharm. opioids	1	1 (100)	27	17 (63)	28	18 (64)
Methadone	2	0 (0)	35	28 (80)	37	28 (76)
Methamphetamine	7	1 (14)	26	9 (35)	33	10 (30)
Other drugs	1	1 (100)	18	10 (56)	19	11 (58)
2004						
Pharm. opioids	1	1 (100)	19	7 (37)	20	8 (40)
Methadone	2	1 (50)	39	29 (74)	41	30 (73)
Methamphetamine	7	0 (0)	25	8 (32)	32	8 (25)
Other drugs	1	0 (0)	10	4 (40)	11	4 (36)

Table 7.3.3 HCV antibody prevalence by drug last injected, years of injection and year

Tasmania	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Pharm. opioids	4	2 (50)	23	16 (70)	27	18 (67)
Methadone	2	0 (0)	28	20 (71)	30	20 (67)
Methamphetamine	10	1 (10)	54	29 (54)	64	30 (47)
Other drugs	1	0 (0)	11	9 (82)	12	9 (75)
2006						
Pharm. opioids	2	2 (100)	21	15 (71)	23	17 (74)
Methadone	1	1 (100)	34	27 (79)	35	28 (80)
Methamphetamine	6	0 (0)	66	28 (42)	72	28 (39)
Other drugs	0	0 (0)	13	8 (62)	13	8 (62)
2007						
Pharm. opioids	2	1 (50)	33	23 (70)	35	24 (69)
Methadone	1	0 (0)	41	29 (71)	42	29 (69)
Methamphetamine	4	0 (0)	34	16 (47)	38	16 (42)
Other drugs	2	1 (50)	14	11 (79)	16	12 (75)
2008						
Pharm. opioids	0	0 (0)	12	9 (75)	12	9 (75)
Methadone	0	0 (0)	24	18 (18)	24	18 (75)
Methamphetamine	0	0 (0)	12	11 (92)	12	11 (92)
Other drugs	1	1 (100)	6	5 (83)	7	6 (86)
2009						
Pharm. opioids	2	0 (0)	30	19 (63)	32	13 (69)
Methadone	2	1 (50)	37	20 (54)	39	21 (54)
Methamphetamine	8	0 (0)	22	9 (41)	30	9 (30)
Other drugs	1	1 (100)	14	10 (71)	15	11 (73)
2010						
Pharm. opioids	4	1 (25)	31	15 (48)	35	16 (46)
Methadone	0	0 (0)	30	17 (57)	30	17 (56)
Methamphetamine	2	0 (0)	27	9 (33)	29	9 (31)
Other drugs	1	0 (0)	11	6 (55)	12	6 (50)
2011						
Pharm. opioids	2	0 (0)	20	8 (40)	22	8 (36)
Methadone	0	0 (0)	21	12 (57)	21	12 (57)
Methamphetamine	4	1 (25)	14	6 (43)	18	7 (39)
Other drugs	2	1 (50)	4	3 (75)	6	4 (67)
2012						
Pharm. opioids	3	1 (33)	27	14 (52)	30	15 (50)
Methadone	0	0 (0)	13	7 (54)	13	7 (54)
Methamphetamine	3	2 (67)	19	7 (37)	22	9 (41)
Other drugs	2	0 (0)	6	3 (50)	8	3 (38)
2013						
Pharm. opioids	2	1 (50)	21	12 (57)	23	13 (57)
Methadone	0	0 (0)	19	10 (53)	19	10 (53)
Methamphetamine	1	0 (0)	15	8 (53)	16	8 (50)
Other drugs	2	0 (0)	9	6 (67)	11	6 (55)
2014						
Pharm. opioids	0	0 (0)	24	13 (54)	25	13 (52)
Methadone	0	0 (0)	10	9 (90)	10	9 (90)
Methamphetamine	0	0 (0)	18	10 (56)	18	10 (56)
Other drugs	0	0 (0)	7	3 (43)	8	3 (38)
2014 p value		--		0.161		0.106

8. VICTORIA

8.1 Victorian sample


Two NSP services in Victoria participated in the ANSPS in all 20 survey years 1995 to 2014 (Health Information Exchange in St Kilda and Innerspace Drug Safety Services in Collingwood, formerly known as MINE). A further two NSP services (SHARPS in Frankston and Health Works in Footscray) participated in the ANSPS in ten or more survey years and two additional services (Barwon NSP and North Richmond NSP) have participated in all years since 2007. Victorian sample sizes ranged from 120 (in 1995) to 506 (in 2011). Response rates ranged between 20% (in 2006) and 61% (in 2013).

8.2 Demographic Characteristics

As occurred nationally, around two thirds of Victorian ANSPS respondents were male in all survey years 1995 to 2014. The majority of respondents (70% to 85%) identified as heterosexual, with between 7% and 14% of respondents identifying as bisexual and 2% to 8% identifying as homosexual. The proportion of Indigenous respondents increased significantly over the 20 year period in Victoria, from 5% in 1995 to 12% in 2014 (χ^2 trend $p < 0.001$). A minority of respondents were born outside Australia (range 12% to 18%) or reported that their parents spoke a language other than English at home (range 7% to 14%). In 2014, 83% of Victorian respondents were born in Australia and 86% reported that their parents spoke English at home (Table 8.1.1).

The proportion of young people (those aged less than 25 years) increased in the late 1990s, but declined significantly in subsequent years (Figure 8.2.1). There was a concomitant increase in the median age of respondents, from less than 30 years over the period 1995 to 2002, to a high of 39 years in 2014. In the late 1990s less than 10% of Victorian ANSPS respondents were aged 40 years or older, increasing to half in 2014 (Figure 8.2.1). The median age at first injection remained stable at 18-19 years across all survey years.

Figure 8.2.1 Victoria proportion of younger and older PWID by year



8.3 Injecting behaviour

Drug last injected

Heroin was the most commonly reported drug last injected in Victoria in all survey years, with prevalence ranging from 90% in 1998 to 36% in 2006 (Figure 8.3.1). Reports of heroin as the last drug injected declined over the 20 year survey period (χ^2 trend $p < 0.001$) although prevalence of heroin injection was stable in more recent years, 2010 to 2014 (χ^2 trend $p = 0.268$). Methamphetamine was the second most commonly reported drug last injected in Victoria, with an increase in methamphetamine injection (χ^2 trend $p < 0.001$) observed in the period immediately following changes in Australia's heroin markets in 2001 (Maher et al., 2007; Degenhardt et al., 2006; Topp et al., 2003). Prevalence of methamphetamine injection also increased in more recent years, from 13% in 2010 to 22% in 2014 (χ^2 trend $p < 0.001$).

Figure 8.3.1 Victoria prevalence of heroin and methamphetamine as the drug last injected by year





Figure 8.3.2 Victoria prevalence of pharmaceutical opioids and buprenorphine as the drug last injected by year




Prevalence of pharmaceutical opioids as the class of drugs most recently injected increased following changes to heroin markets in 2001 (χ^2 trend $p < 0.001$), however prevalence has declined in more recent years, from 8% in 2010 to 4% in 2014 (χ^2 trend $p = 0.020$). Reports of buprenorphine injection in Victoria also increased from 5% in 2002 (when data collection commenced) to 11% in 2006, however reports of buprenorphine declined over the period 2002 to 2014 (χ^2 trend $p = 0.002$) including over more recent period from 2010 to 2014 (χ^2 trend $p = 0.045$). In 2014, 3% of Victorian ANSPS respondents reported last injecting buprenorphine. Reports of all other drugs, including cocaine and performance and PIEDs were rare in Victoria.

Injection risk behaviour

There was a significant reduction in the proportion of Victorian ANSPS respondents who reported re-using needles and syringes (including re-use of one's own used syringes) from one in three respondents in 1998 (when data collection commenced) to one in five in 2012 (χ^2 trend $p < 0.001$), however reports of syringe re-use increased over the period 2010 to 2014 (χ^2 trend $p = 0.053$). In 2014, one in four respondents reported reusing needles and syringes in the preceding month. Reports of receptive sharing of syringes in the month preceding survey participation were stable over the 20 year period 1995 to 2014 (χ^2 trend $p = 0.233$) and over the more recent period 2010 to 2014 (χ^2 trend $p = 0.850$, Figure 8.3.3). The proportion of Victorian ANSPS respondents who reported receptive syringe sharing ranged from 11% in 2001 to 22% in 2012, and was 17% in 2014. Reports of receptive sharing of drug preparation equipment also declined, from 67% in 1999 to 39% in 2014 (χ^2 trend $p < 0.001$). Reports of receptive sharing of drug preparation equipment were stable over the more recent period, 2010 to 2014 (χ^2 trend $p = 0.695$).

As occurred nationally and in other jurisdictions, prevalence of public injecting in the month preceding survey participation declined significantly from a high of 79% in 1999 to around one half of respondents in more recent years (χ^2 trend $p = 0.002$, Table 8.1.3).

Figure 8.3.3 Victoria re-use of syringes and receptive sharing (RS) of syringes and drug preparation equipment by year



8.4 Imprisonment, OST and BBV testing

The proportion of Victorian ANSPS respondents with a history of imprisonment increased over the period 2002 to 2014 (χ^2 trend $p \leq 0.012$), with around one in two ANSPS respondents reporting a history of imprisonment in most survey years (Figure 8.4.1). Conversely, the proportion of respondents in Victoria reporting incarceration in the 12 months preceding survey participation declined from around 20% in 2001 to 11% in 2013 and 2014 (χ^2 trend $p < 0.001$). Among respondents who were recently incarcerated, between one quarter and one half reported injecting in prison over the 20 year period 1995 to 2014 (Table 8.1.1).

Figure 8.4.1 Victoria prison history and proportion of respondents who reported injecting in prison in the last 12 months by year






Figure 8.4.2 Victoria current and history of OST by year



As occurred nationally and elsewhere, the proportion of Victorian ANSPS respondents who reported a history of OST increased significantly over the survey period 1995 to 2014 (χ^2 trend $p < 0.001$, Figure 8.4.2, Table 8.1.7). The proportion of respondents who reported currently receiving OST also increased significantly, with a significant increase

occurring between 2001 and 2004 (χ^2 trend $p < 0.001$). The proportion of respondents who reported a history of OST was high (~80%) and stable over the more recent survey period 2010 to 2014 (χ^2 trend $p = 0.627$). The proportion of Victorian ANSPS respondents who reported currently receiving OST was also stable over the period 2010 to 2014, with around one in two respondents reporting current OST in each of the past five years (χ^2 trend $p = 0.834$).

Figure 8.4.3 Victoria HCV and HIV testing in the last 12 months by year




Between 84% and 92% of Victorian ANSPS respondents reported a lifetime history of testing for HCV and/or HIV in all survey years (Table 8.1.5). The proportion of respondents who reported a recent HCV antibody test (last 12 months) declined over the survey period, from 65% in 1998 to 60% in 2014 (χ^2 trend $p = 0.023$). The proportion of Victorian respondents who reported a recent HIV test also declined significantly, from 67% in 1995 to 56% in 2014 (χ^2 trend $p < 0.001$, Figure 8.4.3). The proportion of respondents in Victoria who reported a recent HCV or HIV test was stable over the more recent period 2010 to 2014 (χ^2 trend $p = 0.936$ and $p = 0.391$ respectively).

8.5 Blood borne viral infections

HIV antibody prevalence

HIV antibody prevalence remained low at less than 2.5% in all survey years in Victoria (Figure 8.5.1, Table 8.2.1), however prevalence increased over the period 2010 (0.5%) to 2014 (1.7%, χ^2 trend $p = 0.042$). HIV prevalence was lower than observed nationally in most survey years, except in 1996 and the most recent year (2014) when seven HIV positive respondents were observed. As per the methodological notes (Appendix 2), tables reporting demographic and drug use variables among Victorian HIV positive respondents are not included in this report due to less than five cases in most survey years. However, of the seven HIV positive respondents identified in 2014, four were men and three were women and all identified as heterosexual. The median age of HIV antibody positive respondents was 38 years and heroin was the most commonly reported last drug injected (71%). Three of the seven HIV positive respondents identified as Indigenous.

Figure 8.5.1 Victoria HIV antibody prevalence by year




HCV antibody prevalence

In Victoria, HCV antibody prevalence was consistently higher than observed nationally over the period 1995 to 2014, with prevalence of >60% in most years between 1995 and 2010 (Figure 8.5.2, Table 8.3.1). HCV antibody prevalence increased over the period 1995 to 2014 in Victoria (χ^2 trend $p < 0.001$), from 53% in 1995 to 67% in 2014. HCV antibody prevalence was stable at 65% to 69% over the past five years, 2010 to 2014 (χ^2 trend $p = 0.636$).

In Victoria in 2014, the median age of HCV antibody positive respondents was 40 years, and more than half (58%) reported last injecting heroin (Table 8.3.3).

Figure 8.5.2 Victoria and National HCV antibody prevalence by year



Among new initiates to injection in Victoria, HCV antibody prevalence fluctuated, likely in part due to smaller sample sizes in more recent years, but was stable among this sub-population over the period 2005 to 2014 (χ^2 trend $p = 0.832$). HCV antibody prevalence was highest among new initiates in 2000, when more than half were exposed to HCV. HCV antibody prevalence was stable over the period 1995 to 2014 among respondents

who first injected more than 10 years previously (χ^2 trend $p=0.130$) and among those who first injected between 4 and 9 years previously (χ^2 trend $p=0.427$).

Figure 8.5.3 Victoria HCV antibody prevalence by time since first injection and year




Table 8.1.1 Number (percentage) of respondents by demographic characteristic and year

Victoria	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Number of sites	5	3	4	4	3	3	4	4	4	5
N° surveyed	N=120	N=195	N=457	N=288	N=214	N=293	N=340	N=265	N=237	N=228
Response rate	25%	45%	44%	35%	26%	43%	39%	23%	25%	42%
Gender (%)										
Male	79 (66)	131 (67)	308 (67)	197 (68)	141 (66)	177 (60)	219 (64)	167 (63)	144 (61)	152 (67)
Female	41 (34)	63 (32)	147 (32)	91 (32)	72 (34)	115 (39)	119 (35)	96 (36)	90 (38)	74 (32)
Transgender	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)	2 (<1)	0 (0)
Not reported	0 (0)	1 (1)	1 (<1)	0 (0)	1 (<1)	1 (<1)	0 (0)	2 (1)	1 (<1)	2 (1)
Sexual identity (%)										
Heterosexual	96 (80)	159 (82)	364 (80)	246 (85)	174 (81)	239 (82)	264 (78)	206 (78)	168 (71)	182 (80)
Bisexual	15 (13)	21 (11)	56 (12)	22 (8)	29 (14)	39 (13)	35 (10)	37 (14)	30 (13)	23 (10)
Homosexual	9 (8)	11 (6)	27 (6)	12 (4)	7 (3)	10 (3)	17 (5)	2 (<1)	14 (6)	12 (5)
Not reported	0 (0)	4 (2)	10 (2)	8 (3)	4 (2)	5 (2)	24 (7)	20 (8)	25 (10)	11 (5)
Age and time since first injection (years)										
<i>Median age</i>	28.5	27	26	26	26	27	28	29	31	30
<i>Age range</i>	17-50	16-53	15-50	14-51	16-47	15-50	16-55	15-54	18-58	16-58
Age group (%)										
≤24 years	37 (31)	64 (33)	183 (40)	120 (42)	88 (41)	101 (34)	110 (32)	73 (28)	53 (22)	51 (22)
25+ years	83 (69)	131 (67)	274 (60)	168 (58)	124 (58)	192 (66)	230 (68)	192 (72)	183 (77)	176 (77)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)	0 (0)	1 (1)	1 (<1)
<i>Median age 1st injection</i>	18	18	18	18	18	18	18	18	18	18
<i>Age range</i>	10-40	11-37	10-45	11-42	11-44	10-40	10-45	10-51	11-48	11-42
<i>N° not reported</i>	0	4	5	3	1	2	8	6	5	5
<i>Median years injection</i>	8	8	7	6	7	8	9	10	11	10
<i>Range</i>	<1-31	<1-37	<1-33	<1-33	<1-27	<1-31	<1-37	<1-37	<1-42	<1-44
Time since first injection										
≤3 years	38 (32)	49 (25)	119 (26)	93 (32)	58 (27)	62 (21)	54 (16)	30 (11)	20 (8)	22 (10)
4+ years	82 (68)	141 (72)	331 (72)	192 (67)	154 (72)	227 (77)	275 (81)	226 (85)	211 (89)	199 (87)
Not reported	0 (0)	5 (3)	7 (2)	3 (1)	2 (1)	4 (1)	11 (3)	9 (3)	6 (3)	7 (3)

Table 8.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

Victoria	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Number of sites	5	4	6	6	6	5	6	6	6	6
N° surveyed	N=194	N=195	N=243	N=308	N=334	N=445	N=506	N=463	N=448	N=436
Response rate	44%	20%	33%	36%	--	58%	55%	52%	61%	41%
Gender (%)										
Male	116 (60)	126 (65)	166 (68)	206 (67)	216 (65)	310 (70)	341 (67)	322 (70)	302 (67)	288 (66)
Female	78 (40)	68 (35)	76 (31)	102 (33)	116 (35)	133 (30)	163 (32)	140 (30)	139 (31)	146 (33)
Transgender	0 (0)	0 (0)	1 (<1)	0 (0)	2 (<1)	1 (<1)	1 (<1)	1 (<1)	4 (<1)	2 (<1)
Not reported	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	1 (<1)	1 (<1)	0 (0)	3 (<1)	0 (0)
Sexual identity (%)										
Heterosexual	151 (78)	165 (85)	192 (79)	258 (84)	273 (82)	373 (84)	415 (82)	367 (79)	338 (75)	349 (81)
Bisexual	19 (10)	18 (9)	37 (15)	22 (7)	34 (10)	36 (8)	45 (9)	46 (10)	31 (7)	36 (8)
Homosexual	12 (6)	4 (2)	8 (3)	7 (2)	8 (2)	8 (2)	14 (3)	17 (4)	25 (6)	11 (3)
Not reported	12 (6)	8 (4)	6 (2)	21 (7)	19 (6)	28 (6)	32 (6)	33 (7)	54 (12)	40 (9)
Age and time since first injection (years)										
<i>Median age</i>	32	32	33	34	34	35	37	37	38	39
<i>Age range</i>	16-53	15-54	14-62	16-65	17-61	18-62	18-63	17-64	15-66	16-65
Age group (%)										
≤24 years	33 (17)	27 (14)	19 (8)	19 (6)	29 (9)	46 (10)	38 (8)	21 (5)	18 (4)	12 (3)
25+ years	161 (83)	167 (86)	224 (92)	289 (94)	305 (91)	399 (90)	464 (92)	440 (95)	429 (96)	422 (97)
Not reported	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)	0 (0)	4 (1)	2 (<1)	1 (<1)	2 (<1)
<i>Median age 1st injection</i>	18	18	17	18	18	17	18	18	18	18
<i>Age range</i>	11-35	10-41	10-42	10-45	11-51	10-50	10-50	10-59	10-52	10-52
N° not reported	7	1	6	9	9	9	11	17	23	6
<i>Median years injection</i>	12	13	13	15	14	15	17	18	18	20
<i>Range</i>	<1-37	<1-35	<1-46	<1-40	<1-40	<1-42	<1-47	<1-43	<1-40	<1-41
Time since first injection										
≤3 years	16 (8)	9 (5)	16 (7)	28 (9)	26 (8)	19 (4)	25 (5)	20 (4)	19 (4)	22 (5)
4+ years	171 (88)	172 (88)	221 (91)	172 (88)	299 (90)	414 (93)	469 (93)	425 (92)	406 (91)	394 (90)
Not reported	7 (4)	14 (7)	6 (2)	9 (3)	9 (3)	12 (3)	12 (2)	18 (4)	23 (5)	20 (5)

Table 8.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

Victoria N° surveyed	1995 N=120	1996 N=195	1997 N=457	1998 N=288	1999 N=214	2000 N=293	2001 N=340	2002 N=265	2003 N=237	2004 N=228
Aboriginal and Torres Strait Islander origin (%)										
No	114 (95)	184 (94)	438 (96)	281 (97)	196 (92)	276 (94)	312 (92)	251 (95)	226 (95)	212 (93)
Yes	6 (5)	6 (3)	12 (3)	5 (2)	15 (7)	15 (5)	20 (6)	11 (4)	6 (3)	9 (4)
Not reported	0 (0)	5 (3)	7 (2)	2 (1)	3 (1)	2 (1)	8 (2)	3 (1)	5 (2)	7 (3)
Region/country of birth (%)										
Australia	--	--	--	--	179 (84)	251 (86)	277 (82)	210 (79)	200 (84)	185 (81)
Other Oceania	--	--	--	--	--	12 (4)	11 (3)	15 (6)	11 (5)	5 (2)
Asia	--	--	--	--	3 (1)	4 (1)	5 (1)	5 (2)	2 (1)	9 (4)
UK & Ireland	--	--	--	--	--	17 (6)	17 (5)	17 (6)	14 (6)	11 (5)
Other	--	--	--	--	30 (14)	6 (2)	23 (7)	16 (6)	8 (3)	15 (7)
Not reported	--	--	--	--	2 (1)	3 (1)	7 (2)	2 (1)	2 (1)	3 (1)
Main language spoken at home by parents (%)										
English	--	--	--	--	179 (84)	252 (86)	287 (84)	231 (87)	217 (92)	154 (67)
Non-English	--	--	--	--	27 (12)	30 (10)	40 (12)	33 (12)	14 (6)	31 (14)
Not reported	--	--	--	--	8 (4)	11 (4)	13 (4)	1 (<1)	6 (2)	43 (19)
Imprisonment last year (%)										
No	103 (86)	169 (89)	391 (86)	245 (85)	170 (79)	228 (78)	259 (76)	204 (77)	192 (81)	185 (81)
Yes	17 (14)	20 (11)	65 (14)	40 (14)	42 (20)	54 (18)	68 (20)	58 (22)	41 (17)	42 (18)
Not reported	0 (0)	0 (0)	1 (<1)	3 (1)	2 (1)	11 (4)	13 (4)	3 (1)	4 (2)	1 (<1)
Injected in prison last year (%)										
N° in prison	N=17	N=20	N=65	N=40	N=42	N=54	N=68	N=58	N=41	N=42
Injected in prison	4 (24)	8 (40)	20 (31)	16 (40)	18 (43)	21 (39)	21 (31)	20 (34)	11 (27)	22 (52)
Frequency of injection last month (%)										
Not last month	11 (9)	6 (3)	23 (5)	8 (3)	12 (6)	13 (4)	27 (8)	17 (6)	16 (6)	13 (6)
Less than weekly	24 (20)	27 (14)	96 (21)	23 (8)	25 (12)	32 (11)	59 (17)	47 (18)	47 (20)	27 (12)
Weekly not daily	41 (34)	68 (34)	75 (16)	64 (22)	42 (20)	60 (20)	79 (23)	57 (22)	52 (22)	68 (30)
Daily or more	44 (37)	93 (48)	262 (57)	193 (67)	134 (63)	186 (64)	168 (50)	141 (53)	120 (51)	118 (52)
Not reported	0 (0)	1 (1)	1 (<1)	0 (0)	1 (<1)	2 (1)	7 (2)	3 (1)	2 (<1)	2 (<1)

Table 8.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

Victoria N° surveyed	2005 N=194	2006 N=195	2007 N=243	2008 N=308	2009 N=334	2010 N=445	2011 N=506	2012 N=463	2013 N=448	2014 N=436
Aboriginal and Torres Strait Islander origin (%)										
No	178 (92)	170 (87)	217 (89)	266 (86)	304 (91)	405 (91)	442 (87)	389 (84)	380 (85)	378 (87)
Yes	9 (5)	14 (7)	14 (6)	28 (9)	23 (7)	36 (8)	55 (11)	67 (14)	52 (12)	53 (12)
Not reported	7 (4)	11 (6)	12 (5)	14 (5)	7 (2)	4 (1)	9 (2)	7 (2)	16 (4)	5 (1)
Region/country of birth (%)										
Australia	156 (80)	160 (82)	202 (83)	259 (84)	285 (85)	392 (88)	444 (88)	388 (84)	364 (81)	360 (83)
Other Oceania	9 (5)	4 (2)	5 (2)	5 (2)	8 (2)	9 (2)	11 (2)	14 (3)	10 (2)	10 (2)
Asia	3 (2)	2 (1)	7 (3)	10 (3)	7 (2)	7 (2)	6 (1)	14 (3)	20 (4)	20 (5)
UK & Ireland	11 (6)	15 (8)	12 (5)	20 (6)	12 (4)	13 (3)	20 (4)	21 (5)	22 (5)	20 (5)
Other	15 (8)	8 (4)	10 (4)	8 (3)	20 (6)	15 (3)	24 (5)	24 (5)	30 (7)	25 (6)
Not reported	0 (0)	6 (3)	7 (3)	6 (2)	2 (<1)	9 (2)	1 (<1)	2 (<1)	2 (<1)	1 (<1)
Main language spoken at home by parents (%)										
English	158 (81)	171 (88)	221 (91)	270 (88)	303 (91)	412 (93)	457 (90)	417 (90)	393 (88)	378 (87)
Non-English	36 (19)	10 (5)	17 (7)	32 (10)	23 (7)	26 (6)	45 (9)	45 (10)	54 (12)	57 (13)
Not reported	0 (0)	14 (7)	5 (2)	6 (2)	8 (2)	7 (2)	4 (1)	1 (<1)	1 (<1)	1 (<1)
Imprisonment last year (%)										
No	162 (84)	161 (83)	195 (80)	241 (78)	285 (85)	319 (72)	403 (80)	368 (80)	354 (79)	359 (82)
Yes	22 (11)	20 (10)	30 (12)	40 (13)	39 (12)	45 (10)	59 (12)	75 (16)	48 (11)	50 (11)
Not reported	10 (5)	14 (7)	18 (7)	27 (9)	10 (3)	81 (18)	44 (9)	20 (4)	46 (10)	27 (6)
Injected in prison last year (%)										
N° in prison	N=22	N=20	N=30	N=40	N=39	N=45	N=59	N=75	N=48	N=50
Injected in prison	10 (45)	5 (25)	9 (30)	12 (30)	12 (31)	15 (33)	19 (32)	22 (29)	14 (29)	19 (38)
Frequency of injection last month (%)										
Not last month	12 (6)	10 (5)	11 (5)	21 (7)	21 (6)	30 (7)	46 (9)	26 (6)	33 (7)	38 (9)
Less than weekly	31 (16)	31 (16)	30 (12)	53 (17)	44 (13)	72 (16)	68 (13)	93 (20)	84 (19)	68 (16)
Weekly not daily	41 (21)	47 (24)	53 (22)	61 (20)	69 (21)	101 (23)	109 (22)	99 (21)	102 (23)	122 (28)
Daily or more	110 (57)	106 (54)	143 (59)	167 (54)	196 (59)	235 (53)	278 (55)	236 (51)	210 (47)	204 (47)
Not reported	0 (0)	1 (<1)	6 (2)	6 (2)	4 (1)	7 (2)	5 (1)	9 (2)	19 (4)	4 (1)
Experienced overdose in the previous 12 months										
Yes	--	--	--	--	--	--	--	--	25 (11)	82 (19)

Table 8.1.2 Number (percentage) of respondents by drug last injected and year

Victoria	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
N° surveyed	N=120	N=195	N=457	N=288	N=214	N=293	N=340	N=265	N=237	N=228
Drug last injected (%)										
Cocaine	1 (1)	0 (0)	3 (1)	0 (0)	0 (0)	0 (0)	5 (1)	0 (0)	0 (0)	1 (<1)
Methamphetamine	37 (31)	18 (9)	37 (8)	13 (5)	15 (7)	19 (6)	84 (24)	60 (23)	57 (24)	37 (16)
Heroin	75 (63)	159 (82)	391 (86)	259 (90)	186 (87)	255 (87)	197 (58)	150 (57)	137 (58)	134 (59)
Pharm. opioids	2 (2)	0 (0)	4 (1)	1 (<1)	2 (1)	5 (2)	9 (3)	6 (2)	8 (3)	7 (3)
Methadone	1 (1)	2 (1)	2 (<1)	2 (1)	1 (<1)	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)
Buprenorphine	--	--	--	--	--	--	--	12 (5)	8 (3)	18 (8)
Buprenorphine/naloxone	--	--	--	--	--	--	--	--	--	--
PIEDs	1 (1)	5 (3)	2 (<1)	1 (<1)	0 (0)	1 (<1)	2 (1)	6 (2)	0 (0)	4 (2)
More than one	1 (1)	7 (4)	12 (3)	10 (3)	0 (0)	11 (4)	34 (10)	27 (10)	20 (8)	23 (10)
Other	1 (1)	3 (2)	5 (1)	1 (<1)	2 (1)	0 (0)	3 (3)	2 (1)	7 (3)	1 (<1)
Not reported	1 (1)	1 (1)	1 (<1)	1 (<1)	8 (4)	2 (1)	6 (2)	1 (<1)	0 (0)	3 (1)

Victoria	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
N° surveyed	N=194	N=195	N=243	N=308	N=334	N=445	N=506	N=463	N=448	N=436
Drug last injected (%)										
Cocaine	5 (3)	4 (2)	0 (0)	2 (1)	0 (0)	4 (1)	2 (<1)	0 (0)	1 (<1)	6 (1)
Methamphetamine	47 (24)	69 (35)	51 (21)	55 (18)	45 (13)	57 (13)	91 (18)	82 (18)	96 (21)	98 (22)
Heroin	96 (49)	71 (36)	131 (54)	180 (58)	205 (61)	265 (60)	307 (61)	299 (65)	241 (54)	240 (55)
Pharm. opioids	7 (4)	10 (5)	8 (3)	22 (7)	21 (6)	34 (8)	26 (5)	15 (3)	19 (4)	18 (4)
Methadone	3 (2)	3 (2)	6 (2)	8 (3)	9 (3)	13 (3)	12 (2)	7 (2)	8 (2)	10 (2)
Buprenorphine	19 (10)	22 (11)	27 (11)	21 (7)	26 (8)	31 (7)	20 (4)	13 (3)	22 (5)	14 (3)
Buprenorphine/naloxone	--	--	--	--	3 (1)	13 (3)	16 (3)	10 (2)	10 (2)	14 (3)
PIEDs	0 (0)	1 (<1)	1 (<1)	3 (1)	1 (<1)	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0 (0)
More than one	8 (4)	10 (5)	8 (3)	6 (2)	10 (3)	23 (5)	26 (5)	32 (7)	43 (10)	27 (6)
Other	2 (1)	2 (1)	6 (2)	2 (1)	8 (2)	4 (1)	2 (<1)	2 (<1)	4 (<1)	6 (1)
Not reported	7 (4)	3 (2)	5 (2)	9 (3)	6 (2)	0 (0)	3 (<1)	1 (<1)	1 (<1)	3 (<1)

Table 8.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

Victoria	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
N° injected last month	N=109	N=188	N=433	N=280	N=201	N=278	N=306	N=245	N=219	N=213
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	--	--	--	--	113 (56)	81 (29)	111 (36)	101 (41)	81 (37)	82 (39)
Water	--	--	--	--	79 (39)	50 (18)	59 (19)	77 (31)	44 (20)	63 (30)
Filter	--	--	--	--	70 (35)	36 (13)	53 (17)	74 (30)	31 (14)	55 (26)
Drug mix	--	--	--	--	99 (49)	35 (13)	42 (14)	60 (24)	23 (11)	47 (22)
None	--	--	--	--	--	--	--	--	--	--
Public injecting in last month (%)										
Any public	--	--	277 (64)	210 (75)	158 (79)	209 (75)	202 (66)	158 (64)	139 (63)	146 (69)
All private	--	--	148 (34)	65 (23)	37 (18)	56 (20)	104 (34)	70 (29)	72 (33)	57 (27)
Not reported	--	--	8 (2)	5 (2)	6 (3)	13 (5)	0 (0)	17 (7)	8 (4)	10 (5)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	--	--	--	--	195 (97)	266 (96)	290 (95)	229 (93)	207 (95)	201 (94)
Pharmacy	--	--	--	--	127 (63)	162 (58)	157 (51)	129 (53)	102 (47)	109 (51)
Victoria										
N° injected last month	N=182	N=184	N=226	N=281	N=309	N=409	N=455	N=428	N=396	N=394
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	52 (29)	63 (36)	70 (34)	96 (36)	105 (36)	128 (31)	163 (36)	143 (33)	128 (32)	131 (33)
Water	42 (23)	34 (19)	43 (21)	56 (21)	55 (19)	76 (19)	100 (22)	90 (21)	83 (21)	86 (22)
Filter	35 (19)	32 (18)	36 (17)	45 (17)	49 (17)	52 (13)	76 (17)	68 (16)	56 (14)	69 (18)
Drug mix	31 (17)	15 (9)	21 (10)	31 (12)	31 (11)	51 (12)	53 (12)	60 (14)	43 (11)	49 (12)
None	--	96 (55)	118 (57)	151 (57)	167 (58)	220 (54)	246 (54)	228 (53)	238 (60)	240 (61)
Public injecting in last month (%)										
Any public	102 (57)	110 (60)	139 (62)	174 (62)	195 (63)	257 (63)	292 (64)	259 (61)	224 (57)	215 (55)
All private	62 (35)	65 (35)	80 (35)	100 (36)	113 (37)	126 (31)	149 (33)	148 (35)	164 (41)	177 (45)
Not reported	15 (8)	9 (5)	7 (3)	7 (2)	1 (<1)	26 (6)	14 (3)	21 (5)	8 (2)	2 (<1)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	170 (95)	172 (93)	185 (82)	263 (94)	229 (74)	385 (94)	425 (93)	394 (92)	374 (94)	368 (93)
Pharmacy	70 (39)	74 (40)	49 (22)	112 (40)	62 (20)	75 (18)	92 (20)	88 (21)	90 (23)	87 (22)

Table 8.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

Victoria	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
N° injected last month	N=109	N=188	N=433	N=280	N=201	N=278	N=306	N=245	N=219	N=213
Use of sterile needles and syringes last month (%)										
All injections	--	--	276 (64)	151 (54)	107 (53)	189 (68)	231 (75)	179 (73)	164 (75)	141 (66)
Most of the time	--	--	135 (31)	104 (37)	79 (39)	66 (24)	57 (19)	50 (20)	45 (20)	57 (27)
Half of the time	--	--	7 (2)	14 (5)	6 (3)	9 (3)	2 (1)	7 (3)	4 (2)	8 (4)
Some of the time	--	--	4 (1)	6 (2)	3 (1)	3 (1)	6 (2)	0 (0)	4 (2)	2 (1)
Not last month	--	--	5 (1)	0 (0)	2 (1)	5 (2)	0 (0)	3 (1)	0 (0)	1 (<1)
Not reported	--	--	6 (1)	5 (2)	4 (2)	6 (2)	10 (3)	6 (2)	2 (1)	4 (2)
Re-used someone else's used needle & syringe last month (%)										
None	87 (80)	146 (78)	353 (82)	227 (81)	156 (78)	226 (81)	257 (84)	193 (79)	179 (82)	163 (77)
Once	12 (11)	18 (9)	24 (6)	16 (6)	14 (7)	20 (7)	13 (4)	14 (6)	17 (8)	15 (7)
Twice	6 (6)	7 (4)	15 (4)	16 (6)	8 (4)	11 (4)	11 (4)	14 (6)	4 (2)	13 (6)
3-5 times	4 (4)	9 (5)	19 (4)	8 (3)	10 (5)	7 (3)	6 (2)	7 (3)	4 (2)	9 (4)
>5 times	0 (0)	8 (4)	6 (1)	9 (3)	6 (3)	4 (1)	3 (1)	5 (2)	9 (4)	7 (3)
Not reported	0 (0)	0 (0)	16 (4)	4 (1)	7 (3)	10 (4)	16 (5)	12 (5)	6 (2)	6 (3)
Number of people needle & syringe was re-used after last month (%)										
None	87 (80)	146 (78)	353 (82)	227 (81)	156 (78)	226 (81)	257 (84)	193 (79)	172 (79)	163 (76)
One	11 (10)	19 (10)	67 (15)	45 (17)	34 (16)	38 (14)	17 (5)	28 (11)	26 (12)	23 (11)
Two	7 (6)	20 (10)	5 (1)	4 (1)	1 (1)	1 (<1)	3 (1)	2 (1)	2 (<1)	4 (2)
Three to five	3 (3)	3 (2)	2 (1)	0 (0)	3 (1)	1 (<1)	2 (1)	1 (<1)	1 (<1)	2 (1)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	2 (1)	2 (1)	1 (<1)	2 (<1)	2 (1)
Don't know	1 (1)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	4 (1)	1 (<1)	6 (3)	2 (1)
Not reported	0 (0)	0 (0)	6 (1)	4 (1)	5 (2)	10 (4)	21 (7)	19 (8)	10 (5)	17 (8)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	--	--	42 (10)	35 (13)	24 (12)	25 (9)	20 (7)	16 (7)	19 (9)	16 (8)
Casual sex partner	--	--	1 (<1)	3 (1)	2 (1)	3 (1)	3 (1)	2 (1)	4 (2)	4 (2)
Close friend	--	--	22 (5)	9 (3)	8 (4)	9 (3)	11 (4)	9 (4)	10 (5)	10 (5)
Acquaintance	--	--	5 (1)	3 (1)	5 (2)	4 (1)	7 (2)	4 (2)	2 (1)	1 (<1)
Other	--	--	5 (1)	1 (<1)	4 (2)	3 (1)	1 (<1)	2 (1)	1 (<1)	2 (1)

Table 8.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

Victoria	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
N° injected last month	N=182	N=184	N=226	N=281	N=309	N=409	N=455	N=428	N=396	N=394
Use of sterile needles and syringes last month (%)										
All injections	131 (72)	117 (64)	150 (66)	186 (66)	224 (72)	289 (71)	327 (72)	319 (75)	269 (68)	278 (71)
Most of the time	47 (26)	48 (26)	64 (28)	76 (27)	69 (22)	76 (19)	87 (19)	70 (16)	103 (26)	92 (23)
Half of the time	3 (2)	8 (4)	3 (1)	7 (2)	7 (2)	5 (1)	13 (3)	9 (2)	2 (<1)	10 (3)
Some of the time	0 (0)	5 (3)	2 (1)	6 (2)	5 (2)	6 (1)	5 (1)	4 (1)	8 (2)	3 (1)
Not last month	1 (1)	2 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (<1)	2 (<1)	0 (0)
Not reported	0 (0)	4 (2)	7 (3)	6 (2)	4 (1)	33 (8)	23 (5)	24 (6)	12 (3)	11 (3)
Re-used someone else's used needle & syringe last month (%)										
None	147 (81)	142 (77)	172 (76)	226 (80)	252 (82)	307 (75)	330 (73)	316 (74)	313 (79)	318 (81)
Once	5 (3)	8 (4)	14 (6)	11 (4)	16 (5)	20 (5)	30 (7)	43 (10)	19 (5)	23 (6)
Twice	7 (4)	9 (5)	9 (4)	19 (7)	13 (4)	16 (4)	25 (5)	18 (4)	18 (5)	15 (4)
3-5 times	5 (3)	10 (5)	9 (4)	11 (4)	9 (3)	16 (4)	21 (5)	17 (4)	20 (5)	17 (4)
>5 times	6 (3)	7 (4)	10 (4)	7 (2)	11 (4)	11 (3)	16 (4)	16 (4)	16 (4)	12 (3)
Not reported	12 (7)	8 (4)	12 (5)	7 (2)	8 (3)	39 (10)	33 (7)	18 (4)	10 (3)	9 (2)
Number of people needle & syringe was re-used after last month (%)										
None	139 (76)	142 (77)	172 (76)	226 (80)	252 (82)	307 (75)	330 (73)	316 (74)	313 (79)	318 (81)
One	20 (11)	19 (10)	24 (11)	27 (10)	26 (8)	33 (8)	49 (11)	50 (12)	30 (8)	31 (8)
Two	2 (1)	2 (1)	2 (1)	2 (1)	1 (<1)	4 (1)	9 (2)	5 (1)	8 (2)	6 (2)
Three to five	1 (1)	0 (0)	3 (1)	1 (<1)	2 (<1)	4 (1)	5 (1)	5 (1)	2 (<1)	1 (<1)
More than five	0 (0)	3 (2)	2 (1)	0 (0)	1 (<1)	7 (2)	5 (1)	3 (1)	6 (2)	2 (<1)
Don't know	5 (3)	5 (3)	8 (4)	13 (5)	7 (2)	8 (2)	20 (4)	16 (4)	18 (5)	11 (3)
Not reported	15 (8)	13 (7)	15 (7)	12 (4)	20 (6)	46 (11)	37 (8)	33 (8)	19 (5)	25 (6)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	18 (10)	16 (9)	21 (9)	19 (7)	24 (8)	41 (10)	47 (10)	28 (7)	28 (7)	25 (6)
Casual sex partner	0 (0)	1 (<1)	2 (1)	0 (0)	0 (0)	4 (1)	3 (1)	3 (1)	5 (1)	0 (0)
Close friend	6 (3)	9 (5)	10 (4)	13 (5)	8 (3)	33 (8)	50 (11)	29 (7)	18 (5)	17 (4)
Acquaintance	5 (3)	3 (2)	6 (3)	2 (1)	2 (<1)	8 (2)	23 (5)	13 (3)	14 (4)	7 (2)
Other	2 (1)	1 (<1)	3 (1)	3 (1)	4 (1)	6 (1)	13 (3)	10 (2)	6 (2)	5 (1)

Table 8.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

Victoria N° surveyed	1995 N=120	1996 N=195	1997 N=457	1998 N=288	1999 N=214	2000 N=293	2001 N=340	2002 N=265	2003 N=237	2004 N=228
Sex last month (%)										
No	31 (26)	45 (23)	150 (33)	84 (29)	76 (36)	100 (34)	85 (25)	74 (28)	61 (26)	63 (28)
Yes	86 (72)	147 (75)	306 (67)	204 (71)	134 (63)	188 (64)	251 (74)	190 (72)	173 (73)	162 (71)
Not reported	3 (3)	3 (2)	1 (<1)	0 (0)	4 (2)	5 (2)	4 (1)	1 (<1)	3 (1)	3 (1)
Condom use at last sex (%)										
No	68 (57)	99 (51)	284 (62)	184 (64)	137 (64)	166 (57)	209 (61)	166 (62)	163 (69)	169 (74)
Yes	27 (23)	45 (23)	171 (37)	94 (33)	71 (33)	115 (39)	119 (35)	95 (36)	72 (30)	57 (25)
Not reported	25 (21)	51 (26)	2 (<1)	10 (3)	6 (3)	12 (4)	12 (4)	4 (2)	2 (1)	2 (1)
Condom use with regular sex partner(s) last month (%)										
No	--	96 (71)	195 (69)	106 (70)	77 (66)	93 (66)	125 (69)	85 (68)	75 (70)	83 (67)
Sometimes	--	12 (9)	37 (13)	20 (13)	16 (14)	16 (11)	25 (14)	13 (10)	15 (14)	19 (15)
Always	--	28 (20)	50 (18)	26 (17)	24 (20)	32 (23)	31 (17)	28 (22)	17 (16)	23 (18)
Condom use with new sex partner(s) last month (%)										
No	--	13 (27)	35 (30)	9 (36)	7 (23)	13 (25)	40 (31)	38 (41)	30 (39)	27 (32)
Sometimes	--	4 (8)	11 (10)	3 (12)	2 (6)	5 (9)	21 (16)	12 (13)	11 (14)	23 (27)
Always	--	31 (65)	69 (60)	13 (52)	22 (71)	35 (66)	68 (53)	42 (46)	35 (46)	34 (41)
Condom use with casual sex partner(s) last month (%)										
No	--	--	--	23 (37)	16 (29)	22 (26)	38 (35)	36 (40)	36 (49)	28 (39)
Sometimes	--	--	--	10 (16)	6 (11)	9 (11)	15 (14)	9 (10)	9 (12)	18 (25)
Always	--	--	--	29 (47)	33 (60)	54 (63)	55 (51)	44 (50)	29 (39)	26 (36)
Sex work last month (%)										
No	104 (87)	163 (84)	419 (92)	264 (92)	189 (88)	237 (81)	283 (83)	223 (84)	199 (84)	201 (88)
Yes	7 (6)	17 (9)	35 (8)	17 (6)	20 (9)	50 (17)	45 (13)	37 (14)	33 (14)	25 (11)
Not reported	9 (8)	15 (8)	3 (1)	7 (2)	5 (3)	6 (2)	12 (4)	5 (2)	5 (2)	2 (1)
Condom used at last sex work (%)										
Yes	6 (100)	16 (94)	26 (90)	14 (88)	17 (94)	47 (98)	40 (95)	33 (89)	27 (82)	22 (88)

Table 8.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

Victoria N° surveyed	2005 N=194	2006 N=195	2007 N=243	2008 N=308	2009 N=334	2010 N=445	2011 N=506	2012 N=463	2013 N=448	2014 N=436
Sex with a regular partner last month (%)										
No	86 (44)	85 (44)	115 (47)	146 (47)	140 (42)	216 (49)	249 (49)	256 (55)	244 (54)	240 (55)
Yes	107 (55)	101 (52)	114 (47)	153 (50)	179 (54)	215 (48)	209 (41)	196 (42)	182 (41)	175 (40)
Not reported	1 (1)	9 (5)	14 (6)	9 (3)	15 (4)	14 (3)	48 (9)	11 (2)	22 (5)	21 (5)
Condom used with regular partner last month (%)										
Never	N=107	N=101	N=114	N=153	N=179	N=215	N=209	N=196	N=182	N=175
Sometimes	69 (64)	68 (67)	82 (72)	101 (66)	126 (70)	138 (64)	146 (70)	124 (63)	117 (64)	129 (74)
Every time	21 (20)	17 (17)	20 (18)	22 (14)	23 (13)	31 (14)	29 (14)	28 (14)	30 (16)	24 (14)
Not reported	12 (11)	12 (12)	7 (6)	19 (12)	24 (13)	36 (17)	25 (12)	25 (13)	20 (11)	12 (7)
Not reported	5 (5)	4 (4)	5 (4)	11 (7)	6 (3)	10 (5)	9 (4)	19 (10)	15 (8)	10 (6)
Sex with other partner(s) last month (%)										
No	156 (80)	158 (81)	194 (80)	259 (84)	273 (82)	353 (79)	406 (80)	359 (78)	351 (78)	350 (80)
Yes	37 (19)	22 (11)	36 (15)	35 (11)	45 (13)	65 (15)	81 (16)	86 (19)	70 (16)	60 (14)
Not reported	1 (1)	15 (8)	13 (5)	14 (5)	16 (5)	27 (6)	19 (4)	18 (4)	27 (6)	26 (6)
Condom used with other partner(s) last month (%)										
Never	N=37	N=22	N=36	N=35	N=45	N=65	N=81	N=86	N=70	N=60
Sometimes	7 (19)	6 (27)	8 (22)	9 (26)	14 (31)	21 (32)	28 (35)	30 (35)	17 (24)	20 (33)
Every time	5 (14)	6 (27)	13 (36)	14 (40)	10 (22)	17 (26)	16 (20)	24 (28)	24 (34)	11 (18)
Not reported	23 (62)	8 (36)	14 (39)	10 (29)	20 (44)	23 (35)	32 (40)	30 (35)	24 (34)	21 (35)
Not reported	2 (5)	2 (9)	1 (3)	2 (6)	1 (2)	4 (6)	5 (6)	2 (2)	5 (7)	8 (13)
Sex work last month (%)										
No	168 (87)	169 (67)	218 (90)	266 (86)	308 (92)	393 (88)	454 (90)	418 (90)	390 (87)	372 (85)
Yes	24 (12)	12 (6)	15 (6)	17 (6)	17 (5)	28 (6)	31 (6)	34 (7)	19 (4)	28 (6)
Not reported	2 (1)	14 (7)	10 (4)	25 (8)	9 (3)	24 (5)	21 (4)	11 (2)	39 (9)	36 (8)
Condom used at last sex work (%)										
Yes	47 (98)	10 (83)	12 (86)	11 (73)	15 (88)	21 (78)	25 (89)	29 (85)	12 (75)	16 (64)

Table 8.1.5 Number (percentage) of respondents by testing for HIV and HCV infection by year

Victoria	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
N° surveyed	N=120	N=195	N=457	N=288	N=214	N=293	N=340	N=265	N=237	N=228
Previous HIV test (%)										
Yes, ever	105 (88)	162 (83)	397 (87)	249 (86)	186 (87)	267 (91)	298 (88)	242 (91)	214 (90)	201 (88)
Yes, last year	76 (63)	109 (56)	298 (65)	189 (66)	134 (63)	209 (71)	219 (64)	184 (69)	137 (58)	124 (54)
>1 year ago	25 (21)	50 (26)	95 (21)	59 (20)	50 (23)	58 (20)	79 (23)	58 (22)	77 (32)	77 (34)
Never tested	15 (13)	33 (17)	4 (1)	1 (<1)	27 (13)	26 (9)	36 (11)	22 (8)	17 (7)	24 (11)
Not reported	4 (3)	3 (2)	60 (13)	39 (14)	3 (1)	0 (0)	6 (2)	1 (1)	6 (3)	3 (1)
Previous HCV test (%)										
Yes, ever	87 (73)	145 (74)	382 (84)	254 (88)	193 (90)	271 (92)	312 (92)	246 (93)	220 (93)	212 (93)
Yes, last year	--	--	294 (63)	202 (70)	142 (66)	208 (71)	227 (67)	187 (71)	160 (68)	131 (57)
>1 year ago	--	--	85 (19)	50 (17)	51 (24)	63 (22)	85 (25)	59 (22)	60 (25)	81 (36)
Never tested	29 (24)	46 (24)	76 (16)	36 (13)	22 (10)	19 (6)	24 (7)	19 (7)	15 (6)	13 (6)
Not reported	4 (3)	4 (2)	2 (<1)	0 (0)	1 (<1)	3 (1)	4 (1)	0 (0)	2 (1)	3 (1)
Victoria										
N° surveyed	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
	N=194	N=195	N=243	N=308	N=334	N=445	N=506	N=463	N=448	N=436
Previous HIV test (%)										
Yes, ever	176 (91)	170 (87)	216 (89)	260 (84)	295 (88)	377 (85)	430 (85)	404 (87)	381 (85)	386 (89)
Yes, last year	121 (62)	104 (53)	151 (62)	151 (49)	174 (52)	233 (52)	264 (52)	274 (59)	253 (56)	244 (56)
>1 year ago	55 (28)	66 (34)	65 (27)	109 (35)	121 (36)	144 (32)	166 (33)	130 (28)	128 (29)	142 (33)
Never tested	16 (8)	18 (9)	19 (8)	34 (11)	29 (9)	40 (9)	52 (10)	44 (10)	42 (9)	33 (8)
Not reported	2 (1)	7 (4)	8 (3)	14 (5)	10 (3)	28 (6)	24 (5)	15 (3)	25 (6)	17 (4)
Previous HCV test (%)										
Yes, ever	177 (91)	172 (88)	232 (95)	274 (89)	304 (91)	393 (88)	458 (91)	417 (90)	393 (88)	395 (91)
Yes, last year	127 (65)	114 (58)	154 (63)	176 (57)	194 (58)	268 (60)	305 (60)	295 (64)	268 (60)	263 (60)
>1 year ago	50 (26)	58 (30)	78 (32)	98 (32)	110 (33)	125 (28)	153 (30)	122 (26)	125 (28)	132 (30)
Never tested	15 (8)	15 (8)	6 (2)	20 (6)	14 (4)	24 (5)	18 (4)	22 (5)	13 (3)	19 (4)
Not reported	2 (1)	8 (4)	5 (2)	14 (5)	16 (5)	28 (6)	30 (6)	24 (5)	42 (9)	22 (5)

Table 8.1.6 Number (percentage) of respondents by HCV treatment by year

Victoria	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Self-report HCV diagnosis	--	--	--	--	N=92	N=139	N=167	N=137	N=124	N=126
Any treatment for HCV (%)										
Interferon +/- Ribavirin	--	--	--	--	1 (1)	3 (2)	6 (4)	4 (3)	7 (6)	8 (6)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	2 (2)	3 (2)	8 (5)	8 (6)	2 (2)	4 (3)
No treatment	--	--	--	--	88 (96)	130 (94)	147 (88)	125 (92)	114 (92)	110 (88)
Not reported	--	--	--	--	1 (1)	3 (2)	6 (4)	0 (0)	1 (<1)	4 (3)
Current treatment for HCV (%)										
Interferon +/- Ribavirin	--	--	--	--	0	0	2	1	0	1
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	1	3	2	1	0	1
Victoria										
Self-report HCV diagnosis	N=103	N=101	N=141	N=185	N=201	N=280	N=321	N=313	N=263	N=276
Any treatment for HCV (%)										
Interferon +/- Ribavirin	4 (4)	4 (4)	8 (6)	15 (8)	14 (7)	27 (10)	23 (7)	22 (7)	20 (8)	22 (8)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	1 (<1)	1 (<1)
Other	4 (4)	3 (3)	3 (2)	6 (3)	5 (2)	5 (2)	2 (<1)	4 (1)	5 (2)	7 (3)
No treatment	95 (92)	92 (91)	122 (87)	158 (85)	176 (88)	238 (84)	278 (87)	272 (87)	224 (85)	235 (85)
Not reported	0 (0)	2 (2)	8 (6)	6 (3)	6 (3)	12 (4)	18 (6)	15 (5)	13 (5)	8 (3)
Current treatment for HCV (%)										
Interferon +/- Ribavirin	1	2	2	3	2	1	6	2	7	1
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	2	2
Other	4	1	1	2	0	3	0	4	2	2

Table 8.1.7 Number (percentage) of respondents by drug treatment by year

Victoria N° surveyed	1995 N=120	1996 N=195	1997 N=457	1998 N=288	1999 N=214	2000 N=293	2001 N=340	2002 N=265	2003 N=237	2004 N=228
Ever any treatment/therapy for drug use (%)										
No	47 (39)	56 (29)	129 (28)	76 (26)	44 (20)	44 (15)	72 (21)	41 (15)	57 (24)	29 (13)
Yes	73 (61)	137 (70)	328 (72)	212 (74)	168 (79)	247 (84)	266 (78)	224 (85)	180 (76)	197 (86)
Not reported	0 (0)	2 (1)	0 (0)	0 (0)	2 (1)	2 (1)	2 (1)	0 (0)	0 (0)	2 (1)
History of methadone maintenance treatment (%)										
Current	18 (15)	46 (24)	104 (23)	44 (15)	40 (19)	55 (19)	53 (16)	45 (17)	49 (21)	58 (25)
Previous	25 (21)	42 (22)	113 (25)	88 (31)	75 (35)	112 (38)	145 (43)	112 (42)	94 (40)	86 (38)
Never	77 (64)	105 (53)	240 (52)	156 (54)	97 (46)	124 (52)	138 (40)	107 (40)	93 (39)	78 (34)
Not reported	0 (0)	2 (1)	0 (0)	0 (0)	2 (1)	2 (1)	4 (1)	1 (1)	1 (<1)	6 (3)
History of other pharmacotherapy treatment (%)										
Current	--	--	--	--	--	9 (3)	27 (8)	65 (25)	61 (26)	74 (32)
Previous	--	--	--	--	--	48 (16)	53 (16)	60 (23)	67 (28)	56 (25)
Never	--	--	--	--	--	236 (81)	256 (75)	137 (51)	104 (44)	97 (43)
Not reported	--	--	--	--	--	0 (0)	4 (1)	3 (1)	5 (2)	1 (<1)
Victoria N° surveyed										
2005 N=194										
2006 N=195										
2007 N=243										
2008 N=308										
2009 N=334										
2010 N=445										
2011 N=506										
2012 N=463										
2013 N=448										
2014 N=2378										
Ever any treatment/therapy for drug use (%)										
No	22 (11)	22 (11)	23 (9)	34 (11)	29 (9)	36 (8)	58 (11)	38 (8)	39 (9)	36 (8)
Yes	172 (89)	169 (87)	215 (88)	272 (88)	304 (91)	404 (91)	441 (87)	423 (91)	406 (91)	396 (91)
Not reported	0 (0)	4 (2)	5 (2)	2 (1)	1 (<1)	5 (1)	7 (1)	2 (<1)	3 (<1)	4 (1)
History of methadone maintenance treatment (%)										
Current	56 (29)	58 (30)	78 (32)	100 (32)	88 (26)	140 (31)	169 (33)	162 (35)	171 (38)	152 (35)
Previous	66 (34)	66 (34)	81 (33)	104 (34)	125 (37)	155 (35)	157 (31)	176 (38)	142 (32)	153 (35)
Never	72 (37)	67 (34)	79 (33)	99 (32)	114 (34)	133 (30)	162 (32)	123 (27)	133 (30)	126 (30)
Not reported	0 (0)	4 (2)	5 (2)	5 (2)	7 (2)	17 (4)	18 (4)	2 (<1)	2 (<1)	5 (1)
History of other pharmacotherapy treatment (%)										
Current	55 (28)	48 (25)	61 (25)	59 (19)	83 (25)	102 (23)	90 (18)	78 (17)	80 (18)	71 (16)
Previous	55 (28)	65 (33)	84 (35)	125 (41)	128 (38)	169 (38)	197 (39)	213 (46)	202 (45)	210 (48)
Never	83 (43)	77 (40)	92 (38)	122 (40)	120 (36)	172 (39)	211 (42)	170 (37)	164 (37)	151 (35)
Not reported	1 (1)	5 (3)	6 (2)	2 (<1)	3 (1)	2 (<1)	8 (2)	2 (<1)	2 (<1)	4 (1)

HIV antibody prevalence

Table 8.2.1 HIV antibody prevalence by gender and year

Victoria	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995	77	1 (1.3)	41	0 (0.0)	118	1 (0.9)
1996	131	3 (2.3)	63	1 (1.6)	195	4 (2.1)
1997	294	4 (1.4)	141	1 (0.7)	436	5 (1.2)
1998	193	0 (0.0)	90	0 (0.0)	283	0 (0.0)
1999	137	2 (1.5)	69	0 (0.0)	207	2 (1.0)
2000	177	1 (0.6)	115	0 (0.0)	293	1 (0.3)
2001	214	2 (0.9)	117	0 (0.0)	333	2 (0.6)
2002	151	1 (0.7)	91	0 (0.0)	244	1 (0.4)
2003	144	1 (0.7)	90	1 (1.1)	237	2 (0.8)
2004	122	1 (0.8)	65	0 (0.0)	189	1 (0.5)
2005	103	1 (1.0)	77	0 (0.0)	180	1 (0.6)
2006	122	1 (0.8)	68	0 (0.0)	191	1 (0.5)
2007	163	0 (0.0)	76	0 (0.0)	243	0 (0.0)
2008	199	2 (1.0)	93	0 (0.0)	292	2 (0.7)
2009	215	3 (1.4)	116	0 (0.0)	333	3 (0.9)
2010	305	2 (0.7)	131	0 (0.0)	438	2 (0.5)
2011	335	4 (1.2)	162	0 (0.0)	499	4 (0.8)
2012	304	1 (0.3)	128	0 (0.0)	433	1 (0.2)
2013	300	5 (1.7)	139	1 (0.7)	446	6 (1.3)
2014	277	4 (1.4)	143	3 (2.1)	421	7 (1.7)
X ² p trend: 1995-2014		0.942		0.444		0.680
X ² p trend: 2010-2014		0.288		0.014		0.042

HCV antibody prevalence

Table 8.3.1 HCV antibody prevalence by gender and year

Victoria	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995	77	43 (56)	41	20 (49)	118	63 (53)
1996	127	56 (44)	62	35 (56)	190	92 (48)
1997	294	140 (48)	141	81 (57)	436	221 (51)
1998	193	104 (54)	90	48 (53)	283	152 (54)
1999	135	81 (60)	69	40 (58)	205	122 (60)
2000	177	114 (64)	115	68 (59)	293	183 (62)
2001	218	150 (69)	119	87 (73)	339	237 (70)
2002	152	84 (55)	91	57 (63)	245	143 (58)
2003	144	95 (66)	90	59 (66)	237	157 (66)
2004	122	82 (67)	65	48 (74)	189	130 (69)
2005	101	64 (63)	76	55 (72)	177	119 (67)
2006	121	84 (69)	67	50 (75)	189	135 (71)
2007	139	100 (72)	65	48 (74)	205	149 (73)
2008	188	141 (75)	90	58 (64)	278	199 (72)
2009	212	120 (57)	115	60 (52)	329	182 (55)
2010	303	204 (67)	130	72 (55)	435	278 (64)
2011	332	229 (69)	158	93 (59)	492	324 (66)
2012	301	214 (71)	127	83 (65)	429	297 (69)
2013	299	199 (67)	138	94 (68)	444	296 (67)
2014	267	183 (69)	138	90 (65)	406	273 (67)
X ² p trend: 1995-2014		<0.001		0.451		<0.001
X ² p trend: 2010-2014		0.999		0.287		0.636

Table 8.3.2 HCV antibody prevalence by age group, gender and year

Victoria	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	16	6 (38)	21	9 (43)	37	15 (41)
25-34 years	42	23 (55)	16	8 (50)	58	31 (53)
35-44 years	15	10 (67)	4	3 (75)	19	13 (68)
45+ years	4	4 (100)	0	0 (0)	4	4 (100)
1996						
<25 years	35	6 (17)	27	7 (26)	62	13 (21)
25-34 years	61	28 (46)	29	25 (86)	91	54 (59)
35-44 years	26	21 (81)	5	4 (80)	31	25 (81)
45+ years	5	5 (100)	1	1 (100)	6	6 (100)
1997						
<25 years	102	21 (21)	68	24 (35)	170	45 (26)
25-34 years	122	60 (49)	58	45 (78)	180	105 (58)
35-44 years	62	51 (82)	13	10 (77)	76	61 (80)
45+ years	8	8 (100)	2	2 (100)	10	10 (100)
1998						
<25 years	68	32 (47)	51	17 (33)	119	49 (41)
25-34 years	92	45 (49)	28	20 (71)	120	65 (54)
35-44 years	29	23 (79)	10	10 (100)	39	33 (85)
45+ years	4	4 (100)	1	1 (100)	5	5 (100)
1999						
<25 years	47	22 (47)	40	20 (50)	87	42 (48)
25-34 years	69	43 (62)	19	12 (63)	88	55 (63)
35-44 years	16	14 (88)	8	6 (75)	24	20 (83)
45+ years	2	1 (50)	2	2 (100)	4	3 (75)
2000						
<25 years	46	23 (50)	55	32 (58)	101	55 (54)
25-34 years	92	61 (66)	47	28 (60)	139	89 (64)
35-44 years	37	28 (76)	12	7 (58)	50	36 (72)
45+ years	2	2 (100)	1	1 (100)	3	3 (100)
2001						
<25 years	61	33 (54)	47	29 (62)	110	62 (55)
25-34 years	103	71 (69)	50	40 (80)	153	111 (73)
35-44 years	44	37 (84)	21	17 (81)	65	54 (83)
45+ years	10	9 (90)	1	1 (100)	11	10 (91)
2002						
<25 years	35	19 (54)	29	19 (66)	65	39 (60)
25-34 years	72	35 (49)	49	28 (57)	122	64 (52)
35-44 years	38	23 (61)	11	9 (82)	49	32 (65)
45+ years	7	7 (100)	2	1 (50)	9	8 (89)
2003						
<25 years	28	16 (57)	24	18 (75)	53	35 (66)
25-34 years	59	34 (58)	47	26 (55)	106	60 (57)
35-44 years	49	39 (80)	17	14 (82)	67	54 (81)
45+ years	8	6 (75)	1	1 (100)	10	8 (80)
2004						
<25 years	23	13 (56)	18	12 (67)	42	25 (59)
25-34 years	60	39 (65)	30	23 (77)	90	62 (69)
35-44 years	27	19 (70)	14	10 (71)	41	29 (71)
45+ years	12	11 (92)	3	3 (100)	15	14 (93)

Table 8.3.2 HCV antibody prevalence by age group, gender and year (continued)

Victoria	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<25 years	14	5 (36)	19	13 (68)	33	18 (55)
25-34 years	44	23 (52)	27	16 (59)	71	39 (55)
35-44 years	30	25 (83)	24	20 (83)	54	45 (83)
45+ years	13	11 (85)	7	7 (100)	20	18 (90)
2006						
<25 years	10	7 (70)	15	9 (60)	25	16 (64)
25-34 years	68	41 (60)	29	22 (76)	97	63 (65)
35-44 years	31	24 (77)	15	12 (80)	47	37 (79)
45+ years	11	11 (100)	8	7 (88)	19	18 (95)
2007						
<25 years	9	2 (22)	8	4 (50)	17	6 (35)
25-34 years	72	48 (67)	33	25 (76)	106	74 (70)
35-44 years	44	38 (86)	19	14 (74)	63	52 (83)
45+ years	14	12 (86)	5	5 (100)	19	17 (89)
2008						
<25 years	9	3 (33)	9	1 (11)	18	4 (22)
25-34 years	79	54 (68)	48	32 (67)	127	86 (68)
35-44 years	68	55 (81)	25	19 (76)	93	74 (80)
45+ years	32	29 (91)	8	6 (75)	40	35 (88)
2009						
<25 years	15	2 (13)	14	1 (7)	29	3 (10)
25-34 years	95	49 (52)	49	27 (55)	145	77 (53)
35-44 years	80	54 (68)	45	28 (68)	126	83 (66)
45+ years	22	15 (68)	7	4 (57)	29	19 (66)
2010						
<25 years	14	3 (21)	29	7 (24)	43	10 (23)
25-34 years	112	69 (62)	44	26 (59)	157	96 (61)
35-44 years	129	93 (72)	42	28 (67)	121	121 (71)
45+ years	46	37 (80)	13	9 (69)	46	46 (78)
2011						
<25 years	18	8 (44)	20	5 (25)	38	13 (34)
25-34 years	102	68 (67)	60	40 (67)	163	109 (67)
35-44 years	135	93 (69)	53	33 (62)	188	126 (67)
45+ years	75	59 (79)	24	15 (63)	99	47 (75)
2012						
<25 years	14	3 (21)	7	2 (29)	21	5 (24)
25-34 years	91	63 (69)	50	32 (64)	142	95 (67)
35-44 years	132	101 (77)	50	35 (70)	182	136 (75)
45+ years	63	46 (73)	20	14 (70)	83	60 (72)
2013						
<25 years	8	1 (13)	10	4 (40)	18	5 (28)
25-34 years	79	37 (47)	48	28 (58)	131	67 (51)
35-44 years	135	101 (75)	47	36 (77)	184	137 (74)
45+ years	76	59 (78)	33	26 (79)	110	86 (78)
2014						
<25 years	5	2 (40)	5	3 (60)	11	5 (45)
25-34 years	69	42 (61)	48	26 (54)	117	68 (58)
35-44 years	120	80 (67)	49	38 (78)	169	118 (70)
45+ years	71	58 (82)	36	23 (64)	107	81 (76)
2014 p value		0.019		0.093		0.016

Table 8.3.3

HCV antibody prevalence by drug last injected, years of injection and year

Victoria	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heroin	19	9 (47)	55	45 (82)	74	54 (73)
Methamphetamine	0	1 (6)	20	6 (30)	36	7 (19)
Other opioids	1	0 (0)	2	1 (50)	3	1 (33)
Other drugs	1	0 (0)	3	1 (33)	4	1 (25)
1996						
Heroin	36	10 (28)	119	79 (66)	155	89 (57)
Methamphetamine	7	0 (0)	11	3 (27)	18	3 (17)
Other opioids	0	0 (0)	2	1 (50)	2	1 (50)
Other drugs	4	1 (25)	10	4 (40)	14	5 (36)
1997						
Heroin	90	19(21)	284	181 (64)	374	200 (53)
Methamphetamine	13	2 (15)	21	5 (24)	34	7 (21)
Other opioids	1	0 (0)	4	4 (100)	5	4 (80)
Other drugs	6	0 (0)	16	9 (56)	22	9 (41)
1998						
Heroin	82	32 (39)	173	107 (62)	255	139 (55)
Methamphetamine	4	0 (0)	8	3 (38)	12	3 (25)
Other opioids	0	0 (0)	3	2 (67)	3	2 (67)
Other drugs	5	3 (60)	7	4 (57)	12	7 (58)
1999						
Heroin	55	22 (40)	122	81 (66)	177	130 (58)
Methamphetamine	2	1 (50)	13	9 (69)	15	10 (67)
Other opioids	0	0 (0)	3	1 (31)	3	1 (33)
Other drugs	1	0 (0)	1	1 (100)	2	1 (50)
2000						
Heroin	55	28 (51)	200	133 (67)	255	161 (63)
Methamphetamine	3	2 (67)	16	8 (50)	19	10 (53)
Other opioids	1	1 (100)	4	3 (75)	5	4 (80)
Other drugs	3	1 (33)	9	6 (67)	12	7 (58)
2001						
Heroin	30	14 (47)	167	135 (81)	197	149 (76)
Methamphetamine	19	4 (21)	65	43 (66)	84	47 (56)
Other opioids	0	0 (0)	9	8 (89)	9	8 (89)
Other drugs	5	2 (40)	38	28 (74)	43	30 (70)
2002						
Heroin	15	6 (40)	129	90 (70)	144	96 (67)
Methamphetamine	5	0 (0)	49	15 (31)	54	15 (28)
Other opioids	2	1 (50)	15	9 (60)	17	10 (59)
Other drugs	4	2 (50)	25	20 (80)	29	22 (76)
2003						
Heroin	8	2 (25)	129	90 (70)	137	92 (67)
Methamphetamine	10	3 (30)	47	30 (64)	57	33 (58)
Other opioids	1	1 (100)	15	12 (80)	16	13 (81)
Other drugs	1	1 (100)	26	18 (69)	27	19 (70)
2004						
Heroin	9	1 (11)	104	81 (78)	113	82 (73)
Methamphetamine	4	0 (0)	24	14 (58)	28	14 (50)
Other opioids	1	0 (0)	24	20 (83)	28	20 (80)
Other drugs	2	1 (50)	19	13 (68)	21	14 (67)

Table 8.3.3 HCV antibody prevalence by drug last injected, years of injection and year

Victoria	≤3 years		4+ years		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
2005						
Heroin	6	5 (83)	83	59 (71)	89	64 (72)
Methamphetamine	4	0 (0)	38	23 (61)	42	23 (55)
Other opioids	2	1 (50)	26	20 (77)	28	21 (75)
Other drugs	2	0 (0)	11	7 (64)	13	7 (54)
2006						
Heroin	3	1 (33)	67	54 (81)	70	55 (79)
Methamphetamine	4	1 (25)	62	41 (66)	66	42 (64)
Other opioids	0	0 (0)	34	26 (76)	34	26 (76)
Other drugs	1	0 (0)	15	9 (60)	16	9 (56)
2007						
Heroin	7	2 (29)	99	79 (80)	106	81 (76)
Methamphetamine	5	0 (0)	37	27 (73)	42	27 (64)
Other opioids	3	0 (0)	36	28 (78)	39	28 (72)
Other drugs	1	0 (0)	13	10 (77)	14	10 (71)
2008						
Heroin	11	4 (36)	150	116 (77)	161	120 (75)
Methamphetamine	8	3 (38)	42	29 (69)	50	32 (64)
Other opioids	5	0 (0)	42	31 (74)	47	31 (66)
Other drugs	1	0 (0)	11	9 (82)	12	9 (75)
2009						
Heroin	14	2 (14)	187	117 (63)	201	119 (59)
Methamphetamine	2	0 (0)	43	21 (49)	45	21 (47)
Other opioids	5	1 (20)	53	25 (47)	58	26 (45)
Other drugs	2	1 (50)	17	12 (71)	19	13 (68)
2010						
Heroin	11	5 (45)	246	171 (70)	257	176 (68)
Methamphetamine	2	0 (0)	54	25 (46)	56	25 (45)
Other opioids	3	2 (67)	88	57 (65)	91	59 (65)
Other drugs	2	0 (0)	29	18 (62)	31	18 (58)
2011						
Heroin	16	4 (25)	281	204 (73)	297	208 (70)
Methamphetamine	3	2 (67)	86	48 (56)	89	50 (56)
Other opioids	5	2 (40)	69	44 (64)	74	46 (62)
Other drugs	1	0 (0)	28	18 (64)	29	18 (62)
2012						
Heroin	13	4 (31)	274	195 (71)	287	199 (69)
Methamphetamine	3	0 (0)	66	45 (68)	69	45 (65)
Other opioids	2	1 (50)	37	31 (84)	39	32 (82)
Other drugs	2	0 (0)	31	20 (65)	33	20 (61)
2013						
Heroin	7	3 (43)	230	167 (73)	237	170 (72)
Methamphetamine	5	1 (20)	91	57 (63)	96	58 (60)
Other opioids	2	0 (0)	57	38 (67)	59	38 (64)
Other drugs	5	3 (60)	46	26 (57)	51	29 (57)
2014						
Heroin	9	2 (22)	204	150 (74)	223	159 (71)
Methamphetamine	4	1 (25)	84	47 (56)	91	50 (55)
Other opioids	1	0 (0)	48	35 (73)	51	37 (73)
Other drugs	3	1 (33)	33	25 (76)	38	27 (71)
2014 p value		1.000		0.026		0.036

9. WESTERN AUSTRALIA


9.1 Western Australian sample

One Western Australian NSP participated in the ANSPS in all 20 survey years 1995 to 2014 (Western Australian AIDS Council Mobile Exchange). The Western Australia Substance Users Association (WASUA) NSP in Perth participated in all years from 1998 and the WASUA South Coast NSP participated between 2001 and 2006 and in all years since 2007. Western Australian sample sizes ranged from 30 respondents (in 1995) to 225 respondents (in 2014). Response rates ranged between 29% (in 1995) and 82% (in 2014).

9.2 Demographic Characteristics

More than half of Western Australian ANSPS respondents were male in all survey years 1995 to 2014, with men comprising two thirds of the sample in most years (range 54% to 71%). The majority of respondents (74% to 85%) identified as heterosexual, with between 7% and 17% identifying as bisexual and 2% to 10% identifying as homosexual. The proportion of Indigenous respondents in Western Australia was stable over the survey period 1995 to 2014 (range 0% to 9%, χ^2 trend $p=0.151$). The majority of respondents were born in Australia in most years (range 72% to 93%) and reported that their parents spoke English at home (range 70% to 97%). Among respondents who were born overseas, the majority were born in the United Kingdom, Ireland or New Zealand. In 2014, 78% of Western Australian respondents were born in Australia and 94% reported that their parents spoke English at home (Table 9.1.1).

Figure 9.2.1 Western Australia proportion of younger and older PWID by year



As occurred nationally and elsewhere, the proportion of young people (those aged less than 25 years) declined significantly over the 20 year period 1995 to 2014 (Figure 9.2.1). In 1996, 41% of Western Australian ANSPS respondents were aged less than 25 years, declining to just 3% in 2014. There was a concomitant increase in the median age of respondents, from a low of 27 years over the period 1995 to 1997, to a high of 41 years in 2014. In 1995, 3% of Western Australian ANSPS respondents were aged 40 years or

older, increasing to more than half in all years 2010 to 2014 (Figure 8.2.1). The median age at first injection remained relatively stable at 17-19 years across all survey years.


9.3 Injecting behaviour

Drug last injected

Heroin and methamphetamine were the most commonly reported drugs last injected in Western Australia in all survey years. Heroin was reported as the drug most recently injected by the majority of ANSPS respondents in the years 1995 to 2000 (Figure 9.3.1), however, there was a marked decline in prevalence of heroin injection commensurate with major changes in Australia's heroin markets in 2001 (Maher et al., 2007; Degenhardt et al., 2006; Topp et al., 2003). Prevalence of heroin as the last drug injected in Western Australia remained stable in all years over the past decade (2005 to 2014), with between one quarter and one half of respondents reporting last injecting heroin (χ^2 trend $p=0.432$).

Methamphetamine was the most common drug last injected in Western Australia over the period 2001 to 2007 and in more recent years, 2011 to 2013. Methamphetamine injection was stable over the five year period 2010 to 2014, with between one quarter and one half of respondents reporting last injecting this drug (χ^2 trend $p=0.180$).

Figure 9.3.1 Western Australia prevalence of heroin and methamphetamine as the drug last injected by year




Prevalence of pharmaceutical opioids as the drug most recently injected in Western Australia also increased over the period following changes to Australian heroin markets in 2001 (χ^2 trend $p=0.003$). In 2000, 5% of Western Australian ANSPS respondents reported last injecting pharmaceutical opioids, however prevalence increased to a high of 21% in 2007 and 2008. Prevalence of pharmaceutical opioid injection subsequently declined to 13% in 2014 and 5% in 2014 (χ^2 trend $p=0.002$). Reports of cocaine and performance and PIEDs were rare in Western Australia.

Injection risk behaviour

There was a significant reduction in self-reported blood borne viral transmission risk behaviours among Western Australian respondents over the 20 year survey period. The proportion of respondents reporting re-use of needles and syringes (including re-use of one's own used syringe) in the month preceding ANSPS participation declined from more than half in 1999, to around one in three respondents in 2014 (χ^2 trend $p < 0.001$, Figure 9.3.3). Similarly, prevalence of recent receptive syringe sharing (use of someone else's used needle/syringe) in Western Australia declined from around one third of respondents in 1995 to between 20% in 2014 (χ^2 trend $p = 0.049$). Reports of receptive sharing of drug preparation equipment also declined from more than half of respondents over the period 1999 to 2001 to around one third of respondents in 2014 (χ^2 trend $p < 0.001$). Notwithstanding these declines, reports of injection risk behaviour (re-use of syringes and receptive sharing of syringes and drug preparation equipment) were stable over the most recent survey period 2010 to 2014 (χ^2 trend $p = 0.349$, $p = 0.200$ and $p = 0.185$ respectively).

The proportion of Western Australian ANSPS respondents who reported public injection in the month preceding survey participation was stable over the period 1997 (when data collection commenced) to 2014 (range 35% to 61%, χ^2 trend $p = 0.118$, Table 9.1.3).


Figure 9.3.2 Western Australia re-use of syringes and receptive sharing (RS) of syringes and drug preparation equipment by year



9.4 Imprisonment, OST and BBV testing


The proportion of Western Australian ANSPS respondents with a history of imprisonment was stable, with just under half of ANSPS respondents reporting a history of imprisonment in most survey years (χ^2 trend $p = 0.531$, Figure 9.4.1). The proportion of respondents in Western Australia reporting incarceration in the 12 months preceding survey participation declined from a high of 20% in 2004 to 11% in 2014 (χ^2 trend $p < 0.001$). Among respondents who were recently incarcerated, the proportion who reported injecting in prison varied over the 20 year period, from 67% in 1995 to 12% in 2013 (Table 9.1.1).

Figure 9.4.1 Western Australia prison history and proportion of respondents who reported injecting in prison in the last 12 months by year




More than half of Western Australian ANSPS respondents reported a history of OST in most survey years over the period 1995 to 2014 (Figure 9.4.2, Table 9.1.7). A significant increase in the proportion reporting lifetime OST use was observed over the period 1995 to 2014 (χ^2 trend $p < 0.001$). The proportion of ANSPS respondents in Western Australia who reported current OST was stable over the period 1995 to 2014, with around one in three respondents reporting currently receiving OST in all survey years (χ^2 trend $p = 0.522$).

Figure 9.4.2 Western Australia current and history of OST by year



More than three quarters of Western Australian ANSPS respondents reported a lifetime history of testing for HCV and/or HIV in all survey years (Table 9.1.5). The proportion of respondents in Western Australia who reported a recent HCV antibody test (last 12 months) declined significantly over the survey period, from a high of 78% in 2000 to 50% in 2014 (χ^2 trend $p < 0.001$). The proportion of Western Australian respondents who reported a recent HIV test also declined significantly, from 76% in 1998 to 44% in 2014 (χ^2 trend $p < 0.001$, Figure 9.4.3).

Figure 9.4.3 Western Australia HCV and HIV testing in the last 12 months by year




9.5 Blood borne viral infections

HIV antibody prevalence

HIV antibody prevalence remained low at 2.5% or less in all survey years in Western Australia, except in 1995 when HIV antibody prevalence was 8.3% (Figure 9.5.1, Table 9.2.1). Nonetheless, HIV antibody prevalence in Western Australia was stable over the 20 year survey period 1995 to 2014 (χ^2 trend $p=0.346$). In 2014, one HIV positive respondent was identified (Table 9.2.1).


Figure 9.5.1 Western Australia HIV antibody prevalence by year



HCV antibody prevalence


In Western Australia, HCV antibody prevalence was stable over the period 1995 to 2014, with prevalence of around 50% observed in most years between 1995 and 2014 (χ^2 trend $p=0.171$, Figure 9.5.2, Table 9.3.1). HCV antibody prevalence was also stable at between 46% and 57% over the past five years 2010 to 2014 (χ^2 trend $p=0.529$).

Figure 9.5.2 Western Australia and National HCV antibody prevalence by year



In Western Australia in 2014 the median age of HCV antibody positive respondents was 44 years, with just over one third (38%) reporting last injecting heroin and just over one quarter (27%) reporting last injecting methamphetamine (Table 9.3.3).

Figure 9.5.3 Western Australia HCV antibody prevalence by time since first injection and year



Among West Australian new initiates to injecting, HCV antibody prevalence fluctuated, likely in part due to smaller sample sizes in more recent years. HCV antibody prevalence in Western Australia was highest among new initiates in 2012, when 7 of the 10 new initiates had been exposed to HCV. Among respondents who first injected more than 10 years previously, HCV antibody prevalence tended towards a decline, but was high at 50% or more and stable over the period 1995 to 2014 (Figure 9.5.3, χ^2 trend $p=0.077$). HCV antibody prevalence was also stable among West Australian respondents who first injected between 4 and 9 years previously (χ^2 trend $p=0.920$).

Table 9.1.1 Number (percentage) of respondents by demographic characteristic and year

Western Australia	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Number of sites	1	1	1	2	2	2	3	3	3	3
N° surveyed	N=30	N=83	N=48	N=161	N=86	N=143	N=164	N=127	N=133	N=161
Response rate	29%	51%	28%	40%	43%	68%	57%	73%	--	65%
Gender (%)										
Male	18 (60)	51 (62)	26 (54)	97 (60)	53 (62)	101 (71)	100 (60)	90 (71)	75 (56)	99 (61)
Female	12 (40)	30 (36)	22 (46)	62 (38)	33 (38)	42 (29)	62 (38)	37 (29)	57 (43)	61 (38)
Transgender	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)
Not reported	0 (0)	2 (2)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)
Sexual identity (%)										
Heterosexual	23 (77)	68 (82)	38 (79)	123 (77)	65 (76)	105 (74)	131 (80)	99 (78)	104 (78)	133 (83)
Bisexual	5 (17)	9 (11)	7 (15)	18 (11)	11 (13)	14 (10)	11 (7)	11 (9)	9 (7)	11 (7)
Homosexual	2 (6)	5 (6)	3 (6)	15 (9)	6 (7)	15 (10)	8 (5)	7 (6)	7 (5)	8 (5)
Not reported	0 (0)	1 (1)	0 (0)	5 (3)	4 (4)	9 (6)	14 (8)	10 (8)	13 (10)	9 (5)
Age and time since first injection (years)										
Median age	27.5	27.5	27	28	28	28	29	33	34	35
Age range	16-43	16-43	20-51	15-54	17-51	16-49	15-55	14-53	16-55	16-60
Age group (%)										
≤24 years	9 (30)	34 (41)	17 (35)	53 (33)	27 (31)	48 (34)	50 (30)	27 (21)	18 (14)	30 (19)
25+ years	21 (70)	48 (58)	31 (65)	108 (67)	59 (69)	93 (65)	114 (70)	100 (79)	115 (86)	130 (81)
Not reported	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)	0 (0)	0 (0)	1 (<1)
Median age 1 st injection	17	18	18	18	18	18	17	18	18	17
Age range	14-34	12-33	12-36	11-44	11-42	12-42	12-43	12-46	12-46	10-40
N° not reported	0	4	0	6	2	12	7	5	6	5
Median years injection	10.5	7	7	8	8	8	10	11	14	13
Range	<1-23	1-29	2-32	<1-27	<1-28	<1-28	<1-35	<1-35	<1-39	<1-46
Time since first injection										
≤3 years	8 (27)	25 (30)	9 (19)	32 (20)	15 (17)	23 (16)	28 (17)	15 (12)	15 (11)	13 (8)
4+ years	22 (74)	53 (64)	39 (81)	122 (76)	69 (80)	105 (73)	129 (79)	107 (84)	111 (83)	142 (88)
Not reported	0 (0)	5 (6)	0 (0)	7 (4)	2 (2)	15 (10)	7 (4)	5 (4)	7 (5)	6 (4)

Table 9.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

Western Australia	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Number of sites	3	3	2	2	2	3	3	3	3	3
N° surveyed	N=170	N=160	N=110	N=196	N=222	N=219	N=192	N=186	N=220	N=225
Response rate	48%	53%	51%	73%	80%	56%	77%	79%	77%	82%
Gender (%)										
Male	110 (65)	104 (65)	71 (65)	123 (63)	134 (60)	127 (58)	114 (59)	121 (65)	135 (61)	142 (63)
Female	60 (35)	55 (34)	39 (35)	73 (37)	87 (39)	92 (42)	77 (40)	64 (34)	83 (38)	81 (36)
Transgender	0 (0)	1 (<1)	0 (0)	0 (0)	1 (<1)	0 (0)	1 (<1)	1 (<1)	1 (<1)	2 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (<1)	0 (0)
Sexual identity (%)										
Heterosexual	138 (81)	135 (84)	93 (85)	158 (81)	185 (83)	183 (84)	159 (83)	150 (81)	177 (80)	184 (82)
Bisexual	14 (8)	14 (9)	8 (7)	22 (11)	15 (7)	14 (6)	17 (9)	17 (9)	19 (9)	25 (11)
Homosexual	8 (5)	7 (4)	7 (6)	7 (4)	10 (5)	8 (4)	9 (5)	4 (2)	7 (3)	6 (3)
Not reported	10 (6)	4 (3)	2 (2)	9 (5)	12 (5)	14 (6)	7 (4)	15 (8)	17 (8)	10 (4)
Age and time since first injection (years)										
Median age	36	35	36.5	35	36	40	40	40	39	41
Age range	17-57	16-68	16-55	17-65	15-62	18-63	16-64	20-65	15-66	18-67
Age group (%)										
≤24 years	31 (18)	18 (11)	10 (9)	12 (6)	16 (7)	8 (4)	8 (4)	4 (2)	13 (6)	6 (3)
25+ years	139 (82)	142 (89)	100 (91)	183 (93)	206 (93)	211 (96)	183 (95)	181 (97)	204 (93)	217 (96)
Not reported	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	0 (0)	1 (<1)	1 (<1)	3 (1)	2 (1)
Median age 1st injection	18	18	18	18	18	18	19	19	19	18
Age range	12-40	12-46	12-49	11-47	11-52	11-50	11-47	10-53	12-50	11-45
N° not reported	3	0	2	5	7	3	5	6	9	5
Median years injection	15	15	15	15	16	18	18	19	17	20
Range	<1-37	<1-41	<1-37	<1-42	<1-44	<1-47	<1-45	<1-47	<1-49	<1-49
Time since first injection										
≤3 years	6 (4)	10 (6)	11 (10)	12 (6)	12 (5)	11 (5)	11 (6)	7 (4)	18 (8)	9 (4)
4+ years	161 (95)	148 (93)	97 (88)	179 (91)	203 (91)	204 (93)	175 (91)	173 (93)	193 (88)	210 (93)
Not reported	5 (4)	2 (1)	2 (2)	5 (3)	7 (3)	4 (2)	6 (3)	6 (3)	9 (4)	6 (3)

Table 9.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Western Australia										
N° surveyed	N=30	N=83	N=48	N=161	N=86	N=143	N=164	N=127	N=133	N=161
Aboriginal and Torres Strait Islander origin (%)										
No	30 (100)	80 (97)	45 (94)	143 (89)	78 (91)	128 (90)	154 (94)	123 (97)	122 (92)	146 (91)
Yes	0 (0)	2 (2)	3 (6)	14 (9)	6 (7)	10 (7)	10 (6)	1 (1)	7 (5)	9 (5)
Not reported	0 (0)	1 (1)	0 (0)	4 (2)	2 (2)	5 (3)	0 (0)	3 (2)	4 (3)	6 (4)
Region/country of birth (%)										
Australia	--	--	--	--	80 (93)	102 (72)	128 (78)	98 (77)	105 (79)	123 (76)
Other Oceania	--	--	--	--	--	7 (5)	7 (4)	3 (2)	6 (4)	6 (4)
Asia	--	--	--	--	0 (0)	3 (2)	1 (1)	6 (5)	0 (0)	5 (3)
UK & Ireland	--	--	--	--	--	19 (13)	17 (10)	9 (7)	14 (11)	17 (11)
Other	--	--	--	--	0 (0)	9 (6)	9 (6)	7 (6)	6 (4)	7 (4)
Not reported	--	--	--	--	6 (7)	3 (2)	2 (1)	4 (3)	2 (2)	3 (2)
Main language spoken at home by parents (%)										
English	--	--	--	--	80 (93)	127 (89)	151 (92)	111 (87)	127 (96)	113 (70)
Non-English	--	--	--	--	0 (0)	13 (9)	7 (4)	10 (8)	3 (2)	15 (9)
Not reported	--	--	--	--	6 (7)	3 (2)	6 (4)	6 (5)	3 (2)	33 (21)
Imprisonment last year (%)										
No	25 (83)	68 (82)	39 (81)	133 (83)	75 (87)	116 (81)	133 (81)	113 (89)	110 (83)	127 (79)
Yes	3 (10)	12 (14)	7 (15)	24 (15)	11 (13)	25 (18)	26 (16)	13 (10)	19 (14)	32 (20)
Not reported	2 (7)	3 (4)	2 (4)	4 (2)	0 (0)	2 (1)	5 (3)	1 (1)	4 (3)	2 (1)
Injected in prison last year (%)										
N° in prison	N=3	N=12	N=7	N=24	N=11	N=25	N=26	N=13	N=19	N=32
Injected in prison	2 (67)	4 (33)	3 (43)	8 (33)	2 (18)	10 (40)	14 (54)	4 (31)	7 (37)	17 (53)
Frequency of injection last month (%)										
Not last month	1 (3)	10 (12)	1 (2)	16 (10)	5 (6)	7 (5)	9 (5)	15 (12)	3 (2)	12 (7)
Less than weekly	4 (13)	16 (19)	9 (19)	24 (15)	13 (15)	12 (9)	24 (15)	25 (20)	19 (14)	18 (11)
Weekly not daily	13 (44)	25 (30)	5 (10)	34 (21)	16 (19)	36 (25)	40 (25)	29 (23)	32 (24)	42 (26)
Daily or more	12 (40)	31 (38)	33 (69)	85 (53)	52 (60)	79 (55)	87 (53)	56 (43)	75 (56)	83 (52)
Not reported	0 (0)	1 (1)	0 (0)	2 (1)	0 (0)	9 (6)	4 (2)	2 (2)	4 (3)	6 (4)

Table 9.1.1 Number (percentage) of respondents by demographic characteristic and year (continued)

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Western Australia										
N° surveyed	N=170	N=160	N=110	N=196	N=222	N=219	N=192	N=186	N=220	N=225
Aboriginal and Torres Strait Islander origin (%)										
No	157 (92)	153 (96)	102 (93)	179 (91)	208 (94)	200 (91)	177 (92)	166 (89)	191 (87)	200 (89)
Yes	10 (6)	4 (3)	5 (5)	9 (5)	12 (5)	11 (5)	13 (7)	16 (9)	15 (7)	19 (8)
Not reported	3 (2)	3 (2)	3 (3)	8 (4)	2 (1)	8 (4)	2 (1)	4 (2)	14 (6)	6 (3)
Region/country of birth (%)										
Australia	138 (82)	130 (81)	90 (82)	149 (76)	179 (81)	176 (80)	150 (78)	150 (95)	172 (78)	176 (78)
Other Oceania	6 (4)	3 (2)	1 (1)	16 (8)	8 (4)	13 (6)	11 (6)	12 (6)	10 (5)	10 (4)
Asia	2 (1)	0 (0)	1 (1)	2 (1)	5 (2)	3 (1)	3 (2)	1 (<1)	1 (<1)	2 (1)
UK & Ireland	16 (9)	12 (8)	9 (8)	18 (9)	18 (8)	16 (7)	19 (10)	14 (8)	19 (9)	18 (8)
Other	6 (4)	11 (7)	5 (5)	7 (4)	7 (3)	7 (3)	9 (5)	8 (4)	14 (6)	16 (7)
Not reported	2 (1)	4 (3)	4 (4)	4 (2)	5 (2)	4 (2)	0 (0)	1 (<1)	4 (2)	3 (1)
Main language spoken at home by parents (%)										
English	143 (85)	144 (90)	105 (95)	186 (86)	216 (97)	208 (95)	186 (97)	176 (95)	205 (93)	211 (94)
Non-English	26 (15)	6 (4)	2 (2)	10 (5)	5 (2)	7 (3)	6 (3)	9 (5)	11 (5)	12 (5)
Not reported	1 (<1)	10 (6)	3 (3)	0 (0)	1 (<1)	4 (2)	0 (0)	1 (<1)	4 (2)	2 (1)
Imprisonment last year (%)										
No	146 (86)	130 (81)	85 (77)	168 (86)	193 (87)	160 (73)	162 (84)	159 (85)	178 (81)	175 (78)
Yes	18 (11)	21 (13)	18 (16)	21 (11)	21 (9)	16 (7)	16 (8)	20 (11)	17 (8)	24 (11)
Not reported	6 (4)	9 (6)	7 (6)	7 (4)	8 (4)	43 (20)	14 (7)	7 (4)	25 (11)	26 (12)
Injected in prison last year (%)										
N° in prison	N=18	N=21	N=18	N=21	N=21	N=16	N=16	N=20	N=17	N=24
Injected in prison	11 (61)	7 (33)	6 (33)	8 (38)	7 (33)	3 (19)	4 (25)	4 (20)	2 (12)	11 (46)
Frequency of injection last month (%)										
Not last month	7 (4)	5 (3)	6 (5)	7 (4)	6 (3)	11 (5)	11 (6)	8 (4)	19 (9)	16 (7)
Less than weekly	18 (11)	20 (13)	9 (8)	15 (8)	22 (10)	29 (13)	27 (14)	27 (15)	28 (13)	23 (10)
Weekly not daily	38 (22)	42 (26)	21 (19)	49 (25)	43 (19)	48 (22)	46 (24)	36 (19)	38 (17)	36 (16)
Daily or more	106 (63)	92 (58)	73 (66)	124 (63)	150 (68)	131 (60)	106 (55)	112 (60)	124 (56)	146 (65)
Not reported	1 (<1)	1 (<1)	1 (1)	1 (1)	1 (<1)	0 (0)	2 (1)	3 (2)	11 (5)	4 (2)
Experienced overdose in the previous 12 months										
Yes	--	--	--	--	--	--	--	--	25 (11)	49 (22)

Table 9.1.2 Number (percentage) of respondents by drug last injected and year

Western Australia N° surveyed	1995 N=30	1996 N=83	1997 N=48	1998 N=161	1999 N=86	2000 N=143	2001 N=164	2002 N=127	2003 N=133	2004 N=161
Drug last injected (%)										
Cocaine	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	2 (1)	0 (0)	0 (0)	1 (1)
Methamphetamine	10 (33)	12 (14)	6 (13)	35 (22)	16 (19)	33 (23)	92 (56)	50 (39)	55 (41)	74 (46)
Heroin	13 (43)	56 (68)	32 (67)	101 (62)	57 (66)	71 (49)	24 (15)	25 (19)	39 (29)	31 (19)
Pharm. opioids	4 (13)	7 (8)	3 (6)	9 (5)	6 (7)	7 (5)	19 (12)	10 (8)	12 (9)	18 (11)
Methadone	0 (0)	0 (0)	2 (4)	0 (0)	2 (2)	3 (2)	4 (2)	6 (5)	1 (1)	3 (2)
Buprenorphine	--	--	--	--	--	--	--	5 (4)	1 (1)	4 (2)
Buprenorphine/naloxone	--	--	--	--	--	--	--	--	--	--
PIEDs	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	2 (2)	1 (1)	0 (0)
More than one	2 (7)	4 (5)	2 (4)	11 (7)	5 (6)	16 (11)	14 (9)	15 (12)	9 (7)	22 (14)
Other	1 (3)	4 (5)	3 (6)	1 (1)	0 (0)	1 (1)	5 (3)	10 (8)	11 (8)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	3 (2)	0 (0)	10 (7)	4 (2)	4 (3)	4 (3)	8 (5)

Western Australia N° surveyed	2005 N=170	2006 N=160	2007 N=110	2008 N=196	2009 N=222	2010 N=219	2011 N=192	2012 N=186	2013 N=220	2014 N=225
Drug last injected (%)										
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)	0 (0)	1 (<1)	1 (<1)	3 (1)	0 (0)
Methamphetamine	57 (34)	72 (45)	34 (31)	54 (28)	43 (19)	58 (26)	65 (34)	59 (32)	79 (36)	78 (35)
Heroin	48 (28)	30 (19)	28 (25)	62 (32)	74 (33)	66 (30)	48 (25)	48 (26)	51 (23)	79 (35)
Pharm. opioids	24 (14)	19 (12)	23 (21)	42 (21)	37 (17)	31 (14)	34 (18)	28 (15)	28 (13)	20 (9)
Methadone	6 (4)	9 (6)	4 (4)	5 (3)	12 (5)	13 (6)	12 (6)	6 (3)	10 (5)	6 (3)
Buprenorphine	19 (11)	16 (10)	7 (6)	18 (9)	16 (7)	8 (4)	8 (4)	11 (6)	9 (4)	4 (2)
Buprenorphine/naloxone	--	--	--	--	4 (2)	10 (5)	11 (6)	9 (5)	13 (6)	7 (3)
PIEDs	0 (0)	2 (1)	0 (0)	0 (0)	1 (<1)	1 (<1)	0 (0)	1 (<1)	5 (2)	6 (3)
More than one	4 (2)	7 (4)	5 (5)	10 (5)	25 (11)	22 (10)	12 (6)	19 (10)	18 (8)	23 (10)
Other	5 (3)	4 (3)	6 (6)	0 (0)	0 (0)	4 (2)	0 (0)	1 (<1)	1 (<1)	1 (<1)
Not reported	7 (4)	1 (<1)	3 (3)	5 (3)	8 (4)	6 (3)	1 (<1)	3 (2)	3 (1)	1 (<1)

Table 9.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year

Western Australia N° injected last month	1995 N=29	1996 N=72	1997 N=47	1998 N=143	1999 N=81	2000 N=127	2001 N=151	2002 N=110	2003 N=126	2004 N=143
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	--	--	--	--	39 (48)	46 (36)	53 (35)	25 (23)	28 (22)	32 (22)
Water	--	--	--	--	22 (27)	31 (25)	40 (26)	22 (20)	22 (17)	28 (20)
Filter	--	--	--	--	21 (26)	30 (24)	36 (24)	19 (17)	16 (13)	23 (16)
Drug mix	--	--	--	--	14 (17)	17 (13)	35 (23)	13 (12)	6 (5)	17 (12)
None	--	--	--	--	--	--	--	--	--	--
Public injecting in last month (%)										
Any public	--	--	21 (45)	67 (47)	47 (58)	77 (61)	76 (50)	54 (49)	54 (43)	67 (47)
All private	--	--	25 (53)	68 (48)	28 (35)	41 (32)	75 (50)	52 (47)	68 (54)	69 (48)
Not reported	--	--	1 (2)	8 (6)	6 (7)	9 (7)	0 (0)	4 (4)	4 (3)	7 (5)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	--	--	--	--	70 (86)	109 (86)	133 (88)	98 (89)	113 (90)	128 (90)
Pharmacy	--	--	--	--	59 (73)	85 (67)	91 (60)	58 (53)	74 (59)	67 (47)

Western Australia N° injected last month	2005 N=163	2006 N=154	2007 N=103	2008 N=188	2009 N=215	2010 N=208	2011 N=179	2012 N=175	2013 N=190	2014 N=205
Equipment used after someone else last month (%) [more than one could be selected]										
Spoon	31 (19)	25 (16)	22 (22)	37 (23)	48 (24)	36 (17)	42 (23)	39 (22)	49 (26)	44 (21)
Water	31 (19)	27 (18)	14 (14)	29 (18)	37 (19)	28 (13)	15 (8)	30 (17)	43 (23)	41 (20)
Filter	25 (16)	23 (15)	13 (13)	20 (12)	35 (18)	23 (11)	17 (10)	27 (15)	24 (13)	23 (11)
Drug mix	16 (10)	17 (11)	12 (12)	20 (12)	20 (10)	19 (9)	11 (6)	18 (10)	16 (8)	17 (8)
None	--	97 (63)	63 (64)	100 (61)	131 (66)	126 (61)	107 (60)	107 (61)	116 (61)	139 (68)
Public injecting in last month (%)										
Any public	61 (38)	66 (43)	50 (49)	103 (55)	105 (49)	88 (42)	75 (42)	61 (35)	95 (50)	89 (43)
All private	81 (50)	82 (53)	48 (47)	83 (44)	110 (51)	97 (47)	91 (51)	105 (60)	92 (48)	112 (55)
Not reported	20 (12)	6 (4)	5 (5)	2 (1)	0 (0)	23 (11)	13 (7)	9 (5)	3 (2)	4 (2)
Needle/syringe acquisition in the last month (%) [more than one could be selected]										
Needle Syringe Program	148 (91)	142 (92)	52 (50)	159 (85)	102 (47)	175 (84)	154 (86)	134 (77)	160 (84)	167 (81)
Pharmacy	65 (40)	77 (50)	35 (34)	96 (51)	72 (33)	55 (26)	44 (25)	60 (34)	58 (31)	53 (26)

Table 9.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

Western Australia N° injected last month	1995 N=29	1996 N=72	1997 N=47	1998 N=143	1999 N=81	2000 N=127	2001 N=151	2002 N=110	2003 N=126	2004 N=143
Use of sterile needles and syringes last month (%)										
All injections	--	--	32 (68)	79 (55)	35 (43)	66 (52)	84 (55)	69 (63)	78 (62)	91 (64)
Most of the time	--	--	14 (30)	42 (29)	32 (40)	45 (36)	50 (33)	31 (28)	38 (30)	37 (26)
Half of the time	--	--	0 (0)	10 (7)	8 (10)	8 (6)	6 (4)	7 (6)	5 (4)	8 (5)
Some of the time	--	--	1 (2)	7 (5)	3 (4)	3 (2)	6 (4)	2 (2)	4 (3)	6 (4)
Not last month	--	--	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	0 (0)	0 (0)	0 (0)
Not reported	--	--	0 (0)	5 (4)	2 (2)	5 (4)	4 (3)	1 (1)	1 (1)	1 (1)
Re-used someone else's used needle & syringe last month (%)										
None	20 (69)	57 (78)	37 (79)	106 (75)	55 (68)	83 (65)	108 (72)	91 (82)	100 (79)	110 (77)
Once	3 (10)	4 (6)	4 (9)	6 (4)	1 (1)	13 (10)	11 (7)	5 (5)	7 (6)	10 (7)
Twice	2 (7)	4 (6)	2 (4)	13 (9)	10 (13)	8 (6)	15 (10)	5 (5)	7 (6)	11 (8)
3-5 times	2 (7)	3 (4)	3 (6)	6 (4)	6 (7)	9 (7)	8 (5)	4 (4)	5 (4)	7 (5)
>5 times	2 (7)	4 (6)	1 (2)	6 (4)	7 (9)	10 (8)	4 (3)	3 (3)	4 (3)	4 (3)
Not reported	0 (0)	0 (0)	0 (0)	6 (4)	2 (2)	4 (3)	5 (3)	2 (2)	3 (2)	1 (<1)
Number of people needle & syringe was re-used after last month (%)										
None	20 (69)	57 (79)	37 (79)	106 (75)	55 (68)	83 (65)	108 (72)	91 (82)	97 (77)	110 (77)
One	4 (14)	8 (11)	8 (17)	25 (16)	11 (14)	27 (22)	22 (14)	10 (9)	19 (15)	12 (8)
Two	4 (14)	6 (8)	2 (4)	4 (3)	6 (8)	5 (4)	5 (3)	2 (2)	3 (2)	5 (4)
Three to five	1 (3)	1 (2)	0 (0)	1 (1)	2 (2)	2 (2)	4 (3)	1 (1)	1 (1)	1 (1)
More than five	0 (0)	0 (0)	0 (0)	0 (0)	3 (4)	3 (2)	1 (1)	0 (0)	1 (1)	0 (0)
Don't know	0 (0)	0 (0)	0 (0)	1 (1)	2 (2)	3 (2)	4 (3)	3 (3)	0 (0)	9 (6)
Not reported	0 (0)	0 (0)	0 (0)	6 (4)	2 (2)	4 (3)	7 (4)	3 (3)	5 (4)	6 (4)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	--	--	5 (11)	20 (14)	16 (20)	22 (17)	17 (11)	7 (6)	14 (11)	10 (7)
Casual sex partner	--	--	1 (2)	1 (1)	0 (0)	2 (2)	2 (1)	0 (0)	0 (0)	2 (1)
Close friend	--	--	2 (4)	12 (8)	8 (10)	11 (9)	15 (10)	6 (5)	7 (6)	12 (8)
Acquaintance	--	--	1 (2)	1 (2)	7 (9)	4 (3)	9 (6)	3 (3)	3 (2)	1 (1)
Other	--	--	1 (4)	0 (0)	6 (7)	4 (3)	1 (1)	1 (1)	0 (0)	2 (1)

Table 9.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year (continued)

Western Australia N° injected last month	2005 N=163	2006 N=154	2007 N=103	2008 N=188	2009 N=215	2010 N=208	2011 N=179	2012 N=175	2013 N=190	2014 N=205
Use of sterile needles and syringes last month (%)										
All injections	103 (64)	102 (66)	58 (56)	119 (63)	148 (69)	131 (63)	126 (70)	118 (67)	128 (67)	141 (69)
Most of the time	44 (27)	40 (26)	29 (28)	56 (30)	56 (26)	47 (23)	33 (18)	34 (19)	50 (26)	47 (23)
Half of the time	5 (3)	6 (4)	6 (6)	5 (3)	4 (2)	5 (2)	2 (1)	5 (3)	3 (2)	4 (2)
Some of the time	4 (2)	3 (2)	7 (7)	3 (2)	3 (1)	2 (1)	6 (3)	6 (3)	4 (2)	5 (2)
Not last month	1 (1)	1 (<1)	0 (0)	3 (2)	1 (<1)	0 (0)	0 (0)	1 (<1)	2 (1)	2 (1)
Not reported	6 (3)	2 (1)	3 (3)	2 (1)	3 (1)	23 (11)	12 (7)	11 (6)	3 (2)	6 (3)
Re-used someone else's used needle & syringe last month (%)										
None	124 (77)	127 (82)	75 (73)	150 (80)	168 (78)	151 (73)	131 (73)	128 (73)	148 (78)	157 (77)
Once	7 (4)	8 (5)	10 (10)	11 (6)	13 (6)	8 (4)	7 (4)	15 (9)	11 (6)	15 (7)
Twice	9 (6)	4 (3)	1 (1)	10 (5)	12 (6)	13 (6)	9 (5)	7 (4)	7 (4)	7 (3)
3-5 times	8 (5)	5 (3)	11 (11)	8 (4)	12 (6)	4 (2)	9 (5)	9 (5)	10 (5)	11 (5)
>5 times	3 (2)	6 (4)	3 (3)	8 (4)	6 (3)	4 (2)	9 (5)	6 (3)	8 (4)	9 (4)
Not reported	11 (7)	4 (3)	3 (3)	1 (1)	4 (2)	28 (13)	14 (8)	10 (6)	6 (3)	6 (3)
Number of people needle & syringe was re-used after last month (%)										
None	119 (73)	127 (82)	75 (73)	150 (80)	168 (78)	151 (73)	131 (73)	128 (73)	148 (78)	157 (77)
One	17 (10)	14 (9)	13 (13)	16 (9)	23 (11)	16 (8)	20 (11)	14 (8)	18 (9)	16 (8)
Two	3 (2)	0 (0)	0 (0)	2 (1)	5 (2)	4 (2)	1 (<1)	3 (2)	4 (2)	1 (<1)
Three to five	1 (1)	1 (<1)	1 (1)	1 (1)	1 (<1)	1 (<1)	2 (1)	1 (<1)	2 (1)	3 (1)
More than five	2 (1)	3 (2)	1 (1)	0 (0)	1 (<1)	1 (<1)	3 (2)	5 (3)	2 (1)	6 (3)
Don't know	5 (3)	4 (3)	4 (4)	8 (4)	6 (3)	5 (2)	4 (2)	5 (3)	6 (3)	6 (3)
Not reported	16 (9)	5 (3)	9 (9)	11 (6)	11 (5)	30 (14)	18 (10)	19 (11)	10 (5)	16 (8)
Relationship to people needle & syringe was used after last month (%) [more than one could be selected]										
Regular sex partner	15 (9)	9 (6)	12 (12)	16 (9)	18 (8)	21 (10)	19 (11)	10 (6)	17 (9)	15 (7)
Casual sex partner	2 (1)	0 (0)	1 (1)	3 (2)	0 (0)	2 (1)	2 (1)	1 (<1)	3 (2)	2 (1)
Close friend	11 (7)	9 (6)	7 (7)	8 (4)	13 (6)	11 (5)	8 (4)	13 (7)	11 (6)	9 (4)
Acquaintance	4 (2)	1 (<1)	0 (0)	3 (2)	5 (2)	6 (3)	5 (3)	7 (4)	9 (5)	3 (1)
Other	3 (1)	0 (0)	1 (1)	2 (1)	5 (2)	3 (1)	5 (3)	3 (2)	7 (4)	5 (2)

Table 9.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year

Western Australia N° surveyed	1995 N=30	1996 N=83	1997 N=48	1998 N=161	1999 N=86	2000 N=143	2001 N=164	2002 N=127	2003 N=133	2004 N=161
Sex last month (%)										
No	11 (37)	31 (37)	16 (33)	42 (26)	26 (30)	44 (31)	45 (27)	33 (26)	40 (30)	51 (32)
Yes	19 (63)	50 (61)	30 (63)	116 (72)	59 (69)	98 (68)	118 (72)	89 (70)	89 (67)	103 (64)
Not reported	0 (0)	2 (2)	2 (4)	3 (2)	1 (1)	1 (1)	1 (1)	5 (4)	4 (3)	7 (4)
Condom use at last sex (%)										
No	13 (43)	31 (37)	29 (61)	94 (58)	64 (74)	84 (59)	122 (75)	89 (70)	97 (73)	116 (72)
Yes	8 (27)	20 (24)	17 (35)	63 (39)	22 (26)	53 (37)	38 (23)	36 (28)	31 (23)	43 (27)
Not reported	9 (30)	32 (39)	2 (4)	4 (3)	0 (0)	6 (4)	4 (2)	2 (2)	5 (4)	2 (1)
Condom use with regular sex partner(s) last month (%)										
No	--	27 (57)	13 (48)	58 (62)	39 (76)	52 (64)	53 (70)	44 (73)	42 (74)	51 (73)
Sometimes	--	6 (13)	6 (22)	15 (16)	4 (8)	10 (12)	8 (10)	7 (12)	3 (5)	5 (7)
Always	--	14 (30)	8 (30)	20 (22)	8 (16)	20 (24)	15 (20)	9 (15)	12 (21)	14 (20)
Condom use with new sex partner(s) last month (%)										
No	--	6 (35)	4 (31)	13 (33)	7 (35)	10 (28)	33 (53)	20 (51)	15 (50)	26 (49)
Sometimes	--	0 (0)	1 (8)	9 (22)	3 (15)	7 (19)	9 (15)	8 (21)	5 (17)	6 (11)
Always	--	11 (65)	8 (61)	18 (45)	10 (50)	19 (53)	20 (32)	11 (28)	10 (33)	21 (40)
Condom use with casual sex partner(s) last month (%)										
No	--	--	--	17 (38)	7 (32)	9 (23)	28 (47)	19 (51)	13 (50)	20 (43)
Sometimes	--	--	--	7 (16)	1 (4)	9 (23)	12 (20)	5 (14)	2 (8)	5 (11)
Always	--	--	--	21 (46)	14 (64)	21 (54)	20 (33)	13 (35)	11 (42)	21 (46)
Sex work last month (%)										
No	26 (86)	76 (92)	36 (75)	136 (85)	78 (91)	126 (88)	152 (93)	115 (91)	115 (86)	141 (88)
Yes	2 (7)	7 (8)	8 (17)	20 (12)	8 (9)	15 (11)	8 (5)	8 (6)	13 (10)	16 (10)
Not reported	2 (7)	0 (0)	4 (8)	5 (3)	0 (0)	2 (1)	4 (2)	4 (3)	5 (4)	4 (2)
Condom used at last sex work (%)										
Yes	1 (50)	5 (71)	7 (88)	17 (89)	7 (88)	12 (92)	6 (86)	6 (75)	11 (85)	13 (81)

Table 9.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year (continued)

Western Australia N° surveyed	2005 N=170	2006 N=160	2007 N=110	2008 N=196	2009 N=222	2010 N=219	2011 N=192	2012 N=186	2013 N=220	2014 N=225
Sex with a regular partner last month (%)										
No	86 (51)	77 (48)	42 (38)	81 (41)	103 (46)	99 (45)	86 (45)	105 (56)	108 (49)	113 (50)
Yes	82 (49)	77 (48)	66 (60)	113 (58)	113 (51)	109 (50)	93 (48)	74 (40)	96 (44)	93 (41)
Not reported	2 (1)	6 (4)	2 (2)	2 (1)	6 (3)	11 (5)	13 (7)	7 (4)	16 (7)	19 (8)
Condom used with regular partner last month (%)										
Never	N=82	N=77	N=66	N=113	N=113	N=109	N=93	N=74	N=96	N=93
Sometimes	59 (72)	57 (74)	46 (70)	80 (71)	89 (79)	77 (71)	70 (75)	56 (76)	70 (73)	73 (78)
Every time	9 (11)	9 (12)	8 (12)	12 (11)	12 (11)	12 (11)	10 (11)	8 (11)	13 (14)	8 (9)
Not reported	11 (13)	5 (6)	8 (12)	14 (12)	5 (4)	12 (11)	10 (11)	6 (8)	8 (8)	7 (8)
Not reported	4 (5)	6 (8)	4 (6)	7 (6)	7 (6)	8 (7)	3 (3)	4 (5)	5 (5)	5 (5)
Sex with other partner(s) last month (%)										
No	134 (79)	124 (78)	97 (88)	164 (84)	180 (81)	187 (85)	163 (85)	147 (79)	159 (72)	169 (75)
Yes	32 (19)	29 (18)	11 (10)	29 (15)	32 (14)	22 (10)	24 (13)	28 (15)	39 (18)	34 (15)
Not reported	4 (2)	7 (4)	2 (2)	3 (2)	10 (5)	10 (5)	5 (3)	11 (6)	22 (10)	22 (10)
Condom used with other partner(s) last month (%)										
Never	N=32	N=29	N=11	N=29	N=32	N=22	N=24	N=28	N=39	N=34
Sometimes	8 (25)	10 (34)	2 (18)	6 (21)	12 (38)	8 (36)	11 (46)	14 (50)	12 (31)	14 (41)
Every time	10 (31)	3 (10)	4 (36)	14 (48)	9 (28)	6 (27)	5 (21)	8 (29)	12 (31)	9 (26)
Not reported	13 (41)	14 (48)	5 (45)	7 (24)	11 (34)	8 (36)	7 (29)	5 (18)	14 (36)	7 (21)
Not reported	1 (3)	2 (7)	0 (0)	2 (7)	0 (0)	0 (0)	1 (4)	1 (4)	1 (3)	4 (12)
Sex work last month (%)										
No	160 (94)	145 (91)	99 (90)	177 (90)	203 (91)	200 (91)	173 (90)	169 (91)	188 (85)	181 (80)
Yes	8 (5)	10 (6)	4 (4)	11 (6)	11 (5)	6 (3)	10 (5)	11 (6)	11 (5)	14 (6)
Not reported	2 (1)	5 (3)	7 (6)	8 (4)	8 (4)	13 (6)	9 (5)	6 (3)	21 (10)	30 (13)
Condom used at last sex work (%)										
Yes	4 (50)	7 (88)	4 (100)	9 (82)	8 (73)	5 (83)	8 (80)	8 (80)	9 (90)	6 (55)

Table 9.1.5 Number (percentage) of respondents by testing for HIV and HCV infection by year

Western Australia N° surveyed	1995 N=30	1996 N=83	1997 N=48	1998 N=161	1999 N=86	2000 N=143	2001 N=164	2002 N=127	2003 N=133	2004 N=161
Previous HIV test (%)										
Yes, ever	26 (87)	71 (86)	46 (96)	141 (96)	81 (94)	127 (89)	146 (89)	112 (88)	120 (90)	139 (86)
Yes, last year	13 (43)	62 (75)	35 (73)	107 (66)	62 (72)	104 (73)	100 (61)	75 (59)	90 (68)	100 (62)
>1 year ago	11 (37)	8 (10)	11 (23)	34 (21)	19 (22)	23 (16)	46 (28)	37 (29)	30 (23)	39 (24)
Never tested	2 (7)	1 (1)	0 (0)	18 (11)	5 (6)	16 (11)	17 (10)	15 (12)	12 (9)	21 (13)
Not reported	4 (13)	12 (14)	2 (4)	2 (1)	0 (0)	0 (0)	1 (1)	0 (0)	1 (1)	1 (1)
Previous HCV test (%)										
Yes, ever	25 (83)	63 (76)	44 (92)	140 (87)	81 (94)	128 (90)	149 (91)	110 (87)	123 (92)	136 (84)
Yes, last year	--	--	34 (71)	117 (73)	61 (71)	112 (78)	115 (70)	81 (70)	94 (71)	106 (66)
>1 year ago	--	--	10 (21)	23 (14)	20 (23)	16 (11)	34 (21)	29 (21)	29 (22)	30 (19)
Never tested	3 (10)	17 (20)	2 (4)	18 (11)	5 (6)	14 (10)	15 (9)	17 (13)	9 (7)	23 (14)
Not reported	2 (7)	3 (4)	2 (4)	3 (2)	0 (0)	1 (1)	0 (0)	0 (0)	1 (1)	2 (1)
Western Australia N° surveyed										
2005 N=170										
2006 N=160										
2007 N=110										
2008 N=196										
2009 N=222										
2010 N=219										
2011 N=192										
2012 N=186										
2013 N=220										
2014 N=225										
Previous HIV test (%)										
Yes, ever	144 (85)	144 (90)	96 (87)	174 (89)	189 (85)	173 (79)	167 (87)	148 (80)	167 (76)	173 (77)
Yes, last year	96 (56)	83 (52)	58 (53)	99 (51)	111 (50)	113 (52)	104 (54)	81 (44)	95 (43)	98 (44)
>1 year ago	48 (28)	61 (38)	38 (35)	75 (38)	78 (35)	60 (27)	63 (33)	67 (36)	72 (33)	75 (33)
Never tested	25 (15)	12 (8)	12 (11)	14 (7)	26 (12)	33 (15)	19 (10)	28 (15)	39 (18)	36 (16)
Not reported	1 (1)	4 (3)	2 (2)	8 (4)	7 (3)	13 (6)	6 (3)	10 (5)	14 (6)	16 (7)
Previous HCV test (%)										
Yes, ever	149 (88)	146 (91)	96 (87)	173 (88)	199 (90)	187 (85)	173 (90)	165 (89)	167 (76)	190 (84)
Yes, last year	103 (61)	94 (59)	62 (56)	108 (55)	128 (58)	124 (57)	115 (60)	96 (52)	106 (48)	113 (50)
>1 year ago	45 (27)	52 (33)	34 (31)	65 (33)	71 (32)	63 (29)	58 (30)	69 (37)	61 (28)	77 (34)
Never tested	19 (11)	11 (7)	11 (10)	15 (8)	15 (7)	13 (6)	8 (4)	10 (5)	25 (11)	14 (6)
Not reported	3 (2)	3 (2)	3 (3)	8 (4)	8 (4)	19 (9)	11 (6)	11 (6)	28 (13)	21 (9)

Table 9.1.6 Number (percentage) of respondents by HCV treatment by year

	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Western Australia					N=28	N=49	N=60	N=38	N=56	N=62
Self-report HCV diagnosis	--	--	--	--	--	--	--	--	--	--
Any treatment for HCV (%)										
Interferon +/- Ribavirin	--	--	--	--	3 (11)	1 (2)	7 (12)	2 (5)	1 (2)	8 (13)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	0 (0)	3 (6)	2 (3)	1 (3)	1 (2)	0 (0)
No treatment	--	--	--	--	25 (89)	43 (88)	50 (84)	35 (91)	53 (94)	54 (87)
Not reported	--	--	--	--	0 (0)	2 (4)	1 (2)	0 (0)	1 (2)	0 (0)
Current treatment for HCV (%)										
Interferon +/- Ribavirin	--	--	--	--	1	0	2	0	0	3
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	--	--
Other	--	--	--	--	0	2	0	1	1	0

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Western Australia					N=92	N=120	N=106	N=93	N=95	N=114
Self-report HCV diagnosis	N=66	N=65	N=31	N=90	N=92	N=120	N=106	N=93	N=95	N=114
Any treatment for HCV (%)										
Interferon +/- Ribavirin	3 (5)	5 (8)	2 (6)	9 (10)	13 (14)	19 (16)	21 (20)	12 (8)	19 (20)	25 (22)
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	1 (1)	2 (2)
Other	1 (2)	2 (3)	1 (3)	4 (4)	1 (1)	2 (2)	3 (3)	2 (2)	1 (1)	3 (3)
No treatment	62 (94)	54 (83)	27 (87)	75 (83)	72 (78)	92 (77)	77 (73)	77 (83)	69 (73)	76 (67)
Not reported	0 (0)	4 (6)	1 (3)	2 (2)	6 (7)	7 (6)	5 (5)	2 (2)	5 (5)	8 (7)
Current treatment for HCV (%)										
Interferon +/- Ribavirin	2	1	1	3	5	4	6	2	6	3
Teleprevir/Boceprevir&INF-RBV	--	--	--	--	--	--	--	--	0	2
Other	0	1	0	2	0	1	2	2	0	3

Table 9.1.7 Number (percentage) of respondents by drug treatment by year

Western Australia N° surveyed	1995 N=30	1996 N=83	1997 N=48	1998 N=161	1999 N=86	2000 N=143	2001 N=164	2002 N=127	2003 N=133	2004 N=161
Ever any treatment/therapy for drug use (%)										
No	13 (43)	37 (45)	13 (27)	57 (35)	26 (30)	48 (34)	53 (32)	39 (31)	47 (35)	39 (24)
Yes	17 (57)	46 (55)	33 (69)	102 (64)	60 (70)	93 (65)	111 (68)	87 (68)	85 (64)	121 (75)
Not reported	0 (0)	0 (0)	2 (4)	2 (1)	0 (0)	2 (1)	0 (0)	1 (1)	1 (1)	1 (1)
History of methadone maintenance treatment (%)										
Current	11 (37)	20 (24)	20 (42)	35 (22)	26 (30)	28 (20)	37 (22)	22 (17)	27 (20)	28 (17)
Previous	5 (17)	15 (18)	4 (8)	23 (14)	13 (15)	29 (20)	39 (24)	37 (29)	37 (28)	43 (27)
Never	14 (47)	48 (58)	22 (46)	101 (63)	47 (55)	84 (59)	88 (54)	67 (53)	68 (51)	89 (55)
Not reported	0 (0)	0 (0)	2 (4)	2 (1)	0 (0)	2 (1)	0 (0)	1 (1)	1 (1)	1 (1)
History of other pharmacotherapy treatment (%)										
Current	--	--	--	--	--	9 (6)	17 (10)	22 (17)	22 (16)	28 (17)
Previous	--	--	--	--	--	36 (25)	30 (18)	23 (18)	29 (22)	31 (19)
Never	--	--	--	--	--	93 (65)	116 (71)	80 (63)	81 (61)	101 (63)
Not reported	--	--	--	--	--	5 (4)	1 (1)	2 (2)	1 (1)	1 (1)
Western Australia N° surveyed										
2005 N=170										
2006 N=160										
2007 N=110										
2008 N=196										
2009 N=222										
2010 N=219										
2011 N=192										
2012 N=186										
2013 N=220										
2014 N=2378										
Ever any treatment/therapy for drug use (%)										
No	40 (24)	41 (26)	31 (28)	54 (28)	57 (26)	50 (23)	43 (22)	49 (26)	67 (30)	56 (25)
Yes	125 (74)	113 (71)	76 (69)	139 (71)	158 (71)	165 (75)	147 (77)	133 (72)	148 (67)	163 (72)
Not reported	5 (2)	6 (4)	3 (3)	3 (2)	7 (3)	4 (2)	2 (1)	4 (2)	5 (2)	6 (3)
History of methadone maintenance treatment (%)										
Current	50 (29)	30 (19)	21 (19)	39 (20)	53 (24)	55 (25)	41 (21)	35 (19)	39 (18)	41 (18)
Previous	34 (20)	43 (27)	27 (25)	55 (28)	52 (23)	56 (26)	59 (31)	49 (26)	53 (24)	54 (24)
Never	83 (49)	84 (53)	60 (55)	99 (51)	112 (50)	97 (44)	84 (44)	101 (54)	125 (57)	124 (55)
Not reported	3 (2)	3 (2)	2 (2)	3 (2)	5 (2)	11 (5)	8 (4)	1 (<1)	3 (1)	6 (3)
History of other pharmacotherapy treatment (%)										
Current	42 (25)	25 (16)	14 (13)	28 (14)	35 (16)	32 (15)	37 (19)	32 (17)	32 (15)	28 (12)
Previous	29 (17)	34 (21)	34 (31)	52 (27)	41 (18)	43 (20)	36 (19)	32 (17)	48 (22)	57 (25)
Never	95 (56)	96 (60)	58 (53)	114 (58)	144 (65)	144 (66)	114 (59)	121 (65)	135 (61)	135 (60)
Not reported	4 (2)	5 (3)	4 (4)	2 (1)	2 (1)	0 (0)	5 (3)	1 (1)	5 (2)	5 (2)

HIV antibody prevalence

Table 9.2.1 HIV antibody prevalence by gender and year

Western Australia	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
1995	14	2 (14.3)	10	0 (0.0)	24	2 (8.3)
1996	51	1 (2.0)	30	0 (0.0)	83	1 (1.2)
1997	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)
1998	76	1 (1.3)	48	1 (2.1)	126	2 (1.6)
1999	53	0 (0.0)	32	0 (0.0)	85	0 (0.0)
2000	56	0 (0.0)	19	0 (0.0)	75	0 (0.0)
2001	83	0 (0.0)	49	0 (0.0)	134	0 (0.0)
2002	87	0 (0.0)	36	0 (0.0)	123	0 (0.0)
2003	75	0 (0.0)	57	0 (0.0)	133	0 (0.0)
2004	69	0 (0.0)	43	0 (0.0)	113	0 (0.0)
2005	100	3 (3.0)	55	0 (0.0)	155	3 (1.9)
2006	82	1 (1.2)	49	0 (0.0)	132	1 (0.8)
2007	54	1 (1.9)	31	0 (0.0)	85	1 (1.2)
2008	106	2 (1.9)	62	0 (0.0)	168	2 (1.2)
2009	126	1 (0.8)	85	1 (1.2)	212	2 (0.9)
2010	121	0 (0.0)	92	1 (1.1)	213	1 (0.5)
2011	112	1 (0.9)	77	3 (3.9)	190	4 (2.1)
2012	120	0 (0.0)	63	3 (4.8)	184	3 (1.6)
2013	126	3 (2.4)	71	2 (2.8)	199	5 (2.5)
2014	131	1 (0.8)	75	0 (0.0)	208	1 (0.5)
X^2 p trend: 1995-2014		0.599		0.030		0.346
X^2 p trend: 2010-2014		0.245		0.643		0.852

HCV antibody prevalence

Table 9.3.1 HCV antibody prevalence by gender and year

Western Australia	Male		Female		Total	
	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)	N ^o tested	N ^o with HCV (%)
1995	13	6 (46)	10	5 (50)	23	11 (48)
1996	47	17 (37)	30	13 (42)	78	32 (41)
1997	12	6 (50)	7	3 (43)	19	9 (47)
1998	76	32 (42)	48	19 (40)	126	52 (41)
1999	53	28 (53)	32	15 (47)	85	43 (51)
2000	57	27 (47)	21	5 (24)	78	32 (41)
2001	84	49 (58)	51	24 (47)	137	75 (55)
2002	87	34 (39)	37	19 (51)	124	53 (43)
2003	75	47 (63)	57	29 (51)	133	77 (58)
2004	69	42 (61)	43	22 (51)	113	65 (58)
2005	101	59 (58)	55	31 (56)	156	90 (58)
2006	82	46 (56)	49	30 (61)	132	76 (58)
2007	54	23 (43)	31	14 (45)	85	37 (44)
2008	101	59 (58)	59	32 (54)	160	91 (57)
2009	125	60 (48)	85	42 (49)	211	102 (48)
2010	119	65 (55)	92	54 (59)	211	119 (56)
2011	110	69 (63)	73	34 (47)	184	104 (57)
2012	120	71 (59)	64	31 (48)	185	103 (56)
2013	123	66 (54)	71	23 (32)	196	90 (46)
2014	128	72 (56)	75	40 (53)	205	113 (55)
X ² p trend: 1995-2014		0.129		0.671		0.171
X ² p trend: 2010-2014		0.839		0.379		0.529

Table 9.3.2 HCV antibody prevalence by age group, gender and year

Western Australia	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
<25 years	1	0 (0)	7	3 (43)	8	3 (38)
25-34 years	7	3 (43)	1	0 (0)	8	3 (38)
35-44 years	5	3 (60)	2	2 (100)	7	5 (71)
45+ years	0	0 (0)	0	0 (0)	0	0 (0)
1996						
<25 years	17	1 (6)	15	4 (27)	32	5 (16)
25-34 years	16	8 (50)	10	7 (70)	27	16 (59)
35-44 years	13	11 (85)	5	4 (80)	19	16 (84)
45+ years	0	0 (0)	0	0 (0)	0	0 (0)
1997						
<25 years	5	1 (20)	1	0 (0)	6	1 (17)
25-34 years	2	1 (50)	4	1 (25)	6	2 (33)
35-44 years	4	3 (75)	2	2 (100)	6	5 (83)
45+ years	1	1 (100)	0	0 (0)	1	1 (100)
1998						
<25 years	21	4 (19)	22	5 (23)	43	9 (21)
25-34 years	36	13 (36)	16	7 (44)	52	20 (38)
35-44 years	17	13 (76)	9	6 (67)	28	20 (71)
45+ years	2	2 (100)	1	1 (100)	3	3 (100)
1999						
<25 years	13	5 (38)	13	3 (23)	26	8 (31)
25-34 years	22	9 (41)	14	7 (50)	36	16 (44)
35-44 years	13	10 (77)	5	5 (100)	18	15 (83)
45+ years	5	4 (80)	0	0 (0)	5	4 (80)
2000						
<25 years	14	4 (29)	5	0 (0)	19	4 (21)
25-34 years	26	11 (42)	10	3 (30)	36	14 (39)
35-44 years	14	9 (64)	6	2 (33)	20	11 (55)
45+ years	3	3 (100)	0	0 (0)	3	3 (100)
2001						
<25 years	20	6 (30)	18	3 (17)	38	9 (24)
25-34 years	30	16 (53)	17	11 (65)	48	28 (58)
35-44 years	23	18 (78)	14	8 (57)	38	27 (71)
45+ years	11	9 (82)	2	2 (100)	13	11 (85)
2002						
<25 years	19	5 (26)	8	1 (13)	27	6 (27)
25-34 years	29	9 (31)	11	7 (64)	40	16 (40)
35-44 years	24	11 (46)	13	7 (54)	37	18 (49)
45+ years	15	9 (60)	5	4 (80)	20	13 (65)
2003						
<25 years	6	1 (17)	12	3 (25)	18	4 (22)
25-34 years	26	13 (50)	23	10 (43)	50	24 (48)
35-44 years	27	20 (74)	15	9 (60)	42	29 (69)
45+ years	16	13 (81)	7	7 (100)	23	20 (87)
2004						
<25 years	10	2 (20)	7	1 (14)	17	3 (18)
25-34 years	20	10 (50)	13	5 (38)	33	15 (45)
35-44 years	24	17 (71)	13	7 (54)	37	24 (65)
45+ years	15	13 (87)	10	9 (90)	25	22 (88)

Table 9.3.2 HCV antibody prevalence by age group, gender and year (continued)

Western Australia	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<25 years	15	5 (33)	11	4 (36)	26	9 (35)
25-34 years	27	14 (52)	18	7 (39)	45	21 (47)
35-44 years	35	18 (51)	15	11 (73)	50	29 (58)
45+ years	24	22 (92)	11	9 (82)	35	31 (89)
2006						
<25 years	8	5 (63)	4	3 (75)	12	8 (67)
25-34 years	33	14 (42)	18	10 (56)	51	24 (47)
35-44 years	24	13 (54)	16	9 (56)	41	22 (54)
45+ years	17	14 (82)	11	8 (73)	28	22 (79)
2007						
<25 years	6	2 (33)	3	0 (0)	9	2 (22)
25-34 years	18	4 (22)	13	6 (46)	31	10 (32)
35-44 years	16	8 (50)	9	4 (44)	25	12 (48)
45+ years	14	9 (64)	6	4 (67)	20	13 (65)
2008						
<25 years	5	1 (20)	5	0 (0)	10	1 (10)
25-34 years	39	21 (54)	25	15 (60)	64	36 (56)
35-44 years	39	25 (64)	17	8 (47)	56	33 (59)
45+ years	17	11 (65)	12	9 (75)	29	20 (69)
2009						
<25 years	8	2 (25)	6	0 (0)	14	2 (14)
25-34 years	36	17 (47)	33	18 (55)	70	35 (50)
35-44 years	42	17 (40)	27	14 (52)	69	31 (45)
45+ years	39	24 (62)	19	10 (53)	58	34 (59)
2010						
<25 years	2	0 (0)	6	3 (50)	8	3 (38)
25-34 years	31	16 (52)	30	14 (47)	61	30 (49)
35-44 years	41	20 (41)	31	21 (68)	72	41 (57)
45+ years	45	29 (64)	25	16 (64)	70	45 (64)
2011						
<25 years	6	1 (17)	2	1 (50)	8	2 (25)
25-34 years	25	13 (52)	24	8 (33)	49	21 (43)
35-44 years	41	28 (68)	22	13 (59)	64	42 (66)
45+ years	26	26 (70)	12	12 (48)	62	38 (61)
2012						
<25 years	3	1 (33)	1	0 (0)	4	1 (25)
25-34 years	29	18 (62)	19	7 (37)	48	25 (52)
35-44 years	45	27 (60)	21	8 (38)	67	36 (54)
45+ years	43	25 (58)	22	15 (68)	65	40 (62)
2013						
<25 years	7	1 (14)	5	0 (0)	12	1 (8)
25-34 years	40	17 (43)	22	7 (32)	62	24 (39)
35-44 years	35	22 (63)	22	6 (27)	57	28 (49)
45+ years	39	25 (64)	22	10 (45)	62	36 (58)
2014						
<25 years	6	1 (17)	0	0 (0)	6	1 (17)
25-34 years	32	13 (41)	14	9 (64)	46	22 (48)
35-44 years	45	26 (58)	26	10 (38)	72	36 (50)
45+ years	44	31 (70)	35	21 (60)	80	53 (67)
2014 p value		0.011		0.174		0.02

Table 9.3.3 HCV antibody prevalence by drug last injected, years of injection and year

Western Australia	≤3 years		4+ years		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
1995						
Heroin	5	2 (40)	8	5 (63)	8	5 (63)
Methamphetamine	0	0 (0)	4	2 (50)	9	4 (44)
Other opioids	0	0 (0)	4	2 (50)	4	2 (50)
Other drugs	1	0 (0)	1	0 (0)	2	0 (0)
1996						
Heroin	0	0 (0)	40	27 (63)	53	27 (51)
Methamphetamine	6	2 (33)	6	1 (17)	12	3 (25)
Other opioids	1	0 (0)	6	5 (83)	7	5 (71)
Other drugs	2	0 (0)	5	2 (40)	7	2 (29)
1997						
Heroin	0	0 (0)	12	8 (67)	12	8 (67)
Methamphetamine	1	0 (0)	4	1 (25)	5	1 (20)
Other opioids	1	0 (0)	0	0 (0)	1	0 (0)
Other drugs	0	0 (0)	1	0 (0)	1	0 (0)
1998						
Heroin	14	2 (14)	70	39 (56)	84	41 (49)
Methamphetamine	6	1 (17)	19	3 (16)	25	4 (16)
Other opioids	1	0 (0)	5	2 (40)	6	2 (33)
Other drugs	2	0 (0)	6	4 (67)	8	4 (50)
1999						
Heroin	9	1 (11)	48	29 (60)	57	30 (53)
Methamphetamine	5	1 (20)	10	4 (40)	15	5 (33)
Other opioids	0	0 (0)	8	6 (75)	8	6 (75)
Other drugs	1	0 (0)	4	2 (50)	5	2 (40)
2000						
Heroin	7	3 (43)	35	19 (54)	42	22 (52)
Methamphetamine	4	0 (0)	14	5 (36)	18	5 (28)
Other opioids	0	0 (0)	6	4 (67)	6	4 (67)
Other drugs	1	0 (0)	9	1 (11)	10	1 (10)
2001						
Heroin	1	1 (100)	21	15 (71)	22	16 (73)
Methamphetamine	14	2 (14)	63	36 (57)	77	38 (49)
Other opioids	4	0 (0)	16	12 (75)	20	12 (60)
Other drugs	0	0 (0)	15	9 (60)	15	9 (60)
2002						
Heroin	1	0 (0)	24	14 (58)	25	14 (56)
Methamphetamine	5	3 (60)	42	16 (38)	47	19 (40)
Other opioids	3	0 (0)	18	9 (50)	21	9 (43)
Other drugs	6	0 (0)	21	10 (48)	27	10 (37)
2003						
Heroin	4	0 (0)	35	27 (77)	39	27 (69)
Methamphetamine	8	2 (25)	47	23 (49)	55	25 (45)
Other opioids	1	0 (0)	13	10 (77)	14	10 (71)
Other drugs	2	0 (0)	19	14 (74)	21	14 (67)
2004						
Heroin	1	0 (0)	27	21 (78)	28	21 (75)
Methamphetamine	5	2 (40)	43	13 (30)	48	15 (31)
Other opioids	1	1 (100)	19	15 (79)	20	16 (80)
Other drugs	0	0 (0)	14	12 (86)	14	12 (86)

Table 9.3.3 HCV antibody prevalence by drug last injected, years of injection and year

Western Australia	≤3 years		4+ years		Total	
	≤3 years	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	1	1 (100)	46	30 (65)	47	31 (66)
Methamphetamine	3	0 (0)	47	22 (47)	50	22 (44)
Other opioids	0	0 (0)	43	29 (67)	43	29 (67)
Other drugs	0	0 (0)	10	4 (40)	10	4 (40)
2006						
Heroin	2	0 (0)	25	19 (76)	27	20 (74)
Methamphetamine	2	0 (0)	58	30 (52)	60	30 (50)
Other opioids	1	0 (0)	33	17 (52)	34	17 (50)
Other drugs	1	0 (0)	9	7 (78)	10	8 (80)
2007						
Heroin	1	0 (0)	22	18 (82)	23	18 (78)
Methamphetamine	4	0 (0)	22	5 (23)	26	5 (19)
Other opioids	3	0 (0)	24	11 (46)	27	11 (41)
Other drugs	1	0 (0)	6	2 (33)	7	2 (29)
2008						
Heroin	2	1 (50)	50	36 (72)	52	37 (71)
Methamphetamine	2	0 (0)	40	13 (33)	42	13 (31)
Other opioids	4	2 (50)	51	31 (61)	55	33 (60)
Other drugs	0	0 (0)	8	6 (75)	8	6 (75)
2009						
Heroin	2	1 (50)	69	38 (55)	71	39 (55)
Methamphetamine	4	0 (0)	37	7 (19)	41	7 (17)
Other opioids	4	0 (0)	61	36 (59)	65	36 (55)
Other drugs	1	0 (0)	27	16 (59)	28	16 (57)
2010						
Heroin	5	3 (60)	61	42 (69)	66	45 (68)
Methamphetamine	2	0 (0)	53	17 (32)	55	17 (31)
Other opioids	1	1 (100)	59	41 (69)	60	42 (70)
Other drugs	4	0 (0)	20	12 (60)	24	12 (50)
2011						
Heroin	5	3 (60)	41	27 (66)	46	30 (65)
Methamphetamine	3	0 (0)	58	25 (43)	61	25 (41)
Other opioids	3	2 (67)	60	38 (63)	63	40 (63)
Other drugs	0	0 (0)	13	9 (69)	13	9 (69)
2012						
Heroin	0	0 (0)	48	32 (67)	48	32 (67)
Methamphetamine	4	2 (50)	54	16 (30)	58	18 (31)
Other opioids	1	1 (100)	53	35 (66)	54	36 (67)
Other drugs	2	2 (100)	20	13 (65)	22	15 (68)
2013						
Heroin	0	1 (10)	49	29 (59)	49	29 (59)
Methamphetamine	10	0 (0)	58	16 (28)	68	17 (25)
Other opioids	0	0 (0)	50	32 (64)	50	32 (64)
Other drugs	4	0 (0)	22	11 (50)	26	11 (42)
2014						
Heroin	1	0 (0)	73	43 (59)	74	43 (58)
Methamphetamine	3	0 (0)	66	31 (47)	70	31 (44)
Other opioids	0	0 (0)	36	24 (67)	36	24 (67)
Other drugs	5	0 (0)	16	11 (69)	24	14 (58)
2014 p value		--		0.176		0.133

APPENDIX 1: REFERENCES

Peer reviewed publications describing ANSPS methodology

1. Topp, L., Iversen, J., Wand, H., Day, C., Kaldor, J. & Maher, L. (2008a). Representativeness of injecting drug users who participate in HIV surveillance: Results from Australia's Needle and Syringe Program Survey. *Journal of Acquired Immune Deficiency Syndromes*, 47(5), 632-638.
2. White, B., Day, C. & Maher, L. (2007). Self reported drug use and risk behaviour among injecting drug users: self versus assisted questionnaire completion. *AIDS Care*, 19, 441-447.
3. MacDonald, M., Wodak, A.D., Ali, R., Crofts, N., Cunningham, P.H., Dolan, K.A., Kelaher, M., Loxley, W.M., van Beek, I. & Kaldor, J.M. (1997). HIV prevalence and risk behaviour in needle exchange attenders: a national study. *Medical Journal of Australia*, 166, 237-240.

Peer reviewed publications describing ANSPS results

1. Iversen J, Grebely J, Topp L, Wand H, Dore G, Maher L (2014). Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011. *Journal of Viral Hepatitis* 21(3):198-207.
2. Iversen J, Wand H, Topp L, Kaldor J, Maher L (2014). Extremely low and sustained HIV incidence among people who inject drugs in a setting of harm reduction. *AIDS* 28(2): 275-278.
3. Iversen J, Wand H, Topp L, Kaldor J, Maher L. (2013) Reduction in HCV Incidence Among Injection Drug Users Attending Needle and Syringe Programs in Australia: A Linkage Study. *American Journal of Public Health* 103(8):1436-1444.
4. Islam M, Topp L, Iversen J, Day C, Conigrave K, Maher L (2013). Healthcare utilization and disclosure of injecting drug use among clients of Australia's needle and syringe programs. *Aust N Z J Public Health* 37(2):148-154.
5. Iversen J, Topp L, Wand H, Maher L (2013). Are people who inject performance and image-enhancing drugs an increasing population of Needle and Syringe Program attendees? *Drug Alcohol Rev* 32(2):205-207.
6. Topp L, Iversen J, Baldry E, Maher L (2013). Housing instability among people who inject drugs: Results from the Australian Needle and Syringe Program Survey. *J Urban Health* 90(4):699-716.
7. Ward J, Topp L, Iversen J, Wand H, Akre S, Kaldor J, Maher L (2011). Higher HCV antibody prevalence among Indigenous clients of Needle and Syringe Programs. *Aust N Z J Public Health* 35:421-426.
8. Topp, L., Day, C.A., Iversen, J., Wand, H. & Maher, L. (2011). Fifteen years of HIV surveillance among people who inject drugs: The Australian Needle and Syringe Program Survey 1995-2009. *AIDS*, 25(6), 835-842.

9. Iversen, J., Wand, H., Gonnermann, A. & Maher, L. (2010) Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998-2008. *International Journal of Drug Policy*, 21, 471-476.
10. Falster, K., Kaldor, J.M. & Maher, L. (2009). Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of Needle and Syringe Program attendees in Australia, 1995-2004. *Journal of Urban Health*, 86, 106-118.
11. Day, C., Topp, L., Iversen, J. & Maher, L. (2008) Blood-borne virus prevalence and risk among steroid injectors: Results from the Australian Needle and Syringe Program Survey. *Drug and Alcohol Review*, 27, 559-561.
12. Topp, L., Iversen, J., Conroy, A., Salmon, A. & Maher, L. (2008b). Prevalence and predictors of injecting-related injury and disease among clients of Australia's Needle and Syringe Programs. *Australian and New Zealand Journal of Public Health*, 32, 34-37.
13. Thein, H-H., Denoe, M., van Beek, I., Dore, G. & MacDonald, M. (2003). Injecting behaviour of injecting drug users at needle and syringe programmes and pharmacies in Australia. *International Journal of Drug Policy*, 14, 425-430.
14. MacDonald, M.A., Wodak, A.D., Dolan, K.A., van Beek, I., Cunningham, P.H. & Kaldor, J.M. (2000). Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. *Medical Journal of Australia*, 172, 57-61.

Other references

1. Maher, L., Li, J., Jalaludin, B., Wand, H., Jayasuriya, R., Dixon, D., et al. (2007). Impact of a reduction in heroin availability on patterns of drug use, risk behaviour and incidence of hepatitis C virus infection in injecting drug users in New South Wales, Australia. *Drug Alcohol Dependence*, 89(2-3), 244-250.
2. Degenhardt, L., Day, C., Dietze, P., Pointer, S., Conroy, E., Collins, L., et al. (2005). Effects of a sustained heroin shortage in three Australian States. *Addiction*, 100(7), 908-920.
3. Topp, L., Day, C., & Degenhardt, L. (2003). Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. *Drug & Alcohol Dependence*, 70(3), 275-286.
4. Topp, L., Day, C., Dore, G., & Maher, L. (2009). Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: a review. *Drug and Alcohol Review*, 28, 669-675.

APPENDIX 2: METHODOLOGICAL NOTES

Data presented in this report were analysed using Stata, Version 12 (Stata Corporation, College Station TX). Changes for HIV and HCV antibody prevalence overtime were assessed using the χ^2 test for linear trends. Associations between demographic and behavioural variables and HIV/HCV antibody prevalence were assessed using the χ^2 test or Fisher's exact test where expected frequencies were less than five. Ethical approvals were obtained from Human Research Ethics Committees associated with the investigators and participating NSP services.

Tables reporting HIV antibody prevalence stratified by sexual identity, age group and last drug injected are not included in this report for states and territories where the number of HIV antibody positive participants was less than 5 in the majority of survey years.

Percentage values in tables may not add to 100 due to rounding. Totals in HIV and HCV antibody prevalence tables stratified by gender include people whose gender was not reported or reported as transgender. Time since initiation to injecting was calculated by subtracting age at first injection from age at survey completion. Totals in HIV and HCV antibody prevalence tables stratified by time since first injection include people who did not report age at survey completion or age at first injection.

The symbol "--" shown in some Tables denotes missing data; and is used to identify circumstances where data were not collected in the reported format. Where data were collected but no participants endorsed a particular response, results are presented as "0 (0)". While the majority of survey questions were consistent over all survey years, this was not always the case. Notably, questions on sexual behaviour were amended in 2005 in a manner which renders comparison over time invalid. The question on receptive sharing of drug preparation equipment was modified; with the addition in 2006 of the response option to report "no shared items". Supplementary response options were added to items assessing drug treatment history as new opioid replacement therapies became available. Following a review of the literature which concluded that the accuracy of self-reported hepatitis B status among people who inject drugs is poor (Topp, L., Day, C., Dore, G., & Maher, L., 2009) ANSPS items designed to assess participants' hepatitis B infection and vaccination histories were removed from the questionnaire in 2008.

APPENDIX 3: LIST OF TABLES

Behavioural tables

- 1.1.1 Number (percentage) of respondents by demographic characteristic and year
- 1.1.2 Number (percentage) of respondents by drug last injected and year
- 1.1.3 Number (percentage) of respondents by injecting behaviour in the month prior to survey and year
- 1.1.4 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year
- 1.1.5 Number (percentage) of respondents by testing for HIV and HCV infection by year
- 1.1.6 Number (percentage) of respondents by HCV treatment by year
- 1.1.7 Number (percentage) of respondents by drug treatment by year

HIV antibody prevalence

- 1.2.1 HIV antibody prevalence by gender and year
- 1.2.2 HIV antibody prevalence by sexual identity, gender and year
- 1.2.3 HIV antibody prevalence by age group, gender and year
- 1.2.4 HIV antibody prevalence by drug last injected, gender and year

HCV antibody prevalence

- 1.3.1 HCV antibody prevalence by gender and year
- 1.3.2 HCV antibody prevalence by age group, gender and year
- 1.3.3 HCV antibody prevalence by drug last injected, time since initiation and year

APPENDIX 4: PARTICIPATING NSP SERVICES		1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014		
AUSTRALIAN CAPITAL TERRITORY (N° OF SITES)	ACT IV League	✓																					
	Directions ACT, Canberra																						
NEW SOUTH WALES (N° OF SITES)	ACON Hunter	4	4	7	11	13	13	14	16	18	18	19	18	21	22	20	22	20	20	19	19	19	
	Albury Base Hospital & Community Health Centre																						
	Auburn NSP Service					✓			✓														
	Ballina/Byron Harm Reduction Services																						
	Blacktown NSP Service	✓																					
	Central Access Service, St George & Sutherland	✓																					
	Coffs Harbour/Grafton Harm Reduction Services																						
	Fairfield Harm Reduction, Cabramatta & Fairfield																						
	First Step Program Port Kembla																						
	Gosford/Long Jetty & Woy Woy NSP Services																						
	Health ConneXions, Liverpool																						
	Indo-Chinese Outreach Network																						
	Clinic 180, Kings Cross (formerly K2)																						
	Kirketon Road Centre, Kings Cross	✓																					
	Long Jetty NSP Service																						
	Merrylands NSP Service																						
	Mt Druitt NSP Service																						
	Murwillumbah/Tweed Harm Reduction Services																						
	Newcastle Harm Minimisation Program																						
	Nimbin/Lismore Harm Reduction Services																						
	NSW Users and AIDS Association (NUAA)																						
	Parramatta NSP Service	✓																					
	Harm Reduction Program, Canterbury																						
	Harm Reduction Program, Redfern																						
	Response User Services Health, Ryde, Manly & St Leonards																						
	South Court Primary Care, Nepean																						
	Wagga Wagga NSP Service																						

PARTICIPATING NSP SERVICES		1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
NORTHERN TERRITORY (N° OF SITES)		2	2	2	2	1	2	2	1	1	2	3	1	3	3	3	3	3	3	3	3
NT AIDS and Hepatitis C Council, Alice Springs		✓	✓	✓	✓		✓	✓				✓		✓	✓	✓	✓	✓	✓	✓	✓
NT AIDS and Hepatitis C Council, Darwin		✓	✓	✓	✓		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
NT AIDS and Hepatitis C Council, Palmerston											✓	✓		✓	✓	✓	✓	✓	✓	✓	✓
QUEENSLAND (N° OF SITES)		4	5	5	6	6	6	6	9	10	7	7	7	7	8	8	8	8	8	8	7
Bodyline		✓																			
Biala Community Alcohol and Drugs Services, Brisbane		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cairns Needle and Syringe Program			✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cairns Youth Link										✓											
Gold Coast Hospital					✓																
Kobi House, Toowoomba			✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Logan Youth Health Service									✓	✓											
Mackay Sexual Health Services									✓	✓											
QuiHN, Brisbane		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
QuiHN, Gold Coast		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
QuiHN, Sunshine Coast						✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Townsville ATODS NSP															✓	✓	✓	✓	✓	✓	✓
West Moreton Sexual Health Service, Ipswich									✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
SOUTH AUSTRALIA (N° OF SITES)		2	2	2	5	6	8	6	6	6	6	7	6	7	7	7	7	7	7	7	7
Hindmarsh Centre CNP							✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Lyell McEwin							✓														
Nunkuarrin Yunti CNP											✓				✓	✓	✓	✓	✓	✓	✓
SAVIVE, Noarlunga					✓		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
SAVIVE, Norwood			✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
SAVIVE, Parks					✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
SAVIVE, Port Adelaide						✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
SAVIVE, Shopfront		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Street Link																					
Warinilla Clinic					✓	✓	✓														

PARTICIPATING NSP SERVICES		1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
TASMANIA (N° OF SITES)		1	1	1	2	1	1	1	4	4	4	3	2	4	4	4	4	4	4	3	4
Clarence Community Health Centre										✓	✓	✓		✓	✓	✓	✓	✓	✓	✓	✓
Salvation Army, Launceston									✓					✓	✓	✓	✓	✓	✓	✓	✓
Glenorchy NSP (Anglicare)									✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Hobart NSP (Anglicare)		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
The Link- Youth Health Service									✓	✓	✓										
Users Health Support League, Hobart					✓																
VICTORIA (N° OF SITES)		5	3	4	4	3	3	4	4	4	5	5	4	6	6	6	5	6	6	6	6
Ballarat CHS		✓																			
Barwon NSP, Geelong		✓												✓	✓	✓	✓	✓	✓	✓	✓
Health Works, Cohealth				✓	✓	✓	✓	✓	✓	✓	✓	✓						✓	✓	✓	✓
Innerspace Drug Safety Services , Cohealth		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
North Richmond NSP Service														✓	✓	✓	✓	✓	✓	✓	✓
Northcote NSP Service														✓	✓	✓	✓	✓	✓	✓	✓
SHARPS, Frankston		✓	✓	✓	✓				✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
South East Alcohol and Drug Service, Dandenong								✓			✓	✓	✓								
St Kilda NSP Service		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
WESTERN AUSTRALIA (N° OF SITES)		1	1	1	2	2	2	3	3	3	3	3	3	2	2	2	3	3	3	3	3
WA Substance Users Association (WASUA), Perth					✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
WA Substance Users Association (WASUA), Bunbury								✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
WA AIDS Council Mobile Exchange		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

